WO2004087138A1 - Method for treating vascular hyperpermeable disease - Google Patents

Method for treating vascular hyperpermeable disease Download PDF

Info

Publication number
WO2004087138A1
WO2004087138A1 PCT/JP2004/004596 JP2004004596W WO2004087138A1 WO 2004087138 A1 WO2004087138 A1 WO 2004087138A1 JP 2004004596 W JP2004004596 W JP 2004004596W WO 2004087138 A1 WO2004087138 A1 WO 2004087138A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
thiazol
amino
phenyl
acetamide
Prior art date
Application number
PCT/JP2004/004596
Other languages
French (fr)
Inventor
Ryuji Ueno
Akira Nagashima
Takayuki Inoue
Mitsuru Ohkubo
Kousei Yoshihara
Original Assignee
Sucampo Ag
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag, Astellas Pharma Inc. filed Critical Sucampo Ag
Priority to CN2004800090708A priority Critical patent/CN1794988B/en
Priority to EP04724735.8A priority patent/EP1608365B1/en
Priority to CA2520957A priority patent/CA2520957C/en
Priority to US10/550,414 priority patent/US20060229346A1/en
Priority to JP2006507702A priority patent/JP4758337B2/en
Publication of WO2004087138A1 publication Critical patent/WO2004087138A1/en
Priority to KR1020057018312A priority patent/KR101267552B1/en
Priority to US11/930,466 priority patent/US20080119462A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a method for. treating a vascular hyperpermeable disease (except macular edema) .
  • Vascular adhesion protein-1 (hereinafter to be abbreviated as VAP-1) is amine oxidase (semicarbazide sensitive amine oxidase, SSAO) which is abundant in human plasma, and shows remarkably increased expression in vascular endothelium and vascular smooth muscle of the inflammatory region. While the physiological role of VAP-1 has not been clarified until recently, VAP-1 " gene was cloned in 1 ' 998, and VAP-1 has been reported to be a membrane ⁇ protein that regulates rolling and migration of ' lymphocyte and NK cell as an adhesion molecule under regulation of expression by inflammatory cytokine.
  • VAP-1 amine oxidase
  • the amine to be a substrate is unknown, it is considered to be methylamine generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydejs produced by the amine oxidase activity in a molecule are important factors of adhesion activity.
  • VAP-1 enzyme activity in plasma and vascular permeability are correlated, and therefore, a VAP-1 inhibitor is useful for the prophylaxis or treatment of a vascular hyperpermeable disease (except macular edema) -and completed the present invention.
  • the present invention provides the following. (1) A method for treating a vascular hyperpermeable disease (except macular edema) , which method comprises administering to a subject in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said subject for said disease.
  • VAP-1 vascular adhesion protein-1
  • X is a bivalent residue derived from optionally substituted thiazole
  • Y is a bond, lower alkylene, lower alkenylene or -CONH-;
  • Z is a group of the formula:
  • Q is -S- or -NH-
  • R 3 is hydrogen, lower alkyl, lower alkylthio or -NH-R 4 wherein R 4 is hydrogen, -NH 2 or lower alkyl; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • -NH 2 ; -CH 2 NH 2 ; -CH 2 ONH 2 ; -CH 2 0N CH 2 ;
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen or lower alkyl
  • -CH 2 NH -CH 2 ONH 2
  • -CH 2 ON CH 2 ;
  • VAP-1 inhibitor N- ⁇ 4- [2- (4- ⁇ [amino (imino) methyl] amino ⁇ phenyl) ethyl] -1, 3- thiazol-2-yl ⁇ acetamide
  • VAP-1 inhibitor is N- ⁇ 4- [2- (4- ⁇ [amino (imino) methyl] amino ⁇ phenyl ) ethyl] -1, 3- thiazol-2-yl ⁇ acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for the treatment of a vascular hyperpermeable disease (except macular edema) , which comprises, as an active ingredient, a VAP-1 inhibitor.
  • composition of (11), wherein the VAP-1 inhibitor is Compound (I) ; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
  • R 2 is a group of the formula:
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • -NH 2 is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • -NH 2 is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • R 4 is hydrogen, -NH 2 or lower alkyl
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen or lower alkyl
  • -CH 2 NH 2 is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen or lower alkyl
  • -CH 2 NH 2 is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen or lower alkyl
  • -CH 2 NH 2 ;
  • -CH 2 ON CH 2 ;
  • VAP-1 vascular adhesion protein-1
  • SSAO semicarbaside sensitive amine oxidase
  • copper-containing amine oxidase copper-containing amine oxidase
  • the "treating a vascular hyperpermeable disease (except macular edema) " and “treatment of a vascular hyperpermeable disease (except macular edema)” are intended to include the administration of a compound having a VAP-1 inhibitory activity to a subject for purposes, which can include prophylaxis, amelioration, prevention and cure of a vascular hyperpermeable disease (except macular edema) .
  • a target of the administration of VAP-1 inhibitor in the present invention which is specifically any animal such as human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
  • the vascular hyperpermeable disease (except macular edema) , which is to be treated by the method of the present invention, includes the disease caused/accompanied by increased vascular permeability, for example, diseases in mucous membrane such as ocular, cutis, otorhinology, respiratory tract and the like.
  • diseases in ocular-mucous membrane such as aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, ulceris, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, ocular inflammatory diseases caused by bacterial or viral infection
  • the method comprises the administration of a VAP-1 inhibitor in an amount sufficient to treat a vascular hyperpermeable disease (except macular edema) .
  • a VAP-1 inhibitor can be used in the method of the present invention as long as it is safe and efficacious.
  • the "VAP-1 inhibitor” will be used to refer to such compounds and is intended to encompass all compounds that inhibit enzyme activity of VAP-1 at any and all points in the action mechanism thereof.
  • the VAP-1 inhibitor in the present invention includes, for example, a compound represented by the following formula ( I) [Compound ( I) ] : R 1 —NH—X—Y—Z (I) wherein R 1 is acyl;
  • X is a bivalent residue derived from optionally substituted 5 thiazole
  • Y is a bond, lower alkylene, lower alkenylene or -CONH-; and Z is a group of the formula:
  • R 2 is a group of the formula: -A-B-D-E
  • A is a bond, lower alkylene, -NH- or -S0 2 -;
  • B is a bond, lower alkylene, -CO- or -0-;
  • D is a bond, lower alkylene, -NH- or -CH 2 NH-;
  • Q is -S- or -NH-
  • R 3 is hydrogen, lower alkyl, lower alkylthio or -NH-R 4 wherein R 4 is hydrogen, -NH 2 or lower alkyl; 20 or a derivative thereof; or a pharmaceutically acceptable salt thereof.
  • Suitable "halogen” includes fluorine, chlorine, bromine 25 and iodine.
  • lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
  • Suitable “lower alkyl” includes straight or branched 30 . alkyl having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C1-C4 alkyl.
  • Suitable "lower alkylthio" includes lower alkylthio containing the above lower alkyl, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, tert-pentylthio and hexyl hio.
  • Suitable "lower alkylene” includes straight or branched alkylene having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, propylene, ethylidene and propylidene, in which more preferred one is C 1 -C 4 alkylene.
  • the above lower alkenylene may be in E or Z form, respectively. Thus, those skilled in the art will recognize that the lower alkenylene includes all E, Z-structures when it has 2 or more double bonds.
  • Suitable “aryl” includes C 6 -C ⁇ o aryl such as phenyl and naphthyl, in which more preferred one is phenyl.
  • the “aryl” may be substituted by 1 to 3 substituent (s) and the substitution sites are not particularly limited.
  • Suitable “aralkyl” includes aralkyl wherein the aryl moiety has 6 to 10 carbon atoms [i.e. the aryl moiety is C 6 - Cio aryl of the above “aryl”] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl .moiety is C ⁇ -C 6 alkyl of the above “lower alkyl”], such as benzyl, phenethyl, 1- naphthylmethyl, 2-naphthylmethyl, 3-phenylpropyl, 4- phenylbutyl and 5-phenylpentyl .
  • the "optionally protected amino” means that an ' amino group may be protected with a suitable protecting group according to a method known per se, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • the suitable "protecting group” includes tert-butoxycarbonyl (i.e., Boc) , an acyl group as mentioned below, substituted or unsubstituted aryl (lower) alkylidene [e.g., benzylidene, hydroxybenzylidene, etc.], aryl (lower) alkyl such as mono-, di- or triphenyl- (lower) alkyl [e.g., benzyl, phenethyl, benzhydryl, trityl, etc.] and the like.
  • Suitable “optionally protected amino” includes amino and tert-butoxycarbonylamino (i.e. -NHBoc).
  • Suitable “heterocycle” includes “aromatic heterocycle' and “non-aromatic heterocycle”.
  • Suitable "aromatic heterocycle” includes 5 to 10- membered aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s), and includes, for example, thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine and the like.
  • non-aromatic heterocycle includes 5 to 10- membered non-aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s), and includes, for example, pyrrolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dioxolan, oxazolidine, thiazolidine, triazolidine and the like.
  • heteroatom selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s)
  • pyrrolidine imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dioxolan, oxazolidine, thiazolidine, triazolidine and the like.
  • acyl includes acyl having 1 to 20 carbon atom(s), such as formyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl and aralkyloxycarbonyl.
  • alkylcarbonyl includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is C ⁇ -C 6 alkyl of the above “lower alkyl”] , such as acetyl, propionyl, butyryl, isobutyryl, , valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl, in which more preferred one is C1-C4 alkyl-carbonyl .
  • Suitable "arylcarbonyl” includes arylcarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C 6 -C ⁇ 0 aryl of the above “aryl”] , such as benzoyl and naphthoyl.
  • alkoxycarbonyl includes alkoxycarbonyl wherein the alkoxy moiety has 1 to 6 carbon atom(s), such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec- butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, tert-pentyloxycarbonyl and hexyloxycarbonyl, in which more, preferred one is alkoxycarbonyl wherein the alkoxy moiety has 1 to 4 carbon atom(s) .
  • Suitable “aralkyloxycarbonyl” includes aralkyloxycarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C 6 -C ⁇ 0 aryl of the above “aryl”] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e.
  • the alkyl moiety is Ci-C ⁇ alkyl of the above "lower alkyl”], such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl, 2-naphthylmethyloxycarbonyl, 3- phenylpropyloxycarbonyl, 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
  • lower alkyl such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl, 2-naphthylmethyloxycarbonyl, 3- phenylpropyloxycarbonyl, 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
  • Suitable "bivalent residue derived from thiazole" of the "bivalent residue derived from optionally substituted thiazole” includes
  • the “thiazole” may have 1 to 3 substituent (s) and the substitution sites are not particularly limited.
  • Suitable "substituent" of the above “optionally substituted thiazole” includes, for example, (1) halogen which is as defined above;
  • alkoxycarbonyl which is as defined above, such as ethoxycarbonyl
  • aryl which aryl is as defined above and the substitution sites are not particularly limited, such as phenyl and 4- ( ethylsulfonyl ) phenyl ;
  • R a is hydrogen, lower alkyl, aryl or aralkyl and R b is hydrogen, lower alkyl, aryl or aralkyl, wherein the lower alkyl, aryl and aralkyl are as defined above, such as N- methylaminocarbonyl, N-phenylaminocarbonyl, N,N- dimethylaminocarbonyl and N-benzylaminocarbonyl;
  • (5) a group of the formula: -CONH- (CH 2 ) k ⁇ aryl wherein k is an integer of 0 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -N0 2 , -S0 2 - (lower alkyl) wherein the lower alkyl is as defined above, -CF 3 and -O-aryl wherein the aryl is as defined above, and the substitution sites are not particularly limited; (6) a group of the formula: -CONH- (CH 2 ) m -heterocycle wherein is an integer of 0 to 6; the heterocycle is as defined above, such as pyridine;
  • -CO-heterocycle wherein the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of -CO- (lower alkyl) wherein the lower alkyl is as defined above, -CO-O- (lower alkyl) wherein the lower alkyl is as defined above, -S0 2 - (lower alkyl) wherein the lower alkyl is as defined above, oxo (i.e.
  • R c is hydrogen, lower alkyl, aryl or aralkyl and R d is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
  • n is an integer of 1 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -S- (lower alkyl) wherein the lower alkyl is as defined above, -S0 2 - (lower alkyl) wherein the lower alkyl is as defined above, -C0 2 - (lower alkyl) wherein the lower alkyl is as- defined above, -NHCO-O- (lower alkyl) wherein the lower alkyl is as defined " above and a group of the formula: -CONR e R f wherein R e is hydrogen, lower alkyl, aryl or aralkyl and R f is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
  • (9) a group of the formula: - (CH 2 ) 0 -heterocycle wherein o is an integer of 0 to 6; the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of oxo (i.e.
  • (10) a group of the formula: - (CH 2 ) p -NR i R j wherein p is an integer of 0 to 6;
  • R 1 is hydrogen,- acyl, lower alkyl, aryl or aralkyl and
  • R j is hydrogen, acyl, lower alkyl, aryl or aralkyl wherein the acyl, lower alkyl, aryl and aralkyl are as defined above, and the lower alkyl may have 1 to 5 substituent (s) selected from the group consisting of a group of the formula: -C0NR k R 1 wherein R is hydrogen, lower alkyl, aryl or aralkyl and R 1 is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
  • (11) a group of the formula: -CON(H or lower alkyl) - (CHR m ) q -T wherein q is an integer of 0 to 6; the lower alkyl is as defined above; R m is hydrogen, aralkyl which is as defined above, or alkyl which is as defined above, which may be substituted by 1 to 3 substituent (s) selected from the group consisting of -OH and -CONH 2 and the substitution sites are not particularly limited; and T is hydrogen; a group of the formula: -CONR n R° wherein R n is hydrogen, lower alkyl, aryl or aralkyl and R° is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above; -NH-CO-R p wherein R p is lower alkyl which is as defined above or aralkyl which is as defined above;
  • substitution site on the aryl or heterocycle is any suitable position thereof, but not particularly limited.
  • substituted thiazole is methylsulfonylbenzyl.
  • (I) is not particularly limited.
  • substitution sites on the group are not particularly limited
  • Compound (I) may be protected according to the methods, which are known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • the Compound (I) and derivatives thereof, or compounds reported to have inhibited VAP-1 enzyme may include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1, 3, 4-oxadiazine derivatives, 2, 6-diethoxybenzylamine, 2,6- di (n-propoxy)benzylamine, 2, 6-diisopropoxybenzylamine, 2,6- di (n-butoxy) benzylamine, 2, 6-bis (methoxymethoxy) benzylamine, 2, 6-bis (methoxymethyl) benzylamine, 2, 6-diethylbenzylamine, 2, 6-di-n-propylbenzylamine, 2, 6-bis (2- hydroxyethoxy) benzylamine, and the like.
  • VAP-1 inhibitor and in WO 93/23023 as an SSAO inhibitor, such as those described in Lyles et al . (Biochem. Pharmacol. 36:2847, 1987) and in USP 4650907, USP 4916151, USP 4943593, USP 4965288, USP 5021456, USP 5059714, USP 4699928, European patent application 295604, European patent application 224924 and European patent application 168013, are also encompassed in the VAP-1 inhibitor.
  • Compound (I) more preferably, a compound of the formula (I) wherein Z is a group of the formula:
  • R 2 is a group of the formula:
  • G is a bond, -NHCOCH 2 - or lower alkylene and R 4 is hydrogen, -NH 2 or lower alkyl
  • R 4 is hydrogen, -NH 2 or lower alkyl
  • R 1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl and derivatives thereof.
  • N- ⁇ 4- [2- (4- ⁇ [hydrazino (imino)methyl] amino ⁇ henyl) ethyl] -1,3- thiazol-2-yl ⁇ acetamide see Production Example 58
  • N- (4- ⁇ 2- [4- (2- ⁇ [amino (imino) ethyl] amino ⁇ ethyl) phenyl] ethyl ⁇ - 1, 3-thiazol-2-yl) acetamide see Production Example 110
  • the term "derivative" is intended to include all compounds derived from the original compound.
  • the VAP-1 inhibitor can be administered as a prodrug to a subject.
  • prodrug is intended to include all compounds that convert to the VAP-1 inhibitor in the body of administration subject.
  • the prodrug can be any pharmaceutically acceptable prodrug of VAP-1 inhibitor.
  • the VAP-1 inhibitor can be administered to an administration subject as a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt of VAP-1 inhibitor in the present invention is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like), alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methy1amine salt and the like) .
  • alkali metal salt e.g., sodium salt, potassium salt and the like
  • alkaline earth metal salt e.g., calcium salt, magnesium salt and the like
  • ammonium salt e.g., triethylamine salt, N- benzyl-N-methy1amine salt and the like
  • the VAP-1 inhibitor can be also formulated as a pharmaceutically acceptable acid addition salt.
  • the pharmaceutically acceptable acid addition salts for use in the pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
  • a pharmaceutically acceptable salt of VAP-1 inhibitor represented by the formula (I) a pharmaceutically acceptable acid addition salt such as (mono-, di- or tri-) hydrochloride and hydriodide, particuraly hydrochloride, is preferable.
  • VAP-1 inhibitor may be commercially available or can be produced based on a known reference.
  • Compound (I) particularly Compound A: N- ⁇ 4-[2- (4- ⁇ [amino (imino) methyl] amino ⁇ phenyl) ethyl] -1, 3-thiazol-2- yl ⁇ acetamide and Compound B: N-[4-(2- ⁇ 4-
  • the VAP-1 inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method by any suitable route.
  • Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconjunctival, intraocular, intravitreal, intracameral, subretinal, suprachoroidal and retrobulbar administrations.
  • periocular e.g., subTenon's
  • subconjunctival intraocular
  • intravitreal intracameral
  • subretinal suprachoroidal and retrobulbar administrations.
  • the manner in which the VAP-1 inhibitor is administered is dependent, in part, upon whether the treatment of a vascular hyperpermeable disease (except .macular edema) is prophylactic or therapeutic.
  • the VAP-1 inhibitor is preferably administered as soon as possible after it has been determined that a subject such as a mammal, specifically a human, is at risk for a vascular hyperpermeable disease (except macular edema) (prophylactic treatments) or has begun to develop a vascular hyperpermeable disease (except macular edema) (therapeutic treatments) .
  • Treatment will depend, in part, upon the particular VAP-1 inhibitor used, the amount of the VAP-1 inhibitor administered, the route of administration, and the cause and extent, if any, of a vascular hyperpermeable disease (except macular edema) realized.
  • VAP-1 inhibitor which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular VAP-1 inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are . merely .exemplary and are in no way limiting.
  • the dose of the VAP-1 inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention should be sufficient to effect the desired response in the subject over a reasonable time frame.
  • dosage will depend upon a variety of factors, including the strength of the particular VAP-1 inhibitor to be employed, the age, species, conditions or disease states, and body weight of the subject, as well as the degree of a vascular hyperpermeable disease (except macular edema) .
  • the size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular VAP-1 inhibitor and the desired physiological effect.
  • Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the VAP-1 inhibitor can be administered in the dose of from 0.001 ⁇ g/kg/day to about 300 mg/kg/day, preferably from about 0.01 ⁇ g/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner.
  • compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-1 inhibitor sufficient to treat a vascular hyperpermeable disease
  • the carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
  • the amount of the VAP-1 inhibitor in the composition may vary depending on the formulation of the composition, and may generally be 0.00001 - 10.0 wt%, preferably 0.0001 - 5 wt%, more preferably 0.001 - 1 wt%.
  • the VAP-1 inhibitor can be administered in various manners to achieve the desired -VAP-1 inhibitory effect.
  • the VAP-1 inhibitors can be administered alone or in combination with pharmaceutically acceptable carriers or diluents, the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice.
  • the VAP-1 inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions.
  • the inhibitor may also be injected parenterally in the form of sterile solutions or suspensions.
  • Solid oral forms may contain conventional excipients, for instance, ' lactose, sucrose, magnesium stearate, resins, and like materials.
  • Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents.
  • Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or suspending agents. If desired, additives, such as saline or glucose, may be added to make the solutions isotonic.
  • the present inventive method also can involve the co- administration of other pharmaceutically active compounds.
  • co-administration is meant administration before, concurrently with, e.g., in combination with the VAP-1 inhibitor in the same formulation or in separate formulations, or after administration of a VAP-1 inhibitor as described above.
  • corticosteroids prednisone, methylprednisolone, dexamethasone, or triamcinolone acetinide, or noncorticosteroid anti- inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered.
  • vitamins and minerals e.g., zinc
  • anti-oxidants e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein)
  • micronutrients can be co-administered.
  • the present invention provides a use of a VAP-1 inhibitor for preparing a medicament for the treatment of a vascular hyperpermeable disease (except macular edema) .
  • Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; Z is as defined above;
  • halogen e.g., chlorine, bromine, iodine
  • X is as defined above, in this case, — ⁇ ;
  • R 1 is acyl
  • L 2 is a leaving group such as -OH, halogen (e.g., chlorine, bromine, iodine) , -O-acyl wherein the acyl is as defined above (e.g., -0-acetyl and the like) .
  • halogen e.g., chlorine, bromine, iodine
  • -O-acyl wherein the acyl is as defined above (e.g., -0-acetyl and the like) .
  • Compound (1) is reacted with Compound (2) or its salt to give Compound (3) .
  • Suitable salt of Compound (2) may be the same as those exemplified for Compound (I) .
  • Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 11) .
  • the reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the conventional acylation method may be employed in the present invention.
  • Compound (4) may be commercially available or can be prepared in accordance with the methods known per se .
  • the reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction is also preferably carried out in the presence of a conventional base such as 4- dimethyla inopyridine, pyridine etc.
  • a liquid base can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (5) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the acylation may be applied to Compound (1) in advance .
  • the nitrogen atom in Compound (1), (2), (3) or (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • L 3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; and R 1 , X and Z are as defined above.
  • halogen e.g., chlorine, bromine, iodine
  • Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8).
  • Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I) .
  • Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 1 and 3) .
  • the reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, • dimethylsulfoxide, tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction is also usually carried out in the presence of triphenylphosphine and a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
  • catalytic hydrogenation is preferable.
  • the catalytic hydrogenation is carried out in the presence of a catalyst such as palladium carbon, preferably 10% palladium carbon.
  • the catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
  • the catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like.
  • a liquid acid can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) . Therefore, Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I) •
  • the nitrogen atom in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • L 4 is a hydrogen atom or a protecting group, which is known per se r such as tert-butoxycarbonyl as described in the above “optionally protected amino” ( see Protective Groups in Organic Synthesis, published by John Wiley and Sons ( 1980 ) , etc . ) ; and R 1 , X and Z are as defined above .
  • Suitable reactive derivative of Compound (12) includes an acid halide, an acid anhydride and an activated ester.
  • the suitable example may be an acid chloride; -an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, hologenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imi
  • Suitable salts of Compound (12) and a reactive derivative thereof as well as Compound (13) may be the same as those exemplified for Compound (I) .
  • Compound (12) and a reactive derivative thereof as well as Compound (13) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 7) .
  • the conventional amidation method may be employed in the present invention.
  • the reaction is usually carried out in a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
  • a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
  • the reaction is also preferably carried out in the presence of a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N' -carbonylbis (2- methylimidazole) triphenylphosphine, and an additive such as 1-hydroxybenzotriazole, 1-hydroxysuccinimide, 3, -dihydro-3- hydroxy-4-oxo-l, 2, 3-benzotriazine .
  • a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N' -carbonylbis (2- methylimidazole) triphenylphosphine
  • an additive such as 1-hydroxybenzotriazole, 1-hydroxysuccinimide
  • reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (14) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the nitrogen atom in Compound (12) , (13) or (14) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
  • test compounds used in the Examples were N- ⁇ 4-[2-(4- ⁇ [amino (imino) methyl] amino ⁇ phenyl) ethyl] -1, 3-thiazol-2- yl ⁇ acetamide (hereinafter Compound A) synthesized in Production Example 1 and N-[4-(2- ⁇ 4- [ (aminooxy) methyl] phenyl ⁇ ethyl) -1, 3-thiazol-2-yl] acetamide
  • N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid, mp.
  • N- (4- (2- (4-Aminophenyl) ethyl) -1, 3-thiazol-2- yl) acetamide (1.8 g) prepared in a similar manner according to Step 6 of Production Example 1, 2- (methylsulfanyl) -4, 5- dihydro-1, 3-thiazole (918 mg) , hydrochloric acid concentrate (0.57 ml) and 2-methoxyethanol (28 ml) were combined under nitrogen atmosphere, and stirred at 120°C for 10 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo . The residue was dissolved in tetrahydrofuran / water, and made basic with aqueous potassium carbonate. The mixture was extracted with ethyl acetate.
  • N- (4- (2- (4-Aminophenyl) ethyl) -1, 3-thiazol-2-yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, methyl ethanimidothioate hydriodide (166 mg) and methanol (3 ml) were combined, and refluxed for 1.5 hours. After cooled to room temperature, the mixture was concentrated in vacuo.
  • Aluminium chloride (1.63 g) was dissolved in 1,2- dichloroethane (15 mL) . Chloroacetylchloride (0.732 mL) was added to the mixture at 0°C, and stirred additionally for 20 minutes, then N- (2-phenylethyl) acetamide (1 g) in 1,2-dichloroethane (5 mL) was added dropwise. The mixture was stirred for 1 hour at room temperature, and then poured into ice-water. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo.
  • N- ⁇ 2- [4- (2-Amino-l, 3-thiazol-4-yl) phenyl] ethyl ⁇ acetamide (0.6 g) was dissolved in ethanol (10 mL) and hydrochloric acid concentrate (10 mL) . The mixture was refluxed for 5 hours. The solvent was evaporated in vacuo. The residue was washed with ethyl ether to give 4- [4- (2-aminoethyl) phenyl] -1, 3- thiazol-2-amine dihydrochrolide (0.5 g, 84.6%). MS m/z 220 (M++1) .
  • Step 8 Di-tert-butyl ⁇ [ (2- ⁇ 4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl ⁇ ethyl) amino]methylidene ⁇ biscarbamate (268 mg, 79.2%)
  • Step 1 ethyl 4- (hydroxymethyl) -1, 3-thiazol-2-ylcarbamate
  • Step 5 Ethyl 4- [2- (4- ⁇ N' ,N"-bis (tert-butoxycarbonyl) - [amino (imino)methyl] amino ⁇ phenyl) ethyl] -1, 3-thiazol-2- ylcarba ate was obtained in a similar manner according to Step 3 of the following Production Example 14.
  • Step 1 N- ⁇ 4- [2- (3-nitrophenyl) ethenyl] -1, 3-thiazol-2- yl ⁇ acetamide (E-Z mixture) To a solution of 1- (bromomethyl) -3-nitrobenzene (276 mg) in N,N-dimethylformamide (7 mL) was added triphenylphosphine (335 mg) at room temperature. After the mixed solution was stirred for 4 hours, potassium tert-butoxide (172 mg) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (217 mg) were successively added to the solution at the same temperature.
  • Step 3 N- ⁇ 4-[2-(3- ⁇ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] amino ⁇ phenyl) ethyl] -1, 3-thiazol-2-yl ⁇ acetamide
  • Step 4 N- ⁇ 4-[2-(3- ⁇ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] amino ⁇ phenyl) ethyl] -5-bromo-l, 3-thiazol-2- yl ⁇ acetamide
  • N'- ( (E) -Ethanoyl) carbamimidothioic acid (2.74 g) and acetone (20 ml) were combined under nitrogen atmosphere. Then 2-bromomalonaldehyde (3.5 g) was added to the solution under reflux. The reaction mixture was refluxed for an hour, and cooled to room temperature . The precipitate was filtered in vacuo. The solid was washed with water and acetone, and purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N-(5-formyl- 1, 3-thiazol-2-yl) acetamide (1.21 g) as an off-white solid, mp.
  • Step 6 The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 105-107°C
  • Step 4 Ethyl 2- (acetylamino) -4- ⁇ 2- [4- ( ⁇ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino] ethyl ⁇ - amino) phenyl] ethyl ⁇ -!, 3-thiazole-5-carboxylate was prepared in a similar manner according to Step 5 of Production Example 18.
  • Production Example 23 Synthesis of N- ⁇ 4-[2-(4- ⁇ [ (ethylamino) (imino) ethyl] amino ⁇ phenyl) ethyl] -1, 3-thiazol-2- yl ⁇ acetamide The title compound was prepared in a similar manner according to Production Example 19.
  • Step 1 To an ice-cold mixture of ethyl 2-amino-l, 3-thiazole-4- carboxylate (5 g) , pyridine (3.36 ml) and dichloromethane (50 ml) was added benzyloxycarbonyl chloride (3.1 ml), and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate (30 ml), dried over sodium sulfate and concentrated in vacuo. The crystalline residue was collected and washed with diisopropyl ether to give ethyl 2- ⁇ [ (benzyloxy) carbonyl] amino ⁇ -l, 3-thiazole-4-carboxylate (5.1 g ) .
  • Step 4 of Production Example 24 and 6N hydrochloric acid (50 ml) were combined.
  • the reaction mixture was refluxed for 3 hours. After cooled to room temperature, the precipitate was filtered in vacuo. The solid was washed with water and acetonitrile to give 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-amine (1.34 g) as a yellow solid. mp. 278-278.5°C
  • Step 5 The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 229-232°C
  • Step 8 Potassium peroxymonosulfate (408 mg) was suspended in water (1 ml) and tetrahydrofuran (1 ml), and then N- ⁇ 5-[4-
  • Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-benzyl-1, 3- thiazole-5-carboxamide was prepared from tert-butyl [4-(2- ⁇ 2-
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • Step 2 The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. p. 206-207.5°C
  • Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 118-119°C
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • Methyl 2- (acetylamino) -5-phenyl-l, 3-thiazole-4- carboxylate (2.34 g) was suspended in THF (23 ml), and then lithium aluminium hydride (482 mg) was added portionwise to the solution at 0°C.
  • the reaction mixture was stirred at 0°C for 1.5 hours and quenched with MeOH.
  • AcOEt and IN HCl were added to the mixture, and the mixture was extracted.
  • the aqueous layer was extracted with AcOEt (twice) .
  • the combined organic layer was washed with brine, dried over anhydrous MgS0 4 , and concentrated in vacuo.
  • the residual solid was dissolved in MeOH (5 ml) and CHC1 3 (90 ml) .
  • Step 6 A mixture of N- ⁇ 4- [ (E) -2- (4-nitrophenyl) vinyl] -5-phenyl- l,3-thiazol-2-yl ⁇ acetamide and N- ⁇ 4- [ (Z) -2- (4- nitrophenyl) vinyl] -5-phenyl-l, 3-thiazol-2-yl ⁇ acetamide (E : Z
  • N- ⁇ 4-Formyl-5- [4- (methylthio) benzyl] -1, 3-thiazol-2- yl ⁇ acetamide was prepared in a similar manner according to Step 4 of Production Example 46.
  • Step 3 The title compound was prepared in a similar manner according to the following Production Example 58.
  • Step 10 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. The agents are 2-acylamino thiazole compounds.

Description

DESCRIPTION
METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE
TECHNICAL FIELD
The present invention relates to a method for. treating a vascular hyperpermeable disease (except macular edema) .
BACKGROUND ART Vascular adhesion protein-1 (hereinafter to be abbreviated as VAP-1) is amine oxidase (semicarbazide sensitive amine oxidase, SSAO) which is abundant in human plasma, and shows remarkably increased expression in vascular endothelium and vascular smooth muscle of the inflammatory region. While the physiological role of VAP-1 has not been clarified until recently, VAP-1 "gene was cloned in 1'998, and VAP-1 has been reported to be a membrane ■ protein that regulates rolling and migration of 'lymphocyte and NK cell as an adhesion molecule under regulation of expression by inflammatory cytokine. Although the amine to be a substrate is unknown, it is considered to be methylamine generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydejs produced by the amine oxidase activity in a molecule are important factors of adhesion activity.
However, the correlation between the VAP-1 enzyme activity in plasma and vascular permeability has not been heretofore known.
DISCLOSURE OF INVENTION The present inventors have found that VAP-1 enzyme activity in plasma and vascular permeability are correlated, and therefore, a VAP-1 inhibitor is useful for the prophylaxis or treatment of a vascular hyperpermeable disease (except macular edema) -and completed the present invention. Thus, the present invention provides the following. (1) A method for treating a vascular hyperpermeable disease (except macular edema) , which method comprises administering to a subject in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said subject for said disease.
(2) The method of (1), wherein said disease is a disease in mucous membrane .
(3) The method of (2), wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract.
(4) The method of (1), wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, • neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativu ultiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
(5) The method of (1), wherein the VAP-1 inhibitor is a compound of the formula (I) [hereinafter sometimes referred to as Compound (I ) ] :
R1-NH-X-Y-Z (I) wherein R1 is acyl;
X is a bivalent residue derived from optionally substituted thiazole;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000004_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and E.is optionally protected amino, -N=CH2,
Figure imgf000004_0002
wherein
Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a derivative thereof; or a pharmaceutically acceptable salt thereof. (6) The method of (5), wherein, in the formula (I), Z is a group of the formula:
YJ A2 wherein R2 is a group of the formula:
NH
-G-NH NH-R4* (wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl); -NH2; -CH2NH2; -CH2ONH2; -CH20N=CH2;
Figure imgf000005_0001
(7) The method of (6), wherein, in the formula (I), R 2 is a group of the formula: NH
Λ. 4
-G-NH NH-R*
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH; -CH2ONH2; -CH2ON=CH2;.
Figure imgf000005_0002
(8) The method of any of (5) to. (7), wherein, in the formula (I), R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl .
(9) The method of (1), wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl } acetamide,
N- [4- (2-{4- [ (aminooxy) ethyl] phenyl} ethyl) -1, 3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide,
N-{4- [2- (4-{ [hydrazino (imino) ethyl] amino}phenyl) ethyl] -5- [4-
( ethylsulfonyl) benzyl] -1, 3-thiazol-2-yl } acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl} acetamide, or jτ_ (4_{2- [4- (2-{ [amino (imino) methyl] amino} ethyl) phenyl] ethyl}-
1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(10) The method of (1) , wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino }phenyl ) ethyl] -1, 3- thiazol-2-yl}acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(11) A pharmaceutical composition for the treatment of a vascular hyperpermeable disease (except macular edema) , which comprises, as an active ingredient, a VAP-1 inhibitor.
(12) The composition of (11), wherein said disease is a disease in mucous membrane.
(13) The composition of (12) , wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract.
(14) The composition of (11), wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
(15) The composition of (11), wherein the VAP-1 inhibitor is Compound (I) ; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(16) The composition of (15), wherein, in the formula (I), Z is a group of the formula:
Figure imgf000007_0001
wherein R2 is a group of the formula:
NH -G-NH NH-R4*
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl); -NH2; -CH2NH2; -CHONH2;
-CH2ON=CH2;
;
Figure imgf000007_0002
(17) The composition of (16), wherein, in the formula (I), R2 is a group of the formula:
NH
- 4 -G-NH NH-R1
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000007_0003
(18) The composition of any of . (15) to (17), wherein, in the formula (I), R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl .
(19) The composition of (11), wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1,3- thiazol-2-yl}acetamide, N- [4- (2- { 4- [ (aminooxy) methyl] phenyl } ethyl) -1 , 3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] amino }phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl} acetamide, or
N-(4-{2-[4-(2-{ [amino (imino) ethyl] amino} ethyl) phenyl] ethyl}-
1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(20) The composition of (11), wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl } acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(21) A use of a VAP-1 inhibitor for preparing a medicament for the treatment of a vascular hyperpermeable disease (except macular edema) . (22) The use of (21), wherein said disease is a disease in mucous membrane.
(23) The use of (22), wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract. (24) The use of (21) , wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory- disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
(25) The use of (21), wherein the VAP-1 inhibitor is Compound (I); or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(26) The use of (25), wherein, in the formula (I), Z is a group of the formula:
A2
VJ wherein R2 is a group of the formula:
NH
• 4
-G-NH NH-R4
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl) ; -NH2; -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000010_0001
NH
-N ^ ^^^NH n or \ ^ ^ NIj2 .
( 27 ) The use of ( 26 ) , wherein, in the formula ( I ) , R2 is a group of the formula :
NH 4
-G-NH NH-R (wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH2; -CHONH2; -CH2ON=CH2;
Figure imgf000010_0002
(28) The use of any of (25) to (27), wherein, in the formula (I), R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl.
(29) The use of (21), wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide,
N-[4-(2-{4-[ (aminooxy)methyl]phenyl}ethyl)-l,3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [2- (4-{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide, N-{4- [2- (4-{ [hydrazino (imino) ethyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino)methyl] amino}ethyl) phenyl] ethyl}- 1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
(30) The use of (21), wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl } acetamide ; or a derivative thereof; or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION
The present invention is predicated on the discovery that VAP-1 enzyme activity in plasma and vascular permeability are correlated, and therefore, an inhibitor of vascular adhesion protein-1 (VAP-1; also referred to as semicarbaside sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating a vascular hyperpermeable disease (except macular edema) . Accordingly, the present invention provides a method for treating a vascular hyperpermeable disease (except macular edema) . The "treating a vascular hyperpermeable disease (except macular edema) " and "treatment of a vascular hyperpermeable disease (except macular edema)" are intended to include the administration of a compound having a VAP-1 inhibitory activity to a subject for purposes, which can include prophylaxis, amelioration, prevention and cure of a vascular hyperpermeable disease (except macular edema) . As used herein, by the "subject" is meant a target of the administration of VAP-1 inhibitor in the present invention, which is specifically any animal such as human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human. The vascular hyperpermeable disease (except macular edema) , which is to be treated by the method of the present invention, includes the disease caused/accompanied by increased vascular permeability, for example, diseases in mucous membrane such as ocular, cutis, otorhinology, respiratory tract and the like. Examples thereof include diseases in ocular-mucous membrane, such as aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, ocular inflammatory diseases caused by bacterial or viral infection, and by an ophthalmic operation, ocular inflammatory diseases caused by a physical injury to the eye and symptoms caused by ocular inflammatory diseases including itching, flare, edema and ulcer; mucocutaneous diseases, such as erythema, erythema- exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis and angioneurotic edema; and diseases in mucous membrane (e.g., otorhinology, respiratory tract etc.), such as laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis and otitis media.
The method comprises the administration of a VAP-1 inhibitor in an amount sufficient to treat a vascular hyperpermeable disease (except macular edema) . Any VAP-1 inhibitor can be used in the method of the present invention as long as it is safe and efficacious. Herein, the "VAP-1 inhibitor" will be used to refer to such compounds and is intended to encompass all compounds that inhibit enzyme activity of VAP-1 at any and all points in the action mechanism thereof. The VAP-1 inhibitor in the present invention includes, for example, a compound represented by the following formula ( I) [Compound ( I) ] : R1—NH—X—Y—Z (I) wherein R1 is acyl;
X is a bivalent residue derived from optionally substituted 5 thiazole;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and Z is a group of the formula:
Figure imgf000013_0001
wherein R2 is a group of the formula: -A-B-D-E
10 wherein A is a bond, lower alkylene, -NH- or -S02-;
B is a bond, lower alkylene, -CO- or -0-;
D is a bond, lower alkylene, -NH- or -CH2NH-; and
E is optionally protected amino, -N=CH2,
Figure imgf000013_0002
15 wherein
Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; 20 or a derivative thereof; or a pharmaceutically acceptable salt thereof.
The definition of each group of Compound (I) is shown in the following.
Suitable "halogen" includes fluorine, chlorine, bromine 25 and iodine.
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
Suitable "lower alkyl" includes straight or branched 30. alkyl having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C1-C4 alkyl.
Suitable "lower alkylthio" includes lower alkylthio containing the above lower alkyl, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, tert-pentylthio and hexyl hio.
Suitable "lower alkylene" includes straight or branched alkylene having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, propylene, ethylidene and propylidene, in which more preferred one is C1-C4 alkylene.
Suitable "lower alkenylene" includes straight or branched alkenylene having 2 to 6 carbon atom(s), such as -CH=CH-, -CH2-CH=CH-, -CH2-CH=CH-CH2-, -CH2-CH2-CH=CH-, -CH=CH-CH=CH-, -CH=CH-CH2-CH2-CH2-, -CH=CH-CH=CH-CH2-CH2- and -CH=CH-CH=CH-CH=CH-, in which more preferred one is C2-C4 alkenylene. The above lower alkenylene may be in E or Z form, respectively. Thus, those skilled in the art will recognize that the lower alkenylene includes all E, Z-structures when it has 2 or more double bonds.
Suitable "aryl" includes C6-Cιo aryl such as phenyl and naphthyl, in which more preferred one is phenyl. The "aryl" may be substituted by 1 to 3 substituent (s) and the substitution sites are not particularly limited.
Suitable "aralkyl" includes aralkyl wherein the aryl moiety has 6 to 10 carbon atoms [i.e. the aryl moiety is C6- Cio aryl of the above "aryl"] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl .moiety is Cι-C6 alkyl of the above "lower alkyl"], such as benzyl, phenethyl, 1- naphthylmethyl, 2-naphthylmethyl, 3-phenylpropyl, 4- phenylbutyl and 5-phenylpentyl .
The "optionally protected amino" means that an' amino group may be protected with a suitable protecting group according to a method known per se, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like. The suitable "protecting group" includes tert-butoxycarbonyl (i.e., Boc) , an acyl group as mentioned below, substituted or unsubstituted aryl (lower) alkylidene [e.g., benzylidene, hydroxybenzylidene, etc.], aryl (lower) alkyl such as mono-, di- or triphenyl- (lower) alkyl [e.g., benzyl, phenethyl, benzhydryl, trityl, etc.] and the like.
Suitable "optionally protected amino" includes amino and tert-butoxycarbonylamino (i.e. -NHBoc). Suitable "heterocycle" includes "aromatic heterocycle' and "non-aromatic heterocycle".
Suitable "aromatic heterocycle" includes 5 to 10- membered aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s), and includes, for example, thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine and the like.
Suitable "non-aromatic heterocycle" includes 5 to 10- membered non-aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s), and includes, for example, pyrrolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dioxolan, oxazolidine, thiazolidine, triazolidine and the like.
Suitable "acyl" includes acyl having 1 to 20 carbon atom(s), such as formyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl and aralkyloxycarbonyl.
Suitable "alkylcarbonyl" includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Cι-C6 alkyl of the above "lower alkyl"] , such as acetyl, propionyl, butyryl, isobutyryl, , valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl, in which more preferred one is C1-C4 alkyl-carbonyl .
Suitable "arylcarbonyl" includes arylcarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C6-Cι0 aryl of the above "aryl"] , such as benzoyl and naphthoyl.
Suitable "alkoxycarbonyl" includes alkoxycarbonyl wherein the alkoxy moiety has 1 to 6 carbon atom(s), such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec- butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, tert-pentyloxycarbonyl and hexyloxycarbonyl, in which more, preferred one is alkoxycarbonyl wherein the alkoxy moiety has 1 to 4 carbon atom(s) . Suitable "aralkyloxycarbonyl" includes aralkyloxycarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C6-Cι0 aryl of the above "aryl"] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Ci-Cβ alkyl of the above "lower alkyl"], such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl, 2-naphthylmethyloxycarbonyl, 3- phenylpropyloxycarbonyl, 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
Suitable "bivalent residue derived from thiazole" of the "bivalent residue derived from optionally substituted thiazole" includes
Figure imgf000016_0001
The "thiazole" may have 1 to 3 substituent (s) and the substitution sites are not particularly limited.
Suitable "substituent" of the above "optionally substituted thiazole" includes, for example, (1) halogen which is as defined above;
(2) alkoxycarbonyl which is as defined above, such as ethoxycarbonyl;
(3) optionally substituted aryl, which aryl is as defined above and the substitution sites are not particularly limited, such as phenyl and 4- ( ethylsulfonyl ) phenyl ;
(4) a group of the formula: -C0NRaRb wherein Ra is hydrogen, lower alkyl, aryl or aralkyl and Rb is hydrogen, lower alkyl, aryl or aralkyl, wherein the lower alkyl, aryl and aralkyl are as defined above, such as N- methylaminocarbonyl, N-phenylaminocarbonyl, N,N- dimethylaminocarbonyl and N-benzylaminocarbonyl;
(5) a group of the formula: -CONH- (CH2) k~aryl wherein k is an integer of 0 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -N02, -S02- (lower alkyl) wherein the lower alkyl is as defined above, -CF3 and -O-aryl wherein the aryl is as defined above, and the substitution sites are not particularly limited; (6) a group of the formula: -CONH- (CH2)m-heterocycle wherein is an integer of 0 to 6; the heterocycle is as defined above, such as pyridine;
(7) a group of the formula: -CO-heterocycle wherein the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of -CO- (lower alkyl) wherein the lower alkyl is as defined above, -CO-O- (lower alkyl) wherein the lower alkyl is as defined above, -S02- (lower alkyl) wherein the lower alkyl is as defined above, oxo (i.e. =0) and a group of the formula: -CONRcRd wherein Rc is hydrogen, lower alkyl, aryl or aralkyl and Rd is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(8) a group of the formula: -(CH2)n-aryl wherein n is an integer of 1 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -S- (lower alkyl) wherein the lower alkyl is as defined above, -S02- (lower alkyl) wherein the lower alkyl is as defined above, -C02- (lower alkyl) wherein the lower alkyl is as- defined above, -NHCO-O- (lower alkyl) wherein the lower alkyl is as defined" above and a group of the formula: -CONReRf wherein Re is hydrogen, lower alkyl, aryl or aralkyl and Rf is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(9) a group of the formula: - (CH2) 0-heterocycle wherein o is an integer of 0 to 6; the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of oxo (i.e. =0); -CO-(lower alkyl) wherein the lower alkyl is as defined above; -CO-O- (lower alkyl) wherein the lower alkyl is as defined above; -S02- (lower alkyl) wherein the lower alkyl is as defined above; -CO- (heterocycle) wherein the heterocycle is as defined above such as pyrrolidine, piperazine and morpholine, which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl and halogen, wherein the lower alkyl and halogen are as defined above, and the substitution sites are not particularly limited; and a group of the formula: -CONRgRh wherein Rg is hydrogen, lower alkyl, aryl or aralkyl and Rh is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(10) a group of the formula: - (CH2) p-NRiRj wherein p is an integer of 0 to 6; R1 is hydrogen,- acyl, lower alkyl, aryl or aralkyl and Rj is hydrogen, acyl, lower alkyl, aryl or aralkyl wherein the acyl, lower alkyl, aryl and aralkyl are as defined above, and the lower alkyl may have 1 to 5 substituent (s) selected from the group consisting of a group of the formula: -C0NRkR1 wherein R is hydrogen, lower alkyl, aryl or aralkyl and R1 is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(11) a group of the formula: -CON(H or lower alkyl) - (CHRm)q-T wherein q is an integer of 0 to 6; the lower alkyl is as defined above; Rm is hydrogen, aralkyl which is as defined above, or alkyl which is as defined above, which may be substituted by 1 to 3 substituent (s) selected from the group consisting of -OH and -CONH2 and the substitution sites are not particularly limited; and T is hydrogen; a group of the formula: -CONRnR° wherein Rn is hydrogen, lower alkyl, aryl or aralkyl and R° is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above; -NH-CO-Rp wherein Rp is lower alkyl which is as defined above or aralkyl which is as defined above;
-NH-S02- (lower alkyl) wherein the lower alkyl is as defined above; -S02- (lower alkyl) wherein the lower alkyl is as defined above; -heterocycle wherein the heterocycle is as defined above, such as pyridine, pyrrolidine and morpholine, which may have 1 to 3 substituent (s) such as oxo (i.e. =0), and the substitution sites are not particularly limited; or -CO- (heterocycle) wherein the heterocycle is as defined above, such as piperidine and morpholine; and
(12) a group of the formula: - (CH2) r-CO-NRtRu wherein r is an integer of 1 to 6; R is hydrogen, lower alkyl, aryl or aralkyl and Ru is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above.
The substitution site on the aryl or heterocycle is any suitable position thereof, but not particularly limited.
Preferable "substituent" of the above "optionally substituted thiazole" is methylsulfonylbenzyl. The substitution sites of R2 on the phenyl in Compound
(I) is not particularly limited.
Figure imgf000020_0001
the substitution sites on the group are not particularly
H limited. || ]" —NH -*-s particularly preferable.
Any nitrogen atom in the amino (i.e. -NH2) , imino (i.e.
=NH or -NH-) or the like contained in Compound (I) may be protected according to the methods, which are known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
When Compound (I) has an asymmetric carbon atom in the structure, those skilled in the art will recognize that Compound (I) includes all stereoisomers.
For example, the Compound (I) and derivatives thereof, or compounds reported to have inhibited VAP-1 enzyme (SSAO) may include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1, 3, 4-oxadiazine derivatives, 2, 6-diethoxybenzylamine, 2,6- di (n-propoxy)benzylamine, 2, 6-diisopropoxybenzylamine, 2,6- di (n-butoxy) benzylamine, 2, 6-bis (methoxymethoxy) benzylamine, 2, 6-bis (methoxymethyl) benzylamine, 2, 6-diethylbenzylamine, 2, 6-di-n-propylbenzylamine, 2, 6-bis (2- hydroxyethoxy) benzylamine, and the like.
The above compounds can be exemplified as follows .
1) fluoroallylamine derivatives, semicarbazide derivatives and hydrazide derivatives described in WO 93/23023,
2) hydrazino derivatives described in WO 02/02090,
3) 1, 3, 4-oxadiazine derivatives described in WO 02/02541,
4) 4-alkyl-5-alkoxycarbonyl-4, 5, 6, 7-tetrahydroimidazo [4,5- c] pyridine derivatives described in WO 02/38153, 5) 2, 6-diethoxybenzylamine, 2, 6-di (n-propoxy) benzylamine, 2,6- diisopropoxybenzylamine, 2, 6-di (n-butoxy) benzylamine, 2,6- bis (methoxymethoxy) benzylamine, 2, 6- bis (methoxymethyl) benzylamine, 2, 6-diethylbenzylamine, 2, 6-di- n-propylbenzylamine and 2, 6-bis (2-hydroxyethoxy) benzylamine described in USP 4,888,283.
The compounds exemplified in the present invention as a VAP-1 inhibitor and in WO 93/23023 as an SSAO inhibitor, such as those described in Lyles et al . (Biochem. Pharmacol. 36:2847, 1987) and in USP 4650907, USP 4916151, USP 4943593, USP 4965288, USP 5021456, USP 5059714, USP 4699928, European patent application 295604, European patent application 224924 and European patent application 168013, are also encompassed in the VAP-1 inhibitor.
Of the above-mentioned compounds, preferred is Compound (I), more preferably, a compound of the formula (I) wherein Z is a group of the formula:
Figure imgf000021_0001
wherein R2 is a group of the formula:
NH
A 4
-G-NH NH-R4
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl) ; -NH2; -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000022_0001
still more preferably, a compound wherein R2 is a group of the formula: NH
A 4 -G-NH NH-R* (wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000022_0002
, and yet more preferably, a compound wherein R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl and derivatives thereof.
Of the above-mentioned Compound (I), preferable specific compounds include
N-{4- [2- (4-{ [amino (imino) methyl] amino }phenyl) ethyl] -1, 3- thiazol-2-yl } acetamide (hereinafter Compound A; see
Production Example 1) ,
N-[4-(2-{4-[ (a inooxy) methyl]phenyl} ethyl) -1, 3-thiazol-2- yl] acetamide (hereinafter Compound B; see Production Example
16), N-{4- [2- (4-{ [amino (imino) ethyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl]-!, 3-thiazol-2-yl}acetamide (see Production Example 48) ,
N-{4- [2- (4-{ [hydrazino (imino) ethyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl }acetamide ( see Production Example 50) ,
N-{4- [2- (4-{ [hydrazino (imino)methyl] amino} henyl) ethyl] -1,3- thiazol-2-yl}acetamide (see Production Example 58), and N- (4-{2- [4- (2-{ [amino (imino) ethyl] amino}ethyl) phenyl] ethyl}- 1, 3-thiazol-2-yl) acetamide (see Production Example 110), particularly N-{4- [2- (4- { [amino (imino) methyl] amino }- phenyl) ethyl] -1, 3-thiazol-2-yl}acetamide and derivatives thereof.
The term "derivative" is intended to include all compounds derived from the original compound. In the present invention, the VAP-1 inhibitor can be administered as a prodrug to a subject. The term "prodrug" is intended to include all compounds that convert to the VAP-1 inhibitor in the body of administration subject. The prodrug can be any pharmaceutically acceptable prodrug of VAP-1 inhibitor. Moreover, the VAP-1 inhibitor can be administered to an administration subject as a pharmaceutically acceptable salt.
The pharmaceutically acceptable salt of VAP-1 inhibitor in the present invention is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like), alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methy1amine salt and the like) .
The VAP-1 inhibitor can be also formulated as a pharmaceutically acceptable acid addition salt. Examples of the pharmaceutically acceptable acid addition salts for use in the pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
As a pharmaceutically acceptable salt of VAP-1 inhibitor represented by the formula (I) , a pharmaceutically acceptable acid addition salt such as (mono-, di- or tri-) hydrochloride and hydriodide, particuraly hydrochloride, is preferable.
The above-mentioned VAP-1 inhibitor may be commercially available or can be produced based on a known reference.
Also, Compound (I), particularly Compound A: N-{4-[2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide and Compound B: N-[4-(2-{4-
[ (aminooxy)methyl] phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide, can be synthesized according to the Production Method given below.
Those compounds or derivatives thereof that are not commercially available can be prepared using organic synthetic methods known in the art.
The VAP-1 inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method by any suitable route. Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconjunctival, intraocular, intravitreal, intracameral, subretinal, suprachoroidal and retrobulbar administrations. The manner in which the VAP-1 inhibitor is administered is dependent, in part, upon whether the treatment of a vascular hyperpermeable disease (except .macular edema) is prophylactic or therapeutic.
The VAP-1 inhibitor is preferably administered as soon as possible after it has been determined that a subject such as a mammal, specifically a human, is at risk for a vascular hyperpermeable disease (except macular edema) (prophylactic treatments) or has begun to develop a vascular hyperpermeable disease (except macular edema) (therapeutic treatments) . Treatment will depend, in part, upon the particular VAP-1 inhibitor used, the amount of the VAP-1 inhibitor administered, the route of administration, and the cause and extent, if any, of a vascular hyperpermeable disease (except macular edema) realized.
One skilled in the art will appreciate that suitable methods of administering a VAP-1 inhibitor, which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular VAP-1 inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are . merely .exemplary and are in no way limiting.
The dose of the VAP-1 inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention should be sufficient to effect the desired response in the subject over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the strength of the particular VAP-1 inhibitor to be employed, the age, species, conditions or disease states, and body weight of the subject, as well as the degree of a vascular hyperpermeable disease (except macular edema) . The size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular VAP-1 inhibitor and the desired physiological effect. It will be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations. Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
Generally, the VAP-1 inhibitor can be administered in the dose of from 0.001 μg/kg/day to about 300 mg/kg/day, preferably from about 0.01 μg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner.
Pharmaceutical compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-1 inhibitor sufficient to treat a vascular hyperpermeable disease
(except macular edema) prophylactically or therapeutically as an active ingredient. The carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
The amount of the VAP-1 inhibitor in the composition may vary depending on the formulation of the composition, and may generally be 0.00001 - 10.0 wt%, preferably 0.0001 - 5 wt%, more preferably 0.001 - 1 wt%. The VAP-1 inhibitor can be administered in various manners to achieve the desired -VAP-1 inhibitory effect. The VAP-1 inhibitors can be administered alone or in combination with pharmaceutically acceptable carriers or diluents, the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice. The VAP-1 inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions. The inhibitor may also be injected parenterally in the form of sterile solutions or suspensions. Solid oral forms may contain conventional excipients, for instance, ' lactose, sucrose, magnesium stearate, resins, and like materials. Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents. Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or suspending agents. If desired, additives, such as saline or glucose, may be added to make the solutions isotonic.
The present inventive method also can involve the co- administration of other pharmaceutically active compounds. By "co-administration" is meant administration before, concurrently with, e.g., in combination with the VAP-1 inhibitor in the same formulation or in separate formulations, or after administration of a VAP-1 inhibitor as described above. For example, corticosteroids, prednisone, methylprednisolone, dexamethasone, or triamcinolone acetinide, or noncorticosteroid anti- inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered. Similarly, vitamins and minerals, e.g., zinc, anti-oxidants, e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein) , and micronutrients can be co-administered.
In addition, the present invention provides a use of a VAP-1 inhibitor for preparing a medicament for the treatment of a vascular hyperpermeable disease (except macular edema) .
Production Method of Compound (I) Compound (I) is prepared in accordance with, but is not limited to, the following procedures. Those skilled in the art will recognize that the procedures can be modified according to the conventional methods known per se.
Procedure A: Synthesis of Compound (I) wherein Y is a bond
Figure imgf000028_0001
(1) (2) (3) (5) wherein
Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; Z is as defined above;
S^
X is as defined above, in this case, — \\ ;
N"
R1 is acyl; and
L2 is a leaving group such as -OH, halogen (e.g., chlorine, bromine, iodine) , -O-acyl wherein the acyl is as defined above (e.g., -0-acetyl and the like) .
Formation of Thiazole Moiety X
Compound (1) is reacted with Compound (2) or its salt to give Compound (3) . Suitable salt of Compound (2) may be the same as those exemplified for Compound (I) .
Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 11) . The reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
Acylation Compound (3) or its salt is reacted with Compound (4) to give Compound (5) . Since R1 is an acyl group, this reaction is an acylation.
The conventional acylation method may be employed in the present invention. Compound (4) may be commercially available or can be prepared in accordance with the methods known per se .
The reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is also preferably carried out in the presence of a conventional base such as 4- dimethyla inopyridine, pyridine etc. A liquid base can be also used as the solvent. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (5) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) . The acylation may be applied to Compound (1) in advance .
The nitrogen atom in Compound (1), (2), (3) or (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
Procedure B: Synthesis of Compound (I) wherein Y is lower alkylene such as ethylene (i.e. -CH2-CH2-) or lower alkenylene such as vinylene (i.e. -CH=CH-), for example,
R1-NH-X-CHO + L3-CH2-Z ■ R1-NH-X-CH=CH-Z
(6) (7) (8) ptiiirt- on i
» R -NH-X-CH2-CH2-Z
(9) wherein
L3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; and R1, X and Z are as defined above.
Formation of Olefin Compound
Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8). Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I) .
Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 1 and 3) . The reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, • dimethylsulfoxide, tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof. The reaction is also usually carried out in the presence of triphenylphosphine and a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
Reduction
Compound (8) or its salt is reduced in accordance with a conventional method to give Compound (9) .
The conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
Among others, catalytic hydrogenation is preferable.
The catalytic hydrogenation is carried out in the presence of a catalyst such as palladium carbon, preferably 10% palladium carbon.
The catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
The catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like. A liquid acid can be also used as the solvent.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) . Therefore, Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I) •
R1-NH-X- (lower alkenylene) -Z (10)
Reduction ^ RANH_X_ (iower alkylene) -Z (11)
The nitrogen atom in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
Procedure C: Synthesis of Compound (I) wherein Y is -CONH-
R1-NH-X-COOH + L4-NH-Z *■ R1-NH-X-CONH-Z
(12) (13) (14) wherein L4 is a hydrogen atom or a protecting group, which is known per ser such as tert-butoxycarbonyl as described in the above "optionally protected amino" ( see Protective Groups in Organic Synthesis, published by John Wiley and Sons ( 1980 ) , etc . ) ; and R1, X and Z are as defined above . Amidation
Compound (12) or a reactive derivative thereof, or its salt is reacted with Compound (13) or its salt to give an a idated compound (14) .
Suitable reactive derivative of Compound (12) includes an acid halide, an acid anhydride and an activated ester.
The suitable example may be an acid chloride; -an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, hologenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [ (CH ) 2N+=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4- dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); or an ester with an N-hydroxy compound (e.g., N, N-dimethlhydroxylamine, 1- hydroxy-2- (IH) -pyridone, N-hydroxysuccinimide, N- hydroxybenzotriazole, N-hydroxyphthalimide, l-hydroxy-6- chloro-lH-benzotriazole, etc.). These reactive derivatives can be optionally selected from them according to the kind of Compound (12) to be used.
Suitable salts of Compound (12) and a reactive derivative thereof as well as Compound (13) may be the same as those exemplified for Compound (I) . Compound (12) and a reactive derivative thereof as well as Compound (13) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 7) .
The conventional amidation method may be employed in the present invention.
The reaction is usually carried out in a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
The reaction is also preferably carried out in the presence of a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N' -carbonylbis (2- methylimidazole) triphenylphosphine, and an additive such as 1-hydroxybenzotriazole, 1-hydroxysuccinimide, 3, -dihydro-3- hydroxy-4-oxo-l, 2, 3-benzotriazine .
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating. Compound (14) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
The nitrogen atom in Compound (12) , (13) or (14) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.
The present invention is explained in more detail in the following by way of Production Examples and Examples, which are not to be construed as limitative.
The test compounds used in the Examples were N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-2- yl}acetamide (hereinafter Compound A) synthesized in Production Example 1 and N-[4-(2-{4- [ (aminooxy) methyl] phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide
(hereinafter Compound B) synthesized in Production Example 16. Production Example 1: Step 1
Figure imgf000035_0001
A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-l, 3-thiazol- 4-yl) methyl acetate hydrochloride (3.5 g) as white crystals.
^•H-NMR (DMSO-de) , δ (ppm): 2.07 (3H, s), 4.92 (2H, s) , 6.87(1H, s) .
MS: 173 (M+H) +
Step 2
Figure imgf000035_0002
To a mixture of (2-amino-l, 3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L) The organic layer was dried over sodium sulfate and concentrated in vacuo. The residual solid was collected by filtration with isopropyl ether to give (2- (acetylamino) -1, 3- thiazol-4-yl)methyl acetate (47 g) as white crystals.
1H- MR (CDC13) , δ (ppm): 2.12 (3H, s) , 2.29 (3H, s) , 5.08 (2H, s) , 6.93(1H, s) . MS: 215 (M+H) + Step 3
Figure imgf000036_0001
A mixture of (2- (acetylamino) -1, 3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo. The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol. / chloroform (1/99) . The resulted solid was collected by filtration with isopropyl ether to give N- (4- (hydroxymethyl) -1, 3-thiazol-2- yl) acetamide (35 g) as white crystals. 1H-N R (DMSO-ds) , δ (ppm): 2.12 (3H, s), 4.44 (2H, d, J=5.0Hz), 5.20(1H, t, J=5.0Hz), 6.88(1H, s) , 12.02(1H, brs) . MS: 173 (M+H) + Step 4
Figure imgf000037_0001
N- (4- (Hydroxymethyl) -1, 3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) . Then manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The resulting solid was washed with ethyl ether to give N- (4-formyl-l, 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid, mp. 195.5-199°C XH-NMR (DMSO-de) , δ (ppm): 2.17 (3H, s) , 8.28 (IH, s) , 9.79 (IH, s) , 12.47 (IH, brs) . Step 5
Figure imgf000037_0002
1- (Bromomethyl) -4-nitrobenzene (1.9 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. Then potassium tert-butoxide (1.19 g) and N- (4-formyl-l, 3-thiazol-2- yl) acetamide (1.5 g) were added and the mixture was stirred at room temperature for 14 hours. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —» (1:2) as an eluent, and triturated with ethyl ether to give N-{4- [ (Z) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl} cetamide (1.59 g) as a yellow solid, mp. 155-157°C
^-H-NMR (DMSO-d6) , δ (ppm): 2.13 (3H, s) , 6.64 (IH, d, J=12.5Hz), 6.71(1H, d, J=12.5Hz), 7.18(1H, s) , 7.79(2H, d, J=9.0Hz), 8.17 (2H, d, J=9.0Hz), 12.02 (IH, brs) . MS: 290 (M+H) + Step 6
Figure imgf000038_0001
A mixture of N-{4- [ (Z) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-yl} acetamide (2 g) and 10% palladium carbon (400 mg) in methanol (25 ml) , tetrahydrofuran (25 ml) and acetic acid (18 ml) was stirred under 4 atm hydrogen at ambient temperature for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:2) —» ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N- (4- (2- (4-aminophenyl) ethyl) -1, 3-thiazol-
2-yl) acetamide (539.6 mg) as an off-white solid. mp. 102.5-104°C
1H- MR (DMSO-de) , δ (ppm): 2.11 (3H, s), 2.75 (4H, brs), 4.82 (2H, s), 6.46(2H, d, J=8.5Hz), 6.69(1H, s) , 6.83(2H, d, J=8.5Hz), 12.07 (IH, brs) . MS: 262 (M+H) + Step 7
Figure imgf000039_0001
To a suspension of N- (4- (2- (4-aminophenyl) ethyl) -1, 3- thiazol-2-yl) acetamide (26 g) in ethanol (500 ml) was added 4N hydrogen chloride in ethyl acetate (25 ml) and cyanamide (6.3 g) . The mixture was refluxed for 26 hours. The reaction mixture was cooled to ambient temperature and poured into a mixture of ethyl acetate (500 ml) and saturated sodium hydrogen carbonate solution (500 ml) . The resulted precipitate was collected by filtration and washed with water (300 ml) and ethanol (300 ml) to give N-{4- [2- (4-{ [amino (imino)methyl] - amino}phenyl) ethyl] -1, 3-thiazol-2-yl}acetamide (18 g) as white crystals.
XH-NMR (DMS0-ds) , δ (ppm): 2.10 (3H, s) , 2.85(4H, s) , 6.79 (IH, s), 6.83 (2H, d, J=7Hz), 7.10 (2H, d, J=7Hz) . MS: 304 (M+H) + Production Example 2: Synthesis of N- (4- (2- (4- (4, 5-dihydro- 1, 3-thiazol-2-ylamino) phenyl) ethyl) -1, 3-thiazol-2-yl) acetamide
N- (4- (2- (4-Aminophenyl) ethyl) -1, 3-thiazol-2- yl) acetamide (1.8 g) prepared in a similar manner according to Step 6 of Production Example 1, 2- (methylsulfanyl) -4, 5- dihydro-1, 3-thiazole (918 mg) , hydrochloric acid concentrate (0.57 ml) and 2-methoxyethanol (28 ml) were combined under nitrogen atmosphere, and stirred at 120°C for 10 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo . The residue was dissolved in tetrahydrofuran / water, and made basic with aqueous potassium carbonate. The mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and evaporated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (30:1 -> 20:1) as an eluent, and triturated with ethyl acetate to give N- (4- (2- (4- (4, 5-dihydro-l, 3-thiazol-2- yla ino) phenyl) ethyl) -1, 3-thiazol-2-yl) acetamide (484.7 mg) as an off-white solid, mp. 218-219.5°C
1H-NMR (DMSO-d6), δ (ppm) : 2.11 (3H, s) , 2.84 (4H, s) , 3.26(2H, t, J=7.5Hz), 3.35(2H, t, J=7.5Hz), 4.02(1H, brs), 6.71(1H, brs), 7.05(2H, d, J=8.5Hz), 7.51(1H, brs), 9.25(1H, brs), 12.10(1H, brs) . MS: 347 (M+H) +
Production Example 3: Synthesis of N- (4-{ (E) -2- [4- (4, 5- dihydro-1, 3-thiazol-2-ylamino) phenyl] ethenyl}-l, 3-thiazol-2- yl) acetamide Step 1
A mixture of 4-nitrobenzyl bromide (6.35 g) , triphenylphosphine (7.71 g) and N,N-dimethylformamide (50 ml) was stirred for 5 hours at room temperature. To the mixture were added potassium butoxide (3.96 g) , and then N-(4-formyl- 1, 3-thiazol-2-yl) acetamide (5.0 g) prepared in a similar manner according to Step 4 of Production Example 1, and the mixture was stirred for 13 hours at the same temperature. The reaction mixture was poured into ethyl acetate (200 ml) and water (200 ml) . The organic layer was washed with water (20 ml), dried over sodium sulfate and concentrated in vacuo. The crystalline residue was collected and washed with 30% ethyl acetate / diisopropyl ether to give N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl}acetamide (7.8 g) . XH-NMR (DMSO-ds), δ (ppm): 2.16(3H, s), 7.29(1H, d, J=16Hz) , 7.48 (IH, d, J=16Hz), 7.88 (2H, d, J=7Hz) , 8.22 (2H, d, J=7Hz) . MS (M+H) =290 Step 2
A mixture of N-{4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-yl}acetamide (250 mg) , palladium on carbon (25 mg) and methanol (2.5 ml) was stirred under hydrogen atmosphere for 2 hours at ambient temperature. The catalyst was filtered off and the filtrate was concentrated in vacuo. The crystalline residue was collected and washed with isopropyl ether to give N-{4- [ (E) -2- (4-aminophenyl) ethenyl] -1, 3-thiazol- 2-yl}acetamide (160 mg) .
XH-NMR (DMS0-d6) , δ (ppm) : 2.14 (3H, s) , 5.33 (2H, s), 6.55(2H, d, J=7Hz), 6.82 (IH, d, J=10Hz) , 6.44 (IH, s) , 7.09 (IH, d, J=10Hz), 7.20 (2H, d, J=7Hz) . MS: 260 (M+H) + Step 3
A mixture of N- {4- [ (E) -2- (4-aminophenyl) ethenyl] -1, 3- thiazol-2-yl} acetamide (200 mg) , 2- (methylsulfanyl) -4, 5- dihydro-1, 3-thiazole (103 mg) , hydrochrolic acid (0.064 ml) and 2-methoxyethanol (2 ml) was stirred at 120°C for 8 hours. The reaction mixture was concentrated in vacuo . The residue was purified by silica-gel flash column chromatography with hexane: ethyl acetate (3:1) as an eluent. The crystalline residue was collected and washed with ethyl acetate to give N-(4-{ (E)-2-[4- (4, 5-dihydro-l, 3-thiazol-2- ylamino) phenyl] ethenyl }-l, 3-thiazol-2-yl) acetamide (150 mg) . XH-NMR (CDC13), δ (ppm): 2.27 (3H, s) , 3.33-3.40 (2H, m) , 3.57- 3.65(2H, m) , 6.94(1H, s) , 7.05(1H, d, J=12Hz) , 7.29(1H, d, J=12Hz), 7.30 (2H, d, J=7Hz), 7.57 (2H, d, J=7Hz) . MS: 345 (M+H) +
Production Example : Synthesis of methyl N-(4-{2-[2- (acetylamino) -1, 3-thiazol-4-yl] ethyl Jphenyl) imidothiocarbamate hydriodide Step 1
To an ice-cold solution of N- (4- (2- (4-aminophenyl) ethyl) - 1, 3-thiazol-2-yl) acetamide (300 mg) prepared in a similar manner according to Step 6 of Production Example 1 in acetone (5 ml) was added benzoyl isothiocyanate (187 mg) and the mixture was refluxed for 2 hours. The reaction mixture was cooled to 0°C. The precipitated crystals were filtered and washed with ice-cold acetone to give N-{4-[2-(4- { [ (benzoylamino) carbonothioyl] amino}phenyl) ethyl] -1, 3-thiazol- 2-yl}acetamide (359 mg) .
XH-NMR (CDCI3), δ (ppm): 2.25 (3H, s) , 2.90-3.05 (4H, m) , 6.51(1H, s), 7.21(2H, d, J=7Hz) , 7.50-7.70 (5H, m) , 7.89(2H, d, J=7Hz) , 9.03 (IH, s), 9.12 (IH, s) . MS (M+H) =425 Step 2
A mixture of N- {4- [2- (4- {[ (benzoylamino) carbonothioyl] aminojphenyl) ethyl] -1, 3-thiazol-2-yl}acetamide (200 mg) , 6N aqueous sodium hydroxide (0.19 ml) and ethanol (2 ml) was stirred at 60°C for 2 hours. The reaction mixture was cooled to ambient temperature and neutralized with IN hydrochloric acid (1.2 ml). The precipitated crystals were filtered and washed with water to give N- [4- (2-{4- [ (aminocarbonothioyl) - amino] phenyl} ethyl ) -1, 3-thiazol-2-yl] acetamide (120 mg) . αH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.88 (4H, s) , 6.75 (IH, s), 7.15(2H, d, J=7Hz) , 7.27 (2H, d, J=7Hz) , 9.60(1H, s) . MS (M+H) =321 Step 3
A mixture of N- [4- (2- {4- [ (aminocarbonothioyl) amino] phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide (100 mg) , methyl iodide (0.023 ml) and methanol (2 ml) was refluxed for 3 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with ethyl acetate and stirred for 30 minutes. The precipitated crystals were filtered and washed with ethyl acetate to give methyl N- (4-{2- [2- (acetylamino) - 1, 3-thiazol-4-yl] ethyl }phenyl) imidothiocarbamate hydriodide (130 mg) . XH-NMR (DMSO-d6), δ (ppm) : 2.13(3H, s) , 2.68 (3H, s) , 2.87- 3. 05 ( 4H, m) , 6.75 ( 1H, s) , 7 .24 (2H, d, J=7Hz) , 7 . 35 (2H, d, J=7Hz ) . MS (M+H) =463
Production Example 5: Synthesis of N- (4-{2- [4- (4, 5-dihydro-lH- imidazol-2-ylamino) phenyl] ethyl }-l,3-thiazol-2-yl) acetamide
A mixture of N- (4- (2- (4-aminophenyl) ethyl) -1, 3-thiazol-2- yl) acetamide (65 mg) prepared in a similar manner according to Step 6 of Production Example 1, ethyl 2- (methylsulfanyl) -4, 5- dihydro-lH-imidazole-1-carboxylate (56 mg) , acetic acid (0.1 ml), ethanol (0.9 ml) was stirred at 65°C for 6 hours, and then refluxed for 5 hours. The reaction mixture was poured into ethyl acetate (5 ml) and saturated aqueous sodium bicarbonate. The precipitated solid was filtered, and the solid was dissolved in 50% methanol/chloroform. The insoluble materials were filtered off and the filtrate was concentrated in vacuo. The solid residue was collected and washed with ethyl acetate to give N- (4- {2- [4- (4, 5-dihydro-lH-imidazol-2-ylamino) phenyl] - ethyl}-l, 3-thiazol-2-yl) acetamide (40 mg) . XH-NMR (DMSO-de) , δ (ppm) : 2.11(3H, s) , 2.72(4H, s) , 3.33(4H, s), 6.73(1H, s), 6.85-7.08 (4H, m) . MS (M+H) =330
Production Example 6: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2-yl}-2- methylpropanamide Step 1
To an ice-cold mixture of ethyl 2-amino-l, 3-thiazole-4- carboxylate (2 g) prepared in a similar manner according to Step 1 of the following Production Example 7, pyridine (1.3 ml) and dichloromethane (20 ml) was added isobutyryl chloride (0.91 ml) and stirred for 30 minutes. To the mixture was added saturated aqueous hydrogen bicarbonate (30 ml), and the organic layer was separated, dried over sodium sulfate and concentrated in vacuo. The crystalline residue was collected and washed with ethyl acetate to give ethyl 2- (isobutyrylamino)-l, 3-thiazole-4-carboxylate (1.34 g) . 1H-NMR (CDC13), δ (PPm): 1.30(6H, d, J=7Hz) , 1.40(3H, t, J=7Hz), 2.57-2.73 (IH, ) , 4.41 (2H, q, J=7Hz) , 7.83(1H, s) , 8.98(1H, s) . MS: 243 (M+H) + Step 2
To a mixture of ethyl 2- (isobutyrylamino) -1, 3-thiazole-4- carboxylate (1.4 g) and tetrahydrofuran (28 ml) was added lithium borohydride (252 mg) portionwise, and the mixture was refluxed for 6 hours. The reaction mixture was cooled to 0°C, quenched with methanol (5 ml) and concentrated in vacuo. The residue was suspended with 10% methanol / chloroform (100 ml), and the insoluble materials were filtered off. The filtrate was purified by flash column chromatography on silica-gel with 5% methanol / chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give N-[4- (hydroxymethyl) -1, 3-thiazol-2-yl] -2-methylpropanamide (1.0 g) . XH-NMR (CDCI3), δ (PPm): 1.32 (6H, d, J=5Hz) , 2.58-2.73 (IH, m) , 4.68(2H, s), 6.82(1H, s) . MS (M+H) =200 Step 3
A mixture of N- [4- (hydroxymethyl) -1, 3-thiazol-2-yl] -2- methylpropanamide (520 mg) , manganese (IV) oxide (2.26 g) , methanol (0.5 ml) and chloroform (5 ml) was stirred at ambient temperature for 18 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The crystalline residue was collected and washed with diisopropyl ether to give N- (4-formyl-l, 3-thiazol-2-yl) -2- methylpropanamide (365 mg) .
XH-NMR (CDCI3), (Ppm): 1.13(6H, d, J=5Hz) , 2.60-2.77 (IH, ) , 7.86(1H, s) . MS (M+H) =199 Step 4
A mixture of 4-nitrobenzyl bromide (381 mg) , triphenylphosphine (463 mg) and N,N-dimethylformamide (3 ml) was stirred for 5 hours at room temperature. To the mixture were added potassium butoxide (238 mg) and then N- (4-formyl- 1, 3-thiazol-2-yl) -2-methylpropanamide (350 mg) , and the mixture was stirred for 13 hours at the same temperature. The reaction mixture was poured into ethyl acetate (20 ml) and water (20 ml) . The organic layer was washed with water (20 ml), dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected and washed to give 2-methyl- N- {4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3-thiazol-2- yl}propanamide (360 mg) . ^■H-NMR (CDC13), δ (PPm): 1.25(6x2/3H, d, J=5Hz) , 1.30(6xl/3H, d, J=5Hz), 2.50-5.70(lH, m) , 6.63(1H, s) , 6.79(lx2/3H, s) , 6.97(lx2/3H, s) , 7.14(lxl/3H, d, J=12Hz) , 7.33(lxl/3H, d, J=12Hz), 7.53(2x2/3H, d, J=7Hz) , 7.62(2xl/3H, d, J=7Hz) , 8.13(2x2/3H, d, J=7Hz) , 8.22(2xl/3H, d, J=7Hz) . MS (M+H) =318 Step 5
A mixture of 2-methyl-N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl}propanamide (333 mg) , palladium on carbon (33 mg) , acetic acid (1 ml) , methanol (2 ml) and tetrahydrofuran (2 ml) was stirred under hydrogen atmosphere (4 atm) at ambient temperature for 5 hours. The catalyst was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with 5% methanol / ethyl acetate as an eluent. The solid residue was collected and washed with diisopropyl ether to give N-{4- [2- (4-aminophenyl) ethyl] -1, 3- thiazol-2-yl}-2-methylpropanamide (260 mg) .
XH-NMR (CDCI3), δ (PPm) : 1.38 (6H, d, J=5Hz) , 2.57-2.73 (IH, m) , 2.39-2.43 (4H, m) , 6.45(1H, s) , 6.62(2H, d, J=7Hz) , 6.97 (2H, d, J=7Hz ) .
MS (M+H) =290
Step 6
The title compound was prepared in a similar manner according to Step 7 of Production Example 1.
XH-NMR (DMSO-d6) , δ (ppm): 1.01(6H, d, J=5Hz) , 2.62-2.78 (IH, ) , 2.83(4H, s) , 6.72(2H, d, J=7Hz) , 6.75(1H, s) , 7.04(2H, d,
J=7Hz) .
MS (M+H) =332 Production Example 7: Synthesis of 2- (acetylamino) -N- (4-
{ [amino (imino) ethyl] amino }phenyl) -1, 3-thiazole-4-carboxamide
Step 1
A mixture of ethyl 3-bromo-2-oxopropanoate (100 g) , thiourea (39 g) and ethanol (500 ml) was refluxed for 2 hours. The reaction mixture was concentrated in vacuo. The crystalline residue was collected and washed with ethyl acetate to give ethyl 2-amino-l, 3-thiazole-4-carboxylate hydrobromide (116 g) .
XH-NMR (DMSO-d6) , δ (ppm): 1.28(3H, t, J=7Hz) , 4.26(2H, q, J=7Hz) , 7.60(1H, s) .
Step 2
To an ice-cold mixture of ethyl 2-amino-l, 3-thiazole-4- carboxylate hydrobromide (80 g) , pyridine (52.5 g) and dichloromethane (800 ml) was added acetyl chloride (27.3 g) dropwise at 0°C, and the mixture was stirred for 30 minutes at the same temperature. The reaction mixture was washed with water (500 ml) , dried over sodium sulfate and concentrated in vacuo. The crystalline residue was collected and washed with ethyl acetate to give ethyl 2- (acetylamino) -1, 3-thiazole-4- carboxylate (60 g) .
1H- MR (DMSO-dβ) , δ (ppm) : 1.29(3H, t, J=7Hz) , 2.15(3H, s) ,
4.27 (2H, q, J=7Hz) , 8.03 (IH, s) .
MS (M+H) =215 Step 3
A mixture of ethyl 2- (acetylamino) -1, 3-thiazole-4- carboxylate (2 g) , 2N sodium hydroxide (7 ml) and methanol (13 ml) was stirred at ambient temperature for 5 hours. The reaction mixture was neutralized by IN hydrochloric acid (14 ml) . The precipitated crystals were filtered and washed with water to give 2- (acetylamino) -1, 3-thiazole-4-carboxylic acid (1.3 g) . XH-NMR (DMSO-de) , δ (ppm): 2.14 (3H, s) , 7.94 (IH, s) . Step 4
A mixture of 2- (acetylamino) -1, 3-thiazole-4-carboxylic acid (500 mg) , tert-butyl 4-aminophenylcarbamate (615 mg) , 1- ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (566 mg) , 1-hydroxybenzotriazole (399 mg) and dichloromethane (5 ml) was stirred at ambient temperature for 3 hours. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate, and the organic layer was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with 3% methanol / chloroform as an eluent. The crystalline residue was collected and washed with ethyl acetate to give tert-butyl 4- ({ [2- (acetylamino) - 1, 3-thiazol-4-yl] carbonyl} amino) phenylcarbamate (580 mg) . 1H-N R (DMSO-de) , δ (ppm): 1.48 (9H, s) , 2.18 (3H, s) , 7.42 (2H, d, J=7Hz), 7.61 (2H, d, J=7Hz) , 7.91 (IH, s) , 9.32 (IH, s) , 9.63(1H, s) . MS (M+H) =377 Step 5
To a solution of tert-butyl 4- ({ [2- (acetylamino) -1,3- thiazol-4-yl] carbonyl}amino)phenylcarbamate (85 mg) in methanol (1 ml) was added 4N hydrogen chloride in ethyl acetate (1 ml) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo. The solid residue was collected and washed with ethyl acetate to give 2- (acetylamino) -N- (4-aminophenyl) -1, 3- thiazole-4-carboxamide hydrochloride (70 mg) . 1H-NMR (DMSO-de), δ (ppm) : 2.15(3H, s) , 7.42(2H, d, J=7Hz) , 7.37 (2H, d, J=7Hz), 7.41 (IH, s) . MS (M+H) =313 Step 6
A mixture of 2- (acetylamino) -N- (4-aminophenyl) -1, 3- thiazole-4-carboxamide hydrochloride (70 mg) , cyanamide (11 mg) and 2-methoxyethanol (2 ml) was stirred at 100°C for 72 hours. The reaction mixture was concentrated in vacuo. To the residue was added ethyl acetate (5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) . The precipitated solid was filtered and washed with ethyl acetate and water to give 2- (acetylamino) -N- (4-{ [amino (imino) methyl] amino}phenyl) -1, 3- thiazole-4-carboxamide (45 mg) .
XH-NMR (DMSO-de), δ (ppm): 2.18 (3H, s) , 7.60-7.88 (4H, br) ,
7.95(1H, s).
MS (M+H) =319
Production Example 8: Synthesis of N-(4-{2-[4- (ethanimidoylamino) phenyl] ethyl }-l, 3-thiazol-2-yl) acetamide
N- (4- (2- (4-Aminophenyl) ethyl) -1, 3-thiazol-2-yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, methyl ethanimidothioate hydriodide (166 mg) and methanol (3 ml) were combined, and refluxed for 1.5 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residue was purified by flash column chromatography over NH silica gel with chloroform / methanol (20:1 —> 10:1) as an eluent to give N-(4-{2-[4- (ethanimidoylamino) phenyl] ethyl}-!, 3-thiazol-2-yl) acetamide (165 mg) as a pale yellow amorphous substance.
1H-N R (CDC13), δ (PPm): 2.03 (3H, brs), 2.19 (3H, s) , 2.92 (4H, s), 6.47(1H, s), 6.78(2H, d, J=8.0Hz), 7.08(2H, d, J=8.0Hz). MS: 303 (M+H) + Production Example 9: Synthesis of N-[4-(2-{4- [amino (imino)methyl]phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide hydrochloride Step 1 4- (Bromomethyl) benzonitrile (1.73 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours. Then potassium tert-butoxide (1.19 g) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (1.5 g) prepared in a similar manner according to Step 4 of Production Example 1 were added to the mixture, and stirred at room temperature for 3 hours. The reaction mixture was poured into ice-water, and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) as an eluent, and triturated with ethyl ether to give a mixture of N-{4- [ (Z) -2- (4-cyanophenyl) ethenyl] -1, 3- thiazol-2-yl} acetamide and N-{4- [ (E) -2- (4- cyanophenyl) ethenyl] -1, 3-thiazol-2-yl}acetamide (Z : E = 3 :
1) (1.63 g) as a pale yellow solid. mp. 175-176°C
XH-NMR (DMSO-de), δ (ppm): 2.13(3Hx3/4, s) , 2.16(3Hxl/4, s) , 6.59(lHx3/4, d, J=13.0Hz), 6.65(lHx3/4, d, J=13.0Hz),
7.11(lHx3/4, s), 7.24(lHxl/4, d, J=16.0Hz), 7.28(lHxl/4, s) , 7.40(lHxl/4, d, J=16.0Hz), 7.65(2Hx3/4, d, J=8.5Hz), 7.74(2Hxl/4, d, J=8.5Hz), 7.75(2Hx3/4, d, J=8.5Hz), 7.83(2Hxl/4, d, J=8.5Hz), 12.00 (IH, brs). MS: 270 (M+H) + Step 2
A mixture of N- { 4- [ (Z) -2- (4-cyanophenyl) ethenyl] -1, 3- thiazol-2-yl}acetamide and N-{4- [ (E) -2- (4- cyanophenyl) ethenyl] -1, 3-thiazol-2-yl}acetamide (Z : E = 3 : 1) (1.5 g) , 10% palladium on carbon (323 mg) , methanol (20 ml), tetrahydrofuran (10 ml) and acetic acid (5 ml) were combined. The reaction mixture was stirred under 4 atm hydrogen at ambient temperature for 9 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —> chloroform / methanol (30:1) as an eluent, and triturated with ethyl ether to give N- {4- [2- (4-cyanophenyl) ethyl] -1, 3-thiazol-2- yl} acetamide (1.18 g) as a colorless solid, mp. 205-206.5°C
1H-N R (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.90 (2H, t, J=8.0Hz), 3.01(2H, t, J=8.0Hz), 6.73(1H, s) , 7.40(2H, d, J=8.0Hz), 7.74 (2H, d, J=8.0Hz), 12.09 (IH, brs). MS: 272 (M+H) + Step 3
N-{4- [2- (4-Cyanophenyl) ethyl] -1, 3-thiazol-2-yl} acetamide (600 mg) was dissolved in ethanol (5 ml) and chloroform (5 ml), and then hydrochloric acid gas was bubbled at 0°C for 5 minutes with stirring. The reaction mixture was stood for 15 hours, and concentrated in vacuo. The residual solid was washed with diethyl ether to give ethyl 4-{2- [2- (acetylamino) - 1, 3-thiazol-4-yl] ethyl }benzenecarboximidoate hydrochloride (924.7 mg) as a pale green solid, mp. 129-130°C
XH-NMR (DMSO-d6), δ (ppm) : 1.48 (3H, t, J=7.0Hz), 2.12 (3H, s) , 2.95 (2H, t, J=8.0Hz), 3.07 (2H, t, J=8.0Hz), 4.61 (2H, q, J=7.0Hz), 6.72 (IH, s) , 7.46(2H, d, J=8.5Hz), 8.02 (2H, d, J=8.5Hz), 11.25(1H, brs), 11.98 (IH, brs), 12.11 (IH, brs). MS: 318 (M+H) + free Step 4
Ethyl 4- {2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl Jbenzenecarboximidoate hydrochloride (300 mg) was dissolved in ethanol (6 ml) . Then ammonium chloride (68 mg) and ammonia in methanol (1 ml) were added to the solution. The reaction mixture was refluxed for 5 hours under nitrogen atmosphere. After cooled to room temperature, the suspension was filtered in vacuo. The filtrate was concentrated in vacuo, and the residue was solidified with ethanol / diethyl ether to give N- [4- (2-{4- [amino (imino) methyl] phenyl}ethyl) -1,- 3-thiazol- 2-yl] acetamide hydrochloride (234 mg) as a colorless solid. mp. 229.5-231°C
XH-NMR (DMSO-de), δ (ppm) : 2.12(3H, s), 2.94(2H, t, J=8.0Hz), 3.06(2H, t, J=8.0Hz), 6.75(1H, s) , 7.44(2H, d, J=8.5Hz), 7.76(2H, d, J=8.5Hz), 12.10(1H, brs). MS: 289 (M+H) + free Production Example 10: Synthesis of N- (4-{2- [2- (acetylamino) - 1, 3-thiazol-4-yl] ethyl}phenyl) -2-{ [amino (imino) methyl] amino}- acetamide hydrochloride Step 1
A mixture of N- (4- (2- (4-aminophenyl) ethyl) -1, 3-thiazol-2- yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, ( (tert- butoxycarbonyl) amino) acetic acid (74 mg) , l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (81 mg) , 1- hydroxybenzotriazole (57 mg) and dichloromethane (5 ml) was stirred at ambient temperature for 3 hours. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate, and the organic layer was concentrated in vacuo . The residue was purified by flash column chromatography on silica-gel with 3% methanol / chloroform as an eluent. The crystalline residue was collected and washed with ethyl acetate to give tert-butyl 2- [ (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl Jphenyl) amino] -2-oxoethylcarbamate (580 mg) . XH-NMR (CDC13)/ δ (ppm): 1.47 (9H, s) , 2.25(3H, s) , 2.92 (4H, s) , 3.92 (2H, d, J=5Hz), 6.46(1H, s) , 7.10 (2H, d, J=7Hz) , 7.38 (2H, d, J=7Hz) . MS (M+H) =419 Step 2 To a solution of tert-butyl 2- [ (4-{2- [2- (acetylamino) - 1, 3-thiazol-4-yl] ethyl}phenyl) amino] -2-oxoethylcarbamate (100 mg) in ethyl acetate (1 ml) was added 4N hydrogen chloride in ethyl acetate (1 ml), and the mixture was stirred at ambient temperature for 103 hours. The precipitated solid was filtered and washed with ethyl acetate to give N-(4-{2-[2-
(acetylamino) -1, 3-thiazol-4-yl] ethyl }phenyl) -2-aminoacetamide hydrochloride (80 mg) .
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.87 (4H, s) , 6.70 (IH, s), 7.17 (2H, d, J=7Hz) , 7.49 (2H, d, J=7Hz) . MS (M+H) =319 Step 3
The title compound was prepared in a similar manner according to Step 7 of Production Example 1. XH-NMR (DMSO-de), δ (ppm) : 2.11(3H, s) , 2.80-2.95 (4H, m) , 3.76(2H, s), 6.70(1H, s) , 7.26(2H, d, J=7Hz) , 7.49(2H, d, J=7Hz) , 8.16 (2H, s) . MS (M+H) =361
Production Example 11: Synthesis of N-{4-[4-(2- { [amino (imino) methyl] amino}ethyl) phenyl] -1, 3-thiazol-2- yl} acetamide hydrochloride Step 1
Aluminium chloride (1.63 g) was dissolved in 1,2- dichloroethane (15 mL) . Chloroacetylchloride (0.732 mL) was added to the mixture at 0°C, and stirred additionally for 20 minutes, then N- (2-phenylethyl) acetamide (1 g) in 1,2-dichloroethane (5 mL) was added dropwise. The mixture was stirred for 1 hour at room temperature, and then poured into ice-water. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The solid was washed with ethyl acetate and ethyl ether, and dried in vacuo to give N-{2- [4- (2-chloroacetyl) phenyl] ethyl}- acetamide as a white powder (1.18 g, 80.4%).
XH-NMR (300 MHz, DMSO-de), δ (ppm) : 7.92 (2H, d, J=6Hz), 7.34(2H, d, J=6Hz), 5.66(1H, br) , 4.70(2H, s) , 3.55-3.60 (2H, m) , 2.90-2.94 (2H, m) , 1.98 (3H, s) . Step 2 N- {2- [4- (2-Chloroacetyl) phenyl] ethyl}acetamide (1.06 g) and thiourea (505 mg) were dissolved in ethanol (20 mL) . The mixture was refluxed for 1 hour and allowed to cool to room temperature. The white solid was collected with filtration and washed with ethanol to give N-{2- [4- (2-amino-l, 3-thiazol-4- yl) phenyl] ethyl} acetamide hydrochloride (1.19 g, 90.4%). MS m/z 262 (M++1) .
^-NMR (300 MHz, DMSO-de), δ (ppm) : 7.93-7.96 (2H, m) , 7.69(2H, d, J=6Hz), 7.30(2H, d, J=6Hz) , 7.16(1H, s) , 3.23-3.30 (2H, m) , 2.70-2.76(2H, m) , 1.78 (3H, s) . Step 3
N-{2- [4- (2-Amino-l, 3-thiazol-4-yl) phenyl] ethyl}acetamide (0.6 g) was dissolved in ethanol (10 mL) and hydrochloric acid concentrate (10 mL) . The mixture was refluxed for 5 hours. The solvent was evaporated in vacuo. The residue was washed with ethyl ether to give 4- [4- (2-aminoethyl) phenyl] -1, 3- thiazol-2-amine dihydrochrolide (0.5 g, 84.6%). MS m/z 220 (M++1) .
XH-NMR (300 MHz, DMSO-de), δ (ppm): 8.15(3H, br) , 7.78(2H, d, J=6Hz), 7.39 (2H, d, J=6Hz) , 7.24 (IH, s) , 3.03-3.10 (2H, m) , 2.90-2.98 (2H, m) . Step 4
4- [4- (2-Aminoethyl) phenyl] -1, 3-thiazol-2-amine dihydrochrolide (0.45 g) was dissolved in 1,4-dioxane (10 mL) , water (3 mL) and IN sodium hydroxide solution (3.1 mL) . Di- tert-butyl dicarbonate (336 mg) was added at 0°C. The mixture was stirred at room temperature overnight, then extracted with ethyl acetate, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The solid was washed with ethyl ether, and dried in vacuo to give tert-butyl {2- [4- (2-amino-l, 3-thiazol-4-yl) phenyl] ethyl}- carbamate as a white solid (311 mg, 63.2%) . MS m/z 320 (M++1) . 1H-NMR (300 MHz, DMSO-d5) , δ (ppm): 7.69(2H, d, J=6Hz),
7.18(2H, d, J=6Hz) , 7.02(2H, br) , 7.69(1H, s) , 3.10-3.27 (2H, m) , 2.65-2.72 (2H, ) , 1.37 (9H, s) . Step 5 tert-Butyl {2- [4- (2-amino-l, 3-thiazol-4- yl) phenyl] ethyl}carbamate (290 mg) was dissolved in dichloromethane (5 mL) , then acetic anhydride (0.103 mL) , 4- dimethylaminopyridine (10 mg) and pyridine (0.147 mL) were added. The mixture was stirred overnight. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The solid was washed with ethyl ether, and dried in vacuo to give tert-butyl (2-{4- [2- (acetylamino) - 1, 3-thiazol-4-yl]phenyl}ethyl) carbamate as a white solid (280 mg, 85.3%) . MS m/z 362 (M++1) .
1H-NMR (300 MHz, DMS0-ds) , δ (ppm): 7.80(2H, d, J=6Hz), 7.53(1H, s), 7.24(2H, d, J=6Hz) , 6.90(1H, m) , 3.12-3.18 (2H, m) , 2.16-2.63(2H, m) , 2.16(3H, s) , 1.37(9H, s) . Step 6 tert-Butyl (2- { 4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl} ethyl) carbamate (250 mg) was dissolved in ethyl acetate (4 mL) and 4 N hydrogen chloride in ethyl acetate (2 mL) . The solvent was evaporated in vacuo. The solid was washed with ethyl acetate and ethyl ether to give N-{4-[4-(2- aminoethyl) phenyl] -1, 3-thiazol-2-yl } acetamide hydrochloride
(220 mg, 106%) .
MS m/z 262 (M++1) . ^-H- MR (300 MHz, DMSO-de), δ (ppm) : 8.05(3H, br) , 7.85(2H, d,
J=6Hz), 7.58 (IH, s), 7.32 (2H, d, J=6Hz) , 3.12-3.18 (2H, m) ,
2.88-2.94(2H, m) , 2.16(3H, s) .
Step 7
N-{4- [4- (2-Aminoethyl) phenyl] -1, 3-thiazol-2-yl} acetamide hydrochloride (200 mg) and diisopropylethylamine (0.175 L) were dissolved in tetrahydrofuran (5 mL) . The mixture was stirred at room temperature overnight, then evaporated in vacuo. The residue was purified with silica gel chromatography
(5% methanol / chloroform) to give di-tert-butyl {[(2-{4-[2- (acetylamino) -1, 3-thiazol-4- yl] phenyl } ethyl) amino] methylidenej-biscarbamate (268 mg,
79.2%) .
MS m/z 504 (M++1) .
Step 8 Di-tert-butyl {[ (2-{4- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl} ethyl) amino]methylidene}biscarbamate (268 mg, 79.2%)
(170 mg) was dissolved in 4 N hydrogen chloride in 1,4-dioxane
(5 mL) . The mixture was stirred at room temperature for 2 days, and then evaporated in vacuo. The residue was washed with ethyl ether, dried in vacuo to give N-{4-[4-(2-
{ [amino (imino) methyl] amino} ethyl) phenyl] -1, 3-thiazol-2- yl}acetamide hydrochloride (50 mg, 43.6%).
MS m/z 304 (M++1) .
^- MR (300 MHz, DMSO-d6) , δ (ppm) : 7.83(2H, d, J=8Hz) , 7.62- 7.66(1H, m), 7.56(1H, s) , 7.34(2H, d, J=8Hz) , 3.37-3.45 (2H, m) , 2.78-2.85(2H, m), 2.16(3H, s) .
Production Example 12: Synthesis of N-(4-{2-[4-
(aminomethyl) phenyl] ethyl } -1, 3-thiazol-2-yl) acetamide Step 1
To a mixture of N- (4- {2- [4- (hydroxymethyl) phenyl] ethyl }- 1, 3-thiazol-2-yl) acetamide (50 mg) prepared in a similar manner according to Step 3 of the following Production Example 16, carbon tetrabromide (72 mg) and dichloromethane (1 ml) was added triphenylphosphine (71 mg) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was purified by flash column chromatography on silica gel with 1% methanol / chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give N-(4- {2- [4- (bromomethyl) phenyl] ethyl }-l, 3-thiazol-2-yl) acetamide (48 mg) .
XH-NMR (CDCI3), δ (ppm): 2.25 (3H, s) , 2.85-3.03 (4H, m) , 4.49(2H, s), 6.48(1H, s) , 7.13(2H, d, J=7Hz) , 7.30(2H, d, J=7Hz) .
MS (M+H) =339 Step 2
To a mixture of N- (4- {2- [4- (bromomethyl) phenyl] ethyl }- 1, 3-thiazol-2-yl) acetamide (100 mg) , tetrahydrofuran (2 ml) and N, N-dimethylformamide (2 ml) was added sodium diformylimide (42 mg) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with water (3 ml), and the precipitated solid was filtered and washed with water to give N- [4- (2-{4- [ (diformylamino) - methyl] phenyl} ethyl) -1, 3-thiazol-2-yl] acetamide (80 mg) . 1H-NMR (CDCI3), δ (ppm): 2.23(3H, s) , 2.83-3.00 (4H, m) , 4.72(2H, s), 6.48(1H, s) , 7.10(2H, d, J=7Hz) , 7.38(2H, d, J=7Hz) . MS (M+H) =318 Step 3
To a solution of N- [4- (2- {4- [ (diformylamino) methyl] - phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide (56 mg) in methanol (0.5 ml) was added 4N hydrogen chloride in ethyl acetate (0.5 ml) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo . The residue was separated between chloroform (5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) , and the aqueous layer was extracted with chloroform (5 ml) . The organic layer was dried over sodium sulfate and concentrated in vacuo to give N- (4-{2- [4- (aminomethyl) phenyl] ethyl}-!, 3-thiazol-2- yl) acetamide (50 mg) . XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s), 2.80-3.00 (4H, m) , 3.92- 4.05(2H, m) , 6.72(1H, s) , 7.24(2H, d, J=7Hz) , 7.37(2H, d, J=7Hz) . MS (M+H) =276
Production Example 13: Synthesis of ethyl 4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-2- ylcarbamate hydrochloride
Step 1 : ethyl 4- (hydroxymethyl) -1, 3-thiazol-2-ylcarbamate
A mixed solution of ethyl 4- (chloromethyl) -1, 3-thiazol-2- ylcarbamate (500 mg) in 1,4-dioxane (5 ml) and water (10 ml) was refluxed with stirring for 3.5 hours. After cooling, it was concentrated under reduced pressure. The mixture was partitioned between ethyl acetate and water. The organic phase was separated, washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of hexane and ethyl acetate (2:1) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless syrup (450 mg, 98.2%) . MS (ES+) ; 203 (M+H)+ ^-H-NMR (CDC13), δ (ppm): 1.39 (3H, t, J=7.0Hz), 4.39(2H, q, J=7.0Hz), 4.61(2H, s) , 6.80(1H, s). Step 2 : ethyl 4-formyl-l, 3-thiazol-2-ylcarbamate
To a mixed solution of ethyl 4- (hydroxymethyl) -1, 3- thiazol-2-ylcarbamate (446 mg) in chloroform (30 ml) and methanol (3 ml) was added portionwise manganese (IV) oxide chemicals treated (1.92 g) at room temperature. After the mixture was stirred at the same temperature for 2 hours, then treated manganese (IV) oxide chemicals (250 mg) was added again to the solution, and it was stirred at 50°C for 3 hours.
Manganese (IV) oxide was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of hexane and ethyl acetate (4:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless powder
(470 mg, 106.4%) .
1H-NMR (CDC13), δ (PPm): 1.36 (3H, t, J=7.0Hz), 4.34 (2H, q, J=7.0Hz), 7.83(1H, s) , 9.54(1H, br) , 9.88(1H, s) .
Step 3
Ethyl 4- [2- (4-nitrophenyl) ethenyl] -1, 3-thiazol-2- ylcarbamate (E-Z mixture) was obtained in a similar manner according to Step 5 of Production Example 1. 1H-NMR (CDCI3) (cis-trans product mixture), δ (ppm) : 1.20-
1.40(3H, m) , 4.20-4.40 (2H, m) , 6.60, 6.66(1.2H, ABq, J=13Hz) ,
6.74(0.6H, s), 6.94(0.4H, s) , 7.12, 7.30(0.8H, ABq, J=16Hz) ,
7.53 (1.2H, d, J=8.9Hz), 7.61 (0.8H, d, J=8.9Hz), 8.11 (1.2H, d,
J=8.9Hz), 8.22 (0.8H, d, J=8.9Hz). Step 4
Ethyl 4- [2- (4-aminophenyl) ethyl] -1, 3-thiazol-2- ylcarba ate was obtained in a similar manner according to Step
6 of Production Example 1.
MS (ES+); 292 (M+H) + I-H-NMR (DMS0-d6), δ (ppm) : 1.24 (3H, t, J=7.1Hz), 2.65-2.80 (4H, m), 4.18 (2H, q, J=7.1Hz), 4.82 (2H, br) , 6.46 (2H, d, J=8.5Hz),
6.69(1H, s), 6.84(2H, d, J=8.5Hz).
Step 5 Ethyl 4- [2- (4- {N' ,N"-bis (tert-butoxycarbonyl) - [amino (imino)methyl] amino }phenyl) ethyl] -1, 3-thiazol-2- ylcarba ate was obtained in a similar manner according to Step 3 of the following Production Example 14. -NMR (CDC13) , δ (ppm): 1.29 (3H, t, J=7.0Hz), 1.40-1.70 (18H, m) , 2.94(4H, s) , 4.27(2H, q, J=7.0Hz), 6.45(1H, s) , 7.12 (2H, d, J=8.4Hz), 7.48 (2H, d, J=8.4Hz), 10.25(1H, s) . Step 6
The title compound was prepared in a similar manner according to Step 5 of the following Production Example 14. MS (ES+); 334 (M+H)+ free
1H-NMR (DMSO-de), δ (ppm) : 1.24 (3H, t, J=7.0Hz), 2.80-3.00 (4H, m), 4.19(2H, q, J=7.0Hz), 6.76(1H, s) , 7.14 (2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 7.46(3H, br) , 9.91 (IH, s) . Production Example 14: Synthesis of N-{4-[2-(3-
{ [amino (imino) methyl] amino}phenyl) ethyl] -5-bromo-l, 3-thiazol-
2-yl}acetamide hydrochloride
Step 1: N-{4- [2- (3-nitrophenyl) ethenyl] -1, 3-thiazol-2- yl} acetamide (E-Z mixture) To a solution of 1- (bromomethyl) -3-nitrobenzene (276 mg) in N,N-dimethylformamide (7 mL) was added triphenylphosphine (335 mg) at room temperature. After the mixed solution was stirred for 4 hours, potassium tert-butoxide (172 mg) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (217 mg) were successively added to the solution at the same temperature. After the whole solution was stirred at room temperature for 5 hours, the mixture was poured into water, the pH of the aqueous layer was adjusted to 7 with IN-hydrochloric acid. The resulting mixture was extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of n-hexane and ethyl acetate (4:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give brown powder of the title compound (E-Z mixture) (323 mg, 87.4%). 1H-NMR (DMSO-de) (cis-trans product mixture), δ (ppm) : 2.11(2.49H, s) , 2.16(0.51H, s) , 6.66(1.66H, s) , 7.13(0.83H, s), 7.28(0.17H, s), 7.29, 7.46(0.34H, ABq, J=16Hz) , 7.60 (IH, t, J=7.9Hz), 7.91(0.83H, d, J=7.9Hz), 8.01(0.17H, d, J=7.9Hz), 8.09-8.13(lH, ) , 8.28(0.83H, m) , 8.38(0.17H, m) . Step 2 : N-{4- [2- (3-aminophenyl) ethyl] -1, 3-thiazol-2- yl} acetamide
N- { 4- [2- (3-Nitrophenyl ) ethenyl ] -1, 3-thiazol-2- yl}acetamide (E,Z mixture) (315 mg) in a mixed solvent of methyl alcohol (3 ml), tetrahydrofuran (6 ml), and acetic acid (1 ml) was hydrogenated over 10% Palladium on carbon (50% wet, 200 mg) under 4.3 atmospheric pressure at room temperature for 3 hours. The catalyst was removed off by filtration, and the filtrate was evaporated in vacuo. The residue was poured into water, the pH of the aqueous layer was adjusted to 9 with aqueous sodium hydrogen carbonate. The resulting mixture was extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (9 g) using a mixed solvent of n- hexane and ethyl acetate (2:1 to 1:1). The fractions containing the objective compound were collected and evaporated under reduced pressure to give syrup. The syrup of the objective compound was changed to solid in freezer (275 mg, 96.6%) . MS (ES+); 262 (M+H)+ XH-NMR (CDC13), δ (PPm): 2.23 (3H, s), 2.80-3.00 (4H, ) , 3.60(2H, br), 6.51 (IH, s) , 6.45-6.65 (3H, ) , 7.06(1H, t, J=7.9Hz), 9.45 (IH, br) .
Step 3: N-{4-[2-(3-{ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-2-yl} acetamide
To a solution of N-{4- [2- (3-aminophenyl) ethyl] -1, 3- thiazol-2-yl}acetamide (267 mg) in tetrahydrofuran (3 ml) was added N,N' -bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (317 mg) at room temperature. After the mixed solution was stirred for 3 days at the same temperature, and then evaporated under reduced pressure, the resulting residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of n-hexane and ethyl acetate (4:1 to 3:2). The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless foam of the title compound (316 mg, 61.4%) . MS (ES+); 504 (M+H)+ XH-NMR (CDC13) , δ (ppm): 1.40-1.80 (18H, m) , 2.25(3H, s) , 2.97(4H, m) , 6.37(1H, ) , 6.53(1H, s) , 6.91(1H, d, J=7.9Hz), 7.23 (IH, t, J=7.9Hz), 7.34 (IH, s) , 7.52 (IH, d, J=7.9Hz), 7.63- 7.64(1H, m) , 10.28 (IH, s) .
Step 4: N-{4-[2-(3-{ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] amino }phenyl) ethyl] -5-bromo-l, 3-thiazol-2- yl}acetamide
To a suspension of N-{4- [2- (3-{ [N' ,N"-bis (tert- butoxycarbonyl ) amino (imino) methyl] amino}phenyl) ethyl] -1,3- thiazol-2-yl}acetamide (115 mg) in methanol (3 ml) was added N-bromosuccinimide (44.7 mg) at room temperature. After the mixed solution was stirred at the same temperature for 1 hour, the resulting precipitate was collected by filtration, washed with a mixed solvent of diisopropyl ether and n-hexane (1:1) . The title compound was obtained as white powder (70 mg, 52.6%) . MS (ES+); 582 (M+H)+
1H-NMR (CDCI3), δ (ppm): 1.40-1..75 (18H, m) , 2.21 (3H, s) , 2.85- 3.00(4H, ), 6.93(1H, d, J=7.9Hz), 7.23(1H, t, J=7.9Hz), 7.30(1H, s), 7.51(1H, d, J=7.9Hz), 9.26(1H, br) , 10.26(1H, br), 11.63 (IH, br) .
Step 5
To a solution of N-{4- [2- (3-{ [N' ,N"-bis (tert- butoxycarbonyl) amino (imino) ethyl] amino}phenyl) ethyl] -5-bromo- 1, 3-thiazol-2-yl}acetamide (64 mg) in dichloromethane (0.5 ml) was added dropwise 4N-hydrogen chloride in 1,4-dioxane (2 ml) at room temperature. After being stirred at the same temperature for 20 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in a minimum methanol, and the solution was gradually diluted with ethyl acetate. The resulting precipitate was collected by filtration, washed with diisopropyl ether. The title compound was obtained as colorless powder (37 mg, 80.4%). MS (ES+); 382 (M+H)+ free
1H-NMR (DMSO-de), δ (ppm): 2.14 (3H, s) , 2.80-3.00 (4H, m) , 7.00-
7.15(3H, m) , 7.35(1H, t, J=7.9Hz), 7.51(4H, br) , 10.01(1H, br), 12.42 (IH, br) .
Production Example 15: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5-bromo-l, 3-thiazol-
2-yl}acetamide hydrochloride
Step 1-a
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 6 of Production Example 1 in a similar manner according to the following Step 5 of Production
Example 18. p. 275.5-276°C
^-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.11 (3H, s), 2.82-2.96(4H, m) , 6.74 (IH, s) , 7.18 (2H, d, J=8.5Hz),
7.42(2H, d, J=8.5Hz), 9.94(1H, brs), 11.44(1H, brs), 12.09(1H, brs) .
MS: 504 (M+H) + Step 1-b
Di-tert-butyl { [ (4- {2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate (310 mg) prepared in a similar manner according to Step 5 of the following Production Example 18 was dissolved in methanol (6 ml) and tetrahydrofuran (3 ml) under nitrogen atmosphere. Then N-bromosuccinimide (164 mg) was added to the solution at 0°C. The reaction mixture was stirred at room temperature for 4 hours, and concentrated in vacuo. Chloroform and saturated sodium hydrogen carbonate solution were added to the residue. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (2:1) as an eluent to give di-tert-butyl {[(4-{2-[2- (acetylamino) -5-bromo-l, 3-thiazol-4-yl] ethyl }phenyl) amino] - methylidene}biscarbamate (271.4 mg) as a colorless amorphous substance. 1H-N R (CDC13) , δ (ppm): 1.49 (9H, s), 1.53 (9H, s) , 2.22 (3H, s), 2.90 (4H, s), 7.13 (2H, d, J=8.0Hz), 7.45 (2H, d, J=8.0Hz). MS: 582 (M+H) + Step 2
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -5-bromo-l, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate (113 mg) and 4N hydrochloric acid in 1,4-dioxane solution (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo. The residue was washed with ethyl acetate to give N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -5- bromo-1, 3-thiazol-2-yl}acetamide hydrochloride (16.8 mg) as a pale yellow amorphous solid.
1H-N R (DMSO-de), δ (ppm) : 2.14 (3H, s) , 2.82-2.97 (4H, m) , 7.14 (2H, d, J=8.5Hz), 7.25 (2H, d, J=8.5Hz), 7.40 (3H, brs), 9.8K1H, brs), 12.41(1H, brs). MS: 382 (M+H) + free
Production Example 16: Synthesis of N-[4-(2-{4- [ (aminooxy) methyl] phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide Step 1
[4- (Methoxycarbonyl) benzyl] (triphenyl)phosphonium bromide (6.06 g) and N,N-dimethylformamide (50 ml) were combined under nitrogen atmosphere. Then potassium tert-butoxide (1.66 g) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (2.1 g) prepared in a similar manner according to Step 4 of Production Example 1 were added to the suspension at 0°C. The reaction mixture was stirred at room temperature for 6 hours, poured into ice- water, and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1 —» 10:1) as an eluent, and triturated with ethyl ether to give a mixture of methyl 4- { (Z) -2- [2- (acetylamino) - 1, 3-thiazol-4-yl] ethenyl}benzoate and methyl 4-{(E)-2-[2- (acetylamino) -1, 3-thiazol-4-yl] ethenylJbenzoate (Z : E = 3 : 1) (4.05 g) as a colorless solid, mp. 164-165.5°C ^■H-NMR (DMSO-de), δ (ppm) : 2.13(3Hx3/4, s) , 2.16(3Hxl/4, s) , 3.85(3H, s), 6.61(2Hx3/4, s) , 7.05(lHx3/4, s) , 7.26(lHxl/4, d, J=15.5Hz), 7.27(lHxl/4, s) , 7.37(lHxl/4, d, J=15.5Hz), 7.64(2Hx3/4, d, J=8.5Hz), 7.69(2Hxl/4, d, J=8.5Hz), 7.90(2Hx3/4, d, J=8.5Hz), 7.94(2Hxl/4, d, J=8.5Hz), 12.05(1H, brs) . MS: 303 (M+H) + Step 2
Methyl 4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethylJbenzoate was prepared in a similar manner according to Step 2 of Production Example 9. mp. 170-171°C
_JH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.86-2.95 (2H, m) , 2.97- ÷3.05(2H, m), 3.83(3H, s) , 6.72 (IH, s) , 7.35(2H, d, J=8.5Hz), -7.87 (2H, d, J=8.5Hz), 12.08(1H, brs). . MS: 305 (M+H)+ Step 3
To a stirred solution of methyl 4- { 2- [2- (acetylamino) - .1, 3-thiazol-4-yl] ethyl }benzoate (1.8 g) in dry tetrahydrofuran (36 ml) was added dropwise 1.0 M diisobutylaluminium hydride solution in toluene (20.7 ml) at -78°C over 15 minutes under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours, and then the reaction was quenched with water (1 ml) . The mixture was stirred at room temperature for 30 minutes, dried over anhydrous magnesium sulfate, and filtered through a pad of Celite. The solvent was evaporated in vacuo. The residual solid was washed with ethyl ether to give N- (4- {2- [4- (hydroxymethyl) phenyl] ethyl }-l, 3-thiazol-2- yl) acetamide (1.03 g) as a colorless solid. mp. 162-165°C
XH-NMR (DMSO-de) , δ (ppm) : 2 . 11 (3H, s ) , 2 . 80-2 . 95 (4H, m) , 4 . 44 (2H, d, J=5. 5Hz) , 5. 09 (IH, t, J=5.5Hz) , 6.72 (IH, s) , - 7 . 14 (2H, d, J=8 . 0Hz) , 7 .21 (2H, d, J=8 . 0Hz) , 12 . 08 (IH, brs) . MS : 277 (M+H) + Step 4
N-(4-{2- [4- (Hydroxymethyl) phenyl] ethyl}-l, 3-thiazol-2- yl) acetamide (250 mg) , 2-hydroxy-lH-isoindole-l, 3 (2H) -dione (155 mg) , triphenylphosphine (249 mg) and tetrahydrofuran (5 ml) were combined under nitrogen atmosphere, and then diethyl azodicarboxylate (0.15 ml) was added to the solution at 0°C. The reaction mixture was stirred at room temperature for 6 hours, poured into saturated sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent, and triturated with ethyl acetate to give N-{4- [2- (4-{ [ (1, 3- dioxo-l,3-dihydro-2H-isoindol-2-yl) oxy]methyl }phenyl) ethyl] - 1, 3-thiazol-2-yl}acetamide (218.2 mg) as a colorless solid, mp. 225-226°C XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s), 2.82-3.00 (4H, m) , 5.12(2H, s), 6.69(1H, s) , 7.23(2H, d, J=8.0Hz), 7.41(2H, d, J=8.0Hz), 7.86(4H, s) , 12.08(1H, brs). MS: 422 (M+H) + Step 5
N-{4- [2- (4-{ [ (1, 3-Dioxo-l, 3-dihydro-2H-isoindol-2- yl) oxy]methyl Jphenyl) ethyl] -1, 3-thiazol-2-yl} acetamide (200 mg) , methylhydrazine (0.038 ml) and dichloromethane (4 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours, and filtered in vacuo . The filtrate was washed with saturated sodium hydrogen carbonate solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual solid was washed with acetonitrile to give N-[4-(2- {4- [ (aminooxy) methyl] phenyl} ethyl) -1, 3-thiazol-2-yl] acetamide (81.8 mg) as a colorless solid, mp. 130-130.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.82-2.97 (4H, m) , 4.51(2H, s), 6.01(2H, s) , 6.73 (IH, s), 7.17(2H, d, J=8.0Hz), 7.22(2H, d, J=8.0Hz), 12.09(1H, brs). MS: 292 (M+H) +
Production Example 17: Synthesis of N-{4-[2-(4-
{ [ (methyleneamino) oxy] methyl}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide N-[4-(2-{4-[ (Aminooxy) methyl]phenyl} ethyl) -1, 3-thiazol-2- yl] acetamide (30 mg) prepared in a similar manner according to Production Example 16, 37% formaldehyde (8 μl) and dry methanol (1 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 6 hours and concentrated in vacuo. The residue was purified by preparative silica gel column chromatography with chloroform / methanol (20:1) as an eluent, and triturated with ethyl ether to give N-{4- [2- (4-{ [ (methyleneamino) oxy]methyl}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide (20.9 mg) as a colorless solid, mp. 136.5-137°C
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.83-2.97 (4H, m) , 5.01(2H, s), 6.61(1H, d, J=7.5Hz), 6.73(1H, s) , 7.09(1H, d, J=7.5Hz), 7.18 (2H, d, J=8.0Hz), 7.24 (2H, d, J=8.0Hz), 12.08 (IH, brs) . MS: 304 (M+H) +
Production Example 18: Synthesis of N-{5-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl }acetamide hydrochloride Step 1
A solution of 1, 1, 3, 3-tetramethoxypropane (10 g) and hydrochloric acid concentrate (0.43 ml) in water (11 ml) was stirred at room temperature for 10 minutes. Bromine (3.14 ml) was added dropwise to the solution at room temperature over 50 minutes . The reaction mixture was stirred at room temperature for 20 minutes, and concentrated in vacuo. The residual solid was washed with water to give 2-bromomalonaldehyde (3.6 g) as a yellow solid, mp. 147-148°C !H- MR (CDC13), δ (PPm): 4.73-4.80 (IH, m) , 8.47 (2H, brs). MS: 149(M-H)+ Step 2
N'- ( (E) -Ethanoyl) carbamimidothioic acid (2.74 g) and acetone (20 ml) were combined under nitrogen atmosphere. Then 2-bromomalonaldehyde (3.5 g) was added to the solution under reflux. The reaction mixture was refluxed for an hour, and cooled to room temperature . The precipitate was filtered in vacuo. The solid was washed with water and acetone, and purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N-(5-formyl- 1, 3-thiazol-2-yl) acetamide (1.21 g) as an off-white solid, mp. 235-235.5°C ! H- MR (DMSO-de), δ (ppm) : 2.21 (3H, s) , 8.41 (IH, s) , 9.95 (IH, s) , 12.71 (IH, brs) . MS: 169(M-H)+ Step 3
N-{5- [ (Z) -2- (4-Nitrophenyl ) ethenyl] -1, 3-thiazol-2- yl} acetamide was prepared in a similar manner according to Step 5 of Production Example 1. mp. 221-223°C H-NMR (DMSO-de), δ (ppm) : 2.07 (3H, s) , 6.63 (IH, d, J=12.0Hz), 6.92 (IH, d, J=12.0Hz), 7.55(1H, s) , 7.62 (2H, d, J=9.0Hz), 8.24(2H, d, J=9.0Hz), 12.16(1H, brs). MS: 290 (M+H) + Step 4
A mixture of N-{5- [ (Z) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-yl}acetamide (1 g) and 10% palladium carbon (1.04 g) in ethyl acetate (100 ml) and N,N-dimethylformamide (20 ml) was stirred under 4 atm hydrogen at ambient temperature for 4 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with chloroform / methanol (30:1 _» 20:1) as an eluent, and triturated with ethyl ether to give N-{5-[2-(4- aminophenyl) ethyl] -1, 3-thiazol-2-yl} acetamide (240.9 mg) as an off-white solid. mp. 218-219.5°C
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.70 (2H, t, J=7.5Hz),
2.92 (2H, t, J=7.5Hz), 4.85(2H, s), 6.47 (2H, d, J=8.5Hz),
6.86(2H, d, J=8.5Hz), 7.08 (IH, s) , 11.86(1H, brs). MS: 262 (M+H) +
Step 5
N- {5- [2- (4-Aminophenyl) ethyl] -1, 3-thiazol-2-yl} acetamide
(100 mg) , N,N' -bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (119 mg) , N, N-dimethylformamide (1 ml) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at 50°C for 5.5 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo. The residue was purified by preparative silica gel column chromatography with n-hexane / ethyl acetate (1:2) as an eluent to give di-tert-butyl { [ (4-
{2- [2- (acetylamino) -1, 3-thiazol-5-yl] ethyl }phenyl) amino] - methylidenejbiscarbamate (93.9 mg) as a colorless solid. mp. 203-205°C αH-NMR (DMSO-de), δ (ppm): 1.40 (9H, s) , 1.51 (9H, s) , 2.10 (3H, s), 2.87 (2H, t, J=7.5Hz), 3.02 (2H, t, J=7.5Hz), 7.11 (IH, s) ,
7.21(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 9.96(1H, brs),
11.43(1H, brs), 11.88(1H, brs).
MS: 504 (M+H) +
Step 6 The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 105-107°C
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.91 (2H, t, J=7.5Hz),
3.04 (2H, t, J=7.5Hz), 7.14 (IH, s) , 7.14 (2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.46(3H, brs), 9.89(1H, s) , 11.95 (IH, brs) .
MS: 304 (M+H) + free
Production Example 19: Synthesis of N-{4-[2-(4- { [imino (methylamino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide
A mixture of methyl N- (4- {2- [2- (acetylamino) -1, 3-thiazol- 4-yl] ethyl }phenyl) imidothiocarbamate hydriodide (50 mg) prepared in a similar manner according to Production Example 4, 40% methylamine in methanol (0.056 ml) and ethanol (1 ml) was stirred at ambient temperature for 20 hours. The precipitated crystals were filtered and washed with ethanol to give N-{4-[2-(4-{ [imino (methylamino) methyl] amino}phenyl) - ethyl] -l,3-thiazol-2-yl} acetamide (18 mg) .
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s), 2.64 (3H, s) , 2.83 (4H, s), 6.67(2H, d, J=7Hz) , 6.73 (IH, s) , 7.01 (2H, d, J=7Hz) .
MS (M+H) =318
Production Example 20: Synthesis of N- {4- [2- (4- { [amino (imino) - methyl] amino}phenyl) ethyl] -5-chloro-l, 3-thiazol-2-yl}acetamide hydrochloride Step 1
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate (150 mg) prepared in a similar manner according to Step 5 of Production Example 18 was dissolved in methanol (1.5 ml) and tetrahydrofuran (3 ml) under nitrogen atmosphere. Then N- chlorosuccinimide (59.7 mg) was added to the solution at 0°C. The reaction mixture was stirred at room temperature for 29 hours, and diluted in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual solid was washed with ethyl ether to give di-tert- butyl { [ (4-{2- [2- (acetylamino) -5-chloro-l, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene Jbiscarbamate (111 mg) as an off-white solid, mp. 220-221°C ^-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.13 (3H, s), 2.81-2.94 (4H, m) , 7.15 (2H, d, J=8.5Hz), 7.43 (2H, d, J=8.5Hz), 9.95 (IH, brs), 11.43 (IH, brs), 12.38 (IH, brs). MS: 538 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 82-84°C αH-NMR (DMSO-de), δ (ppm) : 2.14 (3H, s) , 2.82-2.97 (4H, m) , 7.14 (2H, d, J=8.5Hz), 7.25 (2H, d, J=8.5Hz), 7.42 (3H, brs), 9.85(1H, brs), 12.38 (IH, brs). MS: 338 (M+H) + free
Production Example 21: Synthesis of N-(4-{2-[4- ( { [amino (imino) ethyl] amino}methyl) phenyl] ethyl }-l, 3-thiazol- 2-yl) acetamide hydrochloride Step 1
A mixture of N- (4-{2- [4- (aminomethyl ) phenyl] ethyl }-l, 3- thiazol-2-yl) acetamide (20 mg) prepared in a similar manner according to Production Example 12, N, N' -bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (23 mg) and tetrahydrofuran (0.5 ml) was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica-gel with chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give di-tert-butyl { [ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}benzyl) amino] methylideneJbiscarbamate (22 mg) . 2H-NMR (CDC13), δ (ppm): 1.47 (9H, s), 1.50 (9H, s) , 2.24 (3H, s), 2.87-3.03(4H, m) , 6.50 (IH, s) , 7.13(2H, d, J=7Hz) , 7.22(2H, d, J=7Hz) .
MS (M+H) =518 Step 2
A mixture of di-tert-butyl {[ (4- {2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl }benzyl) amino] methylideneJbiscarbamate (20 mg) , dichloromethane (2 drops) and 4N hydrogen chloride in 1,4-dioxane (0.5 ml) was stirred for 15 hours. The precipitated crystals were filtered and washed with 1,4- dioxane to give N- (4-{2- [4- ( { [amino (imino) methyl] amino}- ethyl) phenyl] ethyl }-l, 3-thiazol-2-yl) acetamide hydrochloride (13 mg) .
^■H-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 2.80-3.00 (4H, m) , 4.32(2H, d, J=7Hz), 6.73(1H, s), 7.20(4H, s) , 8.04(1H, t, J=7Hz) .
MS (M+H) =318
Production Example 22: Synthesis of ethyl 2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazole-5- carboxylate hydrochloride Step 1
Ethyl 4-chloro-3-oxobutanoate (35 g) was dissolved in dichloromethane (70 ml), and then sulfuryl chloride (17.1 ml) in dichloromethane (20 ml) was added dropwise to the solution at 0°C over 15 minutes under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 hours, and concentrated in vacuo. The residual oil, N'-((E)- ethanoyl) carbamimidothioic acid (25.1 g) and acetone (600 ml) were combined. The reaction mixture was refluxed for 2.5 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residual solid was washed with water and isopropyl ether to give ethyl 2- (acetylamino) -4- (chloromethyl) -1, 3-thiazole-5-carboxylate (21.2 g) as a pale yellow solid, mp. 164-165°C XH-NMR (DMSO-de), δ (ppm): 1.30 (3H, t, J=7.0Hz), 2.19 (3H, s) , 4.29(2H, q, J=7.0Hz), 5.00(2H, s) , 12.72 (IH, s) . MS: 263 (M+H) + Step 2: ethyl 2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazole-5-carboxylate
To a stirring solution of ethyl 2- (acetylamino) -4- (chloromethyl) -1, 3-thiazole-5-carboxylate (1.0 g, 3.81 mmol) in N, N-dimethylformamide (20 L) was added triphenylphosphine (1.2 g, 4.57 mmol) at room temperature. The resultant mixture was stirred at 65°C for 5 hours . To the mixture was added potassium tert-butoxide (555 mg, 4.95 mmol) at 5°C, and the resultant mixture was stirred at 5°C for 30 minutes. p-Nitrobenzaldehyde (805 mg, 5.33 mmol) was added at 5°C. After stirring for 1 hour at room temperature, the reaction was quenched with water, and the mixture was filtered to give the title compound (1.0 g, 72.7%) as a yellow solid. XH-NMR (CDC13) , δ (ppm): 1.40 (3H, t, J=7.2Hz), 2.33 (3H, s) , 4.38 (2H, q, J=7.2Hz), 7.59 (IH, d, J=16.0Hz), 7.70 (2H, d, J=8.8Hz), 8.18 (IH, d, J=16.0Hz), 8.22 (2H, d, J=8.8Hz), 8.90(1H, m) . Step 3
Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3- thiazole-5-carboxylate was prepared in a similar manner according to Step 6 of Production Example 1.
XH-NMR (CDCI3) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.27 (3H, s), 2.84(2H, m), 3.28(2H, m) , 3.56(2H, m) , 4.31(2H, q, J=7.0Hz), 6.61(2H, d, J=8.3Hz), 7.01 (2H, d, J=8.3Hz), 9.12 (IH, m) . Step 4 Ethyl 2- (acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino] ethyl }- amino) phenyl] ethyl}-!, 3-thiazole-5-carboxylate was prepared in a similar manner according to Step 5 of Production Example 18. 1H-N R (CDCI3) , δ (PPm): 1.36 (3H, t, J=7.4Hz), 1.49(9H, s) , 1.53(9H, s), 2.25(3H, s) , 2.94(2H, m) , 3.34(2H, m) , 4.31 (2H, q, J=7.4Hz), 7.15(2H, d, J=8.4Hz), 7.41 (2H, d, J=8.4Hz), 9.69(1H, m) , 10.20(1H, s) , 11.63(1H, s) . Step 5 The title compound was prepared in a similar manner according to Step 2 of Production Example 15.
XH- MR (DMSO-d6), δ (ppm): 1.28 (3H, t, J=7.0Hz), 2.18 (3H, s) , 2.94(2H, m) , 3.28(2H, m) , 4.23(2H, q, J=7.0Hz), 7.16(2H, d, J=8.4Hz), 7.29(2H, d, J=8.4Hz), 7.37(3H, s) , 9.71(1H, s) , 12.55 (IH, s) .
Production Example 23: Synthesis of N-{4-[2-(4- { [ (ethylamino) (imino) ethyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl}acetamide The title compound was prepared in a similar manner according to Production Example 19.
XH-NMR (DMSO-de), δ (ppm) : 1.13(3H, t, J=6Hz) , 2.11(3H, s) , 2.70-3.00(6H, m), 6.70(1H, s) , 6.77(2H, d, J=7Hz) , 7.17(2H, d, J=7Hz) . MS (M+H) =332
Production Example 24 : Synthesis of benzyl 4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- carbamate
Step 1 To an ice-cold mixture of ethyl 2-amino-l, 3-thiazole-4- carboxylate (5 g) , pyridine (3.36 ml) and dichloromethane (50 ml) was added benzyloxycarbonyl chloride (3.1 ml), and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate (30 ml), dried over sodium sulfate and concentrated in vacuo. The crystalline residue was collected and washed with diisopropyl ether to give ethyl 2- { [ (benzyloxy) carbonyl] amino}-l, 3-thiazole-4-carboxylate (5.1 g). XH-NMR (CDC13) , δ (ppm) : 1 . 48 (3H, t, J=7Hz ) , 4 . 38 (2H, q, J=7Hz) , 5. 27 (2H, s ) , 7 .36-7 . 44 (5H, m) , 7 . 82 ( IH, s ) . MS (M+H) =307 Step 2 Benzyl 4- (hydroxymethyl) -1, 3-thiazol-2-ylcarbamate was prepared in a similar manner according to Step 2 of Production
Example 6.
^- MR (CDC13), δ (ppm): 4.56 (2H, s) , 5.27 (2H, s) , 6.80(1H, s) , 7.30-7.46(5H, m) .
MS (M+H) =265
Step 3
Benzyl 4-formyl-l, 3-thiazol-2-ylcarbamate was prepared in a similar manner according to Step 3 of Production Example 6. ifi- MR (CDCI3), δ (ppm): 5.29(2H, s) , 7.35-7.45 (5H, m) ,
7.81(1H, s) , 9.80(1H, s) .
MS (M+H) =263
Step 4
Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3-thiazol-2- ylcarbamate was prepared in a similar manner according to Step
4 of Production Example 6.
XH-NMR (DMSO-de), δ (ppm) : 5.23(2x3/5H, s) , 5.25(2x2/5H, s) ,
6.56-6.70(lH, ) , 7.23(1H, s) , 7.30-7.50 (5H, m) , 7.82(2x2/5H, d, J=7Hz), 7.92(2x3/5H, d, J=7Hz) , 8.14(2x3/5H, d, J=7Hz) , 8.21(2x2/5H, d, J=7Hz) .
MS (M+H) =382
Step 5
A mixture of benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-ylcarbamate (1.4 g) , palladium on carbon (140 mg) and methanol (2 ml) was stirred under hydrogen atmosphere (4 atm) at ambient temperature for 8 hours . The catalyst was filtered off, and the filtrate was concentrated in vacuo to give benzyl 4- [2- (4-aminophenyl) ethyl] -1, 3-thiazol-2- ylcarbamate ( 1 .2 g) . 1H-N R (CDCI3) , δ (ppm) : 2. 77-2 . 90 ( 4H, m) , 5.22 (2H, s ) ,
6. 43 ( IH, s ) , 6. 60 ( 2H, d, J=7Hz ) , 6. 92 (2H, d, J=7Hz) , 7 .32-
7 . 40 ( 5H, m) .
MS (M+H) =354 Step 6
A mixture of benzyl 4- [2- (4-aminophenyl) ethyl] -1, 3- thiazol-2-ylcarbamate (25 mg) , cyanamide (6.0 mg) , 4N hydrogen chloride in ethyl acetate (0.018 ml) and ethanol (1 ml) was stirred at 100°C for 72 hours. The reaction mixture was concentrated in vacuo. To the residue were added ethyl acetate
(5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) . The precipitated solid was filtered and washed with ethylacetate and water to give benzyl 4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-2- carbamate (15 mg) .
^■H-N R (DMSO-de), δ (ppm) : 2.63-2.75 (4H, m) , 5.07 (2H, s) ,
6.40(1H, s), 6.94(2H, d, J=7Hz), 7.25-7.40 (7H, m) .
MS (M+H) =396 Production Example 25: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1, 3-thiazol-2- yl}benzamide hydrochloride
Step 1
Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3-thiazol-2- ylcarbamate (2.7 g) prepared in a similar manner according to
Step 4 of Production Example 24 and 6N hydrochloric acid (50 ml) were combined. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the precipitate was filtered in vacuo. The solid was washed with water and acetonitrile to give 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-amine (1.34 g) as a yellow solid. mp. 278-278.5°C
XH-NMR (DMSO-de), δ (ppm): 7.02 (IH, s), 7.33 (2H, s) , 7.77 (2H, d, J=8.5Hz), 8.25(2H, d, J=8.5Hz). MS: 248 (M+H) +
Step 2
4- [ (E) -2- (4-Nitrophenyl) ethenyl] -1, 3-thiazol-2-amine (300 mg) and N, N-dimethylaniline (4 ml) were combined under nitrogen atmosphere, and then benzoyl chloride (0.31 ml) was added dropwise to the suspension. The reaction mixture was stirred at 110°C for 2 hours. After cooled to room temperature, the mixture was diluted with ethyl acetate. The organic solution was washed with IN hydrochloric acid, water, saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual solid was washed with ethyl ether to give N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl}benzamide (298.6 mg) as a yellow solid. mp. 224.5-225°C
XH-NMR (DMSO-de), δ (ppm) : 7.40 (IH, d, J=16.0Hz), 7.45 (IH, s) , 7.53(1H, d, J=16.0Hz), 7.56(2H, t, J=7.0Hz), 7.66(1H, t, J=7.0Hz), 7.84 (2H, d, J=8.5Hz), 8.13 (2H, d, J=7.0Hz), 8.23 (2H, d, J=8.5Hz), 12.80 (IH, brs). MS: 352 (M+H) + Step 3
N-{4- [2- (4-7Λminophenyl) ethyl] -1, 3-thiazol-2-yl}benzamide was prepared in a similar manner according to Step 2 of Production Example 9.
1H-NMR (CDC13) , δ (PPm): 2.82 (4H, s) , 3.57 (2H, brs), 6.53 (IH, s), 6.61 (2H, d, J=8.0Hz), 6.92 (2H, d, J=8.0Hz), 7.50 (2H, t, J=7.0Hz), 7.60 (IH, t, J=7.0Hz), 7.93 (2H, d, J=7.0Hz), 10.15(1H, brs) . MS: 324 (M+H) + Step 4
Di-tert-butyl { [ (4- {2- [2- (benzoylamino) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene }biscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. mp. 143-144°C
1H-NMR (DMSO-ds), δ (ppm) : 1.39(9H, s), 1.51(9H, s) , 2.95(4H, s), 6.86(1H, s), 7.22(2H, d, J=8.5Hz), 7.44(2H, d, J=8.5Hz), 7 . 54 (2H, t, J=7 .5Hz ) , 7 . 63 ( IH, t, J=7 .5Hz) , 8 . 10 (2H, d,
J=7 . 5Hz) , 9. 94 (IH, s) , 11 . 44 ( 1H, brs ) , 12 . 66 ( 1H, brs ) .
MS : 566 (M+H) +
Step 5 The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 229-232°C
XH-NMR (DMSO-de), δ (ppm) : 2.91-3.05 (4H, m) , 6.88 (IH, s) ,
7.15(2H, d, J=8.5Hz), 7.32 (2H, d, J=8.5Hz), 7.44 (3H, brs), 7.54 (2H, t, J=7.5Hz), 7.64 (IH, t, J=7.5Hz), 8.10 (2H, d,
J=7.5Hz) , 9.88 (IH, s) .
MS: 366 (M+H) + free
Production Example 26: Synthesis of N-{4-[2-(4-
{ [amino (imino) ethyl] amino }phenyl) ethyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl } acetamide hydrochloride
Step 1
4- (Methylsulfanyl) benzaldehyde (31.8 g) ,
(acetylamino) acetic acid (24.5 g) and acetic anhydride (35 ml) were combined, and then sodium acetate (8.57 g) was added to the suspension at room temperature under nitrogen atmosphere.
The reaction mixture was refluxed for 3.5 hours. After cooled to room temperature, the mixture was poured into ice-water and ethyl acetate with stirring, and filtered in vacuo. The filtrate was separated. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue and the previously obtained solid were combined, and the mixture was purified by flash column chromatography over silica gel with chloroform / ethyl acetate (30:1) as an eluent, and triturated with isopropyl ether to give (4Z) -2-methyl-4- (4-
(methylsulfanyl)benzylidene) -l,3-oxazol-5 (4H) -one (17.8 g) as a brown solid. mp . 154-155°C
1H-NMR (DMSO-de), δ (ppm): 2.38 (3H, s), 2.53 (3H, s) , 7.19 (IH, s), 7.36(2H, d, J=8.5Hz), 8.12 (2H, d, J=8.5Hz). Step 2 (4Z)-2-Methyl-4- (4- (methylsulfanyl) benzylidene) -1,3- oxazol-5(4H)-one (17.5 g) , 1,4-dioxane (100 ml) and 4N- hydrochloric acid (27 ml) were combined. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the mixture was concentrated in vacuo. Ethyl acetate and water were added to the residue, and the precipitate was filtered in vacuo to give 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoic acid (6.7 g) as a pale brown solid, mp. 165-167°C XH-NMR (DMSO-de), δ (ppm) : 2.48 (3H, s) , 6.37 (IH, s), 7.23 (2H, d, J=8.5Hz), 7.70 (2H, d, J=8.5Hz), 9.44 (IH, s) . MS: 209(M-H)+ Step 3
3- (4- (Methylsulfanyl) phenyl) -2-oxopropanoic acid (16.2 g) , N,N-dimethylformamide (81 ml) and 1,8- diazabicyclo [5.4.0]undec-7-ene (11.5 ml) were combined at 0°C under nitrogen atmosphere. The mixture was stirred at the same temperature for an hour, and then iodomethane (9.59 ml) was added to the solution at the same temperature. The reaction mixture was stirred at room temperature for 4 hours, poured into IN-hydrochloric acid, and extracted with ethyl acetate (twice) . The combined organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with chloroform / ethyl acetate (30:1) as an eluent, and triturated with isopropyl ether / n-hexane to give methyl 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoate (8.6 g) as a dark yellow solid. p. 112-113°C
XH-NMR (DMSO-de), δ (ppm) : 2.48 (3H, s) , 3.79(3H, s) , 6.41 (IH, s), 7.24 (2H, d, J=8.5Hz), 7.72 (2H, d, J=8.5Hz), 9.52 (IH, brs). MS: 223(M-H)+ Step 4
Methyl 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoate (2.84 g) , pyridinium tribromide (4.95 g) , dichloromethane (140 ml) and acetic acid (0.5 ml) were combined at 0°C under nitrogen atmosphere . The reaction mixture was stirred at 0°C for 2 hours, and poured into water. The mixture was extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual oil was dissolved in ethanol (55 ml), and then thiourea (1.25 g) was added to the solution. The reaction mixture was refluxed for 1 hour under nitrogen atmosphere. After cooled to 0°C, water was added to the solution. The precipitate was filtered in vacuo to give methyl 2-amino-5- [4- (methylthio) phenyl] -1, 3-thiazole-4-carboxylate (2.67 g) as a brown solid. mp. 184-185°C
XH-NMR (DMSO-de), δ (ppm) : 2.50 (3H, s) , 3.64 (3H, s) , 7.25 (2H, d, J=8.5Hz), 7.34 (2H, d, J=8.5Hz). MS: 281 (M+H) + Step 5 Methyl 2-amino-5- [4- (methylthio) phenyl] -1, 3-thiazole-4- carboxylate (8.8 g) was dissolved in pyridine (88 ml), and then acetyl chloride (6.7 ml) was added dropwise to the solution at 0°C under nitrogen atmosphere . The reaction mixture was stirred at room temperature for 30 minutes and at 50°C for 2 hours. After cooled to 0°C, water was added to the solution. The precipitate was filtered in vacuo, and the solid was washed with ethyl ether to give methyl 2- (acetylamino) -5- [4- (methylthio) phenyl] -1, 3-thiazole-4-carboxylate (9.3 g) as an off-white solid, mp. 253-254.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.52 (3H, s), 3.70 (3H, s), 7.30 (2H, d, J=8.5Hz), 7.44 (2H, d, J=8.5Hz). MS: 323 (M+H) + Step 6
Methyl 2- (acetylamino) -5- [4- (methylthio) phenyl] -1,3- thiazole-4-carboxylate (200 mg) was dissolved in tetrahydrofuran (2 ml) , and then lithium aluminium hydride (35.3 mg) was added portionwise to the solution at 0°C. The reaction mixture was stirred at 0°C for 30 minutes and at room temperature for 30 minutes, and quenched with methanol. Ethyl acetate and IN hydrochloric acid were added to the mixture, and extracted. The aqueous layer was extracted with ethyl acetate (twice) . The combined organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was dissolved in methanol (0.4 ml) and chloroform (7 ml) . Then manganase (IV) oxide (1.08 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N-{4-formyl-5- [4- (methylthio) phenyl] -1, 3-thiazol-2- yl}acetamide (153.6 mg) as a pale brown amorphous substance. 1H-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s), 2.54 (3H, s) , 7.38 (2H, d, J=8.5Hz), 7.58(2H, d, J=8.5Hz), 9.77(1H, s) , 12.59(1H, brs) . MS: 293 (M+H) + Step 7
N- { 5- [ 4- (Methylthio) phenyl ] -4- [ (E) -2- ( 4- nitrophenyl) ethenyl] -1 , 3-thiazol-2-yl } acetamide was prepared in a similar manner according to Step 1 of Production Example
9. mp. 228-230°C
XH-NMR (DMSO-de), δ (ppm): 2.19 (3H, s) , 2.54 (3H, s) , 7.32 (IH, d, J=16.0Hz), 7.40 (2H, d, J=8.5Hz), 7.46 (IH, d, J=16.0Hz),
7.47(2H, d, J=8.5Hz), 7.79(2H, d, J=9.0Hz), 8.19 (2H, d,
J=9.0Hz), 12.38 (IH, brs).
MS: 412 (M+H) +
Step 8 Potassium peroxymonosulfate (408 mg) was suspended in water (1 ml) and tetrahydrofuran (1 ml), and then N-{5-[4-
(methylthio) phenyl] -4- [ (E) -2- (4-nitrophenyl) ethenyl] -1, 3- thiazol-2-yl} acetamide (182 mg) in tetrahydrofuran (3 ml) was added dropwise to the suspension at 0°C . The reaction mixture was stirred at room temperature for 2 hours, and then water was added to the suspension. The precipitate was filtered in vacuo . The solid was washed with water and ethyl acetate to give N-{5- [4- (methylsulfonyl) phenyl] -4- [ (E) -2- (4- nitrophenyl) ethenyl] -1, 3-thiazol-2-yl} acetamide (83 mg) as a yellow solid. mp. 294-295°C
XH-NMR (DMSO-d6), δ (ppm) : 2.21 (3H, s) , 3.30 (3H, s) , 7.40 (IH, d, J=16.0Hz), 7.54 (IH, d, J=16.0Hz), 7.82 (2H, d, J=8.5Hz),
7.84 (2H, d, J=8.5Hz), 8.05 (2H, d, J=8.5Hz), 8.20 (2H, d, J=8.5Hz), 12.51 (IH, brs).
MS: 442(M-H) +
Step 9
N- {4- [2- (4-Aminophenyl) ethyl] -5- [4-
(methylsulfonyl) phenyl]-l, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 2 of Production
Example 9. mp. 202-204°C
XH-NMR (DMS0-d6), δ (ppm): 2.17 (3H, s) , 2.77-2.88 (4H, ) , 3.24(3H, s), 6.84(2H, brs), 6.45(2H, d, J=8.5Hz), 6.77(2H, d,
J=8.5Hz), 7.49 (2H, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz),
12.34 (IH, brs) .
MS: 416 (M+H) + Step 10
Di-tert-butyl { [ (4- {2- [2- (acetylamino) -5- (4-
(methylsulfonyl) phenyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] ethylidene}biscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 1.51(9H, s), 2.17 (3H, s), 2.97(4H, s), 3.24(3H, s) , 7.11(2H, d, J=8.5Hz), 7.38(2H, d, J=8.5Hz), 7.56(2H, d, J=8.5Hz), 7.92 (2H, d, J=8.5Hz),
9.92(1H, s), 11.43(1H, brs), 12.34(1H, brs).
MS: 658 (M+H) + Step 11
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 145-146.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.99(4H, brs), 3.25(3H, s), 7.11 (2H, d, J=8.0Hz), 7.22 (2H, d, J=8.0Hz), 7.38 (3H, brs),
7.57 (2H, d, J=8.0Hz), 7.94 (2H, d, J=8.0Hz), 9.79 (IH, s) ,
12.36(1H, brs) .
MS: 458 (M+H) + free
Production Example 27: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N-methyl-1, 3- thiazole-5-carboxamide hydrochloride
Step 1
Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3- thiazole-5-carboxylate (310 mg) prepared in a similar manner according to Step 3 of Production Example 22 was dissolved in tetrahydrofuran (6 ml) under nitrogen atmosphere. Then di (tert-butyl) dicarbonate (223 mg) in tetrahydrofuran (1 ml) was added to the solution at room temperature. The reaction mixture was refluxed for 2 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residual solid was washed with ethyl ether to give ethyl 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl }- ethyl) -l,3-thiazole-5-carboxylate (370.7 mg) as an off-white solid. mp. 213-214°C
XH-NMR (DMSO-de), δ (ppm) : 1.26(3H, t, J=7.0Hz), 1.46 (9H, s) , 2.17 (3H, s), 2.85(2H, t, J=7.5Hz), 3.23(2H, t, J=7.5Hz), 4.22 (2H, q, J=7.0Hz), 7.04 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.23 (IH, brs), 12.55 (IH, brs). MS: 434 (M+H) + Step 2
Ethyl 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) - amino] phenyl} ethyl ) -1, 3-thiazole-5-carboxylate (3 g) , 1N- aqueous sodium hydroxide solution (17.3 ml) and ethanol (30 ml) were combined, and the mixture was refluxed for 5 hours. After cooled to room temperature, the organic solvent was removed in vacuo. The aqueous solution was acidified (pH=4) with IN-hydrochloric acid, and extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was dissolved in pyridine (45 ml), and then acetyl chloride (1.48 ml) was added dropwise to the solution at 0°C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours, and pyridine was removed in vacuo. Water was added to the residue, and acidified with IN- hydrochloric acid. The precipitate was collected in vacuo. The solid was washed with water and ethyl ether to give 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) - amino] phenyl}ethyl) -1, 3-thiazole-5-carboxylic acid (2.23 g) as an off-white solid, mp. 237-238°C XH-NMR (DMSO-de) , δ (ppm) : 1.46 (9H, s), 2.16(3H, s) , 2.85 (2H, m) , 3.23 (2H, m) , 7.0 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.24(1H, s), 12.46(1H, s) . MS: 404(M-H) + Step 3
A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1, 3-thiazole-5- carboxylic acid (80 mg) , 30% methylamine in ethanol solution (0.02 ml), 1-hydroxybenzotriazole (29.3 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (39.7 mg) in dichloromethane (1 ml) and N,N-dimethylformamide (0.5 ml) was stirred at ambient temperature for 20 hours. The reaction mixture was poured into saturated sodium hydrogen carbonate solution, and extracted with chloroform. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give tert-butyl 4- (2- {2- (acetylamino) -5- [ (methylamino) carbonyl] -1, 3-thiazol-4-yl} ethyl) phenylcarbamate (92.8 mg) as an off-white amorphous substance. ifi-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.15 (3H, s) , 2.69 (3H, d, J=4.5Hz), 2.78-2.86(2H, m) , 3.12-3.20 (2H, m) , 7.06(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.91 (IH, q, J=4.5Hz), 9.22 (IH, brs) , 12.34 (IH, brs) . MS: 419 (M+H) + Step 4 tert-Butyl 4- (2-{2- (acetylamino) -5- [ (methylamino) carbonyl] -1, 3-thiazol-4-yl} ethyl) phenylcarbamate (95 mg) and trifluoroacetic acid (2 ml) were combined at 0°C. The reaction mixture was stirred at room temperature for an hour, and concentrated in vacuo. The residue was dissolved in chloroform. The organic solution was washed with IN sodium hydroxide solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by preparative silica gel column chromatography with chloroform / methanol (10:1) as an eluent to give 2- (acetylamino) -4- [2- (4- aminophenyl) ethyl] -N-methyl-1, 3-thiazole-5-carboxamide (49 mg) as an off-white amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 2.15 (3H, s) , 2.68 (3H, d, J=4.5Hz), 2.67-2.75(2H, m) , 3.05-3.15 (2H, m) , 4.83(2H, brs), 6.47(2H, d, J=8.5Hz), 6.84 (2H, d, J=8.5Hz), 7.85 (IH, q, J=4.5Hz)-, 12.33 (IH, brs) . MS: 319 (M+H) + Step 5
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -5- (methylaminocarbonyl) -1, 3-thiazol-4-yl] ethyl }phenyl) amino] - methylidene }biscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. mp. 245-246°C
1H-NMR (DMSO-de), δ (ppm) : 1.40 (9H, s) , 1.51 (9H, s) , 2.14 (3H, s), 2.68(3H, d, J=4.5Hz), 2.85-2.94 (2H, m) , 3.14-3.25 (2H, m) , 7.17 (2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 7.88 (IH, q, J=4.5Hz), 9.94 (IH, s) , 11.44 (IH, brs), 12.38 (IH, brs). MS: 561 (M+H) + Step 6
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 101-104°C
XH-NMR (DMSO-de), δ (ppm) : 2.16(3H, s) , 2.67(3H, d, J=4.5Hz), 2.86-2.96(2H, m) , 3.16-3.26 (2H, m) , 7.14 (2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz), 7.41 (3H, brs), 7.99(1H, q, J=4.5Hz), 9.81(1H, s), 12.36(1H, brs). MS: 361 (M+H) + free
Production Example 28: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N-phenyl-1, 3- thiazole-5-carboxamide hydrochloride Step 1
A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole-5-carboxylic acid (80 mg) , aniline (0.019 ml), benzotriazole-1-yl-oxy-tris- pyrrolidino-phosphonium hexafluorophosphate (113 mg) and N, N- diisopropylethylamine (0.076 ml) in N,N-dimethylformamide (2 ml) was stirred at ambient temperature for 21 hours and at 55°C for 3 hours. The reaction mixture was poured into IN hydrochloric acid, and extracted with chloroform. The organic layer was washed with water, saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual solid was washed with ethyl ether to give tert-butyl 4- {2- [2- (acetylamino) -5- (anilinocarbonyl) -1, 3- thiazol-4-yl] ethyl Jphenylcarbamate (57.2 mg) as a colorless solid. mp. 199-200°C
XH-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.18 (3H, s) , 2.81- 2.91 (2H, ) , 3.14-3.24 (2H, m) , 7.05(2H, d, J=8.5Hz), 7.08(1H, t, J=8.5Hz), 7.26-7.36 (4H, m) , 7.64 (2H, d, J=8.5Hz), 9.22 (IH, brs), 9.95(1H, brs), 12.44 (IH, brs). MS: 481 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-phenyl-1, 3- thiazole-5-carboxamide was prepared from tert-butyl 4-{2-[2- (acetylamino) -5- (anilinocarbonyl) -1, 3-thiazol-4- yl] ethyl }phenylcarbamate in a similar manner according to Step 4 of Production Example 27. mp. 104-105°C ifj-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s), 2.71-2.81 (2H, m) , 3.09- 3.18(2H, ) , 5.07(2H, brs), 6.4ff(2H, d, J=8.0Hz), 6.85(2H, d, J=8.0Hz), 7.08 (IH, t, J=8.0Hz), 7.33 (2H, t, J=8.0Hz), 7.65(2H, d, J=8.0Hz), 9.93(1H, brs), 12.44(1H, brs). MS : 381 (M+H) +
Step 3
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (anilinocarbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-phenyl-1, 3- thiazole-5-carboxamide in a similar manner according to Step 5 of Production Example 18. XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 1.51(9H, s) , 2.18(3H, s), 2.87-2.98(2H, m) , 3.17-3.29 (2H, ) , 7.08(1H, t, J=8.0Hz), 7.16(2H, d, J=8.5Hz), 7.31 (2H, t, J=8.0Hz), 7.41 (2H, d, J=8.5Hz), 7.64 (2H, d, J=8.0Hz), 9.93 (2H, s) , 11.43(1H, brs), 12.46(1H, brs) . MS: 623 (M+H) + Step 4
The title compound was prepared from di-tert-butyl { (Z)- [ (4-{2- [2- (acetylamino) -5- (anilinocarbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 152-155°C
XH-NMR (DMSO-de), δ (ppm) : 2.19 (3H, s) , 2.90-3.01 (2H, m) , 3.17- 3.29(2H, m), 7.09(1H, t, J=8.0Hz), 7.13(2H, d, J=8.0Hz), 7.26(2H, d, J=8.0Hz), 7.33 (2H, t, J=8.0Hz), 7.40 (3H, brs), 7.64(2H, d, J=8.0Hz), 9.79(1H, s) , 10.02(1H, s) , 12.46(1H, s) . MS: 423 (M+H) + free
Production Example 29: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N,N-dimethyl-1, 3- thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl [4- (2- {2- (acetylamino) -5- [ (dimethylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] carbamate was prepared from the compound of Step 2 of Production Example 27 in a similar manner according to Step 3 of Production Example 27.
XH-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.14 (3H, s) , 2.84 (4H, s) , 2.85(6H, s), 7.01(2H, d, J=8.5Hz), 7.31(2H, d, J=8.5Hz),
9.21 (IH, brs), 12.33 (IH, brs). MS: 433 (M+H) +
Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N,N-dimethyl-
1, 3-thiazole-5-carboxamide was prepared from tert-butyl [4- (2-
{2- (acetylamino) -5- [ (dimethylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] carbamate in a similar manner according to
Step 4 of Production Example 27.
XH-NMR (DMSO-de), δ (ppm): 2.14 (3H, s) , 2.70-2.77 (4H, m) ,
2.86(6H, s), 4.83(2H, s) , 6.45(2H, d, J=8.5Hz), 6.78(2H, d,
J=8.5Hz), 12.32 (IH, brs). MS: 333 (M+H) +
Step 3
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5-
[ (dimethylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] amino }methylidene)biscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N, -dimethyl-
1, 3-thiazole-5-carboxamide in a similar manner according to
Step 5 of Production Example 18.
^- MR (DMSO-de), δ (ppm): 1.39 (9H, s), 1.51 (9H, s) , 2.14 (3H, s), 2.85(6H, s), 2.89(4H, s) , 7.12 (2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 9.92 (IH, s) , 11.43 (IH, brs), 12.36(1H, brs).
MS: 575 (M+H) +
Step 4
The title compound was prepared from di-tert-butyl ((Z)-
{ [4- (2- {2- (acetylamino) -5- [ (dimethylamino) carbonyl] -1, 3- thiazol-4-yl } ethyl) phenyl] amino }methylidene)biscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 78-80°C
XH-NMR (DMSO-de), δ (ppm): 2.15 (3H, s) , 2.81-2.96 (4H, m) , 2.88(6H, s), 7.11(2H, d, J=8.5Hz), 7.18(2H, d, J=8.5Hz),
7.38(3H, brs), 9.77(1H, s) , 12.34(1H, s) .
MS: 375 (M+H) + free
Production Example 30: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N-benzyl-1, 3- thiazole-5-carboxamide hydrochloride
Step 1 tert-Butyl [4- (2-{2- (acetylamino) -5-
[ (benzylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] carbamate was prepared from the compound of
Step 2 of Production Example 27 in a similar manner according to Step 3 of Production Example 27. mp. 184-185°C
XH-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.15 (3H, s) , 2.79- 2.87(2H, ) , 3.12-3.22 (2H, m) , 4.37(2H, d, J=6.5Hz), 7.02(2H, d, J=8.5Hz), 7.18-7.36(7H, m) , 8.56(1H, t, J=6.5Hz), 9.22 (IH, brs) , 12.37 (IH, brs) .
MS: 495 (M+H) +
Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-benzyl-1, 3- thiazole-5-carboxamide was prepared from tert-butyl [4-(2-{2-
(acetylamino) -5- [ (benzylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] carbamate in a similar manner according to
Step 4 of Production Example 27. mp. 200-201°C
XH-NMR (DMSO-de), δ (ppm) : 2.15 (3H, s) , 2.66-2.76 (2H, m) , 3.07-
3.15(2H, m) , 4.38(2H, d, J=6.0Hz), 4.83(2H, s) , 6.4β(2H, d,
J=8.5Hz), 6.81 (2H, d, J=8.5Hz), 7.20-7.36 (5H, m) , 8.52 (IH, t,
J=6.0Hz), 12.32 (IH, brs). MS: 395 (M+H) +
Step 3
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5-
[ (benzylamino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] amino}methylidene)biscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-benzyl-1, 3- thiazole-5-carboxamide in a similar manner according to Step 5 of Production Example 18. XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 1.51 (9H, s) , 2.15(3H, s), 2.85-2.94(2H, m) , 3.16-3.25 (2H, m) , 4.37(2H, d, J=6.0Hz), 7.12 (2H, d, J=8.5Hz), 7.22-7.36 (5H, m) , 7.40(2H, d, J=8.5Hz), 8.32 (IH, s), 8.54(1H, t, J=6.0Hz), 9.94(1H, brs), 11.44(1H, brs) . MS: 637 (M+H) + Step 4
The title compound was prepared from di-tert-butyl ((Z)- { [4- (2-{2- (acetylamino) -5- [ (benzylamino) carbonyl] -1, 3-thiazol- 4-yl } ethyl) phenyl] amino }methylidene)biscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 128-130°C
^-H-NMR (DMSO-de), δ (ppm): 2.17 (3H, s) , 2.85-2.96 (2H, m) , 3.16-3.27 (2H, m) , 4.36(2H, d, J=6.0Hz), 7.12(2H, d, J=8.5Hz), 7.17-7.35(7H, m) , 7.40(3H, brs), 8.66(1H, t, J=6.0Hz), 9.78(1H, s) , 12.38(1H, s). MS: 437 (M+H) + free
Production Example 31: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- (4-nitrobenzyl) - 1, 3-thiazole-5-carboxamide hydrochloride Step 1
A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl ) amino] phenyl} ethyl) -1, 3-thiazole-5-carboxylic acid (100 mg) , (4-nitrobenzyl) amine hydrochloride (46.5 mg) , 1-hydroxybenzotriazole (36.7 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (40.2 mg) in DMF (2 ml) was stirred at ambient temperature for 73 hours. The reaction mixture was poured into saturated NaHC0, and extracted with CHCI3. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo to give tert-butyl {4- [2- (2- (acetylamino) -5- { [ (4- nitrobenzyl) amino] carbonyl }-l, 3-thiazol-4- yl) ethyl] phenyl} carbamate (123.7 mg) as a pale yellow solid. mp. 204-205°C
XH-NMR (DMSO-de), δ (ppm) : 1.46(9H, s) , 2.16(3H, s) , 2.77- 2.91 (2H, ) , 3.12-3.27 (2H, m) , 4.49(2H, d, J=5.5Hz), 7.01(2H, d, J=8.5Hz), 7.32 (2H, d, J=8.5Hz), 7.52 (2H, d, J=8.5Hz), 8.21 (2H, d, J=8.5Hz), 8.68 (IH, t, J=5.5Hz), 9.21 (IH, s) , 12.40(1H, s) . MS: 540 (M+H) + Step 2 tert-Butyl {4- [2- (2- (acetylamino) -5- { [ (4- nitrobenzyl) amino] carbonyl }-l, 3-thiazol-4- yl) ethyl] phenyl} carbamate (135 mg) and TFA (2 ml) were combined at 0°C. The reaction mixture was stirred at room temperature for an hour, and concentrated in vacuo. The residue was dissolved in MeOH and CHC13, and made basic (pH=8) by lN-NaOH. The mixture was concentrated in vacuo. The residual solid was washed with water to give 2- (acetylamino) - 4- [2- (4-aminophenyl) ethyl] -N- (4-nitrobenzyl) -1, 3-thiazole-5- carboxamide (92.5 mg) as a pale yellow solid, mp. 120-121°C XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.65-2.81 (2H, m) , 3.04- 3.21(2H, m) , 4.49(2H, d, J=5.5Hz), 5.65(2H, brs), 6.54(2H, d, J=8.0Hz), 6.86 (2H, d, J=8.0Hz), 7.54 (2H, d, J=8.5Hz), 8.21 (2H, d, J=8.5Hz), 8.67 (IH, t, J=5.5Hz), 12.39 (IH, s) . MS: 440 (M+H) + Step 3 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- (4- nitrobenzyl) -1, 3-thiazole-5-carboxamide (83 mg) , N,N'- bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (58.6 mg) and THF (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo. The residual solid was washed with AcOEt to give di- tert-butyl [ (Z)- ({4- [2- (2- (acetylamino) -5-{ [ (4- nitrobenzyl) amino] carbonyl }-l, 3-thiazol-4- yl) ethyl]phenyl}amino) methylidene]biscarbamate (95.4 mg) as an off-white solid, mp. 251-253°C
XH-NMR (DMSO-de), δ (PPm) : 1.38(9H, s) , 1.51(9H, s), '2.16(3H, s) , 2.81-2.98(2H, ) , 3.16-3.29 (2H, m) , 4.49(2H, d, J=5.5Hz), 7.12 (2H, d, J=8.0Hz), 7.40 (2H, d, J=8.0Hz), 7.53 (2H, d,
J=8.5Hz), 8.20(2H, d, J=8.5Hz), 8.67 (IH, t, J=5.5Hz), 9.93(1H, s), 11.44(1H, s) , 12.42 (IH, s) . MS: 682 (M+H) + Step 4 Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ (4- nitrobenzyl) amino] carbonyl}-l, 3-thiazol-4- yl) ethyl]phenyl}amino) methylidene]biscarbamate (70 mg) and 4N HCl in 1,4-dioxane solution (1.5 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 14 hours. The solvent was removed in vacuo. The residue was washed with AcOEt to give 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- (4-nitrobenzyl) - 1, 3-thiazole-5-carboxamide hydrochloride (63.7 mg) as a pale green solid. mp. 138-140°C
XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s), 2.81-3.00 (2H, m) , 3.17- 3.30(2H, m) , 4.48(2H, d, J=5.5Hz), 7.12 (2H, d, J=8.0Hz), 7.25 (2H, d, J=8.0Hz), 7.40 (3H, s) , 7.55 (2H, d, J=8.0Hz), 8.21(2H, d, J=8.0Hz), 8.80(1H, t, J=5.5Hz), 9.81 (IH, s) , 12.42(1H, s) .
MS: 482 (M+H) + free
Production Example 32: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- [4- (methylsulfonyl) benzyl]-!, 3-thiazole-5-carboxamide hydrochloride Step 1
A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl}ethyl) -1, 3-thiazole-5-carboxylic acid (120 mg) , [4- (methylthio) benzyl] amine (45.4 mg) , 1- hydroxybenzotriazole (44 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (59.6 mg) in DMF (2 ml) was stirred at r.t. for 17 hours. The reaction mixture was poured into saturated NaHC03, and extracted with CHCI3. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHCI3 / AcOEt (1:1) as an eluent to give tert-butyl (4-{2- [2- (acetylamino) -5- ( { [4- (methylthio) benzyl] amino}carbonyl) - 1, 3-thiazol-4-yl] ethyl }phenyl) carbamate (163.5 mg) as an off- white solid, mp. 182-183°C 1H-N R (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.15 (3H, s) , 2.45 (3H, s), 2.77-2.91(2H, m) , 3.09-3.24 (2H, m) , 4.32(2H, d, J=5.5Hz), 7.02 (2H, d, J=8.5Hz), 7.22 (4H, s) , 7.33(2H, d, J=8.5Hz), 8.54 (IH, t, J=5.5Hz), 9.22 (IH, s) , 12.36(1H, s) . MS: 541 (M+H) + Step 2 Potassium peroxy onosulfate (264 mg) was suspended in water (1 ml) and THF (1 ml), and then tert-butyl (4- {2- [2- (acetylamino) -5- ( { [4- (methylthio) benzyl] amino}carbonyl) -1,3- thiazol-4-yl] ethyl Jphenyl) carbamate (155 mg) in THF (2 ml) was added dropwise to the suspension at 0°C . The reaction mixture was stirred at r.t. for an hour, and then water was added to the suspension. The solution was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo to give tert-butyl (4-{2- [2- (acetylamino) -5- ({ [4-
( ethylsulfonyl) benzyl] amino }carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate (140.6 mg) as an off-white solid, mp. 192.5-193°C 1H-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.16(3H, s) , 2.73- 2.90(2H, m), 3.11-3.27 (2H, m) , 3.18(3H, s) , 4.47 (2H, d, J=5.5Hz), 7.03 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.53 (2H, d, J=8.5Hz), 7.89(2H, d, J=8.5Hz), 8.68 (IH, t, J=5.5Hz), 9.22(1H, s) , 12.39(1H, s) . MS: 573 (M+H) + Step 3
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [4- (methylsulfonyl) benzyl]-l, 3-thiazole-5-carboxamide was prepared in a similar manner according to Step 2 of Production Example 31. mp. 78-80°C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s), 2.65-2.80 (2H, m) , 3.04- 3.22(2H, m) , 3.19 (3H, s) , 4.46(2H, d, J=5.5Hz), 4.82(2H, s) , 6.46(2H, d, J=8.0Hz), 6.81 (2H, d, J=8.0Hz), 7.53 (2H, d, J=8.0Hz), 7.89 (2H, d, J=8.0Hz), 8.63 (IH, t, J=5.5Hz), 12.39(1H, s) . MS: 473 (M+H) + Step 4
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [4- (methylsulfonyl) benzyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] ethylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. XH-NMR (DMSO-de), δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.16 (3H, s), 2.81-2.98(2H, m) , 3.18 (3H, s) , 3.18-3.29 (2H, m) , 4.46(2H, d, J=5.5Hz), 7.14 (2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 7.54 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.5Hz), 8.67 (IH, t, J=5.5Hz), 9.94 (IH, s) , 11.44(1H, s) , 12.41(1H, s) . MS: 715 (M+H) + Step 5
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 94-96°C XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.85-2.99 (2H, ) ,
3.19(3H, s), 3.19-3.30(2H, m) , 4.46(2H, d, J=5.5Hz), 7.13(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.40(3H, s) , 7.54(2H, d, J=8.5Hz), 7.89(2H, d, J=8.5Hz), 8.78 (IH, t, J=5.5Hz)-, 9.80(1H, s) , 12.4K1H, s) . MS: 515 (M+H) + free
Production Example 33: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [4- (trifluoromethyl) benzyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [4- (trifluoromethyl) benzyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared from 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.16(3H, s) , 2.73- 2.92(2H, m) , 3.12-3.25 (2H, m) , 4.45(2H, d, J=5.5Hz), 7.01(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.47 (2H, d, J=8.5Hz), 7.69(2H, d, J=8.5Hz), 8.64 (IH, t, J=5.5Hz), 9.22 (IH, s) , 12.39(1H, s) . MS: 563 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [4- (trifluoromethyl) benzyl] -1, 3-thiazole-5-carboxamide was prepared in a similar manner according to Step 2 of Production Example 31. mp. 199-201°C XH-NMR (DMSO-de), δ (ppm): 2.10 (3H, s) , 2.63-2.78 (2H, m) , 3.02-
3.18(2H, m) , 4.44(2H, d, J=5.5Hz), 4.81(2H, s) , 6.46(2H, d, J=8.0Hz), 6.81(2H, d, J=8.0Hz), 7.49 (2H, d, J=8.0Hz), 7.69(2H, d, J=8.0Hz), 8.44(1H, t, J=5.5Hz), 12.39(1H, s) . MS: 463 (M+H) + Step 3
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [4- (trifluoromethyl) benzyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. mp. 188-190°C
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.16 (3H, s), 2.83-2.97(2H, m) , 3.17-3.29 (2H, m) , 4.44 (2H, d, J=5.5Hz), 7.12 (2H, d, J=8.5Hz), 7.40 (2H, d, J=8.5Hz), 7.48 (2H, d, J=8.0Hz), 7.69 (2H, d, J=8.0Hz), 8.63(1H, t, J=5.5Hz), 9.94(1H, s), 11.44(1H, s), 12.40(1H, s) . MS: 705 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 156-158°C
XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.82-2.99 (2H, m) , 3.18- 3.31 (2H, ) , 4.44 (2H, d, J=5.5Hz), 7.12 (2H, d, J=8.0Hz), 7.25(2H, d, J=8.0Hz), 7.40(3H, s) , 7.51(2H, d, J=8.0Hz), 7.71(2H, d, J=8.0Hz), 8.76(1H, t, J=5.5Hz), 9.81 (IH, s) , 12.4K1H, s) . MS: 505 (M+H) + free
Production Example 34 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- (3-pyridinyl) -1,3- thiazole-5-carboxamide dihydrochloride Step 1
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3-thiazole- 5-carboxylic acid was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] henyl}ethyl) -1, 3-thiazole-5- carboxylic acid in a similar manner according to Step 2 of Production Example 31. mp. 211.5-212°C XH-NMR (DMSO-de), δ (ppm): 2.15 (3H, s) , 2.67-2.80 (2H, m) ,
3.09-3.23 (2H, m) , 6.51 (2H, d, J=8.0Hz), 6.85 (2H, d, J=8.0Hz), 12.44 (IH, brs) . MS: 306 (M+H) + Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3-thiazole-
5-carboxylic acid (106 mg) was suspended in THF (2 ml) under N2 atmosphere. Bis (trimethylsilyl) acetamide (0.253 ml) was added to the suspension at r.t., and the mixture was stirred at r.t. for 15 minutes. Then, N,N' -bis (tert-butoxycarbonyl) -1H- pyrazole-1-carboxamidine (119 mg) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 20 hours, and concentrated in vacuo . The residue was dissolved in CHC13. • The organic solution was washed with 1N-HC1, water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual solid was washed with ethyl ether to give 2-
(acetylamino) -4-{2- [4- ( { (Z) - [ (tert-butoxycarbonyl) amino] (tert- butoxycarbonyl) iminomethyl } amino) phenyl] ethyl }-l, 3-thiazole-5- carboxylic acid (115.8 mg) as a pale brown solid, mp. 221.5-223°C XH-NMR (DMSO-de), δ (ppm): 1.44 (18H, brs), 2.16(3H, s) , 2.91(2H, t, J=7.0Hz), 3.26(2H, t, J=7.0Hz), 7.17 (2H, d, J=8.5Hz), 7.43 (2H, d, J=8.5Hz), 9.95 (IH, brs), 11.43 (IH, brs), 12.48(1H, s) . MS: 548 (M+H) + Step 3
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (3- pyridinylamino) carbonyl] -1, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMSO-de), δ (ppm): 1.39(9H, s) , 1.51(9H, s) , 2.19(3H, s), 2.87-3.00(2H, m) , 3.19-3.32 (2H, m) , 7.16(2H, d, J=8.5Hz), 7.35 (IH, dd, J=8.5, 4.5Hz), 7.41 (2H, d, J=8.5Hz), 8.07 (IH, m) , 8.28(1H, dd, J=4.5, 1.5Hz), 8.81(1H, d, J=1.5Hz), 9.93(1H, s) , 10.1K1H, s), 11.43(1H, s) , 12.51(1H, s) . MS: 624 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMS0-d6), δ (ppm): 2.21 (3H, s) , 2.84-3.07 (2H, m) , 3.19- 3.39(2H, m) , 7.13(2H, d, J=7.5Hz), 7.28 (2H, d, J=7.5Hz), 7.45(3H, brs), 7.37-8.81 (4H, m) , 9.93(1H, s) , 10.75(1H, s) , 12.61 (IH, s) . MS: 424 (M+H) + free
Production Example 35: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- (4-phenoxybenzyl) - 1, 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl [ (Z)-({4-[2- (2- (acetylamino) -5- { [ (4- phenoxybenzyl) amino] carbonyl }-l, 3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm): 1.38 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s), 2.81-2.97 (2H, m) , 3.13-3.28 (2H, m) , 4.35(2H, d, J=5.5Hz), 6.97 (4H, d, J=8.5Hz), 7.11 (IH, t, J=8.5Hz), 7.13 (2H, d, J=8.5Hz), 7.29-7.41(6H, m) , 8.54(1H, t, J=5.5Hz), 9.93(1H, s) , 11.44 (IH, brs), 12.37 (IH, brs). MS: 729 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.17 (3H, s) , 2.81-3.00 (2H, m) , 3.13- 3.30 (2H, m) , 4.35 (2H, d, J=5.5Hz), 6.98 (4H, d, J=8.5Hz), 7.12 (2H, d, J=8.5Hz), 7.13 (IH, t, J=8.5Hz), 7.25 (2H, d, J=8.5Hz), 7.32 (2H, d, J=8.5Hz), 7.40 (2H, t, J=8.5Hz), 7.46 (3H, brs), 8.67 (IH, t, J=5.5Hz), 9.92 (IH, s) , 12.39(1H, brs). MS: 529 (M+H) + free
Production Example 36: Synthesis of ethyl 4- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -1, 3-thiazol- 5-yl} carbonyl) -1-piperazinecarboxylate Step 1
Ethyl 4-[ (2- (acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl}-!, 3-thiazol-5- yl) carbonyl] -1-piperazinecarboxylate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMSO-de), δ (ppm) : 1.17 (3H, t, J=7.0Hz), 1.39 (9H, brs), 1.50(9H, brs), 2.15(3H, s) , 2.90(4H, m) , 3.38(8H, brs), 4.03 (2H, q, J=7.0Hz), 7.12 (2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 9.94 (IH, s) , 11.46(1H, brs), 12.40 (IH, brs). MS: 688 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. mp. 180-182.5°C
XH-NMR (DMSO-de), δ (ppm): 1.18 (3H, t, J=7.0Hz), 2.07 (3H, s) , 2.77(4H, s), 3.43(8H, brs), 4.05(2H, q, J=7.0Hz), 6.89(2H, d, J=7.5Hz), 7.02 (2H, d, J=7.5Hz). MS: 488 (M+H) +
Production Example 37: Synthesis' of N-{5- [ (4-acetyl-l- piperazinyl) carbonyl] -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide
Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ (4-acetyl-
1-piperazinyl) carbonyl] -1, 3-thiazol-4- yl } ethyl) phenyl] amino } ethylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32. H-NMR (DMS0-d6), δ (ppm) : 1.39 (9H, brs), 1.50 (9H, brs), 1.98 (3H, s), 2.15(3H, s) , 2.90(4H, m) , 3.40(8H, brs), 7.13 (2H, d, J=8.5Hz), 7.41(2H, d, J=8.5Hz), 9.93(1H, s) , 11.43(1H, brs), 12.40 (IH, brs) .
MS: 658 (M+H) +
Step 2 The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. p. 206-207.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.01 (3H, s) , 2.05 (3H, s) , 2.73 (4H, s), 3.42(8H, brs), 6.77-7.08 (4H, m) . MS: 458 (M+H) +
Production Example 38: Synthesis of N-(4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- { [4-
(methylsulfonyl) -1-piperazinyl] carbonyl }-l, 3-thiazol-2- yl) acetamide hydrochloride Step 1
Di-tert-butyl [ (Z)-({4-[2- (2- (acetylamino) -5- { [4-
( ethy1sulfonyl) -1-piperazinyl] carbonyl}-!, 3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
31.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s), 2.89(3H, s), 2.82-2.96(4H, m) , 3.01-3.13 (4H, m) , 3.44- 3.59(4H, m), 7.14 (2H, d, J=8.5Hz), 7.42 (2H, d, J=8.5Hz),
9.94(1H, s), 11.44(1H, brs), 12.40(1H, brs) .
MS: 694 (M+H) +
Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 118-119°C
XH-NMR (DMSO-de), δ (ppm) : 2.16(3H, s) , 2.90(3H, s), -2.83-
2.98(4H, m) , 3.06-3.18 (4H, m) , 3.50-3.61 (4H, m) , 7.12(2H, d, J=8.5Hz), 7.21 (2H, d, J=8.5Hz), 7.43 (3H, s) , 9.90 (IH, s) ,
12.4K1H, s) .
MS: 494 (M+H) + free
Production Example 39: Synthesis of N-[4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- (4- thiomorpholinylcarbonyl) -1, 3-thiazol-2-yl] acetamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (4- thiomorpholinylcarbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 1.51(9H, s) , 2.15(3H, s), 2.45-2.6K4H, m) , 2.79-2.99 (4H, m) , 3.55-3.70 (4H, ) ,
7.13 (2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 9.92 (IH, s) ,
11.44 (IH, brs), 12.38 (IH, brs).
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 134-135.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s), 2.47-2.62 (4H, m) , 2.80-
3.00 (4H, m) , 3.59-3.73(4H, m) , 7.12 (2H, d, J=8.5Hz), 7.20(2H, d, J=8 .5Hz) , 7 .39 ( 3H, s) , 9. 80 ( 1H, s ) , 12 . 38 ( IH, s) .
MS : 433 (M+H) + free
Production Example 40: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- [ (1, l-dioxido-4- thiomorpholinyl) carbonyl] -1, 3-thiazol-2-yl} acetamide hydrochloride
Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [• (1, 1- dioxido-4-thiomorpholinyl) carbonyl] -1, 3-thiazol-4- yl}ethyl) phenyl] amino }methylidene) biscarbamate was prepared from the compound obtained in Step 1 of Production Example 39 in a similar manner according to Step 2 of Production Example
32. mp. 270-271.5°C XH-NMR (DMS0-d6), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.15(3H, s), 2.85-2.96(4H, ) , 3.09-3.21 (4H, m) , 3.69-3.83 (4H, m) ,
7.13 (2H, d, J=8.5Hz), 7.40 (2H, d, J=8.5Hz), 9.93 (IH, s) ,
11.47 (IH, brs), 12.42 (IH, brs).
MS: 665 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 185-186°C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s), 2.92 (4H, s) , 3.11- 3.28(4H, m), 3.76-3.91 (4H, m) , 7.12 (2H, d, J=8.5Hz), 7.22(2H, d, J=8.5Hz), 7.40(3H, s) , 9.84(1H, s), 12.40(1H, s) .
MS: 465 (M+H) + free
Production Example 41: Synthesis of ethyl 1- ( {2- (acetylamino) -
4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1,3-thiazol- 5-yl }carbonyl) -4-piperidinecarboxylate hydrochloride
Step 1
Ethyl l-{ [2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-!, 3-thiazol-5- yl] carbonyl}-4-piperidinecarboxylate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMSO-de), δ (ppm): 1.17 (3H, t, J=7.0Hz), 1.32-1.56 (2H, m) , 1.39(9H, s), 1.50(9H, s) , 1.73-1.89 (2H, m) , 2.15(3H, s) , 2.44-2.64(lH, m) , 2.80-3.01 (6H, m) , 3.74-3.93 (2H, m) , 4.06(2H, q, J=7.0Hz), 7.11 (2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 9.93(1H, s), 11.45(1H, brs), 12.36(1H, brs). MS: 687 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.18 (3H, t, J=7.0Hz), 1.29-1.54 (2H, m) , 1.73-1.93(2H, m) , 2.15 (3H, s) , 2.44-2.71 (IH, m) , 2.79- 3.09(6H, m) , 3.79-3.96 (2H, m) , 4.09(2H, q, J=7.0Hz), 7.11(2H, d, J=8.5Hz), 7.19(2H, d, J=8.5Hz), 7.40(3H, s) , 9.83 (IH, s) , 12.37(1H, s) . MS: 487 (M+H) + free Production Example 42: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl} carbonyl) -4-piperidinecarboxamide hydrochloride Step 1
Ethyl 1- [ (2- (acetylamino) -4-{2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl }-l, 3-thiazol-5- yl) carbonyl] -4-piperidinecarboxylate (277.9 mg) , IN-NaOH (1.01 ml) and 1,4-dioxane (3 ml) were combined at 0°C, and the reaction mixture was stirred at r.t. for 3 hours. The mixture was neutrallized with 1N-HC1, and the organic solvent was evaporated in vacuo. The residual aqueous solution was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo to give 1- [ (2- (acetylamino) -4- {2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl}amino) phenyl] ethyl }-l, 3-thiazol-5- yl) carbonyl] -4-piperidinecarboxylic acid (262.4 mg) as a pale yellow amorphous substance.
XH-NMR (DMSO-de), δ (ppm): 1.28-1.59 (2H, m) , 1.45 (18H, s) , 1.72-1.90(2H, m) , 2.15(3H, s) , 2.40-2.59 (IH, m) , 2.78-3.03 (6H, m) , 3.77-3.94 (2H, m) , 7.12 (2H, d, J=8.5Hz), 7.40 (2H, d, J=8.5Hz), 9.94 (IH, brs), 11.44 (IH, brs), 12.36(1H, s) . MS: 659 (M+H) + Step 2
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [4- (aminocarbonyl) -1-piperidinyl] carbonyl }-1, 3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMSO-de), δ (ppm) : 1.29-1.55 (2H, m) , 1.39 (9H, s) , 1.50 (9H, s), 1.62-1.79(2H, m) , 2.14(3H, s) , 2.22-2.43 (IH, m) , 2.78-2.99(6H, m) , 3.89-4.07 (2H, m) , 6.80(1H, s) , 7.14(2H, d, J=8.5Hz), 7.27 (IH, s) , 7.41(2H, d, J=8.5Hz), 9.93(1H, s) , 11.44(1H, brs), 12.36(1H, s) . MS: 658 (M+H) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMS0-d6) , δ (ppm): 1.27-1.52 (2H, m) , 1.64-
1.79(2H, m), 2.15(3H, s) , 2.25-2.44 (2H, m) , 2.76-3.02 (6H, m) , 6.82(1H, br), 7.11(2H, d, J=8.5 Hz), 7.19(2H, d, J=8.5 Hz), 7.34(1H, br), 7.41(4H, s) , 9.83(1H, s) , 12.36(1H, s) . MS: 458 (M+H) + free Production Example 43: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl } carbonyl) -N-methyl-4-piperidinecarboxamide hydrochloride Step 1 Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( {4- [ (methylamino) carbonyl]-l-piperidinyl} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 1 of Production Example 42 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm): 1.30-1.75 (4H, m) , 1.39 (9H, s) , 1.50 (9H, s), 2.14(3H, s) , 2.22-2.42 (IH, m) , 2.55 (2H,. d, J=4.5Hz), 2.78-2.99(6H, m) , 3.90-4.03 (2H, m) , 7.14(2H, d, J=8.5Hz), 7.41 (2H, d, J=8.5Hz), 7.73 (IH, q, J=4.5Hz), 9.93 (IH, s), 11.43(1H, brs), 12.36(1H, brs). MS: 672 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.29-1.52 (2H, m) , 1.60- 1.77(2H, m) , 2.15(3H, s) , 2.55(3H, d, J=4.5 Hz), 2.78-2.98 (6H, m) , 3.88-4.06 (3H, m) , 7.11 (2H, d, J=8.5 Hz), 7.19 (2H, d, J=8.5 Hz), 7.37(4H, br) , 7.81(1H, m) , 9.75(1H, s) , 12.36(1H, s) . MS: 472 (M+H) + free
Production Example 44 : Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl }carbonyl) -N, N-dimethyl-4-piperidinecarboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4- [ (dimethylamino) carbonyl] -1-piperidinyl} carbonyl) -1, 3-thiazol- 4-yl] ethyl }phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 1 of Production Example 42 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm) : 1.30-1.70 (4H, m) , 1.39 (9H, s) , 1.50(9H, s), 2.15(3H, s) , 2.80(3H, s), 2.79-3.01 (7H, m) , 3 . 00 ( 3H, s ) , 3 . 88-4 . 06 (2H, m) , 7 . 13 ( 2H, d, J=8 . 5Hz) , 7 . 41 (2H, d, J=8.5Hz), 9.92(1H, s) , 11.42(1H, brs), 12.36(1H, brs). MS: 686 (M+H) + Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.27-1.51 (2H, m) , 1.55- 1.72(2H, m) , 2.15 (3H, s) , 2.80(3H, s) , 2.81-3.00 (6H, m) , 3.03(3H, s), 3.89-3.96(3H, m) , 7.11(2H, d, J=8.5 Hz), 7.20(2H, d, J=8.5 Hz), 7.37(4H, br) , 9.79(1H, s) , 12.36(1H, s) . MS: 486 (M+H) +
Production Example 45: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5-phenyl-l, 3-thiazol- 2-yl}acetamide hydrochloride Step 1
2-Oxo-3-phenylpropanoic acid (20 g) , DMF (100 ml) and DBU (18.2 ml) were combined at 0°C under N2 atmosphere, and the mixture was stirred at 0°C for an hour. Then iodomethane (15.2 ml) was added to the solution at 0°C. The reaction mixture was stirred at r.t. for 3 hours, and poured into IN-HCl. The mixture was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / AcOEt (30:1) as an eluent, and triturated with IPE / n-Hexane to give methyl 2-oxo-3-phenylpropanoate (11.2 g) as a pale yellow wax. XH-NMR (CDC13) , δ (PPm): 3.92 (3H, s) , 6.42 (IH, s) , 6.53 (IH, s) , 7.28-7.42 (3H, m) , 7.77 (2H, dd, J=8.5, 1.5Hz). MS: 179 (M+H) + Step 2
Methyl 2-oxo-3-phenylpropanoate (11 g) , pyridinium tribromide (24.1 g) , CH2C12 (490 ml) and AcOH (1.5 ml) were combined at 0°C under N2 atmosphere. The reaction mixture was stirred at 0°C for 1.5 hours, poured into water and participated. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo. The residual oil was dissolved in EtOH (190 ml), and then thiourea (6.11 g) was added to the solution. The reaction mixture was refluxed for an hour under N2 atmosphere. After cooled to 0°C, water was added to the solution. The precipitate was filtered in vacuo to give methyl 2-amino-5-phenyl-l, 3-thiazole-4-carboxylate (6.63 g) as an off-white solid. mp. 208-208.5°C
XH-NMR (DMSO-de), δ (ppm): 3.67 (3H, s) , 7.38-7.53 (5H, m) . MS: 235 (M+H) + Step 3
Methyl 2-amino-5-phenyl-l, 3-thiazole-4-carboxylate (3 g) was dissolved in pyridine (30 ml) , and then acetyl chloride (2.73 ml) was added dropwise to the solution at 0°C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1.5 hours. Water was added to the solution at 0°C. The precipitate was filtered in vacuo, and the solid was washed with ethyl ether to give methyl 2- (acetylamino) -5-phenyl-l, 3- thiazole-4-carboxylate (2.37 g) as a pale brown solid, mp. 224.5-225.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 3.68 (3H, s) , 7.39- 7.57 (5H, m) , 12.56(1H, s) . MS: 277 (M+H) + Step 4
Methyl 2- (acetylamino) -5-phenyl-l, 3-thiazole-4- carboxylate (2.34 g) was suspended in THF (23 ml), and then lithium aluminium hydride (482 mg) was added portionwise to the solution at 0°C. The reaction mixture was stirred at 0°C for 1.5 hours and quenched with MeOH. AcOEt and IN HCl were added to the mixture, and the mixture was extracted. The aqueous layer was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid was dissolved in MeOH (5 ml) and CHC13 (90 ml) . Then manganase (IV) oxide (11 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N- (4-formyl-5-phenyl-l, 3-thiazol-2-yl) acetamide (705.2 mg) as a brown amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 2.19 (3H, s) , 7.49-7.58 (3H, m) , 7.60- 7.69(2H, m), 9.78(1H, s) , 12.60(1H, s) . MS: 247 (M+H) + Step 5 1- (Bromomethyl) -4-nitrobenzene (1.03 g) , triphenylphosphine (1.25 g) and DMF (14 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 6 hours. Then potassium tert-butoxide (629 mg) and N-(4- formyl-5-phenyl-l, 3-thiazol-2-yl) acetamide (690 mg) were added to the mixture, and the mixture was stirred at r.t. for 13 hours. The reaction mixture was poured into ice-water, and extracted with AcOEt. The organic layer was washed with 1N- HC1, water and brine, dried over anhydrous MgS0, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / AcOEt (1:1) as an eluent to give a mixture of N-{4- [ (E) -2- (4- nitrophenyl) vinyl] -5-phenyl-l, 3-thiazol-2-yl } acetamide and N- {4- [ (Z) -2- (4-nitrophenyl) vinyl] -5-phenyl-l, 3-thiazol-2- yl} acetamide (E : Z = 2 : 1) (1.02 g) as an orange wax. XH-NMR (DMSO-de), δ (ppm) : 2.13(3Hxl/3, s) , 2.19(3Hx2/3, s) , 6.65(lHxl/3, d, J=12.5Hz), 6.78(lHxl/3, d, J=12.5Hz), 7.32(lHx2/3, d, J=15.5Hz), 7.39-7.59 (5H+lHx2/3, m) , 7.61(2Hxl/3, d, J=9.0Hz), 7.77(2Hx2/3, d, J=9.0Hz), 8 . 13 (2Hxl/3, d, J=9. 0Hz) , 8 . 19 (2Hx2/3, d, J=9. 0Hz) , 12 . 33 ( 1H, brs) .
MS : 366 (M+H) +
Step 6 A mixture of N- { 4- [ (E) -2- (4-nitrophenyl) vinyl] -5-phenyl- l,3-thiazol-2-yl}acetamide and N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -5-phenyl-l, 3-thiazol-2-yl}acetamide (E : Z
= 2 : 1) (600 mg) , 10% palladium carbon (657 mg) , MeOH (6 ml),
THF (6 ml) and AcOH (1 ml) were combined. The reaction mixture was stirred under 3 atm H2 at r.t. for 3.5 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo .
IN-NaOH was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over MgS04, and concentrated in vacuo to give N-{4- [2- (4-aminophenyl) ethyl] -5-phenyl-l, 3-thiazol-2- yl}acetamide (528.6mg) as a pale brown amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 2.15 (3H, s), 2.80 (4H, s) , 4.82 (2H, s), 6.45(2H, d, J=8.5Hz), 6.78 (2H, d, J=8.5Hz), 7.21-7.44 (5H, m) , 12.18 (IH, brs) . MS: 338 (M+H) +
Step 7
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5-phenyl-l, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.21 (9H, s) , 1.44 (9H, s) , 2.15 (3H, s), 2.83-2.98(4H, m) , 7.10(2H, d, J=8.5Hz), 7.22-7.47 (7H, m) ,
9.92(1H, s), 11.43(1H, s) , 12.22(1H, s) .
MS: 580 (M+H) + Step 8
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 80-82°C XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.83-3.08 (4H, ) , 7.1K2H, d, J=8.0Hz), 7.21 (2H, d, J=8.0Hz), 7.29-7.54 (8H, m) , 9.94(1H, s), 12.22(1H, brs). MS: 380 (M+H) + free Production Example 46: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -5-benzyl-l, 3-thiazol- 2-yl}acetamide hydrochloride Step 1
To a suspension of copper (II) bromide (9.75 g) in AcOEt (150 ml) was added a solution of ethyl 2-oxo-4-phenylbutanoate (3 g) in 75 ml of CHC1. The reaction mixture was refluxed for 23 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1). The solvent was removed in vacuo to give ethyl 3-bromo-2-oxo-4- phenylbutanoate (4.2g) as a yellow liquid.
XH-NMR (CDCI3) , δ (PPm): 1.37 (3H, t, J=7.0Hz), 3.25 (IH, dd, J=14.5, 7.5Hz), 3.54 (IH, dd, J=14.5, 7.5Hz), 4.35 (2H, q, J=7.0Hz), 5.27 (IH, d, J=7.5Hz), 7.18-7.41 (5H, ) . Step 2 Ethyl 3-bromo-2-oxo-4-phenylbutanoate (5.8 g) was dissolved in EtOH (110 ml), and then thiourea (3.1 g) was added to the solution. The reaction mixture was refluxed for 2 hours under N2 atmosphere. The cooled reaction mixture was evaporated in vacuo. The residual solid was suspended (pH=8) in saturated NaHC03 and water. The solid was collected by filtration, and purified by flash column chromatography over silica gel with CHC13 / MeOH (10:1) as an eluent to give ethyl 2-amino-5-benzyl-l, 3-thiazole-4-carboxylate (808.2 mg) as a yellow wax. XH-NMR (DMSO-de), δ (ppm) : 1.25(3H, t, J=7.0Hz), 4.21(2H, q, J=7.0Hz), 4.33(2H, s) , 7.02(2H, s) , 7.11-7.39 (5H, m) . MS: 263 (M+H) + Step 3 Ethyl 2- (acetylamino) -5-benzyl-l, 3-thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 178-180°C XH- MR (DMSO-de), δ (ppm) : 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) , 4.28(2H, q, J=7.0Hz), 4.48(2H, s) , 7.19-7.39 (5H, m) , 12.41(1H, s).
MS: 305 (M+H) + Step 4 Ethyl 2- (acetylamino) -5-benzyl-l, 3-thiazole-4-carboxylate
(1.0 g) was dissolved in THF(20 ml), and then lithium borohydride (124 mg) was added portionwise to the solution at 0°C. The reaction mixture was refluxed for 4.5 hours and quenched with MeOH. The mixture was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent. The residual amorphous substance was dissolved in MeOH (1 ml) and CHC13 (8 ml) . Then manganase ( IV) oxide (1.26 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N- (5-benzyl-4-formyl-l, 3-thiazol-2- yl) acetamide (251 mg) as a pale yellow solid. mp. 191-192.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 4.53 (2H, s) , 7.19- 7.40(5H, m) , 10.04(1H, s) , 12.34(1H, s) . MS: 261 (M+H) + Step 5 N-{5-Benzyl-4-[ (Z) -2- (4-nitrophenyl) vinyl] -l,3-thiazol-2- yl}acetamide was prepared in a similar manner according to Step 5 of Production Example 45. Z : E = 2 : 1 XH-NMR (DMSO-de), δ (ppm): 2.08 (3Hx2/3,' s) , 2.12(3Hxl/3, s) ,
4.08(2Hx2/3, s) , 4.34(2Hxl/3, s) , 6.72(lHx2/3, d, J=12.5Hz),
6.86(lHx2/3, d, J=12.5Hz), 7.17-7.39 (5H+2Hxl/3, m) ,
7.66(2Hx2/3, d, J=9.0Hz), 7.92(2Hxl/3, d, J=9.0Hz), 8.14(2Hx2/3, d, J=9.0Hz), 8.22(2Hxl/3, d, J=9.0Hz),
11.85(lHx2/3, s) , 12.16 (lHxl/3, s) .
MS: 380 (M+H) +
Step 6
N-{4- [2- (4-Aminophenyl) ethyl] -5-benzyl-l, 3-thiazol-2- yl} acetamide was prepared in a similar manner according to
Step 6 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm) : 2.07 (3H, s) , 2.59-2.85 (4H, m) ,
3.85(2H, s), 4.84(2H, s) , 6.46(2H, d, J=8.5Hz), 6.78(2H, d,
J=8.5Hz), 7.07 (2H, d, J=8.0Hz), 7.16-7.31 (3H, m) , 11.96(1H, s).
MS: 352 (M+H) +
Step 7
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5-benzyl-l, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 1.51 (9H, s) , 2.07 (3H, s), 2.85(4H, s), 3.89(2H, s) , 7.05-7.33 (7H, m) , 7.42(2H, d,
J=8.5Hz), 9.95(1H, s) , 11.44(1H, s) , 11.99(1H, s) . MS: 594 (M+H) +
Step 8
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 97-99°C XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s), 2.86(4H, s) , 3.93 (2H, s), 7.05-7.37(9H, m) , 7.47(3H, s) , 9.98(1H, s) , 12.01(1H, brs) .
MS: 394 (M+H) + free Production Example 47: Synthesis of N-{4-[2-(4- aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2- yl}acetamide Step 1 3- (4-Mercaptophenyl)propanoic acid (5 g) , K2C03 (11.4 g) and DMF (30 ml) were combined, and iodomethane (5.12 ml) was added dropwise to the mixture at 0°C under N2 atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and poured into ice-water. The mixture was extracted with AcOEt. The organic layer was washed with water (twice) and brine, dried over anhydrous MgS04, and concentrated in vacuo to give methyl 3- [4- (methylthio) phenyl]propanoate (4.19 g) as pale yellow oil. XH-NMR (CDC13) , δ (ppm): 2.47 (3H, s) , 2.61 (2H, t, J=8.0Hz)-, 2.91 (2H, t, J=8.0Hz), 3.67 (3H, s) , 7.12 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz) . Step 2
Sodium methoxide, 28% solution in MeOH (3.67 ml), was added dropwise to the mixture of methyl 3- [4- (methylthio) phenyl]propanoate (4 g) and diethyl oxalate (5.17 ml) at 0°C with stirring. The reaction mixture was stirred at 65°C for 30 minutes under reduced pressure. 15% Aqueous H2S04 (35 ml) was added to the mixture, and the mixture was refluxed for 15 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual oil was dissolved in EtOH (20 ml), and concentrated H2S04 (0.4 ml) was added dropwise to the solution. The reaction mixture was refluxed for 2 hours. After cooled to r.t., EtOH was removed in vacuo. AcOEt and water were added to the residue, and extracted. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (6:1) as an eluent to give ethyl 4- [4- (methylthio) phenyl] -2- oxobutanoate (2.43 g) as a yellow liquid.
XH-NMR (CDC13) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.46(3H, s) , 2.92 (2H, t, J=7.0Hz), 3.16 (2H, t, J=7.0Hz), 4.31 (2H, q,
J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz).
Step 3
Ethyl 3-bromo-4- [4- (methylthio) henyl] -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production Example 46.
XH-NMR (CDCI3), δ (ppm): 1.37 (3H, t, J=7.0Hz), 2.47 (3H, s),
3.20(1H, dd, J=14.5, 7.5Hz), 3.49(1H, dd, J=14.5, 7.5Hz),
4.35(2H, q, J=7.0Hz), 5.22 (IH, d, J=7.5Hz), 7.17 (2H, d, ■
J=8.5Hz), 7.20 (2H, d, J=8.5Hz). Step 4
Ethyl 2-amino-5- [4- (methylthio) benzyl] -1, 3-thiazole-4- carboxylate was prepared in a similar manner according to Step
2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 1.25 (3H, t, J=7.0Hz), 2.44 (3H, s) , 4.20(2H, q, J=7.0Hz), 4.28(2H, s) , 7.02(2H, s) , 7.19(4H, s) .
MS: 309 (M+H) +
Step 5
Ethyl 2- (acetylamino) -5- [4- (methylthio) benzyl] -1, 3- thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 205-206°C
XH-NMR (DMSO-de), δ (ppm): 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) ,
2.45(3H, s), 4.27(2H, q, J=7.0Hz), 4.43(2H, s) , 7.22(4H, s) ,
12.41(1H, s) . MS: 351 (M+H) +
Step 6
N-{4-Formyl-5- [4- (methylthio) benzyl] -1, 3-thiazol-2- yl} acetamide was prepared in a similar manner according to Step 4 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s) , 2.45 (3H, s) , 4.48 (2H, s), 7.23(4H, s), 10.03(1H, s) , 12.33 (IH, s) . MS: 307 (M+H) + Step 7
N- {5- [4- (Methylthio) benzyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 5 of Production Example 45. Z : E = 2 : 1 J-H- MR (DMSO-de), δ (ppm) : 2.08(3Hx2/3, s) , 2.12(3Hxl/3, s) , 2.44(3H, s), 4.04(2Hx2/3, s) , 4.30(2Hxl/3, s) , 6.71(lHx2/3, d, J=12.5Hz), 6.84(lHx2/3, d, J=12.5Hz), 7.18(4Hx2/3, s) , 7.23(4Hxl/3, s) , 7.24(lHxl/3, d, J=15.5Hz), 7.40(lHxl/3, d, J=15.5Hz), 7.65(2Hx2/3, d, J=9.0Hz), 7.92(2Hxl/3, d, J=9.0Hz), 8.12(2Hx2/3, d, J=9.0Hz), 8.22(2Hxl/3, d, J=9.0Hz), 11.85 (1HX2/3, brs), 12.16 (lHxl/3, brs). MS: 426 (M+H) + Step 8
N-{5- [4- (Methylsulfonyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 2 of Production Example 32. Z : E = 2 : 1
XH-NMR (DMSO-de), δ (ppm) : 2.09(3Hx2/3, s) , 2.13(3Hxl/3, s) , 3.18(3H, s), 4.24(2Hx2/3, s) , 4.49(2Hxl/3, s) , 6.73(lHx2/3, d, J=12.5Hz), 6.86(lHx2/3, d, J=12.5Hz), 7.33(lHxl/3, d, J=15.5Hz), 7.41-7.97 (5/3H, m) , 7.48(2Hx2/3, d, J=9.0Hz), 7.55(2Hxl/3, d, J=9.0Hz), 7.65(2Hx2/3, d, J=9.0Hz), 7.85(2Hx2/3, d, J=9.0Hz), 8.14(2Hx2/3, d, J=9.0Hz), 8.22(2Hxl/3, d, J=9.0Hz), 11.90 (lHx2/3, s) , 12.22 (lHxl/3, s) . MS: 458 (M+H) + Step 9
The title compound was prepared in a similar manner according to Step 6 of Production Example 45. XH-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.58-2.87 (4H, m) , 3.18(3H, s), 3.98(2H, s) , 4.85(2H, s) , 6.46(2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz), 7.82 (2H, d, J=8.5Hz), 12.02 (IH, s) . MS: 430 (M+H) +
Production Example 48: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide Step 1 Di-tert-butyl ( (Z) -{ [4- (2- {2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-4- yl}ethyl) phenyl] amino}methylidene) biscarbamate was prepared from the compound obtained in Example 47 in a similar manner according to Step 3 of Production Example 31. !H- MR (DMSO-de), δ (ppm) : 1.39 (9H, s), 1.51 (9H, s) , 2.08 (3H, s), 2.86(4H, s), 3.16(3H, s) , 4.03(2H, s) , 7.13(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.43 (2H, d, J=8.5Hz), 7.81 (2H, d, J=8.5Hz), 9.97(1H, s) , 11.45(1H, s) , 12.05(1H, s) . MS: 672 (M+H) + Step 2
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4- yl }ethyl) phenyl] amino}methylidene) biscarbamate (953 mg) and 4N HCl in 1,4-dioxane solution (10 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 7 hours. The solvent was removed in vacuo. The residue was dissolved in water and AcOEt. The solution was made basic (pH=8) by saturated NaHC03. The precipitate was filtered in vacuo to give N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -l,3-thiazol-2-yl}acetamide (667.7 mg) as a pale yellow solid, mp. 228-229.5°C XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s), 2.79(4H, m) , 3.18 (3H, s), 4.05(2H, s), 6.72 (2H, d, J=8.0Hz), 6.99(2H, d, J=8.0Hz), 7.37 (2H, d, J=8.5Hz), 7.84 (2H, d, J=8.5Hz). MS: 472 (M+H) + Production Example 49: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide hydrochloride
The title compound was prepared from the compound obtained in Step 1 of Production Example 48 in a similar manner according to Step 4 of Production Example 31. mp. 107-110°C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.87 (4H, s) , 3.19 (3H, s), 4.08(2H, s), 7.13(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 7.44(3H, s), 7.85(2H, d, J=8.5Hz), 9.94(1H, s), 12.05(1H, brs). MS: 472 (M+H) + free
Production Example 50: Synthesis of N-{4-[2-(4- { [hydrazino (imino) methyl] amino }phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide Step 1
To a ice-cold solution of N- {4- [2- (4-aminophenyl) ethyl] - 5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide (247.6 mg) in acetone (4.8 ml) was added benzoyl isothiocyanate (94.1 mg) , and the mixture was stirred at r.t. for 1 hour. Water was added to the mixture, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual amorphous substance was dissolved in EtOH (5 ml), and 6N-NaOH (0.288 ml) was added to the solution at 0°C. The reaction mixture was stirred at 'r.t. for 2 hours, and neutralized with 1N-HC1 at 0°C. The mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was solidified with ethyl ether to give N-{4-(2-{4-
[ (aminocarbonothioyl) amino] phenyl} ethyl) -5- [4-
(methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide (290.7 mg) as an off-white solid. mp. 102-103°C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.85 (4H, s) , 3.18 (3H, s), 4.03(2H, s), 7.1K2H, d, J=8.5Hz), 7.30(2H, d, J=8.5Hz),
7.36(2H, d, J=8.5Hz), 7.84 (2H, d, J=8.5Hz), 9.64 (IH, s) , 12.04(1H, s) .
MS: 489 (M+H) +
Step 2
A mixture of N-{4-(2-{4-
[ (aminocarbonothioyl) amino] phenyl} ethyl) -5-[4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (281.8 mg) , methyl iodide (0.0431 ml) and MeOH (3 ml) was refluxed for 3.5 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with AcOEt and stirred for 30 minutes. The precipitated crystals were filtered and washed with AcOEt to give methyl N- [4- (2-{2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-4- yl } ethyl) phenyl] imidothiocarbamate hydroiodide (291.5 mg) as an off-white amorphous solid.
XH-NMR (DMSO-de), δ (PPm) : 2.09 (3H, s) , 2.68 (3H, s),-2.90(4H, s), 3.18(3H, s), 4.07(2H, s) , 7.22(2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.39(2H, d, J=8.5Hz), 7.86 (2H, d, J=8.5Hz),
9.22 (IH, brs), 11.11(1H, brs), 12.03(1H, s) .
MS: 503 (M+H) + free
Step 3 The title compound was prepared in a similar manner according to the following Production Example 58. H-NMR (DMSO-de), δ (ppm) : 2.09(3H, s) , 2.87(4H, s) , 3.19(3H, s), 4.08(2H, s), 7.12(2H, d, J=8.5Hz), 7.23(2H, d, J=8.5Hz), 7 . 41 (2H, d, J=8 . 5Hz ) , 7 . 85 (2H, d, J=8 . 5Hz) , 8 . 92 (2H, brs ) ,
12 . 03 ( 1H, brs ) .
MS : 487 (M+H) +
Production Example 51: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- [4-
(ethylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide hydrochloride
Step 1
Ethyl 3- [4- (ethylthio) phenyl]propanoate was prepared from 4- (2-carboxyethyl) thiophenol in a similar manner according to
Step 1 of Production Example 47.
XH-NMR (CDC13) , δ (ppm): 1.23 (3H, t, J=7.0Hz), 1.29 (3H, t,
J=7.0Hz), 2.60 (2H, t, J=8.5Hz), 2.82-2.99 (4H, m) , 4.12 (2H, q,
J=7.0Hz), 7.12 (2H, d, J=8.5Hz), 7.26 (2H, d, J=8.5Hz). Step 2
Ethyl 4- [4- (ethylthio) phenyl] -2-oxobutanoate was prepared in a similar manner according to Step 2 of Production Example
47.
XH-NMR (CDCI3) , δ (ppm): 1.31 (3H, t, J=7.0Hz), 1.36(3H, t, J=7.0Hz), 2.92 (2H, q, J=7.0Hz), 2.93 (2H, t, J=7.0Hz), 3.16(2H, t, J=7.0Hz), 4.27 (2H, q, J=7.0Hz), 7.08 (2H, d, J=9.0Hz),
7.26 (2H, d, J=9.0Hz) .
Step 3
Ethyl 3-bromo-4- [4- (ethylthio) phenyl] -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production
Example 46.
XH-NMR (CDCI3) , δ (ppm): 1.31 (3H, t, J=7.5Hz), 1.38 (3H, t,
J=7.5Hz), 2.93 (2H, q, J=7.5Hz), 3.21 (IH, dd, J=14.5, 7.5Hz),
3.49 (IH, dd, J=14.5, 7.5Hz), 4.35(2H, q, J=7.5Hz), 5.23 (IH, t, J=7.5Hz), 7.16 (2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz).
Step 4
Ethyl 2-amino-5- [4- (ethylthio) benzyl] -1, 3-thiazole-4- carboxylate was prepared in a similar manner according to Step 2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm) : 1.22 (6H, t, J=7.0Hz), 2.94(2H, q,
J=7.0Hz), 4.20(2H, q, J=7.0Hz), 4.29(2H, s) , 7.03(2H, s) ,
7.18 (2H, d, J=8.5Hz), 7.26 (2H, d, J=8.5Hz). MS: 323 (M+H) +
Step 5
Ethyl 2- (acetylamino) -5- [4- (ethylthio) benzyl] -1, 3- thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 189.5-190°C H-NMR (DMSO-de), δ (ppm): 1.21 (3H, t, J=7.5Hz), 1.28 (3H, t,
J=7.0Hz), 2.09 (3H, s) , 2.95(2H, q, J=7.5Hz), 4.27 (2H, q,
J=7.0Hz), 4.44(2H, s) , 7.22(2H, d, J=8.5Hz), 7.26(2H, d,
J=8.5Hz) , 12.42 (IH, s) . MS: 365 (M+H) +
Step 6
N-{ 5- [4- (Ethylthio) benzyl] -4-formyl-l, 3-thiazol-2- yl}acetamide was prepared in a similar manner according to
Step 4 of Production Example 46. !H-NMR (DMSO-de), δ (ppm) : 1.21(3H, t, J=7.5Hz), 2.17(3H, s) ,
2.95(2H, q, J=7.5Hz), 4.49(2H, s) , 7.26(4H, s) , 10.03(1H, s) ,
12.34(1H, s) .
Step 7
N-{5- [4- (Ethylthio) benzyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 5 of Production Example 45.
Z : E = 3 : 2
XH-NMR (DMSO-de), δ (ppm) : 1.20(3H, t, J=7.5Hz), 2.08(3Hx3/5, s), 2.12(3Hx2/5, s), 2.93 (2H, q, J=7.5Hz), 4.05(2Hx3/5, s) , 4.31(2Hx2/5, s) , 6.71(lHx3/5, d, J=12.5Hz), 6.84(lHx3/5, d,
J=12.5Hz), 7.13-8.16 (6H+4/5H, m) , 8.12(2Hx3/5, d, J=9.0Hz),
8.22(2Hx2/5, d, J=9.0Hz), 11.86 (lHx3/5, brs), 12.18 (lHx2/5, brs) . MS : 440 (M+H) +
Step 8
N- { 5- [ 4- (Ethylsulfonyl ) benzyl] -4- [ ( Z ) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 2 of Production Example 32.
Z : E = 3 : 2
XH-NMR (DMSO-de), δ (ppm) : 1.06 (3H, t, J=7.5Hz), 2.09(3Hx3/5, s), 2.13(3Hx2/5, s) , 3.25(2H, q, J=7.5Hz), 4.24 (2Hx3/5, s) ,
4.50(2Hx2/5, s) , 6.73(lHx3/5, d, J=12.5Hz), 6.87(lHx3/5, d, J=12.5Hz), 7.43-8.31 (8H+4/5H, m) , 11.91 (1HX3/5, brs),
Figure imgf000122_0001
MS: 472 (M+H) +
Step 9
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [4- (ethylsulfonyl) benzyl] -1, 3-thiazol-4- yl } ethyl) phenyl] amino}methylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 1.05 (3H, t, J=7.5Hz), 1.39 (9H, s) ,
1.51 (9H, s), 2.09(3H, s) , 2.85(4H, s) , 3.22(2H, q, J=7.5Hz), 4.04 (2H, s), 7.11 (2H, d, J=8.5Hz), 7.32 (2H, d, J=8.5Hz),
7.43 (2H, d, J=8.5Hz), 7.77 (2H, d, J=8.5Hz), 9.97 (IH, s) ,
11.44(1H, s) , 12.05(1H, s) .
MS: 686 (M+H) +
Step 10 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-d6), δ (ppm) : 1.07 (3H, t, J=7.5Hz), 2.09 (3H, s) ,
2.86(4H, s), 3.26(2H, q, J=7.5Hz), 4.09(2H, s) , 7.13 (2H, d,
J=8.0Hz), 7.24 (2H, d, J=8.0Hz), 7.44 (3H, brs), 7.60 (2H, d, J=8.0Hz), 7.81 (2H, d, J=8.0Hz), 9.89 (IH, s) , 12.05(1H, brs).
MS: 486 (M+H) + free
Production Example 52: Synthesis of ethyl {4- [2- (4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl } carbamate Step 1
N-{4- [2- (4-Aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (300 mg) was dissolved in THF (3 ml) under N2 atmosphere. Then di (tert- butyl) dicarbonate (168 mg) in THF (3 ml) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 14 hours, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC1 / AcOEt (1:1) as an eluent to give tert-butyl [4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) - benzyl] -1, 3-thiazol-4-yl} ethyl) phenyl] carbamate (248.5 mg) as an off-white amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 1.47 (9H, s) , 2.08 (3H, s) , 2.82 (4H, s), 3.16(3H, s), 3.99(2H, s) , 7.00(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 9.24(1H, s), 12.03(1H, s) . MS: 530 (M+H) + Step 2 tert-Butyl [4- (2-{2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-4-yl } ethyl) phenyl] - carbamate (230 mg) , IN-NaOH (1.09 ml) and EtOH (5 ml) were combined, and the mixture was refluxed for 16 hours. After cooled to r.t., the organic solvent was removed in vacuo . The aqueous solution was neutrallized with 1N-HC1, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHCI3 / MeOH (30:1) as an eluent to give tert-butyl [4- (2- {2-amino-5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4- yl} ethyl) phenyl] carbamate (151.2 mg) as an off-white amorphous substance .
XH-NMR (DMSO-de), δ (ppm) : 1.47 (9H, s), 2.58-2.82 (4H, m) , 3.16(3H, s), 3.84(2H, s) , 6.73(2H, s) , 7.02(2H, d, J=8.5Hz), 7.21 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.77 (2H, d, J=8.5Hz), 9.24 (IH, s) . MS: 488 (M+H) + Step 3 tert-Butyl [4- (2-{2-amino-5- [4- (methylsulfonyl) benzyl] - 1, 3-thiazol-4-yl} ethyl) phenyl] carbamate (140 mg) was dissolved in pyridine (2 ml) under N2 atmosphere. Then, ethyl • chloroformate (30.2 ml) was added to the solution at 0°C. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo. The residue was dissolved in AcOEt, and washed with 1N-HC1, water and brine. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo to give ethyl {4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl}ethyl) -5- [4- (methylsulfonyl) benzyl ] -1, 3-thiazol-2-yl} carbamate (155.8 mg) as an off-white amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 1.21 (3H, t, J=7.0Hz), 1.47 (9H, s) , - 2.79(4H, s), 3.16(3H, s) , 3.97(2H, s), 4.14(2H, q, J=7.0Hz), 7.00 (2H, d, J=8.5Hz), 7.24 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.79 (2H, d, J=8.5Hz), 9.54 (IH, s) , 11.64(1H, brs). MS: 560 (M+H) + Step 4
Ethyl {4-(2-{4-[ (tert-butoxycarbonyl) amino] phenyl} ethyl) - 5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} carbamate (140 mg) and 4N HCl in 1,4-dioxane solution (3 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours. The solvent was removed in vacuo. The residue was dissolved in water and AcOEt. The mixture was made basic (pH=8) by IN-NaOH. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo to give ethyl {4- [2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} carbamate (125.6mg) as an off-white amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 1.21 (3H, t, J=7.0Hz), 2.60-2.80 (4H, m) , 3.18(3H, s) , 3.97(2H, s) , 4.14(2H, q, J=7.0Hz), 4.85(2H, brs), 6.46(2H, d, J=8.5Hz), 6.77(2H, d, J=8.5Hz), 7.29(2H, d, J=8.5Hz), 7.82 (2H, d, J=8.5Hz), 11.62 (IH, brs).' MS: 460 (M+H) + Step 5
Di-tert-butyl ( (Z)-{ [4-(2-{2-[ (ethoxycarbonyl) amino] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4- yl}ethyl) phenyl] amino} ethylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.21 (3H, t, J=7.0Hz), 1.39 (9H, s) , 1.51 (9H, s), 2.84(4H, s) , 3.16(3H, s) , 4.01(2H, s) , 4.14 (2H, q, J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 7.81(2H, d, J=8.5Hz), 9.97 (IH, s) , 11.45(1H, s), 11.61(1H, brs). MS: 702 (M+H) + Step 6
The title compound was prepared in a similar manner according to Step 2 of Production Example 48. ! H-NMR (DMSO-de), δ (ppm) : 1.17 (3H, t, J=7.0Hz), 2.57 (4H, s) , 3.17(3H, s), 4.01(2H, q, J=7.0Hz), 4.03(2H, s) , 7.00(4H, s) , 7.42 (2H, d, J=8.5Hz), 7.83 (2H, d, J=8.5Hz). MS: 502 (M+H) + Production Example 53: Synthesis of N-{4-{2-[4- (aminomethyl) phenyl] ethyl} -5- [4- (methylsulfonyl) benzyl] -1, 3- thiazol-2-yl } acetamide Step 1
[4- (Methoxycarbonyl) benzyl] (triphenyl)phosphonium bromide (4.81 g) and DMF (60 ml) were combined under N2 atmosphere. Then potassium tert-butoxide (1.32 g) and N-{4-formyl-5- [4- (methylthio) benzyl] -1, 3-thiazol-2-yl} acetamide (3 g) were added to the suspension at 0°C. The reaction mixture was stirred at r.t. for 18 hours, poured into ice-water, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCI3 / AcOEt (2:1) as an eluent. The solid was suspended in AcOEt, and the suspension was filtered. The filtrate was concentrated in vacuo to give methyl 4-((Z)- 2- {2- (acetylamino) -5- [4- (methylthio) benzyl] -1, 3-thiazol-4- yl}vinyl)benzoate (4.16 g) as a yellow amorphous substance. XH-NMR (DMSO-d6), δ (ppm) : 2.08 (3H, s) , 2.43 (3H, s) , 3.84 (3H, s), 3.96(2H, s), 6.67(1H, d, J=12.5Hz), 6.74 (IH, d, J=12.5Hz), 7.11 (2H, d, J=8.5Hz), 7.17 (2H, d, J=8.5Hz), 7.50 (2H, d, J=8.5Hz), 7.85 (2H, d, J=8.5Hz), 11.88 (IH, s) . MS: 439 (M+H) + Step 2 Methyl 4- ( (Z) -2- {2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-4-yl}vinyl) benzoate was prepared in a similar manner according to Step 2 of Production Example 32. Z : E = 2 : 1 iπ- MR (DMSO-de), δ (ppm): 2.08(3Hx2/3, s) , 2.12(3Hxl/3, s) , 3.18(3H, s), 3.84(3Hx2/3, s) , 3.86(3Hxl/3, s) , 4.15(2Hx2/3, s), 4.47(2Hxl/3, s) , 6.68(lHx2/3, d, J=12.5Hz), 6.77(lHx2/3, d, J=12.5Hz), 7.30(lHxl/3, d, J=15.5Hz), 7.43 (2H, d, J=8.5Hz), 7.50-7.97(19/3H, m) , 11.93 (1HX2/3, s) , 12.19 (lHxl/3, s) . MS: 471 (M+H) + Step 3
Methyl 4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4-yl} ethyl) benzoate was prepared in a similar manner according to Step 6 of Production Example 45. mp. 209-210°C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.94 (4H, m) , 3.17 (3H, s), 3.84(3H, s), 4.01 (2H, s) , 7.25(2H, d, J=8.5Hz), 7.28(2H, d, J=8.5Hz), 7.76(2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz), 12.05(1H, brs) . MS: 473 (M+H) + Step 4 To a stirred solution of methyl 4- (2-{2- (acetylamino) -5-
[4- (methylsulfonyl) benzyl] -1, 3-thiazol-4-yl} ethyl) benzoate (2 g) in dry THF (40 ml) was added dropwise 1.0M diisobutylaluminium hydride solution in toluene (14.8 ml) at -78°C under N2 atmosphere. The reaction mixture was stirred at r.t. for 4 hours, and then quenched with MeOH. AcOEt and 1N- HC1 were added to the mixture, and extracted. The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N-{4- {2- [4- (hydroxymethyl) phenyl] ethyl}- 5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide (552.3 mg) as a colorless solid, mp. 209.5-211°C XH-NMR (DMSO-de), δ (PPm) : 2.09(3H, s) , 2.86 (4H, s) , 3.17 (3H, s), 4.01(2H, s), 4.46(2H, d, J=5.5Hz), 5.12(1H, t, J=5.5Hz), 7.09(2H, d, J=8.0Hz), 7.20(2H, d, J=8.0Hz), 7.28(2H, d, J=8.5Hz), 7.80 (2H, d, J=8.5Hz), 12.04 (IH, brs). MS: 445 (M+H) + Step 5 N-{ 4- {2- [4- (Hydroxymethyl) phenyl] ethyl}-5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide (539.5 mg) , CH2CI2 (5 ml) and DMF (5 ml) were combined under N2 atmosphere. Then, Et3N (0.211 ml) and MsCl (0.108 ml) were added to the suspension at 0°C. The reaction mixture was stirred at r.t. for 3.5 hours. The reaction mixture was poured into water, and extracted with CHC13. The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid was washed with ethyl ether to give N-{4-{2-[4- (chloromethyl) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1,3- thiazol-2-yl} acetamide (537.5 mg) as an off-white solid, mp. 202-203°C
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.88 (4H, s) , 3.17 (3H, s), 4.01(2H, s), 4.73(2H, s) , 7.15 (2H, d, J=8.0Hz), 7.30(2H, d, J=8.5Hz), 7.34 (2H, d, J=8.0Hz), 7.81 (2H, d, J=8.5Hz), 12.05(1H, brs) . MS: 463 (M+H) + Step 6 N_ r 4_ { 2_ [4_ (Chloromethyl) phenyl] ethyl } -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (150 mg) was suspended in CH3CN (6 ml), and then 28% ammonia solution (0.4 ml) was added to the suspension at 0°C. The reaction mixture was stirred at r.t. for 16 hours, and concentrated in vacuo. The residual solid was washed with water, and purified by preparative silica gel chromatography with CHC13 / MeOH (10:1) as an eluent to give N-{4-{2-[4-
(aminomethyl) phenyl] ethyl} -5- [4- (methylsulfonyl) benzyl] -1,3- thiazol-2-yl} acetamide (32.1mg) as a pale yellow amorphous substance.
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.85(4H, s) , 3.17 (3H, s), 3.69(2H, s), 4.01(2H, s) , 7.07(2H, d, J=8.0Hz), 7.21 (2H, d, J=8.0Hz), 7.29(2H, d, J=8.5Hz), 7.80(2H, d, J=8.5Hz). MS: 444 (M+H) + Production Example 54 : Synthesis of N-{4-{2- [4- (4, 5-dihydro- 1, 3-thiazol-2-ylamino) phenyl] ethyl} -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl } acetamide
A mixture of N-{ 4- [2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}-acetamide (200 mg) , 2- (methylsulfanyl) -4, 5-dihydro-l, 3-thiazole (62 mg) , concentrated HCl (0.064 ml) and 2-methoxyethanol (3 ml) was stirred at 120°C for 13 hours under N2 atmosphere. After cooled to r.t., the reaction mixture was made basic with saturated NaHC03. The mixture was extracted with AcOEt. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo. The residue was purified by preparative silica gel chromatography with CHC1 / MeOH (10:1) as an eluent to give N- { 4- {2- [4- (4, 5-dihydro-l, 3-thiazol-2-ylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (139.8 mg) as a pale yellow amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s), 2.82 (4H, s) , 3.16 (3H, s), 3.17-3.34(4H, m) , 3.98(2H, s) , 6.99(2H, d, J=8.5Hz), 7.25 (2H, d, J=8.5Hz), 7.45 (2H, brd, J=8.5Hz), 7.80 (2H, d, J=8.5Hz), 9.24 (IH, brs), 12.04 (IH, s) . MS: 515 (M+H) +
Production Example 55: Synthesis of N-{4-{2- [4- (4, 5-dihydro- lH-imidazol-2-ylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl} acetamide
A mixture of N-{4- [2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (150 mg) , ethyl 2- (methylthio) -4, 5-dihydro-lH-imidazole-l-carboxylate (78.9 mg) , AcOH (0.3 ml) and EtOH (3 ml) was refluxed for 7 hours under N2 atmosphere. After cooled to r.t., the reaction mixture was made basic with saturated NaHC03. The mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous MgS0, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHCI3 / MeOH (10:1) as an eluent. The amorphous substance was solidified with ethyl ether to give N-{4-{2- [4- (4,5- dihydro-lH-imidazol-2-ylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (17.9 mg) as an off-white amorphous solid. mp. 139-140°C
XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s), 2.71-2.87 (4H, m) , 3.18(3H, s), 3.25-3.41 (4H, m) , 4.03(2H, s) , 6.95(4H, s) , 7.32 (2H, d, J=8.5Hz), 7.82 (2H, d, J=8.5Hz). MS : 498 (M+H) +
Production Example 56: Synthesis of N-{4-{2-[4- (ethanimidoylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] - 1, 3-thiazol-2-yl}acetamide N-{4- [2- (4-Aminophenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide (200 mg) , methyl ethanimidothioate hydroiodide (202 mg) and MeOH (4 ml) were combined under N2 atmosphere. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the mixture was concentrated in vacuo. The residue was purified by preparative NH silica gel chromatography with CHC13 / MeOH (10:1) as an eluent. The amorphous substance was solidified with ethyl ether to give N-{4-{2-[4- (ethanimidoylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] - 1, 3-thiazol-2-yl}acetamide (102.4 mg) as a pale yellow amorphous solid, mp. 81.5-83°C
XH-NMR (CDC13) , δ (PPm): 1.83 (3H, brs), 2.08 (3H, s) , 2.81 (4H, m) , 3.18(3H, s) , 4.02(2H, s) , 6.64(2H, brd, J=8.5Hz), 6.99(2H, d, J=8.5Hz), 7.36 (2H, d, J=8.5Hz), 7.83 (2H, d, J=8.5Hz), 12.03 (IH, brs) . MS: 471 (M+H) +
Production Example 57: Synthesis of N-[4-(2-{4- [ (imino ethyl) amino] phenyl}ethyl) -1, 3-thiazol-2-yl] acetamide N_ {4_ [2- ( -Aninophenyl) ethyl] -1, 3-thiazol-2-yl}acetamide
(150 mg) was dissolved in THF (2 ml) and pH=7 buffer (2 ml) . Then, ethyl imidoformate hydrochloride '(1.26 g) was added to the solution at 0°C. The reaction mixture was stirred at 0°C for 2 hours, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CH3CN / water (7:3) as an eluent'. The oil was purified again by preparative silica gel chromatography with CHCI3 / MeOH (5:1) as an eluent to give N-[4-(2-{4- [ (iminomethyl) amino] phenyl} ethyl) -1, 3-thiazol-2-yl] acetamide (110 mg) as pale brown oil.
XH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 2.81-3.01 (4H, m) , 6.71(1H, s), 7.09-8.00(7H, m) , 12.07 (IH, s) . 5 MS: 289 (M+H) +
Production Example 58: Synthesis of N-{4-[2-(4-
{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide
A mixture of methyl N- (4- {2- [2- (acetylamino) -1, 3-thiazol- io 4-yl] ethyl }phenyl) imidothiocarbamate hydroiodide (100 mg) , - hydrazine monohydrate (0.0525 ml) and THF (3 ml) was stirred at r.t. for 95 hours. The precipitate was filtered off. The ' filtrate was concentrated in vacuo. The residue was purified by- preparative silica gel chromatography with CHC13 / MeOH 15 (10:1) as an eluent to give N-{4-[2-(4-
{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl} acetamide "(62.7 mg) as a pale pink solid, mpr -216.5-218°C . AH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 2.92 (4JH, ) , 6.75 (.IH, 26 s ) , .7.12 (2H, d, J=8.5Hz), 7.27(2H, d, J=8.5Hz), 8.88 (IH, brs), 12.07 (IH, brs) . . MS: 319 (M+H) +
Production Example 59: Synthesis of N- (4-{2- [4- (2-amino-2- iminoethyl) phenyl] ethyl }-l, 3-thiazol-2-yl) acetamide ^5" Step 1
N-(4-{2-[4-(Chloromethyl)phenyl]ethyl}-l,3-thiazol-2- yl) acetamide was prepared from N-(4-{2-[4-
(hydroxymethyl) phenyl] ethyl }-l,3-thia'zol-2-yl) acetamide in a similar manner according to Step 5 of Production Example -53. 30 p. 145-146°C
- XH-NMR (DMSO-de), δ (ppm) :•' 2.11 (3H, s) , 2.82-2.99 (4H, m) , ' 4.72(2H, s)-, 6.-73MH, s) , 7.20 (2H,- d, J=8.0Hz) , 7.33(2H, d, J=8.0Hz), 12.08 (IH, brs). MS : 295 (M+H) +
Step 2
NaCN (115 mg) , KI (130 mg) and water (1.8 ml) were combined, and then a solution of N-(4-{2-[4- (chloromethyl) phenyl] ethyl}-l, 3-thiazol-2-yl) acetamide (230 mg) in DMF (7 ml) was added dropwise to the mixture at 0°C.
The reaction mixture was stirred at r.t. for 19 hours, poured into water, and extracted with CHC13. The organic layer was washed with brine, dried over anhydrous MgS04 and concentrated in vacuo . The residual solid was washed with ethyl ether to give N- (4-{2- [4- (cyanomethyl) phenyl] ethyl}-l, 3-thiazol-2- yl) acetamide (149.1 mg) as a colorless solid. mp. 160-161°C
XH-NMR (DMSO-de), δ (ppm): 2.1-1 (3H, s) , 2.82-2.97 (4H, ) , 3.97(2H, s), 6.73(1H, s) , 7.21 (2H, d, J=8.5Hz), 7.25(2H, d,
J=8.5Hz), 12.08 (IH, brs).
MS: 286 (M+H) +
Step 3
N- (4-{2- [4- (Cyanomethyl)phenyl] ethyl }-l,3-thiazol-2- yl) a'cetamide (600 mg) was dissolved in MeOH (5 ml) and CHCI3 (5 ml) , and then HCl gas was bubbled at 0°C for 5 minutes with stirring. The reaction mixture was stood for 17 hours, and concentrated in vacuo. The residual solid was washed with ethyl ether to give methyl 2- (4-{2- [2- (acetylamino) -1,3- thiazol-4-yl] ethyl }phenyl) ethanimidoate hydrochloride (632.5 mg) as an off-white solid. mp. 77-78°C
XH-NMR (DMSO-de) , δ (ppm) : 2 . 12 ( 3H, s ) , 2 . 88 ( 4H, s) , 4 . 92 ( 6H, ' brs ) , 6. 75 (1H, s ) , 7 . 10-7 . 20 (4H, m) , 12 . 11 ( 1H, brs ) . MS : 318 (M+H) + free
Step 4
Methyl 2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- ' yl] ethyl}phenyl) ethanimidoate hydrochloride (600 mg) was dissolved in EtOH (12 ml) . Then ammonium chloride (136 mg) and ammonia in methanol (2 ml) were added to the solution. The reaction mixture was refluxed for 4 hours under N2 atmosphere. After cooled to r.t., the suspension was filtered in vacuo. The filtrate was concentrated in vacuo, and the residue was solidified with EtOH / diethyl ether to give N- (4-{2- [4- (2- amino-2-iminoethyl) phenyl] ethyl }-l, 3-thiazol-2-yl) acetamide hydrochloride (338.6 mg) as an off-white solid, mp. 190.5-192°C XH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 2.89 (4H, m) , 3.68 (2H, s), 6.74 (IH, s), 7.20(2H, d, J=8.0Hz), 7.39(2H, d, J=8.0Hz). MS: 303 (M+H) +- free Step 5
N- (4-{2- [4- (2-Amino-2-iminoethyl) phenyl] ethyl}-1,3-' thiazol-2-yl) acetamide hydrochloride (67 mg) was dissolved in water (1 ml) and CH3CN (1 ml) . The solution was made basic (pH=8) with saturated NaHC03, and concentrated in vacuo. The residue was purified by preparative NH silica gel chromatography with CH3CN / water (7:3) as an eluent to give N- (4-{2-[4-(2-amino-2-iminoethyl)phenyl]ethyl}-l,3-thiazol-2- yl) acetamide (26 mg) as an off-white amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.89(4H, m) , 3.59 (2H, s), 6.72(1H, s), 7.20(2H, d, J=8.0Hz), 7.30(2H, d, J=8.0Hz), 9.38 (3H, brs) . MS: 303 (M+H) +
Production Example 60: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- [4- (methylthio) enzyl ] -1, 3-thiazol-2-yl } acetamide Step 1 A mixture of N-{5- [4- (methylthio) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide and N-{5-[4- (methylthio) benzyl] -4- [ (E) -2- (4-nitrophenyl) inyl] -1, 3- thiazol-2-yl} acetamide (Z : E = 2 : 1) (570 mg) was dissolved in CH2C12 (6 ml) under N2 atmosphere. Then m-CPBA (254 mg) was added portionwise to the solution at 0°C. The reaction mixture was stirred at r.t. for 1.5 hours, and diluted in MeOH / CHC13. The organic solution was washed with lN-Na2C0, water and brine, dried over MgS04, and concentrated in vacuo to give a mixture of N-{5- [4- (methylsulfinyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide and N-{5-[4- (methylsulfinyl) benzyl] -4- [ (E) -2- (4-nitrophenyl) vinyl] -1,3- thiazol-2-yl}acetamide (Z : E = 2 : 1) (282.8 mg) as a yellow amorphous substance. Z : E = 2 : 1
XH-NMR (DMSO-de), δ (ppm) : 2.08(3Hx2/3, s) , 2.13(3Hxl/3, s) , 2.71(3H, s), 4.18(2Hx2/3, s) , 4.44(2Hxl/3, s) , 6.73(lHx2/3, d, J=12.5Hz), 6.87(lHx2/3, d, J=12.5Hz), 7.34(lHxl/3, d, J=15.5Hz), 7.41-8.17 (7/3H, m) , 7.41(2Hx2/3, d, J=8.0Hz), 7.50(2Hxl/3, d, J=8.0Hz), 7.63(2Hx2/3, d, J=8.0Hz), 7.93(2Hxl/3, d, J=8.0Hz), 8.14(2Hx2/3, d, J=8.0Hz), 8.22(2Hxl/3, d, J=8.0Hz), 11.89 (1HX2/3, s) , 12.20 (lHxl/3, s) . MS: 442 (M+H) + Step 2
N-{4-[2-(4-Aminophenyl)ethyl]-5-[4- (methylsulfinyl) benzyl] -1, 3-thiazol-2-yl}acetamide was prepared in a similar manner according to Step 6 of Production Example 45. !H- MR (DMSO-de), δ (ppm) : 2.08 (3H, s), 2.62-2.84 (4H, m) ,
2.70(3H, s), 3.94(2H, s) , 4.85(2H, s) , 6.46(2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.23 (2H, d, J=8.5Hz), 7.58 (2H, d, J=8.5Hz) , 12.00 (IH, s) . MS: 414 (M+H) + Step 3
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [4- (methylsulfinyl) benzyl] -1, 3-thiazol-4- yl }ethyl) phenyl] amino}methylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.08 (3H, s), 2.69(3H, s), 2.86(4H, s) , 3.98(2H, s) , 7.12 (2H, d, J=8.5Hz), 7.26 (2H, d, J=8.0Hz), 7.43 (2H, d, J=8.5Hz), 7.57 (2H, d, J=8.0Hz), 9.95(1H, s) , 11.43(1H, s) , 12.02(1H, s) . MS: 656 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 2 of Production Example 48. mp. 159.5-161°C
XH-NMR (DMSO-de), δ (ppm) : 2.07 (3H, s) , 2.44 (3H, s) , 2.79 (4H, s), 3.86(2H, s), 6.78(2H, d, J=8.5Hz), 7.02(2H, d, J=8.5Hz), 7.04 (2H, d, J=8.5Hz), 7.30 (2H, d, J=8.5Hz). MS: 440 (M+H) + Production Example 61: Synthesis of N-{4-[4-(3- { [amino (imino) methyl] amino }propyl) phenyl] -5- [4- (methylsulfonyl) phenyl]-l, 3-thiazol-2-yl} acetamide hydrochloride Step 1 To a solution of methyl 4-{[4-
(methylthio) phenyl] acetyl}benzoate (5 g) in dichloromethane (250 ml) were added acetic acid (0.65 ml) and pyridinium bromide perbromide (6.51 g) at 0°C, and the mixture was stirred for 1 h at the same temperarure . The reaction mixture was poured into water (250 ml) and extracted with ethyl acetate (250 ml) . The organic layer was washed with water and brine, dried over magnesium sulfate and evapolated. The residue was washed with diisopropylethyl ether and collected by filtration to give methyl 4- {2-bromo[4- (methylthio) phenyl] acetyl }benzoate as an off-white solid.
XH-NMR (CDCls) , δ (PPm): 2.47 (3H, s) , 3.94 (3H, s) , 6.33 (3H, s) , 7.23 (2H, d, J=8.5Hz), 7.43 (2H, d, J=8.5Hz). Step 2 Methyl 4-{2-amino-5-[4- (methylthio) phenyl] -1, 3-thiazol-4- yl}benzoate was prepared in a similar manner according to Step 2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm) : 2.47 (3H, s) , 3.83 (3H, s) , 7.08- 7.32 (4H, m) , 7.52 (2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz). MS: 357.1 (M+H) + Step 3
To a solution of methyl 4-{2-amino-5- [4- (methylthio) phenyl] -1, 3-thiazol-4-yl}benzoate (100 mg) in tetrahydrofuran (4 ml) was added portionwise lithium aluminium hydride (21.3 mg) , and the mixture was stirred for 1 h at 20°C. To the reaction mixture were added ethyl acetate (10 ml) and water (3 ml) . The resulting precipitate was removed by filtration, and the filtrate was washed with brine, dried over sodium sulfate and evaporated to give (4-{2-amino-5- [4- (methylthio) phenyl] -1, 3-thiazol-4-yl}phenyl) methanol as a yellow solid, that was used as crude in the next reaction. XH-NMR (DMSO-de), δ (ppm) : 2.46 (3H, s), 4.46(2H, d, J=6.0Hz), 5.17 (t, IH, J=5.5Hz), 7.13 (d, 2H, J=5.5Hz), 7.17 (d, 2H, J=5.5Hz), 7.20 (d, 2H, J=8.5Hz), 7.34 (d, 2H, J=8.5Hz). MS: 329.2 (M+H) + Step 4
To a suspension of (4- {2-amino-5- [4- (methylthio) phenyl] - 1, 3-thiazol-4-yl}phenyl) ethanol (89.3 mg) in dichloromethane (1 ml) were added pyridine (0.11 ml) and acetylchloride (42.5 μl) at 0°C, and the mixture was stirred at the same temperature for 1 hr. To the reaction mixture was added IN-hydrochloric acid (10 ml), and the mixture was extracted with ethyl acetate (20 ml x 2) . The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated to give a crude green solid (77.6 mg) . To- a solution of the crude green solid in dichloromethane (3 ml) was added 3-chloroperbenzoic acid (80.7 mg) at 0°C, and the mixture was stirred for 2 hr at 20°C. To the reaction mixture was added saturated. sodium hydrogencarbonate aqueous solution (10 ml), and the mixture was extracted with ethyl acetate (20 ml x 2), washed with water and brine, dried over magnesium sulfate, and evaporated to give 4- {2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1,3- thiazol-4-yl}benzyl acetate as a brown solid.
XH-NMR (CDCls) , δ (ppm): 1.77(3H, s) , 2.14(3H, s) , 3.10(3H,' s), 5.12(2H, s), 7.32 (2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 7.52 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.5Hz), 11.1 (IH, brs). MS: 467.0 (M+Na) + Step 5
To a suspension of 4-{2- (acetylamino) -5- [4- (methylsulfonyl)phenyl]-l, 3-thiazol-4-yl}benzyl acetate (1.218 g) in metanol (24 ml) was added potassium carbonate (379 mg) at 20°C, and the mixture was stirred for 1 h. To the reaction mixture was added 0. IN-hydrochloric acid (27.4 ml), and the mixture was extracted with chloroform (500 ml) , dried over magnesium sulfate and evaporated to give N-{4-[4- (hydroxymethyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1, 3- thiazol-2-yl} acetamide as a yellow solid.
XH-NMR (CDCI3) , δ (ppm): 1.87 (3H, s) , 3.09 (3H, s) , 4.72 (2H, s) , 7.31 (2H, d, J=8.5Hz), 7.42 (2H, d, J=8.5Hz), 7.51 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 10.83 (IH, brs). MS: 425.0 (M+Na) + Step 6
To a solution of N-{4- [4- (hydroxymethyl) phenyl] -5- [4- (methylsulfonyl) phenyl]-l, 3-thiazol-2-yl} acetamide (867.4 mg) in methanol (0.6 ml) and chloroform (10 ml) was added manganese (IV) oxide (6.65 g) at 20°C under N2 atmosphere, and the mixture was stirred for 19 hrs. The reaction mixture was filtered through a celite pad. The filtrate was evaporeted to give N-{4- (4-formylphenyl) -5- [4- (methylsulfonyl) phenyl] -1, 3- thiazol-2-yl} acetamide as a yellow solid, that was used as crude in the next reaction.
XH-NMR (DMSO-de), δ (ppm) : 2.20 (3H, s) , 3.26 (3H, s), 7.63 (2H, d, J=8.5Hz), 7.64 (2H, d, J=8.0Hz), 7.90 (2H, d, J=8.0Hz), 7.92(2H, d, J=8.5Hz), 10.00(1H, s) , 12.5 (IH, brs) . Step 7
To a suspension of N-{4- (4-formylphenyl) -5- [4- (methy1sulfonyl) phenyl] -1, 3-thiazol-2-yl}acetamide (360 mg) in chloroform (7 ml) was added (carbethoxymethylene) triphenylphosphorane (626 mg) at 20°C, and the mixture was stirred for 1 h. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel (150 ml) with hexane / ethyl acetate (1:1-1:2) as an eluent to give ethyl (2E) -3- (4- {2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-4-yl}phenyl) acrylate as a pale yellow solid.
XH-NMR (CDC13) , δ (PPm): 1.34 (3H, t, J=7.0Hz), 1.93(3H, s) , 3.10(3H, s), 4.28(2H, q, J=7.0Hz), 6.45(1H, d, J=16.1Hz), 7.48(4H, s), 7.54(2H, d, J=8.5Hz), 7.67(2H, d, J=16.1Hz), 7.89(2H, d, J=8.5Hz), 10.39(1H, s) . MS: 493.1 (M+Na) + Step 8
To a suspension of ethyl (2E) -3- (4-{2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-4-yl}phenyl) acrylate (306.5 mg) in tetrahydrofuran (3 ml) was added portionwise lithium borohydride (271 mg) at 0°C, and the mixture was stirred for 6.5 h at 20°C. The reaction mixture was poured into a mixture of saturated ammonium chloride aqueous solution (50 ml) and chloroform (50 ml) at 0°C. The organic layer was separeted, dried over maganesium sulfate and evaporarted to give a crude yellow solid (300 mg) . The residue was purified by column chromatography over si'lica gel (80 ml) with hexane / ethyl acetate (1:2-1:5) as an eluent to give N-{4-[4-(3- hydroxypropyl) phenyl] -5- [4- (methylsulfonyl) phenyl]-l, 3- thiazol-2-yl}acetamide as a pale yellow solid. XH-NMR (CDCI3) , δ (ppm): 1.71 (3H, s) , 1.80-1.99 (2H, m) , 2.61- 2.82(2H, ) , 3.09(3H, s) , 3.69(2H, dd, J=6.0, 10.0Hz), 7.17 (2H, d, J=8.0Hz), 7.37 (2H, d, J=8.5Hz), 7.53 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 11.1 (IH, s) . MS: 431.20 (M+l)+ Step 9
To a solution of N-{4- [4- (3-hydroxypropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl}acetamide (75 mg) in tetrahydrofuran (0.7 ml) were added triphenylphosphine (68.5 mg) and carbon tetrabromide (86.7 mg) at 0°C, and the mixture was stirred for 1 h at 20°C. The reaction mixture was purified by preparative thin-layer chromatography over silica gel with hexane / ethyl acetate (1:2) as an eluent to give N-{4-[4-(3- bromopropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol- 2-yl}acetamide as colorless oil.
XH-NMR (DMSO-de), δ (ppm) : 1.67 (3H, s) , 2.08-2.28 (2H, m) , 2.80(2H, t, J=7.5Hz), 3.10(3H, s) , 3.41(2H, t, J=6.5Hz), 7.18 (2H, d, J=8.0Hz), 7.39 (2H, d, J=8.0Hz), 7.53 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 11.1 (IH, s) . MS: 515.0 (M+Na) + Step 10
To a solution of N-{4- [4- (3-bromopropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl} acetamide (82 mg) in N, N-dimethylformamide (0.82 ml) was added phthalimide potassium salt (30.8 mg) , and the mixture was stirred for 2hrs. at 50°C. The reaction mixture was cooled to 20°C, then water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with brine, dried over magnesium sulfate and evaporated to give a crude material (92.0 mg) . The crude material was purified by preparative thin-layer chromatography over silica gel to give N-{4-{4-[3- (1, 3-dioxo-l, 3-dihydro-2H-isoindol-2-yl) propyl] phenyl}-5- [4- (methylsulfonyl)phenyl]-l,3-thiazol-2-yl}acetamide. XH-NMR (CDCl3),.δ (ppm): 1.72 (3H, s) , 1.90-2.13 (2H, m) , 2.60- 2.79(2H, m) , 3.09(3H, s) , 3.74(2H, t, J=7.3Hz), 7.18 (2H, d, J=8.0Hz), 7.37 (2H, d, J=8.0Hz), 7.52 (2H, d, J=8.5Hz), 7.66- 7.78(2H, m) , 7.80-7.92 (4H, m) , 11.0(1H, s) . MS: 582.1 (M+Na)+ Step 11
To a solution of N-{4-{4- [3- (1, 3-dioxo-l, 3-dihydro-2H- isoindol-2-yl) propyl]phenyl}-5- [4- (methylsulfonyl) phenyl] -1, 3- thiazol-2-yl}acetamide (53.2 mg) in acetonitrile (0.5 ml) was added hydrazine monohydrate (46.1 μl) , and the mixture was stirred at 50°C for 30 min. The volatiles were evaporated. To the mixture was added chloroform (1 ml) , and an insoluble material was removed by filtration. The filtrate was purified by preparative thin-layer chromatography over NH silica gel with chloroform / methanol (10:1) as an eluent to give N-{4- [4- (3-aminopropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1, 3- thiazol-2-yl}acetamide as a yellow solid. XH-NMR (DMSO-de), δ (ppm) : 1.69 (3H, s), 1.69-1.88 (2H, m) , 2.60- 2.74(2H, m), 2.76(2H, t, J=7.0Hz), 3.09(3H, s) , 7.15(2H, d,
J=8.5Hz), 7.36 (2H, d, J=8.5Hz), 7.53 (2H, d, J=8.5Hz), 7.86(2H, d, J=8.5Hz) . MS: 428.2 (M-H)~ Step 12 Di-tert-butyl ( (E) -{ [3- (4- {2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1, 3-thiazol-4- yl }phenyl) propyl] amino }methylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. !H-NMR (CDC13) , δ (PPm): 1.49 (9H, s) , 1.50 (9H, s) , 1.87-
1.97 (2H, m), 2.01 (3H, s) , 2.69(2-H, t, J=8.1Hz), 3.09 (3H, s) , 3.41-3.54(2H, ) , 7.16(2H, d, J=8.1Hz), 7.36(2H, d, J=8.1Hz), 7.54 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.4Hz), 8.38 (IH, t, J=5. 1Hz ) , 9. 87 (IH, brs ) , 11 . 5 ( 1H, s ) .
MS : 694 .2 (M+Na) + Step 13
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.72-1.85 (2H, m) , 2.19(3H, s) , 2.58- 2.66(2H, m) , 3.08-3.18 (2H, m) , 3.25(3H, s) , 6.65-7.58 (4H, brs), 7.21 (2H, d, J=8.4Hz), 7.36(2H, d, J=8.1Hz), 7.56(2H, d, J=8.4Hz), 7.67 (IH, t, J=5.1Hz), 7.89 (2H, d, J=8.4Hz), 12.4 (IH, s) .
MS: 472.1 (M+H) + free
Production Example 62: Synthesis of N-{4-(2-{4-
[ (aminooxy) methyl] phenyl} ethyl) -5- [4- (methylsulfonyl) phenyl] -
1, 3-thiazol-2-yl } acetamide Step 1
Methyl 4- ( (E) -2-{2- (acetylamino) -5- [4- (methylthio) phenyl] -1, 3-thiazol-4-yl } inyl) benzoate was prepared from N-{5- [4- (methylthio) phenyl] -4-formyl-l, 3- thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 53.
XH-NMR (DMSO-de), δ (ppm) : 2.12(3Hxl/3, s) , 2.19(3Hx2/3, s) , 2.54(3H, s), 3.85(3H, s) , 6.55(lHxl/3, d, J=12.6Hz), 6.73(lHxl/3, d, J=12.6Hz), 7.17-7.72 (8H+2Hx2/3, m) , 7.84(2Hxl/3, d, J=8.5Hz), 7.93(2Hx2/3, d, J=8.5Hz), 12.31 (IH, brs) .
MS: 423.1 (M-H) ~ Step 2
Methyl 4-( (E) -2-{2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-4-yl}vinyl) benzoate was prepared in a similar manner according to Step 2 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm): 2.15(3Hxl/5, s), 2.21(3Hx4/5, s) , 3.24(3Hxl/5, s) , 3.30(3Hx4/5, s) , 3.84(3Hxl/5, s) , 3.85(3Hx4/5, s) , 6.64(lHxl/5, d, J=12.6Hz), 6.81(lHxl/5, d, J=12.6Hz), 7.31(lHx4/5, d, J=15.6Hz), 7.52(lHx4/5, d, J=15.6Hz), 7.30-8.11(8H, m) , 12.24 (lHxl/5, s), 12.49 (lHx4/5, s). MS: 479.0 (M+Na) + Step 3
Methyl 4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) phenyl]-l, 3-thiazol-4-yl}ethyl) benzoate was prepared in a similar manner according to Step 6 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm): 2.31 (3H, s) , 2.97-3.07 (4H, m) , 3.08(3H, s), 3.91(3H, s) , 7.09(2H, d, J=8.1Hz), 7.32(2H, d, J=8.1Hz), 7.87 (4H, d, J=8.1Hz), 8.75 (IH, s) . MS: 481.0 (M+Na) + Step 4
N- { 4- { 2- [4- (Hydroxymethyl) phenyl] ethyl }-5- [4- (methy1sulfonyl) phenyl]-!, 3-thiazol-2-yl}acetamide was prepared in a similar manner according to Step 4 of Production Example 53. ifr- MR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.96(4H, s) , 3.24 (3H, s), 4.43(2H, s), 7.06(2H, d, J=8.1Hz), 7.18(2H, d, J=8.1Hz), 7.50(2H, d, J=8.4Hz), 7.91 (2H, d, J=8.4Hz), 12.33(1H, s) . MS: 453.1 (M+Na) + Step 5 N-{ 4- {2- [4- (Hydroxymethyl) phenyl] ethyl}-5- [4-
(methylsulfonyl) phenyl]-l, 3-thiazol-2-yl}acetamide (100 mg) , N-hydroxyphthalimide (39.8 mg) , triphenylphosphine (64 mg) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere, then, diethyl azodicarboxylate (40 wt% solution in toluene) (0.111 ml) was added to the solution at 0°C, and the mixture was stirred at 20°C for 5 hrs. The reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution, and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated. The crude material was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (30:1) as an eluent to give N-{4- [2- (4-{ [ (1, 3-dioxo- 1, 3-dihydro-2H-isoindol-2-yl) oxy]methyl}phenyl) ethyl] -5- [4- ( ethylsulfonyl) phenyl] -1, 3-thiazol-2-yl} acetamide as a yellow foam.
XH-NMR (CDC13) , δ (ppm): 2.30 (3H, s) , 2.95-3.00 (4H, m) , 3.09(3H, s), 5.15(2H, s) , 7.04(2H, d, J=8.1Hz), 7.21-7.92 (10H, m) , 9.31 (IH, brs) .
MS: 598.1 (M+Na) \ 574.0 (M-H)~ Step 6
To a solution of N-{4- [2- (4-{ [ (1, 3-dioxo-l, 3-dihydro-2H- isoindol-2-yl) oxy] methyl}phenyl) ethyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl}acetamide (116.8 mg) in N,N-dimethylformamide (1.1 ml) was added methylhydrazine (11.9 μl) under N2 atmosphere, and the mixture was stirred at 20°C for 4hrs. The reaction mixture was concentrated in vacuo . Ethyl acetate was added to the residue, and the precipitate was filtered off. The filtrate was concentrated in vacuo to give a crude yellow solid (105.1 mg) . The crude material was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (30:1) as an eluent to give a pale yellow powder. The obtained powder was washed with acetonitrile, and the precipitate was collected by filtration to give N-{4- (2-{4- [ (aminooxy) methyl] phenyl} ethyl) -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl} acetamide (8.4 mg) as a white solid. XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.91-3.02 (4H, m) , 3.24(3H, s), 4.51(2H, 's), 5.98(2H, s) , 7.09(2H, d, J=8.1Hz), 7.19 (2H, d, J=8.1Hz), 7.51 (2H, d, J=8.4Hz), 7.91 (2H, d, J=8.1Hz), 12.33(1H, brs). MS: 468.0 (M+H) + Production Example 63: Synthesis of N-{4-{2-[4- ({ [amino (imino) methyl] amino}methyl) phenyl] ethyl} -5- [4- (methylsulfonyl) phenyl]-l, 3-thiazol-2-yl} acetamide hydrochloride Step 1
N- { 4- { 2- [4- (Bromomethyl) phenyl] ethyl }-5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl} acetamide was prepared from N- (4- [2-{4- (hydroxymethyl) phenyl } ethyl] -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl) acetamide in a similar manner according to Step 9 of Production Example 61. XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s), 2.90-3.10 (4H, m) , 3.23(3H, s), 4.67(2H, s) , 7.10(2H, d, J=8.1Hz), 7.31 (2H, d, J=8.1Hz), 7.48 (2H, d, J=8.4Hz), 7.90 (2H, d, J=8.4Hz), 12.33(21H, s) . MS: 491.0 (M-H) " Step 2
To a solution of N-{ 4- {2- [4- (bromomethyl) phenyl] ethyl} -5- [4- (methylsulfonyl) phenyl] -1, 3-thiazol-2-yl} acetamide (70 mg) in N, N-dimethylformamide (1 ml) was added diformimide sodium salt (13.5 mg) , and the mixture was stirred for 10 min at 20°C. To the reaction mixture was added water, the mixture was extracted with ethyl acetate, washed with water twice, dried over magnesium sulfate, and evaporated to give a crude diformimide compound. The diformimide compound was suspended in cone, hydrocloric acid (200 μl) , ethanol (2 ml) and methanol (0.5 ml). The reaction mixture was stirred at 20°C for 3hrs., then at 50°C for 3hrs. The volatails were evaporated. To the residue was added saturated sodium hydrogen carbonate aqueous solution, the mixture was extracted with chloroform, dried over maganesium sulfate and evaporated to give crude N-{4-(2- {4- [aminomethyl] phenyl}ethyl) -5-[4- (methylsulfonyl) phenyl] - 1, 3-thiazol-2-yl}acetamide, that was used as crude in the next reaction. S : 428 . 8 (M+H) +
Step 3
Di-tert-butyl ( (E)-{ [4- (2- {2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1, 3-thiazol-4- yl} ethyl) benzyl] amino}methylidene) biscarbamate was prepared in a similar manner .according to Step 3 of Production Example 31.
XH-NMR (CDC1 ) , δ (PPm): 1.48(9H, s) , 1.51(9H, s) , 2.30(3H, s) ,
2.98(4H, s), 3.08(3H, s) , 4.57(2H, d, J=5.1Hz), 7.04(2H, d,
J=8.1Hz), 7.17 (2H, d, J=8.1Hz), 7.38 (2H, d, J=8.4Hz), 7.91 (2H, d, J=8.4Hz), 8.54(1H, t, J=5.1Hz), 8.79(1H, s) , 11.53(1H, s) .
MS: 672.2 (M+H) +
Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.90-3.05 (4H, m) ,
3.25(3H, s), 4.31 (2H, d, J=6.2Hz), 6.65-7.73 (4H, brs),
7.14 (2H, d, J=8.1Hz), 7.18 (2H, d, J=8.lHz), 7.52 (2H, d,
J=8.4Hz), 7.93 (2H, d, J=8.4Hz), 12.35(1H, s) .
MS: 506.0 (M-H)~ Production Example 64 : Synthesis of methyl 4-({2-
(acetylamino) -4- [2- (4-
{ [amino (imino) ethyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl }methyl) benzoate hydrochloride
Step 1 Ethyl 4- (4-iodophenyl) -2-oxobutanoate was prepared from
Ethyl 3- (4-iodophenyl) propanoate in a similar manner according to Step 2 of Production Example 47.
XH-NMR (CDCI3) , δ (PPm): 1.35 (3H, t, J=7.0Hz), 2.90(2H, t,
J=7.5Hz), 3.15(2H, t, J=7.5Hz), 4.31 (2H, q, J=7.0Hz), 6.96(2H, d, J=8.0Hz), 7.61 (8.5Hz).
MS: 331.0(M-H)~
Step 2
Ethyl 3-bromo-4- (4-iodophenyl) -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production Example 46.
XH-NMR (CDC13) , δ (ppm): 1.38 (3H, t, J=7.0Hz), 3.19(1H, dd, J=7.5, 14.6Hz), 3.47 (IH, dd, J=7.5, 14.6Hz), 4.36 (2H, q, J=7.0Hz), 5.21 (IH, dd, J=7.5, 7.5Hz), 7.00 (2H, d, J=8.5Hz), 7.65(2H, d, J=8.5Hz) . MS: 369.2 Step 3
Ethyl 3-bromo-4- (4-iodophenyl) -2-oxobutanoate (1.32 g) was dissolved in ethanol (26 ml) , and then, thiourea (244 mg) was added to the solution. The reaction mixture was refluxed for 1 h under nitrogen atmosphere. The cooled reaction mixture was evaporated in vacuo. The crude material was triturated with diethyl ether to give ethyl 2-amino-5- (4-iodobenzyl) -1, 3- thiazole-4-carboxylate hydrobromide as a pale yellow solid. XH-NMR (DMSO-de), δ (ppm) : 1.27 (3H, t, J=7.0Hz), 4.28 (2H, q, J=7.0Hz), 4.31 (2H, s) , 7.10 (2H, d, J=8.5Hz), 7.69 (2H, d, J=8.5Hz) . MS: 389.0 (M+H) +, 411.0 (M+Na) + Step 4
Ethyl 2-amino-5- (4-iodobenzyl) -1, 3-thiazole-4-carboxylate hydrobromide (1.386 g) was dissolved in dichloromethane (14 ml) under nitrogen atmosphere. Then, pyridine (0.765 ml) and acethyl chloride (0.336 ml) were added dropwise to the solution at 0°C. The reaction mixture was stirred at 20°C for 1 h. The organic solution was washed with IN-hydrochloric acid, water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was washed with diisopropyl ether to give ethyl 2- (acetylamino) -5- (4-iodobenzyl) -1, 3- thiazole-4-carboxylate as a white solid.
XH-NMR (DMSO-de), δ (ppm) : 1.27 (3H, t, J=7.0Hz), 2.09(3H, s) , 4.26 (2H, q, J=7.0Hz), 4.43 (2H, s) , 7.10 (2H, d, J=8.0Hz), 7.67(2H, d, J=8.0Hz), 12.44(1H, s) . MS: 431.0 (M+H) \ 453.0 (M+Na) +
Step 5
N- [4-Formyl-5- (4-iodobenzyl) -1, 3-thiazol-2-yl] acetamide was prepared in a similar manner according to Step 4 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 2.11 (3H, s) , 4.48 (2H, s) , 7.11 (2H, d, J=8.5Hz), 7.68 (2H, d, J=8.5Hz), 10.00 (IH, s) . MS: 409.0 (M+Na) + Step 6 N-{5- (4-Iodobenzyl) -4- [2- (4-nitrophenyl) vinyl] -1,3- thiazol-2-yl}acetamide was prepared in a similar manner according to Step 5 of Production Example 45. XH-MR (CDC13) , δ (ppm): 2.07(3Hx2/3, s) , 2.15(3Hxl/3, s) , 3.96(2Hx2/3, s) , 4.12(2Hxl/3, s) , 6.63(lHx2/3, d, J=12.6Hz), 6.70(lHx2/3, d, J=12.6Hz), 6.94(2Hx2/3, d, J=8.0Hz),
6.99(2Hxl/3, d, J=8.0Hz), 7.12(lHxl/3, d, J=15.6Hz),
7.25(lHxl/3, d, J=15.6Hz), 7.39(2Hx2/3, d, J=9.0Hz),
7.56(2Hxl/3, d, J=8.5Hz), 7.62(2Hx2/3, d, J=8.0Hz),
7.65(2Hxl/3, d, J=8.5Hz), 8.00(2Hx2/3, d, J=8.5Hz), 8.22(2Hxl/3, d, J=8.5Hz), 9.85(lHxl/3, s) , 10.18 (1HX2/3, s) . MS: 528.0 (M+H) + Step 7
To a solution of a mixture of N-{5- (4-iodobenzyl) -4- [ (Z) - 2- (4-nitrophenyl) vinyl]-l, 3-thiazol-2-yl}acetamide and N-{5- (4-iodobenzyl) -4- [ (E)-2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl}acetamide (Z:E=2:1) (558.2 mg) in methanol (2.8 ml) and N,N-dimethylformamide (5.5 ml) were added palladium(II) acetate (49.6 mg) , 1, 3-bis (diphenylphosphino) propane (109 mg) and triethylamine (308 μl) . Carbon monooxide gas was bubbled through the solution for 30 min at 25°C. Then the reaction mixture was stirred for 6 hrs. at 70°C under carbon monooxide atmosphere. The reaction mixture was cooled to 25°C, diluted with ethyl acetete, washed with brine, dried over magnesium sulfate and evaporated to give a crude yellow foam (645 mg) . The crude foam was purified by flash column chromatography over silica gel with toluene / ethyl acetate (2:1-3:2) as an eluent, and triturated with ethyl ether to give a mixture of N-{5-(4-(methoxycarbonyl)benzyl)-4-[ (Z)-2-(4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide and N-{5-(4- (methoxycarbonyl) benzyl) -4- [ (E) -2- (4-nitrophenyl) vinyl] -1, 3- thiazol-2-yl}acetamide (Z:E=2:3) as a yellow solid.- XH-NMR (CDC13) , δ (PPm): 2.09(3Hx2/5, s) , 2.20(3Hx3/5, s) , 3.91(3H, s), 4.10(2Hx2/5, s) , 4.25(2Hx3/5, s), 7.27(2Hx2/5, s), 7.14(lHx3/5, d, J=15.6Hz), 7.25(2Hx2/5, d, J=9.0Hz), 7.29(lHx3/5, d, J=15.6Hz), 7.31(2Hx3/5, d, J=8.5Hz), 7.38(2Hx2/5, d, J=9.0Hz), 7.57(2Hx3/5, d, J=8.5Hz), 7.97(2Hx2/5, d, J=8.5Hz), 7.99(2Hx2/5, d, J=9.0Hz), 8.00(2Hx3/5, d, J=8.5Hz), 8.20(2Hx3/5, d, J=9.0Hz), 9.55(lHx3/5, brs), 10.11 (lHx2/5, brs). MS: 460.1 (M+Na) + Step 8
Methyl 4- ( {2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] - 1, 3-thiazol-5-yl}methyl) benzoate was prepared in a similar manner according to Step 6 of Production Example 45. XH-NMR (CDCI3) , δ (ppm): 2.20 (3H, s) , 2.80 (4H, s) , 3.40- 3.67(2H, m) , 3.83(2H, s) , 3.90(3H, s) , 6.57(2H, d, J=8.5Hz), 6.84 (2H, d, J=8.5Hz), 7.09 (2H, d, J=8.0Hz), 7.91 (2H, d, J=8.5Hz), 8.96 (IH, brs).
MS: 410.2 (M+H) +, 432.2 (M+Na) + Step 9
Methyl 4- [ (2- (acetylamino) -4- {2- [4- ( { (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl } amino) phenyl] ethyl } -1, 3-thiazol-5- yl) methyl] benzoate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (CDCI3) , δ (PPm): 1.49(9H, s) , 1.54(9H, s) , 2.20(2H, s) , 2 . 83 (4H, s ) , 3 . 88 (2H, s) , 3 . 89 (3H, s ) , 7 . 03 (2H, d, J=8 . 5Hz) ,
7.17 (2H, d, J=8.0Hz), 7.44 (2H, d, J=8.0Hz), 7.93 (2H, d, J=8.5Hz), 9.09(1H, brs), 10.24(1H, s) , 11.64 (IH, s) . MS: 652.3 (M+H) +, 652.3 (M+Na) + Step 10
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.86 (4H, s) , -3.83 (3H, s), 3.96-4.10 (2H, m) , 7.13 (2H, d, J=8.5Hz), 7.24 (2H, d, J=9.0Hz), 7.28 (2H, d, J=8.5Hz), 7.35(4H, s) , 7.89(2H, d, J=8.0Hz), 9.71 (IH, s) , 12.01 (IH, s) . MS: 452.2 (M+H)" free
Production Example 65: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N,N-dimethylbenzamide hydrochloride Step 1
Methyl 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazol-5- yl]methyl}benzoate was prepared from the compound obtained in Step 8 of Production Example 64 in a similar manner according to Step 1 of Production Example 52.
XH-NMR (CDC13) , δ (ppm): 1.52 (9H, s) , 2.23 (3H, s) , 2.81 (4H, s) , 3.86(2H, s), 3.90(3H, s) , 6.93(2H, d, J=8.0Hz), 7.13(2H, d, J=8.5Hz), 7.19 (2H, d, J=8.0Hz), 7.91 (2H, d, J=8.5Hz), 8.48- 9.69(1H, brs) .
MS: 510.2 (M+H) +, 532.3 (M+Na) + Step 2
Methyl 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazol-5- yl]methyl}benzoate (287.7 mg) , lN-sodium hydroxide (1.41 ml) and ethanol (2.9 ml) were combined, and the mixture was refluxed for 3 hrs. After cooling to 25°C, the organic solvent was removed in vacuo. The aqueous solution was acidified with IN-hydrochloric acid (pH=4), and the precipitate was filtered in vacuo to give 312.5 mg of a pale yellow solid. The solid was dissolved in pyridine (4.3 ml) under nitrogen atmosphere, and then, acethyl chloride (0.12 ml) was added dropwise to the solution at 0°C. The reaction mixture was stirred at 25°C for 3 hrs., and pyridine was removed in vacuo. The residue was suspended in water, and acidified with IN-hydrochloric acid. The precipitate was collected in vacuo. The solid was washed with water and diethyl ether to give 4-{ [2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazol-5- yl]methyl}benzoic acid as a pale yallow solid. XH-NMR (DMSO-de), δ (ppm) : 1.47 (9H, s) , 2.08 (3H, s) , 2.70- 2.90(4H, m), 3.92(2H, s) , 6.99(2H, d, J=8.4Hz), 7.10(2H, d, J=8.0Hz), 7.33 (2H, d, J=8.0Hz), 7.81 (2H, d, J=8.4Hz), 9.24 (IH, s), 12.00(1H, s), 12.84(1H, brs). MS: 494.4 (M-H) ~ Step 3
To a solution of 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl}ethyl) -1, 3-thiazol-5- yl] ethyl}benzoic acid (50 mg) in 0.5 ml of dichloromethane were added methylamine hydrochloride (10.7 mg) , 1- hydroxybenzotriazole (20.4 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (55.3 μl) , then, the mixture was stirred for 3 hrs. at 25°C. The reaction mixture was diluted with 10 ml of chloroform and washed with water and brine. The organic layer was dried over magnesium sulfate and evaporated under vaccum. The residue was triturated with ethyl acetate and diisopropylether, and collected by filtration to give tert-butyl {4- [2- (2- (acetylamino) -5-{4- [ (dimethylamino) carbonyl]benzyl}-l,3-thiazol-4- yl) ethyl]phenyl }carbamate as a pale yellow solid. XH-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.23 (3H, s) , 2.83(4H, s) , 2.95(3H,s), 3.09(3H, s), 3.82(2H, s) , 6.47-6.81 (IH, brs), 6. 94 (2H, d, J=8 . 1Hz ) , 7 . 05 (2H, d, J=8 . 1Hz) , 7 . 18 (2H, d,
J=8.1Hz), 7.28 (2H, d, J=8.1Hz), 8.50-9.09 (IH, brs). MS: 523.3 (M+H) +, 545.2 (M+Na) + Step 4 tert-Butyl {4- [2- (2- (acetylamino) -5-{4- [ (dimethylamino) carbonyl]benzyl}-l, 3-thiazol-4- yl) ethyl]phenyl}carbamate (39.1 mg) and trifluoroacetic acid (1 ml) were combined at 0°C. The reaction mixture was stirred at 25°C for 2 hrs., and concentrated in vacuo . The residue was added to chloroform (20 ml) and IN-sodium hydroxide (10 ml) . The oraganic layer was separated, dried with magnesium sulfate, and evaporated to give yellow oil (33.3 mg) . The crude yellow oil, N,N' -bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (45.8 mg) and tetrahydrofuran (0.5 ml) were combined under nitrogen atmosphere, and the mixture was stirred at 25°C for 34 hrs. To the reaction mixture was added N,N' -bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (11 mg) , and the mixture was stirred at 50°C for 3 hrs. Then, the mixture was concentrated in vacuo. The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give di-tert- butyl [ (E) -({4- [2- (2- (acetylamino) -5-{4- [ (dimethylamino) carbonyl] benzyl}-l, 3-thiazol-4- yl) ethyl]phenyl}amino) methylidene]biscarbamate as colorless oil (12.9 mg) .
XH-NMR (CDC13) , δ (PPm): 1.50 (9H, s) , 1.54 (9H, s) , 2.21 (3H, s) , 2.85(4H, s), 2.96(3H, brs), 3.08(3H, brs), 3.86(2H, s) , 7.06(2H, d, J=8.5Hz), 7.14 (2H, d, J=8.1Hz), 7.33 (2H, d, J=8.5Hz), 7.46(2H, d, J=8.5Hz), 8.81-9.21 (IH, brs), 10.25(1H, s), 11.63(1H, s) .
MS: 665.3 (M+H) +, 687.2 (M+Na) + Step 5
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.86 (4H, s) , 2.88 (3H, s), 2.96(3H, s), 3.97(2H, s) , 7.12 (2H, d, J=8.4Hz), 7.16(2H, d, J=8.1Hz), 7.23(2H, d, J=8.4Hz), 7.32 (2H, d, J=8.1Hz), 7.34(4H, s), 9.70(1H, s) , 12.01(1H, s) . MS: 465.2 (M+H) + free
Production Example 66: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N-methylbenzamide hydrochloride Step 1 tert-Butyl {4- [2- (2- (acetylamino) -5-{4- [ (methylamino) carbonyl] benzyl}-!, 3-thiazol-4- yl) ethyl]phenyl}carbamate was prepared from the compound obtained in Step 2 of Production Example 65 in a similar manner according to Step 3 of Production Example 65.
XH-NMR (CDC13) , δ (PPm): 1.52 (9H, s) , 2.23 (3H, s) , 2.78- 2.89(4H, m) , 3.00(3H, d, J=4.8Hz), 3.83(2H, s) , 6.20(2H, d, J=4.8Hz), 6.36-6.78 (IH, brs), 6.94 (2H, d, J=8.4Hz), 7.05 (2H, d, J=8.4Hz), 7.18 (2H, d, J=8.4Hz), 7.63 (2H, d, J=8.4Hz), 8.60- 9.09(1H, brs) .
MS: 509.2 (M+H) +, 531.2 (M+Na) + Step 2
Di-tert-butyl [ (E) - ( {4- [2- (2- (acetylamino) -5-{4- [ (methylamino) carbonyl]benzyl }-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (PPm): 1.49 (9H, s) , 1.54 (9H, s) , 2.22 (3H, s) , 2.83(4H, s), 2.99(3H, d, J=4.8Hz), 3.86(2H, s) , 6.16(1H, d, J=4.0Hz), 7.01 (2H, d, J=8.4Hz), 7.13 (2H, d, J=8.4Hz), 7.42 (2H, d, J=8.4Hz), 7.66(2H, d, J=8.4Hz), 8.77-9.10 (IH, brs), 10.24 (IH, s), 11.62(1H, s) . MS: 651.3 (M+H) +, 673.3 (M+Na) + Step 3 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.76 (3H, d, J=4.8Hz), 2.86(4H, s), 3.98(2H, s) , 7.13 (2H, d, J=8.4Hz), 7.19 (2H, d, J=8.1Hz), 7.23 (2H, d, J=8.4Hz), 7.30 (4H, s) , 7.74 (2H, d, J=8.1Hz), 8.38 (2H, d, J=4.4Hz), 9.62 (IH, s) , 11.99(1H, s) . MS: 451.3 (M+H)" free
Production Example 67: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5- [ (dimethylamino) methyl]-l, 3-thiazol-2-yl} acetamide dihydrochloride Step 1
To a solution of N- {4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3- thiazol-2-yl} acetamide (500 mg) in acetic acid (3 ml) were added dimethylamine hydrochloride (169 mg) and paraformaldehyde (62.2 mg) , and the mixture was stirred at 100°C (bath temp.) for 2 hrs. The solvent was removed in vacuo, and the mixture was adjusted to pH=9 with saturated sodium hydrogen carbonate aqueous solution, extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The crude compound was purified by flash column chromatography over silica gel with dichloromethane / methanol (100:1) —> (20:1) as an eluent to give N-{5-[ (dimethylamino) methyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide as a yellow amorphous substance.
XH-NMR (CDC13) , δ (PPm): 2.08 (3H, s) , 2.26 (6H, s) , 3.47 (2H, s) , 6.63(1H, d, J=12.6Hz), 6.70(1H, d, J=12.6Hz), 7.43(2H, d, J=9.0Hz), 8.03 (2H, d, J=9.0Hz), 10.20 (IH, brs). MS: 347 (M+H) +, 369 (M+Na) + Step 2
N-{4- [2- (4-Aminophenyl) ethyl] -5- [ (dimethylamino) ethyl] - 1, 3-thiazol-2-yl} acetamide was prepared in a similar manner according to Step 6 of Production Example 45.
XH-NMR (CDC13), δ (ppm): 2.19(6H, s) , 2.23 (3H,s), 2.80 (4H, s) ,
3.30(2H, s), 3.56(2H, s) , 6.60(2H, d, J=8.4Hz), 6.91 (2H, d,
J=8.4Hz), 8.54-8.84(lH, brs). MS: 317.2 (M-H)~
Step 3
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5-
[ (dimethylamino) methyl] -1, 3-thiazol-4- yl} ethyl) phenyl] amino}methylidene) biscarbamate was prepared in a similar manner according to Step 7 of Production Example 45.
XH-NMR (CDCI3) , δ (PPm): 1.50 (9H, s) , 1.53 (9H, s) , 2.21 (6H, s) ,
2.22(3H, s), 2.87(4H, s) , 3.36(2H, s), 7.09(2H, d, J=8.5Hz),
7.46(2H, d, J=8.5Hz), 8.89-9.97 (IH, brs), 10.24(1H, s) ,
11.63(1H, s) . MS: 561.3 (M+H) +, 583.3 (M+Na) +
Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s), 2.66(3H, s) , 2.68 (3H, s), 2.96(4H, s), 4.37(2H, d, J=4.8Hz), 7.15 (2H, d, J=8.4Hz),
7.32(2H, d, J=8.4Hz), 7.51 (4H, s) , 10.08(1H, s) , 10.64(1H, t,
J=4.8Hz) , 12.33(1H, s) .
MS: 361.1 (M+H) +
Production Example 68: Synthesis of N-{5- [ (4-acetyl-l- piperazinyl) methyl] -4- [2- (4-
{ [amino (imino)methyl] amino}phenyl) ethyl] -1, 3-thiazol-2- yl } acetamide dihydrochloride
Step 1
N- { 5- [ (4-Acetyl-l-piperazinyl) methyl ] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl} acetamide in a similar manner according to Step 1 of
Production Example 67. XH-NMR (CDCI3) , δ (PPm): 2.08 (6H, s) , 2.34-2.59 (4H, m) , 3.41- 3.53(2H, m), 3.56(2H, s) , 3.58-3.69 (2H, m) , 6.62 (IH, d, J=12.6Hz), 6.68 (IH, d, J=12.6Hz), 7.45 (2H, d, J=8.5Hz), 8.05(2H, d, J=9.0Hz), 10.18(1H, s) . MS: 452.0 (M+Na) + Step 2
N-{5-[ (4-Acetyl-l-piperazinyl) methyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} cetamide (1080 mg) , methanol (2 ml), tetrahydrofuran (2 ml), acetic acid (0.3 ml) and then 10% palladium on carbon (150 mg) were combined under nitrogen atmosphere. The mixture was stirred under 3 atm hydrogen for 3 hrs. at 25°C. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give a crude material (192.3 mg) . To the residue was added saturated sodium hydrogen carbonate aqueous solution, and the mixture was extracted with chroloform. The organic layer was washed with brine, dried over MgS04, and concentrated in vacuo to give a pink amorphous substance (124.7 mg) . The pink amorphous substance (124.7 mg) , N,N' -bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (93.6 mg) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at 25°C for 14 hrs., and concentrated in vacuo. The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give di-tert- butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ (4-acetyl-l- piperazinyl)methyl] -1, 3-thiazol-4- yl }ethyl) phenyl] amino}methylidene)biscarbamate as colorless oil (121.1 mg) . XH-NMR (CDCI3) , δ (PPm): 1.50 (9H, s) , 1.53 (9H, s) , 2.06(3H, s), 2.24 (3H, s), 2.20-2.32 (2H, m) , 2.33-2.44 (2H, m) , 2.74-2.96 (4H, m) , 3.30-3.45(4H, m) , 3.52-3.65 (2H, ) , 7.04 (2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 8.85-10.17 (IH, brs), 10.25(1H, s) , 11.63(1H, s) .
MS: 644.3 (M+H) +, 666.1 (M+H) +
Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.03 (3H, s), 2.16(3H, s) , 2.75- 3.15(8H, m), 3.16-3.63 (4H, m) , 4.40(2H, s) , 7.15(2H, d, J=8.0Hz), 7.32 (2H, d, J=8.0Hz), 7.49 (4H, s) , 10.07 (IH, s) , 11.29(1H, brs), 12.33(1H, s) MS: 444.2 (M+H) + free
Production Example 69: Synthesis of N-(4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5-{ [4- (methylsulfonyl) -1-piperazinyl]methyl}-l, 3-thiazol-2- yl) acetamide dihydrochloride Step 1
N- {5-{ [4- (Methylsulfonyl) -1-piperazinyl] methyl}-4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2-yl}acetamide was prepared from N- { 4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl}acetamide in a similar manner according to Step 1 of Production Example 67.
XH-NMR (CDC13) , δ (PPm): 2.08 (3H, s) , 2.54-2.66 (4H, m) , 2.80(3H, s), 3.19-3.34 (4H, m) , 3.58(2H, s) , 6.61 (IH, d, J=12.1Hz), 6.69(1H, d, J=12.1Hz), 7.45 (2H, d, J=8.5Hz), 8.04(2H, d, J=8.5Hz), 10.09(1H, s) . MS : 467 . 2 (M+H) +, 488 . 1 (M+Na) + Step 2
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [4- ( ethylsulfonyl) -1-piperazinyl]methyl}-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s), 2.41-2.56(4H, m) , 2.76(3H, s) , 2.80-2.89 (4H, m) , 3.12-3.27 (4H, m) , 3.42 (2H, s), 7.05(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), , „ _ ^ ^
8 .57-9 . 6K 1H, brs) , 10 .25 ( 1H, s) , 11 . 63 ( 1H, s) . MS : 680 . 3 (M+H) ", 702 .2 (M+Na) " Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.97 (4H, s) , 3.00 (3H, s), 3.05-3.28(4H, ) , 3.28-3.48 (2H, m) , 3.59-3.81 (2H, m) , 4.35-4.60 (2H, brs), 7.16(2H, d, J=8.1Hz), 7.32 (2H, d, J=8.1Hz), 7.39(4H, s) , 9.84(1H, s) , 10.64-10.89 (IH, brs), 12.34(1H, s) .
MS: 480.1 (M+H)" free
Production Example 70: Synthesis of N-[4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- (4- thiomorpholinylmethyl) -1, 3-thiazol-2-yl] acetamide dihydrochloride Step 1
N-[4-[ (Z)-2-(4-Nitrophenyl)vinyl]-5-(4- thiomorpholinylmethyl) -1, 3-thiazol-2-yl] acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl} acetamide in a similar manner according to Step 1 of Production Example 67.
XH-NMR (CDC13) , δ (ppm): 2.08(3H, s) , 2.57-2.86 (8H, m) , 3.53(2H, s), 6.62(1H, d, J=12.6Hz), 6.68(1H, d, J=12.6Hz), 7.43(2H, d, J=9.0Hz), 8.0332(2H, d, J=9.0Hz), 10.16(1H, s) . MS: 405.1 (M+H) \ 427.1 (M+Na) + Step 2
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (4- thiomorpholinylmethyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDCI3) , δ (ppm): 1.50(9H, s) , 1.53 (9H, s) , 2.22 (3H, s), 2.63(8H, s), 2.80-2.90(4H, m) , 3.39(2H, s) , 7.06(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 8.82-9.39 (IH, brs), 10.24(1H, s) , 11 . 63 ( 1H, s) .
MS: 619.3 (M+H) +, 641.2 (M+Na) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.69-2.87 (2H, m) , 2.97(4H, s), 3.02-3.19(4H, m) , 3.48-3.61 (2H, m) , 4.42(2H, s) , 7.15 (2H, d, J=8.4Hz), 7.31 (2H, d, J=8.4Hz), 7.40 (4H, . s) , 9.86(1H, s), 1051-10.69 (IH, brs), 12.34(1H, s) . MS: 419.2 (M+H)" free
Production Example 71: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [2- (dimethylamino) - 2-oxoethyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [2- (dimethylamino) -
2-oxoethyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared from 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.46(9H, s) , 2.15 (3H, s) , 2.72, 2.85(3H, s) , 2.89, 2.98(3H, s) , 3.16(4H, m)., 4.01 (2H, m) , 7.07(2H, d, J=8.2 Hz), 7.32(2H, d, J=8.2 Hz), 7.87- 7.95(1H, m), 9.21(1H, s) , 12.36(1H, s) . MS: 490 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [2- (dimethylamino) -2-oxoethyl] -1, 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16(3H, s), 2.85(3H, s) , 2.86-2.98 (5H, m) , 3.22 (2H, dd, J=8.9, 5.3 Hz), 4.01 (2H, d, J=5. 3 Hz ) , 7 .27 (2H, d, J=8 . 5 Hz ) , 7 . 33 (2H, d, J=8 . 5 Hz ) ,
7.94 (IH, t, J=5.3 Hz), 10.15(2H, br) , 12.38(1H, s) . MS: 390 (M+H) + free Step 3 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [2- (dimethylamino ) -2-oxoethyl] amino} carbonyl) -1 , 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder XH-NMR (200MHz, DMSO-de), δ (ppm): 1.39(9H, s) , 1.51(9H, s) ,
2.15(3H, s), 2.85(3H, s) , 2.85-2.94 (2H, m) , 2.97(3H, s) , 3.17- 3.26(2H, m), 4.00-4.04 (2H, ) , 7.19(1H, d, J=8.0 Hz), 7.42(2H, d, J=8.0 Hz), 7.88(1H, t, J=5.4 Hz), 9.93(1H, s) , 11.43(1H, s) , 12.38 (IH, s) . MS: 632 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder IH-NMR (200MHz, DMSO-de) , δ (ppm) : 2.16 (3H, s), 2.84 (3H, s) , 2.89-2.695 (2H, ) , 2.98(3H, s) , 3.19-3.26 (2H, m) , 3.99(2H, m) , 7.13 (2H, d, J=8.0 Hz), 7.28 (2H, d, J=8.0 Hz), 7.43 (4H, br) , 7.97 (IH, br), 9.86(1H, s) , 12.38(1H, s) . MS: 432 (M+H) + free Production Example 72: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [3- (dimethylamino) - 3-oxopropyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [3- (dimethylamino) - 3-oxopropyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared from 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl } ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.46 (9H, s) , 2.14 (3H, s) ,
2.55(2H, m) , 2.73-2.94 (8H, m) , 3.14(2H, dd, J=9.1, 6.1 Hz),
3.37(2H, m) , 7.05(2H, d, J=8.5 Hz), 7.32(2H, d, J=8.5 Hz), 7.89(1H, m), 9.21(1H, s) , 12.33(1H, s) .
MS: 504 (M+H) +
Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [3-
(dimethylamino) -3-oxopropyl] -1, 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to
Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-dβ) , δ (ppm): 2.15(3H, s) , 2.57(2H, m) ,
2.81(3H, s), 2 84-2.98 (5H, m) , 3.20(2H, dd, J=8.9, 5.4 Hz), 3.36(2H, dd, J=12.8, 7.1 Hz), 7.26(2H, d, J=8.6 Hz), 7.32(2H, d, J=8.6 Hz), 7.95(1H, t, J=5.4 Hz), 10.04(2H, br) , 12.35(1H, br) .
MS: 403 (M+H) + free
Step 3 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [3-
(dimethylamino) -3-oxopropyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder iH-NMR (200MHz, DMSO-de), δ (ppm): 1.39 (9H, s) , 1.50 (9H, s) ,
2.14'(3H, s), 2.80(3H, s) , 2.81-2.93 (2H, m) , 2.94(3H, s) , 3.13-
3.29(6H, m), 3.34-3.43 (2H, m) , 7.17 (2H, d) , 7.42 (2H, d) ,
7.89(1H, m), 9.93(1H, s) , 11.43(1H, s) , 12.3 (IH, m) .
MS: 646 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder XH-NMR (200MHz, DMSO-d5) , δ (ppm) : 2.16(3H, s) , 2.56(2H, m) ,
2.81(3H, s), 2.87-2.95(5H, m) , 3.19(2H, m) , 3.34(2H, m) , 7.11-
7.38(4H, m), 7.43(4H, s) , 8.02 (IH, m) , 8.55(1H, br) , 9.88(1H, br) , 12.36(1H, s) . MS: 445 (M+H) + free
Production Example 73: Synthesis of 2- (acetylamino) -N- [2-
(acetylamino) ethyl] -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazole-5- carboxamide hydrochloride Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ({ [2-
(acetylamino) ethyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared from 2- (acetylamino) -4-
(2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of
Production Example 32.
XH-NMR (200MHz, DMSO-de) ,, δ (ppm) : 1.46(9H, s) , 1.79(3H, s) ,
2A4(3H, s) ,.2.84 (2H, m) , 3.16-3.22 ( 6H, . m) , 7.06 (2H, d, J=8.5
Hz), 7.33(2H, d, J=8.5 Hz), 7.99(2H, m) , 9.21(1H, s) , 12.33(1H, s) .
MS: 490 (M+H) +
Step 2
2- (Acetylamino) -N- [2- (acetylamino) ethyl] -4- [2- (4- aminophenyl) ethyl] -1, 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to Step 2 of
Production Example 31. white powder
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.79 (3H, s) , 2.15 (3H, s) ,
2.90-2.98(2H, dd, ~J=10.1, 6.6 Hz), 3.14-3 :26 (6H, m) , 7.27(2H, d, J=8.9 Hz), 7.32(2H, d, J=8.9 Hz), 7.97-8.06 (2H, m) ,
10.18(2H, br), 12.35(1H, s)'.
MS: 390 (M+H) + free
Step 3 Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [2- (acetylamino) ethyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.39(9H, s) , 1.51 (9H, s) , 1.79(3H, s), 2.15(3H, s) , 2.89(2H, m) , 3.18(6H, m) , 7.18(2H, d, J=8.0 Hz), 7.42(2H, d, J=8.0 Hz), 7.95(2H, m) , 9.93(1H, s), 11.43(1H, s) , 12.35(1H, s) . MS: 632 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.79(9H, s) , 2.16(9H, s) , 2.91 (2H, m) , 3.10-3.25 (6H, m) , 7.14(2H, d, J=8.2 Hz), 7.27(2H, d, J=8.2 Hz), 7.42 (4H, br) , 7.97 (IH, br) , 8.08 (IH, .br) , 9.83(1H, s) , 12.36(1H, s) . MS: 432 (M+H) + free Production Example 74 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N-{2- [ (methylsulfonyl) amino] ethyl }-l, 3-thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl [4- (2-{2- (acetylamino) -5- [( {2-
[ (methylsulfonyl) amino] ethyl}amino) carbonyl] -1, 3-thiazol-4- yl}ethyl) phenyl] carbamate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino]phenyl}ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm)' : 1.46 (9H, s) , 2.15 (3H, s) ," 2.79-2.89(5H, m) , 3.05-3.32 (6H, m) , 7.04-7.14 (3H, ) , 7.33(2H, d, J=8.3 Hz), 8.01 (IH, br) , 9.20(1H, s) , 12.35(1H, s) . MS : 526 (M+H) +
Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- {2-
[ (methylsulfonyl) amino] ethyl }-l, 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to
Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-de), δ (ppm) : 2.15(3H, s) , 2.89 (-3H, s) ,
2.89-3.27 (8H, m) , 7.12 (IH, t, J=5.7 Hz), 7.24 (2H, d, J=8.5 Hz), 7.32(2H, d, J=8.5 Hz), 8.05(1H, t, J=5.4 Hz), 9.95(2H, br), 12.36(1H, s) .
MS: 425 (M+H) + free
Step 3
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ ({2- [ (methylsulfonyl) amino] ethyl }amino) carbonyl] -1, 3-thiazol-4- yl }ethyl) phenyl] amino}methylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.39(9H, s) , 1.51 (9H, s) , 2.15(3H, s), 2.80-2.97(5H, m) , 3.00-3.14 (2H, m) , 3.15-3.30 (4H, m) , 7.1K1H, m) , 7.17 (2H, d, J=8.5 Hz), 7.42(2H, d, J=8.5 Hz),
8.01(1H, m) , 9.93(1H, s) , 11.43(1H, s) , 12.37(1H, s) .
MS: 668 (M+H) +
Step 4 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16(3H, s) , 2.90-2.96 (5H, m) , 3.08(2H, ) , 3.19-3.29 (4H, q) , 7.14(2H, d, J=8.3 Hz), 7.28(2H, d, J=8.3 Hz), 7.43(4H, br) , 8.07(1H, m) , 9.87(1H, s) ,
12.38(1H, s) . ■ MS: 467 (M+H) + free
Production Example 75: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- [3- (dimethylamino) - 3-oxopropyl] -N-methyl-1, 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl [ (Z) - ({4- [2- (2- (acetylamino) -5-{ [[3- (dimethylamino) -3-oxopropyl] (methyl) amino] carbonyl}-!, 3- thiazol-4-yl) ethyl] phenyl}amino) methylidene] biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. ιH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.50(9H, s) , 2.14(3H, s), 2.56(2H, t, J=7.3 Hz), 2.78(3H, s) , 2.84-2.88 (6H, m) , 2.93(3H, s) , 3.47(3H, m) , 7.12(2H, d, J=8.4 Hz), 7.40(2H, d, J=8.4 Hz), 9.92 (IH, s) , 11.43(1H, s) , 12.34(1H, s) . MS: 659 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.15(3H, s) , 2.50-2.60 (6H, m) , 2.79(3H, s),.2.87(3H, s) , 2.94(3H, s) , 3.39-3.64 (2H, m) , 7.09-7.26(4H, m) , 7.46(4H, br) , 9.96(1H, s) , 12.35(1H, s) . MS: 460 (M+H) + free
Production Example 76: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N-{3- [benzyl (methyl) amino] -3-oxopropyl }-l, 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ ({3- [benzyl (methyl) amino] -3-oxopropyl} amino) carbonyl] -1, 3-thiazol- 4-yl} ethyl) phenyl] amino }methylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to' Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.83(9H, s) , 1.50(9H, s) , 1.98-2.15(3H, m) , 2.60-2.63 (2H, m) , 2.80-2.90 (5H, m) , 3.17-
3.2K2H, m), 3.42-3.47(2H, m) , 4.50-4.57 (2H, m) , 7.12-7.43 (9H, m) , 7.95 (IH, m) , 9.93(1H, s) , 11.44(1H, s) , 12.4 (IH, s) .
MS: 722 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , 5 (ppm): 2.16, 2.30(3H, s), 2.64(2H, m) , 2.64(2H, m) , 2.80-2.90 (5H, m) , 3.14-3.25 (2H, m) , 3.43- 3.47(2H, m), 4.51-4.57 (2H, m) , 7.08-7.42 (9H, m) , 8.02-8.04 (IH, m) , 9.83-9.87(lH, m) , 12.36(1H, ) .
MS: 522 (M+H) + free
Production Example 77: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- [4- (dimethylamino) - 4-oxobutyl] -1, 3-thiazole-5-carboxairri.de hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [4-
(dimethylamino) -4-oxobutyl] amino}carbonyl) -1, 3-thiazol-4- _yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39 (9H, s), 1.50(9H, s) ,
1.68(2H, tt, J=6.8 Hz), 2.14(3H, s) , 2.30(2H, t, J=6.8 Hz), 2.80(3H, s), 2.82-2.95(2H, m) , 2.92(3H, s) , 3.10-3.28 (4H, m) ,
7.18(2H, d, .J=8.5 Hz), 7.39(2H, d, J=8.5 Hz), 9.92(1H, s),
Ϊ1.43(1H, br) , 12.3(1H, br) .
MS: 682 (M+Na) +
Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
-χH-NMR (200MHz, DMSO-de), δ (ppm): 1.69(2H, m) , 2.16(2H, s) ,
2.31(2H, t, J=7.2 Hz), 2.81(3H, s) , 2.87-2.95 (2H, m) , 2.93(3H, s ) , 3. 16-3 .24 ( 4H, m) , 3 . 57 (3H, s ) , 7 . 11-7 . 44 ( 4H, m) , 8 . 06-
8 .23 (1H, m) , 9. 83-9. 92 ( IH, m) , 12 . 35 ( 1H, s ) .
MS : 460 (M+H) + free
Production Example 78: Synthesis of (2R) -1- ( {2- (acetylamino) - •5 4_[2-(4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-
5-yl } carbonyl) -N, N-dimethyl-2-pyrrolidinecarboxamide hydrochloride
Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (2R) -2- 0 [ (dimethylamino) carbonyl] -1-pyrrolidinyl Jcarbonyl) -1, 3- thiazol-4-yl] ethyl Jphenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production
Example 34 in a similar manner according to Step 1 of
Production Example 32. 5 XH-NMR (200MHz, DMSO-de), δ (ppm): 1.39(9H, s) , 1.50(9H, s) ,
1.60-1.93(3H, m) , 2.06-2.30 (IH, m) , 2.14 (3H, s) , 2.66-
3.14(10H, ), 3.20-3.50 (2H, m) , 4.89(1H, m) , 7.16(2H, d, J=8.0
Hz), 7.41(2H, d, J=8.0 Hz), 9.92(1H, s) , 11.41(1H, s) ,
12.34(1H, s) . 0 MS: 694 (M+Na) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.60-2.00 (3H, m) , 2.15, 5 2.48(3H, s x2), 2.65-3.50(12H, m) , 3.60-3.75 (2H, ) , 7.09-
7.17(2H, d x2), 7.23-7.3K2H, d x2) , 7.47(3H, br) , 9.94(1H, br), 12.35, 12.59(1H, s x2)".
MS: 472 (M+H) + free
Production Example 79: Synthesis of (2S) -1- ( {2- (acetylamino) - 0 4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-
5-ylJcarbonyl) -N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride
Step 1 _ _ _
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (2S) -2- [ (dimethylamino) carbonyl] -1-pyrrolidinyl} carbonyl) -1, 3- thiazol-4-yl] ethyl }phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production 5 Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39(3H, s) , 1.50(9H, s) , 1.60-1.94(H, m), 2.14(3H, s) , 2.10-2.36 (IH, m) , 2.67--3.11 (10H, m) , 3.30-3.52 (2H, m) , 4.88 (IH, m) , 7.16(2H, d, J=8.0 Hz), ° 7.41(2H, d, J=8.0 Hz), 9.92(1H, s) , 11.41(1H, s) , 12.34(1H, s) .
MS: 694 (M+Na) + Step 2
The title compound was prepared in a similar manner 5 according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de) , δ (ppm) : 1.60-2.00 (3H, m) , 2.15, 2.48(3H, s x2), 2.65-3.50(12H, m) , 3.60-3.75 (2H, m) , 7.09- 7.17(2H, d x2), 7.23-7.31 (2H, d x2), 7.47(3H, br) , 9.94(1H, br) , 12.35, 12.59(1H, s x2) . 0 MS: 472 (M+H) + free
Production Example 80: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [2- (methylsulfonyl) ethyl] —1, 3~thiazole-5-carboxairri.de hydrochloride 5 Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [2- (methylsulfonyl) ethyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 0 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.57 (9H, s) , 2.15(3H, s), 2.87(2H, dd, J=8.8, 6.5 Hz), 3.02(3H, s) , 3.19- 3.28(2H, dd, J=9.0, 5.5 Hz), 3.30-3.36 (2H, m) , 3.59(2H, dd,
J=12.0, 6.0 Hz), 7.17(2H, d, J=8.4 Hz), 7.42(2H, d, J=8.4 Hz),
8.17(1H, s), 9.93(1H, s) , 11.44(1H, s) , 12.40(1H, s) .
MS: 675 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.16(3H, s) , 2.88-2.96 (2H, m) , 3.03(3H, s) , 3.20-3.30 (4H, m) , 3.33-3.60 (2H, m) , 7.12- 7.18(2H, m) , 7.26-7.46 (2H, d) , 7.46(4H, br) , 8.27(1H, t) ,
9.94(1H, s), 12.41 (IH, s) .
MS: 453 (M+H) + free
Production Example 81: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- (4- pyridinylmethyl) -1, 3-thiazole-5-carboxarrri.de dihydrochloride
Step 1
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [ (4- pyridinylmethyl) amino] carbonyl }-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.40-1.50 (18H, br) , 2.15(3H, s), 2.89(2H, m) , 3.22(2H, ) , 4.39(2H, d, J=5.7 Hz), 7.09- 7.18(2H, m), 7.32-7.44 (3H, m) , 7.66(1H, m) , 8.43-8.62 (3H, m) ,
9.94(1H, s), 11.44 (IH, s) , 12.40(1H, s) .
MS: 660 (M+Na) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (PPm)' : 2.18 (3H, s) , 2.92 (2H, m) ,
3.13-3.28 (2H, m) , 4.63 (2H, m) , 7.12 (2H, d, J=8.4 Hz), 7.24 (2H, d, J=8.4 Hz), 7.47 (4H, br) , 7.93(2H, d, J=6.3 Hz), 8.88 (3H, m) , 10 . 00 ( 1H, s ) , 12 . 43 ( 1H, s) .
MS : 438 (M+H) + free
Production Example 82: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- (3- 5 pyridinylmethyl) -1, 3-thiazole-5-carboxairri.de dihydrochloride
Step 1
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5- { [ (3- pyridinylmethyl) amino] carbonyl}-!, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared ° from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMS0-d6) , δ (ppm) : 1.39 (9H, s) , 1.50 (9H, s) ,
2.16(3H, s), 2.89(2H, dd, J=8.6, 6.7 Hz), 3.22(2H, dd, J=8.6, 5 5.7 Hz), 4.38(2H, d, J=5.7 Hz), 7.13(2H, d, J=8.4 Hz),
7.25(2H, s x2, J=5.7 Hz), 7.41(2H, d, J=8.4 Hz), 8.50(2H, s x2, J=5.0 Hz), 8.62(1H, dd, J=5.0, 5.7 Hz), 9.93(1H, s) , 11.43
(IH, s), 12.4K1H, s) .
MS: 660 (M+Na) + 0 Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm): 2.17 (3H, s) , 2.92 (2H, m) ,
3.23(2H, m) , 4.56(2H, m) , 7.10-7.31 (4H, m) , 7.45(4H, br) , 5 8.01(1H, dd, J=8.1, 5.9 Hz), 8.82(1H, d, J=8.0 Hz), 8.84(2H, s), 8.96(1H, s), 12.45(1H, s) .
MS: 438 (M+H) + free
Production Example 83: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N-{2- [ (2- 0 phenylacetyl) amino] ethyl }-l, 3-thiazole-5-carboxairri.de hydrochloride
Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ ({2-[ (2- phenylacetyl) amino] ethyl }amino) carbonyl] -1, 3-thiazol-4- yl} ethyl) phenyl] amino}methylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 5 32.
XH-NMR (200MHz, DMSO-d5) , δ (ppm): 1.39(9H, s) , 1.51 (9H, s) , 2.15(3H, s), 2.88(2H, m) , 3.25-3.31 ( 6H, m) , 3.38(2H, s) , 7.15- 7.44(7H, m) , 7.32(2H, d, J=8.3 Hz), 7.98 (IH, br) , 8.11(1H, br), 9.93(1H, s) , 11.43(1H, s) , 12.35(1H, s) . ° MS: 730 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.' XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16(3H, s) , 2.90(2H, br) , ■ 5 3.20(6H, ) , 7.11-7.31 (9H, m) , 7.38(3H, s) , 8.06-8.16 (2H, m) , 9.75(1H, s) , 12.33(1H, s) . MS: 508 (M+H) + free
Production Example 84 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- [5- (dimethylamino) - 0 5-oxopentyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [5- (dimethylamino) -5-oxopentyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene }biscarbamate was prepared 5 from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.39(9H, s), 1.39-1.50 (4H, m) , 1.57 (9H, s), 2.14(3H, s) , 2.29(2H, br) , 2.79(3H, s) , 2.84- 0 2.94(2H, m), 2.94(3H, s) , 3.15-3.23 (4H, m) , 7.16(2H, d, J=8.3 Hz), 7.42(2H, d, J=8.3 Hz), 7.97(1H, br) , 9.93(1H, s) , 11.44(1H, s) , 12.35(1H, s) . MS: 696 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39-1.56 (4H, m) , 2.16(2H, 5 ) , 2.29(3H, s) , 2.83-2.98 (5H, m) , 3.06-3.28 (4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5 Hz), 7.40(3H, br) , 8.06(1H, br) , 9.79(1H, s) .
MS: 474 (M+H) + free
Production Example 85: Synthesis of 2- (acetylamino) -4- [2- (4- ° { [amino (imino) methyl] amino}phenyl) ethyl] -N- [3- (benzylamino) -3- oxopropyl] -1, 3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [3-
(benzylamino) -3-oxopropyl] amino } carbonyl) -1, 3-thiazol-4- 5 yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.39(9H, s) , 1.50(9H, s) , 0 2.15(3H, s), 2.45(2H, t, J=7.2 Hz), 2.73(2H, m) , 3.20(2H, m) ,
3.39(2H, m) , 4.26(2H, d, J=5.8 Hz), 7.15-7.28 (7H, m) , 7.41(2H, d, J=8.4 Hz), 8.02 (IH, t, J=5.5 Hz), 8.40(1H, t, J=5.5 Hz),
9.93(1H, s), 11.4(1H, br) , 12.3(1H, br) .
MS: 730 (M+Na) + 5 Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.16(3H, s) , 2.41(2H, t,
J=7.0 Hz), 2.90(2H, m) , 3.20(2H, m) , 3.39(2H, m) , 3.63(2H, m) , 0 4.27(2H, d, J=5.8 Hz), 7.11-7.37 (9H, m) , 7.37(4H, s) , 8.09(1H, t, J=5.5 Hz), 8.43(1H, t, J=6.0 'Hz), 9.74(1H, s) , 12.35(1H, s) .
MS: 508 (M+H) + free Production Example 86: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl]-N-[6- (dimethylamino) - 6-oxohexyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1 5 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [6-
(dimethylamino) -6-oxohexyl] amino} carbonyl) -1, 3-thiazol-4- yl] ethyl Jphenyl) amino] methylideneJbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example ι° 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.13-1.50 (24H, m) , 2.14 (3H, s), 2.24(2H, t, J=8.0 Hz), 2.78(3H, s) , 2.88(2H, m) , 2.92(3H, s), 3.07-3.25(4H, m) , 7.16(2H, d, J=8.5 Hz), 7.42(2H, d, J=8.5 Hz), 7.95(1H, t, J=5.52 Hz), 9.94(1H, s) , 11.4(1H, s) ,
25 12.3(1H, s) . MS: 710 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
20 ιH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.27-1.34 (2H, m) , 1.47 (4H, m), 2.16(3H, s) , 2.26(2H, t, J=7.2 Hz), 2.79(3H, s) , 2.94(3H, s), 2.90-2.94 (2H, m) , 3.17 (4H, m) , 7.13 (2H, d, J=8.3 Hz), 7.26(2H, d, J=8.3 Hz), 7.47(4H, br) , 8.05(1H, t, J=5.4 Hz), 9.93(1H, s) .
25 MS: 488 (M+H) + free
Production Example 87: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) ethyl] amino}phenyl) ethyl] -N- [3- (4- morpholinyl) propyl] -1, 3-thiazole-5-carboxairri.de dihydrochloride Step 1
30 Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [3- (4- morpholinyl) propyl ] amino } carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylideneJbiscarba ate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.58(9H, br) , 1.62 (2H, ) , 2.14 (3H, S), 2.31(6H, m) , 2.88(2H, m) , 2.19(4H, m) , 3.58(4H, 5 m) , 7.14(2H, d, J=8.4 Hz), 7.41(2H, d, J=8.4 Hz), 7.95(1H, t, J=5.2 Hz), 9.94(1H, s) , 11.45(1H, s) , 12.30(1H, s) . MS: 696 (M+Na) + Step 2
The title compound was prepared in a similar manner ° according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de) , δ (ppm) : 1.90-2.00 (2H, br) , 2.17(3H, s), 2.83-3.15(6H, m) , 3.15-3.30 (4H, m) , 3.30-3.44 (2H, m) , 3.77-4.00(4H, m) , 7.14 (2H, d, J=8.5 Hz), 7.26(2H, d, J=8.5 Hz), 7.44(4H, br), 8.20 (IH, t, J=5.5 Hz), 9.92(1H, s) , 5 11.0K1H, s), 12.38(1H, s) . MS: 474 (M+H) + free
Production Example 88: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) ethyl] amino}phenyl) ethyl] -N- [3- (2-oxo-l- pyrrolidinyl) propyl] -1, 3-thiazole-5-carboxamide hydrochloride 0 Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [3-(2-oxo- 1-pyrrolidinyl) propyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 5 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.41(9H, br) , 1.49(9H, br) , 1.64 (2H, t, J=6.9 Hz), 1.90(2H, m) , 2.14 (3H, s) , 2.17(2H, m) , 2.91 (2H, m) , 3.16(6H, m) , 3.32(2H, m) , 7.16(2H, d, J=8.4 Hz), 0 7.41 (2H, d, J=8.4 Hz), 7.93 (IH, t, J=5.6 Hz), 9.93(1H, br) , 11.73(1H, br) . MS: 694 (M+Na) + Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de) , δ (ppm): 1.65(2H, m) , 1.91(2H, m) ,
2.16(3H, s), 2.20(2H, q, J=7.5 Hz), 2.90(2H, m) , 3.02-3.27 (6H, ) , 3.33(2H, t, J=7.5 Hz), 7.16(2H, d, J=8.5 Hz), 7.26(2H, d,
J=8.5 Hz), 8.03(1H, br) , 9.92(1H, s) , 12.35(1H, s) .
MS: 472 (M+H) + free
Production Example 89: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N-hexyl-1, 3-thiazole- 5-carboxamide hydrochloride
Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5-
[ (hexylamino) carbonyl] -1, 3-thiazol-4- yl}ethyl) phenyl] amino}methylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMSO-de), δ (ppm): 0.85(3H, t, J=6.4 Hz),
1.25(9H, s), 1.35-1.60(17H, br) , 2.14(3H, s) , 2.88(2H, m) , 3.15 (4H, m) , 7.14 (2H, d, J=8.5 Hz), 7.41 (2H, d, J=8.5 Hz),
7.92(1H, t, J=5.7 Hz), 10.00(1H, br) , 11.60(1H, br) .
MS: 653 (M+Na) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de (+D20) ) , δ (ppm): 0.86(3H, t, J=6.53
Hz), 1.18-1.57(8H, ) , 2.16(3H, s) , 2.91 (2H, dd, J=9.5, 6.0
Hz), 3.16(4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5
Hz), 8.05(1H, br), 9.91(1H, s) , 12.33(1H, s) . MS: 431 (M+H) + free
Production Example 90: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- [4-oxo-4- (1- piperidinyl) butyl] -1, 3-thiazole-5-carboxairri.de hydrochloride Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [4-oxo-4- (1-piperidinyl) butyl] amino}carbonyl) -l,3-thiazol-4- yl] ethyl}phenyl) amino] ethylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.29-1.59 (20H, m) , 1.69(2H, m) , 2.14(3H, s) , 2.30(2H, t, J=7.5 Hz), 2.89(4H, m) , 3.32- 3.45 (4H, m) , 7.16(2H, d, J=8.0 Hz), 7.41 (2H, d, J=8.0 Hz), 7.99(1H, t, J=5.2 Hz), 9.94(1H, s) , 11.43(1H, br) . MS: 722 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm): 1.30-1.79 (8H, ) , 2.16(3H, s), 2.31(2H, t, J=7.5 Hz), 2.92(2H, m) , 3.18 (4H, m) , 3.38(4H, m) , 7.13(2H, d, J=8.0 Hz), 7.25(2H, d, J=8.0 Hz), 7.43(4H, br) , 8.09(1H, t, J=6.0 Hz), 9.87(1H, s) , 12.34(1H, s) . MS: 500 (M+H) + free
Production Example 91: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -N- [4- (4-morpholinyl) - 4-oxobutyl] -1, 3-thiazole-5-carboxamide hydrochloride Step 1 Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [4- (4- morpholinyl) -4-oxobutyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm)': 1.40 (9H, s) , 1.50 (9H, s) , 1.71 (2H, m), 2.14 (3H, s) , 2.32 (2H, t, J=7.3 Hz), 2.89(2H, dd, J=10.1, 6.9 Hz), 3.19(4H, m) , 3.42(4H, m) , 3.51(4H, ) , 7.16(2H, d, J=8.3 Hz), 7.42(2H, d, J=8.3 Hz), 7.99(2H, t,
J=5.3 Hz), 9.94(1H, s) , 11.44(1H, s) , 12.33 (IH, s) .
MS: 724 (M+Na )+
Step 2 5 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.70(2H, m) , 2.16(3H, s) ,
2.33(2H, t, J=7.0 Hz), 2.91 (2H, m) , 3.19(4H, ) , 3.42(4H, m) ,
3.53(4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5 Hz), ° 7.44(4H, br), 8.07(1H, t, J=5.0 Hz), 9.89(1H, s) , 12.34(1H, s) .
MS: 502 (M+H) + free
Production Example 92: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -N- [4- 5 (methylsulfonyl) phenyl ] -1, 3-thiazole-5-carboxairri.de hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [4-
(methylthio) phenyl] amino} carbonyl) -1, 3-thiazol-4- 0 yl] ethyl}phenyl) amino] methylidene Jbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMS0-d6) , δ (ppm): 1.39(9H, s), 1.51 (9H, s) , 5 2.18(3H, s), 2.45(3H, s) , 2.82-3.00 (2H, m) , 3.17-3.30 (2H, m) ,
7.13 (2H, d, J=8.5 Hz), 7.23 (2H, d, J=8.5 Hz), 7.41 (2H, d,
J=8.5 Hz), 7.61 (2H, d,. J=8.5 Hz), 9.92(2H, s), 11.43 (IH, s) ,
12.45(1H, s) .
MS: 691 (M+Na) + 0 Step 2
Di-tert-butyl { (Z)-[ (4-{2-'[2- (acetylamino) -5- ( { [4-
(methylsulfonyl) phenyl] amino}carbonyl) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene }biscarbamate was prepared in a similar manner according to Step 2 of Production Example 32. XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.39 (9H, s), 1.51 (9H, s) , 2.18(3H, S), 2.81-3.03(2H, m) , 3.18(3H, s) , 3.19-3.30 (2H, m) , 7.16(2H, d, J=8.5 Hz), 7.41(2H, d, J=8.5 Hz), 7.86(2H, d, J=9.0 Hz), 7.93(2H, d, J=9.0 Hz), 9.92(1H, s) , 10.34(1H, s) , 11.42(1H, s), 12.52(1H, s) . MS: 723 (M+Na) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm): 2.20 (3H, s) , 2.84-3.07 (2H, ) , 3.17-3.32(2H, m) , 3.18 (3H, s) , 7.12(2H, d, J=8.5 Hz), 7.37(4H, br) , 7.86(2H, d, J=9.0 Hz), 7.92(2H, d, J=9.0 Hz), 9.76(1H, s), 10.42(1H, s) . MS: 501 (M+H) + free
Production Example 93: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [ (IS) -2- (dimethylamino) -l-methyl-2-oxoethyl] -1, 3-thiazole-5- carboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [ (IS) -2- (dimethylamino) -l-methyl-2-oxoethyl] amino} carbonyl) -1, 3- thiazol-4-yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.40(3H, d, J=7.0 Hz), 1.49 (9H, s), 1.53(9H, s) , 2.22(3H, s), 2.95(2H, m) , 3.00(3H, s), 3.10(3H, s), 3.26(2H, m) , 5.01(1H, dt, J=7.0 Hz), 6.87(1H, d, J=7.5 Hz), 7.14 (2H, d, J=8.5 Hz), 7.40 (2H, d, J=8.5 Hz), 9.57(1H, br) , 10.20(1H, s) , 11.62 (IH, s) . MS: 646 (M+H) + Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.23 (3H, d) , 2.16 (3H, s) ,
2.84(3H, s), 2.87-2.95(2H, m) , 3.03(3H, s) , 3.15-3.24 (2H, m) , 5 3.56(1H, s), 4.78(3H, t, J=7.0 Hz), 7.13(2H, d, J=8.4 Hz),
7.25(2H, d, J=8.4 Hz), 8.09(1H, d, J=7.0 Hz), 9.67(1H, s) ,
12.35(1H, s) .
MS: 446 (M+H) + free
Production Example 94 : Synthesis of 2- (acetylamino) -4- [2- (4- ι° { [amino (imino) methyl] amino }phenyl) ethyl]-N- [ (IS) -l-benzyl-2-
(dimethylamino) -2-oxoethyl] -1, 3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [ (1S)-1- 15 benzyl-2- (dimethylamino) -2-oxoethyl] amino}carbonyl) -1, 3- thiazol-4-yl] ethyl Jphenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production
Example 34 in a similar manner according to Step 1 of
Production Example 32. 20 XH-NMR (200MHz, CDC13) , δ (ppm) : 1.48(9H, s) , 1.52 (9H, s) ,
2.22(3H, s), 2.68(3H, s) , 2.84-2.97 (5H, m) , 3.06(2H, d, J=7.5
Hz), 3.17(H, dd, J=8.0, 6.0 Hz), 5.26(1H, q, J=7.5 Hz),
6.80(1H, d, J=8.0 Hz), 7.08(2H, d, J=8.0 Hz), 7.14-7.33 (5H, m) , 7.39(2H, d, J=8.0 Hz), 9.96(1H, br) , 10.19(1H, s) , 25 11.61 (IH, s) .
MS: 722 (M+H) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. 30 XH-NMR (200MHz, DMSO-de), δ (ppm) : 2.15(3H, s) , 2.82-3.15 (13H, m) , 4.91(1H, q, J=6.7 Hz), 7.09(4H, s) , 7.16-7.31 (5H, m) ,
7.36(4H, br), 8.31 (IH, d, J=7.7 Hz), 9.71(1H, s) , 12.33(1H, s). MS: 522 (M+H) + free
Production Example 95: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) ethyl] amino}phenyl) ethyl] -N- [ (IS) -2- (dimethylamino) -1- (hydroxymethyl) -2-oxoethyl] -1, 3-thiazole-5- 5 carboxamide hydrochloride Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [ (IS) -2- (dimethylamino) -1- (hydroxymethyl) -2-oxoethyl] amino} carbonyl) - 1, 3-thiazol-4-yl] ethyl }phenyl) amino]methylidene}biscarbamate ι° was prepared from the compound obtained in Step 2 of
Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.48 (9H, s) , 1.52 (9H, s) , 2.23(3H, s), 2.94(2H, dd, J=7.0 Hz), 3.01(3H, s) , 3.14(3H, s) ,
15 3.26(2H, dd, J=7.0 Hz), 3.78-3.86 (3H, br) , 5.04 (IH, m) , 6.85(1H, d, J=7.5 Hz), 7.08 (2H, d, J=8.5 Hz), 7.37 (2H, d, J=8.5 Hz), 9.70(1H, br) , 10.20(1H, s) , 11.61 (IH, s) . MS: 662 (M+H) + Step 2
20 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMS0-d6) , δ (ppm) : 2.16, 2.19(3H, s x2) , 2.85- 3.50(10H, m), 3.60-3.69 (2H, m) , 4.81(1H, m) , 7.14(2H, m) , 2.27(2H, m) , 7.39(4H, br) , 7.91(1H, br) , 8.48(1H, br) , 9.77,
25 9.94(1H, s x2), 12.37, 12.61(1H, s x2) . MS: 462 (M+H) + free
Production Example 96: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- { ( 1S, 2S) -1- [ (dimethylamino) carbonyl] -2-hydroxypropyl}-l, 3-thiazole-5-
30 carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ ({ (1S,2S)- 1- [ (dimethylamino) carbonyl] -2-hydroxypropyl} amino) carbonyl] - 1, 3-thiazol-4-yl}ethyl) phenyl] amino}methylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. 5 XH-NMR (200MHz, CDC13) , δ (ppm) : 1.18 (3H, d, J=6.5 Hz),
1.48(9H, s), 1.52(9H, s), 2.22(3H, s) , 2.95(2H, m) , 2.99(3H, s), 3.16(3H, s), 3.20-3.32 (2H, m) , 4.06-4.12 (2H, m) , 5.02(1H, dd, J=9.0, 1.5 Hz), 6.55(1H, d, J=9.0 Hz), 7.09(2H, d, J=8.0 Hz), 7.38(2H, d, J=8.0 Hz), 9.70(1H, br) , 10.20(1H, s) ,
10 11.62 (IH, s) . MS: 676 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
I5 XH-NMR (200MHz, DMSO-de) , 5 (ppm) : 1.35(3H, d, J=6.5 Hz), 2.19(3H, S), 2.85-2.97 (6H, m) , 3.11(3H, s) , 3.26(2H, m) , 4.67(1H, br), 5.40(1H, m) , 7.15 (2H, d, J=8.3 Hz), 7.28(2H, d, J=8.3 Hz), 7.43(4H, br) , 8.43(3H, br) , 9.93(1H, s) , 12.59(1H, s) .
20 MS: 475 (M+H) + free
Production Example 97 : Synthesis of (2S) -2- [( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) ethyl] amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}carbonyl) amino] -N1,N1-dimethylpentanediamide hydrochloride Step 1
25 Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ ( { (IS) -4- amino-1- [ (dimethylamino) carbonyl] -4-oxobutyl}amino) carbonyl] - 1, 3-thiazol-4-yl}ethyl) phenyl] amino}methylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1
30 of Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.49 (9H, s) , 1.53(9H, s) , 1.86-2.19(2H, m) , 2.22-2.37 (5H, ) , 2.89(2H, ) , 2.99(3H, s) , 3.05-3.16(5H, m) , 3.20-3.41 (IH, m) , 5.06(1H, m) , 6.27(1H, br) , 6.35(1H, br), 6.81 (IH, d, J=7.5 Hz), 7.09(2H, d, J=8.5 Hz),
7.41(2H, d, J=8.5 Hz), 10.21(1H, s) , 10.55(lH, br) , 11.62(1H, s) .
MS: 703 (M+H) + 5 Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de) , δ (ppm) : 1.70-2.00 (2H, m) , 2.16 (5H, m) , 2.84(3H, s), 2.91 (2H, ) , 3.08(3H, s) , 3.19(2H, m) , ° 4.75(1H, m) , 6.79(1H, ) , 7.12 (2H, d, J=8.3 Hz), 7.25(2H, d,
J=8.3 Hz), 7.39(4H, br) , 8.13(1H, d) , 9.77(1H, s) , 12.35(1H, s).
MS: 503 (M+H) + free
Production Example 98: Synthesis of N-{4-[2-(4- 5 { [imino (methylamino) methyl] amino}phenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide
The title compound was prepared from the compound obtained in Step 2 of Production Example 50 in a similar manner according to Production Example 58. 0 if-NMR (DMSO-de), (ppm) : 2.09 (3H, s) , 2.79 (3H, s) , 2.86 (4H, s), 3.18(3H, s), 4.08(2H, s) , 4.43(2H, m) , 7.08(2H, d,
J=8.5Hz), 7.22(2H, d, J=8.5Hz), 7.39(2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz), 12.05(1H, brs).
MS: 486 (M+H) + 5 Production Example 99: Synthesis of (2S) -1- ( {2- (acetylamino) -
4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-
5-yl}methyl) -N,N-dimethyl-2-pyrrolidinecarboxamide dihydrochloride
Step 1 0 tert-Butyl {4- [2- (2- (acetylamino) -5-
{ [methoxy (methyl) amino] carbonyl}-!, 3-thiazol-4- yl) ethyl] phenyl}carbamate was prepared from 2- (acetylamino) -4-
(2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCls) , δ (PPm): 1.46 (9H, s) , 2.15 (3H, s) , 2.74- 2.93(2H, m) , 3.12-3.29(2H, m) , 3.22(3H, s) , 3.59(3H, s) , 5 7.05(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.21 (IH, s) , 12.34(1H, s) . MS: 471.1 (M+Na) + Step 2
To a solution of the compound obtained in Step 1 (3.93 g) ° in THF (80 mL) was added lithium aluminium hydirde (499 mg) slowly (over 15 min) at 5-10°C (under ice-cooling) . The mixture was stirred at 5°C for 1 h. 30 mL of aqueous solution of potassium sodium tartrate (1M) was added slowly under ice- cooling, and then the mixture was stirred for another 0.5 h at 5 r.t. The mixture was extracted with ethyl acetate, and the organic layer was dried over MgS04, and concecntrated in vacuo to give pale yellow oil. This oil was triturated with IPE and EtOAc to give tert-butyl (4-{2- [2- (acetylamino) -5-formyl-l, 3- thiazol-4-yl] ethyl Jphenyl) carbamate as pale yellow powder 0 (2.67g).
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.46(9H, s) , 2.19(3H, s) , 2.90 (2H, t, J=7.3 Hz), 3.22 (2H, t, J=7.3 Hz), 7.01 (2H, d, J=8.5 Hz), 7.32(2H, d, J=8.5 Hz), 9.22(1H, s) , 9.77(1H, s) , 12.68(1H, s) . 5 MS: 390 (M+H) + Step 3
To a solution of the compound obtained in Step 2 (200 mg) in dichloromethane (6 mL) were added (2S)-2-(N,N- dimethylaminocarbonyl) pyrrolidine hydrochloride and 0 diisopropylethylamine (0.27 ml) at 5°C. The mixture was stirred at 5°C for 10 min. Then sodium triacetoxyborohydride (327 mg) was added, and the mixture was stirred for 3 hrs. aq. NH4CI was added, and the mixuture was extracted with dichloromethane. The organic layer was dried over MgS0. The layer was concentrated under reduced pressure. The resulting crude mixture was purified by silica gel column chlomatography with mixed solvent (dichloromethane/methanol=15/l) as an 5 eluent to give tert-butyl (4-{2- [2- (acetylamino) -5- ({ (2S) -2- [ (N,N-dimethylamino) carbonyl] -l-pyrrolidinyl}methyl) -1,3- thiazol-4-yl] ethyl}phenyl) carbamate as a pale yellow amorphous substance. XH-NMR (200MHz, CDC13) , δ (ppm): 1.67-1.99 (4H, m) , 2.24 (3H, s) , ° 2.04(4H, s), 2.14(3H, s) , 2.95-3.14 (5H, m) , 3.42-3.58 (2H, ) , 3.68-3.83 (IH, m) , 6.97 (2H, d, J=8.3 Hz), 7.94 (2H, d, J=8.3 Hz) .
MS: 516 (M+H) + Step 4 5 (2S) -1- ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3- thiazol-5-yl}methyl) -N,N-dimethyl-2-pyrrolidinecarboxamide was prepared in a similar manner according to Step 2 of Production Example 31. XH-NMR (200MHz, CDCI3) , δ (ppm) : 1.70-2.10 (4H, m) , 2.22 (3H, s) , 0 2.39(1H, q, J=8.4 Hz), 2.77(4H, m) , 2.91 (3H, s) , 3.03(3H, s) , 3.30-3.81 (6H, m) , 6.58(2H, d, J=8.3 Hz), 6.89(2H, d, J=8.3 Hz) , 8.82 (IH, br) . MS; 416 (M+H) + Step 5 5 Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (2S) -2-
[ (N,N-dimethylamino) carbonyl] -l-pyrrolidinyl}methyl) -1,3- thiazol-4-yl] ethyl Jphenyl) amino]methylidene}biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. 0 XH-NMR (200MHz, CDCI3) , δ (ppm) : 1.50 (9H, s) , 1.52 (9H, s) , 1.76-1.92(4H, m) , 2.04-2.14 (IH, m) , 2.43(1H, dd, J=8.1, 8.0 Hz), 2.45(3H, s), 2.85(2H, s) , 3.07(3H, s) , 3.51 (IH, dd, J=5.7, 8.0 Hz), 3.60(1H, d, J=14.3 Hz), 3.84 (IH, d, J=14.3 Hz), 6.37(1H, t, J=2.0 Hz), 7.08(2H, d, J=8.4 Hz), 7.44(2H, d,
J=8.4 Hz), 7.63(1H, d, J=2.0 Hz), 10.23(1H, s) , 11.62(1H, br) .
MS: 658 (M+H) +
Step 6 5 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de) , δ (ppm): 1.60-1.98 (2H, br) , 1.98-
2.16(1H, br), 2.16(3H, s) , 2.85(3H, s) , 2.95(7H, br) , 3.00-
3.30 (IH, br) , 7.15 (2H, d, J=8.3 Hz), 7.30 (2H, d, J=8.3 Hz), ι° 7.55(4H, br) , 7.85(1H, d, J=2.2 Hz), 9.65(1H, br) , 10.21(1H, s) , 12.35(1H, s) .
MS: 458 (M+H) + free
Production Example 100 : Synthesis of 3- [( {2- (acetylamino) -4-
[2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- 15 yl}methyl) (methyl) amino] -N,N-dimethylpropanamide dihydrochloride
Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [3-(N,N- dimethylamino) -3-oxopropyl] amino }methyl) -1, 3-thiazol-4- 20 yl] ethyl}phenyl) carbamate was prepared from the compound obtained in Step 2 of Production Example 99 in a similar manner according to Step 3 of Production Example 99.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.50 (9H, s) , 2.24 (3H, s) ,
2.47(2H, t, J=6.2 Hz), 2.74(2H, t, J=6.2 Hz), 2.82-2.88 (4H, 25 ) , 2.93(3H, s) , 2.97(3H, s) , 3.59(2H, s) , 6.94(2H, d, J=8.3
Hz), 7.21(2H, d, J=8.3 Hz), 8.02(1H, s) .
MS: 4-90 (M+H) +
Step 2
To a solution of the compound obtained in Step 1 (100 mg) 30 in dichloromethane (1.5 mL) was added formaline (35%, 87.6 μl) .
To this suspension was added 0.05 ml of MeOH. Then, sodium triacetoxyborohydride (433 mg) was added, and the mixture was stirred for 12 hrs. To the mixture were added water and IN NaOH to adjust pH of aqueous phase (ca. pH 8-9) . The mixture was extracted with dichloromethane. The organic layer was dried with MgS04 and concentrated under redused pressure. Resulting oil was purified by silica gel column chromatography 5 (mixed solvent of CH2Cl2/MeOH 15/1 as an eluent) to give tert- butyl {4- [2- (2- (acetylamino) -5-{ [ [3- (N,N-dimethylamino) -3- oxopropyl] (methyl) amino] ethyl }-l, 3-thiazol-4- yl) ethyl]phenyl}carbamate as pale yellow oil (90.4 mg) . XH-NMR (200MHz, CDC13) , δ (ppm) : 1.51 (9H, s) , 2.18 (3H, s) , ° 2.24(3H, s), 2.45(2H, m) , 2.62(2H, m) , 2.80(4H, s) , 2.93(3H, s), 2.99(3H, s), 3.35(2H, s) , 6.96(2H, d, J=8.3 Hz), 7.20(2H, d, J=8.3 Hz) . MS: 504 (M+H) + Step 3 5 3- [ ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1,3- thiazol-5-yl}methyl) (methyl) amino] -N,N-dimethylpropanamide was prepared in a similar manner according to Step 2 of Production Example 31. XH-NMR (200MHz, CDCI3) , δ (ppm) : 2.19 (3H, s) , 2.22 (2H, s) , 0 2.43-2.51(2H, ) , 2.62-2.71 (4H, m) , 2.78(3H, s) , 2.93(3H, s) , 2.99(3H, s), 3.33(2H, s) , 3.65(1H, m) , 3.75(1H, m) , 6.58(2H, d, J=8.3 Hz), 6.87 (2H, d, J=8.3 Hz). MS: 404 (M+H) + Step 4 5 Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ [3- (N,N- dimethylamino) -3-oxopropyl] (methyl) amino]methyl}-1, 3-thiazol- 4-yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. 0 XH-NMR (200MHz, CDC13) , δ (ppm) : 1.50 (9H, s) , 1.53(9H, s) , 2.20(3H, s), 2.22(3H, s) , 2.49(2H, dd, J=6.5, 5.5 Hz), 2.7K2H, dd, J=6.5, 5.5 Hz), 2.84(4H, s) , 2.93(3H, s), 2.99(3H, s), 3.43(2H, s) , 7.08(2H, d, J=8.4 Hz), 7.46(2H, d, J=8 .4 Hz) , 7 . 62 ( 1H, s) , 10 .24 ( 1H, s) , 11 . 62 ( IH, s ) . MS : 646 (M+H) + Step 5
The title compound was prepared in a similar manner 5 according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 2.15(3H, s) , 2.68(3H, d, J=4.0 Hz), 2.83-2.88(6H, m) , 2.96(6H, s) , 3.05-3.15 (2H, m) , 4.44 (2H, m) , 7.15(2H, d, J=8.3 Hz), 7.32 (2H, d, J=8.3 Hz), 7.62(4H, br) , 9.90(1H, s) , 12.32(1H, s) . ° MS: 446 (M+H) + free
Production Example 101: Synthesis of 4- (2- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl }ethyl) -N,N-dimethylbenzamide hydrochloride Step 1 5 Methyl 4- {2- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl ) amino] phenyl} ethyl) -1, 3-thiazol-5- yl] vinyl }benzoate was prepared from the compound obtained in Step 2 of Production Example 99 in a similar manner according to Step 1 of Production Example 53. 0 iπ- MR (CDC13) , δ (PPm): 1.50(9Hx4/9, s) , 1.51(9Hx5/9, s) , 2.20(3Hx5/9, s) , 2.29(3Hx4/9, s) , 2.72-3.06 (4H, m) , 3.90(3Hx5/9, s), 3.92(3Hx4/9, s) , 6.42-6.60 (2Hx5/9, m) , 6.69(lHx4/9, d, J=16.6Hz), 6.81-7.03 (4H + lHx4/9, m) , 7.31(2Hx5/9, d, J=8.0Hz), 7.39(2Hx4/9, d, J=8.0Hz), 5 7.96(2Hx5/9, d, J=8.0Hz), 7.99(2Hx4/9, d, J=8.0Hz). MS: 522.2 (M+H) +, 544.2 (M+Na) + Step 2
Methyl 4- {2- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazol-5- 0 yl] ethyl Jbenzoate was prepared in a similar manner according to Step 6 of Production Example '45. MS: 524.25 (M+H) + Step 3 4- {2- [2- (Acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1 , 3-thiazol-5- yl] ethyl Jbenzoic acid was prepared in a similar manner according to Step 2 of Production Example 65. 5 XH-NMR (DMSO-de), δ (ppm) : 1.45 (9H, s), 2.09(3H, s) , 2.57- 2.72(6H, m) , 2.75-2.86 (2H, m) , 6.94(2H, d, J=8.4Hz), 7.21(2H, d, J=8.4Hz), 7.32 (2H, d, J=8.4Hz), 7.82 (2H, d, J=8.4Hz), 9.21(1H, s), 11.94 (IH, s) , 12.41-13.20 (IH, brs). MS: 510.2 (M+H) +, 532.2 (M+Na) + ° Step 4 tert-Butyl (4- {2- [2- (acetylamino) -5- (2- {4- [ (methylamino) carbonyl]phenyl} ethyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared in a similar manner according to Step 3 of Production Example 65. 5 XH-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.24 (3H, s) , 2.56-
2.73(4H, m) , 2.73-2.86 (4H, m) , 2.99(3H, d, J=4.8Hz), 6.05(1H, d, J=4.4Hz), 6.25-6.75 (IH, brs), 6.77 (2H, d, J=6.6Hz),
7.12 (2H, d, J=8.1Hz), 7.15-7.23 (2H, m) , 7.63 (2H, d, J=8.1Hz), 8.43-9.18(lH, brs) . 0 MS: 523.29 (M+H) + Step 5
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (2- {4- [ (methylamino) carbonyl]phenyl} ethyl) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene}biscarbamate was prepared in 5 a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3), δ (ppm): 1.48 (9H, s) , 1.54 (9H, s) , 2.22 (3H, s), 2.51-2.6K2H, m) , 2.61-2.71 (2H, m) , 2.79-2.90 (4H, m) , 2.97(3H, d, J=4.8Hz), 6.20 (IH, d, J=4.8Hz), 6.98 (2H, d, J=8.4Hz),
7.13 (2H, d, J=8.1Hz), 7.40 (2H, d, J=8.4Hz), 7.64 (2H, d, 0 J=8.4Hz), 8.83-9.42(lH, brs), 10.21(lH,s), 11.62(1H, s) .
MS: 687.2 (M+Na) + Step 6
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.09(3H, s) , 2.58-2.79 (6H, m) , 2.80- 3.02(8H, m), 7.13 (2H, d, J=8.4Hz), 7.19(2H, d, J=8.lHz), 7.20 (2H, d, J=8.4Hz), 7.29 (2H, d, J=8.1Hz), 7.32 (4H, s) , 5 9.66(1H, s), 11.93(1H, s) . MS: 479.2 (M+H) + free
Production Example 102 : Synthesis of 4- (2- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl }ethyl) -N-methylbenzamide hydrochloride ι° Step 1 tert-Butyl (4- { 2- [2- (Acetylamino) -5- (2- { 4- [ (dimethylamino) carbonyl] phenyl}ethyl) -1, 3-thiazol-4- yl] ethyl}phenyl) carbamate was prepared from the compound obtained in Step 3 of Production Example 101 in a similar
15 manner according to Step 3 of Production Example 65.
XH-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.23 (3H, s) , 2.66(4H, s) , 2.79(4H, s), 2.93(3H, s) , 3.08(3H, s) , 6.90(2H, d, J=8.0Hz), 7.11 (2H, d, J=8.0Hz), 7.18 (2H, d, J=8.0Hz), 8.56-10.01 (IH, brs) .
20 MS: 537 (M+H) +, 559.2 (M+Na) + Step 2
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (2-{4- [ (dimethylamino) carbonyl] phenyl}ethyl) -1, 3-thiazol-4- yl] ethyljphenyl) amino] methylidene }biscarbamate was prepared in
25 a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (ppm): 1.49 (9H, s), 1.53 (9H, s) , 2.21 (3H, s), 2.57-2.78(4H, m) , 2.82(4H, s) , 2.94(3H, s) , 3.08(3H, s) , 7.03 (2H, d, J=8.5Hz), 7.13 (2H, d, J=8.0Hz), 7.33 (2H, d, J=8.0Hz), 7.45 (2H, d, J=8.5Hz), 8.28-9.61 (IH, brs), 10.24 (IH,
30 s), 11.63(1H, s) .
MS: 679.2 (M+H) +, 701.2 (M+Na) + Step 3
The title compound was prapared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.10 (3H, s) , 2.60-2.72 (4H, ) , 2.72- 2.80(2H, m) , 2.76(3H, d, J=4.4Hz), 2.89(2H, t, J=7.3Hz), 7.12 (2H, d, J=8.4Hz), 7.19 (2H, d, J=8.4Hz), 7.22 (2H, d, 5 J=8.1Hz), 7.33(4H, s) , 7.73(2H, d, J=8.1Hz), 8.36(1H, d, J=4.4Hz), 9.66(1H, s) , 11.93(1H, s) . MS: 465.2 (M+H) + free
Production Example 103: Synthesis of methyl N— [4-({2- (acetylamino) -4- [2- (4- ι° { [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-5- yl }methyl) phenyl] carbamate hydrochloride Step 1
To a suspension of 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1 , 3-thiazol-5-
15 yl] ethyl}benzoic acid (50 mg) in toluene (0.5 ml) and dioxane (0.5 ml) were added triethylamine (28.1 μl) and diphenylphosphoryl azide (39.1 μl) , and the mixture was stirred at 25°C for 2 hrs., then stirred at 100°C for 1 h. To the reaction mixture was added methanol (1 ml) , and the mixture
20 was refluxed for 2 hrs., and concentrated in vacuo. The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give methyl N- (4- { [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl ) amino] phenyl} ethyl) -1, 3-thiazol-5-
25 yl] ethyl}phenyl) carbamate (17.2 mg).
XH-NMR (CDCI3) , δ (ppm): 1.52 (9H, s) , 2.22 (3H, s) , 2.80 (4H, s), 3.76(3H, s), 3.79(2H, s) , 6.62-6.78 (IH, brs), 6.83-7.05 (IH, brs), 6.90 (2H, d, J=8.0Hz), 6.98 (2H, d, J=8.5Hz), 7.17 (2H, d, J=8.0Hz), 7.20-7.33(2H, m) .
30 MS: 547.2 (M+Na) + Step 2
Di-tert-butyl [ (Z)-({4-[2- (2- (acetylamino) -5-{4- [ (methoxycarbonyl) amino] benzyl }-l,3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.54 (9H, s) , 2.19(3H, s) , 2.82(4H, s), 3.76(3H, s) , 3.80(2H, s) , 6.72-6.90 (IH, brs), 5 6.98 (2H, d, J=8.5Hz), 7.00 (2H, d, J=8.5Hz), 7.26(2H, d,
J=8.5Hz), 7.39(2H, d, J=8.5Hz), 9.10-9.59 (IH, brs), 10.19(1H, s) , 11.64(1H, s) .
MS: 667.2 (M+H) +, 689.2 (M+Na) +
Step 3 ι° The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.85 (4H, s) , 3.64 (3H, s), 3.85(2H, s), 7.04 (2H, d, J=8.5Hz), 7.14 (2H, d, J=8.4Hz), 7.24(2H, d, J=8.4Hz), 7.28-7.47 (6H, m) , 9.58 (IH, s) , 9.70(1H, 5 s) , 11.96(1H, s) . MS: 467.2 (M+H) +
Production Example 104 : Synthesis of ethyl l-({2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5-
20 yljmethyl) -4-piperidinecarboxylate dihydrochloride Step 1
Ethyl l-({2- (acetylamino) -4- [ (Z) -2- (4-nitrophenyl) vinyl] - 1, 3-thiazol-5-yl}methyl) -4-piperidinecarboxylate was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2-
25 yl} acetamide in a similar manner according to Step 1 of Production Example 67. MS: 459.17 (M+H) + Step 2
Ethyl l-[ (2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert-
30 butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-!, 3-thiazol-5- yl) methyl] -4-piperidinecarboxylate was prepared in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDCI3) , δ (ppm) : 1 .24 (3H, t, J=7 .2Hz) , 1 . 50 (9H, s ) ,
1.53 (9H, s), 1.65-2.09(6H, m) , 2.13-2.34 (4H, s) , 2.71-2.95 (6H, m) , 3.39(2H, s) , 4.12(2H, q, J=7.2Hz), 7.07(2H, d, J=8.5Hz), 7.46(2H, d, J=8.5Hz), 10.24 (IH, s) , 11.63(1H, brs). 5 MS: 673.3 (M+H) +, 695.3 (M+Na) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.18 (3H, t, J=7.1Hz), 1.73-1.90 (2H, ° m) , 1.93-2.13(2H, ) , 2.16(3H, s) , 2.87-3.01 (6H, m) , 3.30- 3.41(2H, m) , 4.08(2H, q, J=7.1Hz), 4.31-4.43 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.31 (2H, d, J=8.4Hz), 7.42 (4H, s) , 9.90 (IH, s) , 10.23-10.46(1H, brs), 12.3(1H, s) . MS: 473.2 (M+H) +, 495.2 (M+Na) + free 5 Production Example 105: Synthesis of ethyl l-({2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -4-piperidinecarboxylate hydrochloride
The title compound was prepared in a similar manner 0 according to Example 104.
Production Example 106: Synthesis of 4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4-yl} ethyl) -N- [amino (imino) methyl] benzamide
Guanidine hydrochloride (152 mg) was dissolved in DMF (3 5 ml), and then 28 % sodium methoxide methanol solution (0.3 ml) was added to the solution at r.t. The suspension was stirred at r.t. for 15 minutes, and methyl 4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl]-l, 3-thiazol-4-yl}ethyl) benzoate (150 mg) was added to the mixture at r.t. The reaction mixture was 0 stirred at r.t. for 14 hours, and concentrated in vacuo. The residue was dissolved in water, and neutralized with IN-HCl. The precipitate was collected through filtration, and purified by preparative silica gel chromatography with CHC13 / MeOH (10:1) as an eluent. The solid was washed with ethyl ether to give 4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1, 3- thiazol-4-yl } ethyl ) -N- [amino (imino) methyl]benzamide (36.6 mg) as an off-white solid. mp. 108-109.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.09(3H, s), 2.89(4H, s) , 3.16 (3H, s), 4.06(2H, s), 7.15(2H, d, J=8.0Hz), 7.27(2H, d, J=8.0Hz),
7.78 (2H, d, J=8.0Hz), 7.95 (2H, d, J=8.0Hz), 12.04 (IH, s) .
MS: 500 (M+H) + Production Example 107: Synthesis of tert-butyl (2-{ [4- (2-{2-
(acetylamino) -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-4- yl } ethyl) phenyl] amino} -2-oxoethyl) carbamate
The title compound was prepared from 2- (acetylamino) -4-
[2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3- thiazol in a similar manner according to Step 1 of Production
Example 10. mp. 186-187.5°C
XH-NMR (DMSO-de), δ (ppm) : 1.39(9H, s) , 2.08 (3H, s) , 2.84 (4H, s), 3.17(3H, s), 3.71(2H, d, J=6.0Hz), 4.00(2H, s) , 7.01(1H, t, J=6.0Hz), 7.06 (2H, d, J=8.5Hz), 7.28 (2H, d, J=8.5Hz),
7.46(2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 9.86(1H, s) ,
12.04(1H, s) .
MS: 587 (M+H) +
Production Example 108: Synthesis of N- [4- (2- {2- (acetylamino) - '5- [4- (methylsulfonyl) benzyl] -l,3-thiazol-4-yl}ethyl) phenyl] -2- aminoacetamide hydrochloride
The title compound was prepared from the compound of
Production Example 107 in a similar manner according to Step.2 of Production Example 10. mp. 142.5-144°C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.85(4H, s) , 3.18 (3H, s), 3.78(2H, m), 4.00(2H, s) , 7.10(2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz), 7.50 (2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 8 . 22 (3H, brs ) , 10 . 63 ( 1H, s ) , 12 . 06 (1H, s ) . MS : 487 (M+H) + free
Production Example 109: Synthesis of N- (4-{2- [4- (2- aminoethyl)phenyl] ethyl}-1, 3-thiazol-2-yl) acetamide 5 hydrochloride Step 1
N- (4-{2- [4- (Cyanomethyl) phenyl] ethyl}-!, 3-thiazol-2- yl) acetamide (1 g) , IN-NaOH (7 ml) and EtOH (14 ml) were combined, and the reaction mixture was refluxed for 8 hours.
1° After cooled to r.t., the organic solvent was removed in vacuo. The aqueous solution was neutralized with IN-HCl, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual yellow wax (1.03 g) was dissolved in THF ϊ5 (10 ml), and then lithium aluminium hydride (266 mg) was added to the solution at 0°C. The reaction mixture was refluxed for 3 hours, and quenched with MeOH. Then Na2S04 / 10H20 was added to the mixture, the mixture was stirred at r.t. for 1 hour and filtered through a celite pad. The filtrate was concentrated
20 in vacuo. The residual yellow amorphous (835.5 mg) was dissolved in THF (10 ml) and DMF (10 ml) under N2 atmosphere. Then di (tert-butyl) dicarbonate (841 mg) in THF (5 ml) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 12 hours, and concentrated in vacuo to give tert-
25 butyl (2-{4- [2- (2-amino-l, 3-thiazol-4- yl) ethyl]phenyl}ethyl) carbamate (171.6 mg) as yellow oil. XH-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 2.60-2.70 (4H, m) , 2.79- 2.88(4H, m), 6.82(1H, s) , 7.07(2H, d, J=8.0Hz), 7.11 (2H, d, J=8.0Hz) .
30 MS: 348 (M+H) + Step 2 tert-Butyl [2- (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) ethyl] carbamate was prepared from the compound of Step 1 in a similar manner according to Step 3 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm) : 1.36 (9H, s) , 2.11 (3H, s) , 2.58- 2.70(1H, ) , 2.80-2.97(6H, m) , 3.02-3.18 (IH, m) , 6.72(1H, s) , 5 7.08 (2H, d, J=8.0Hz), 7.23 (2H, d, J=8.0Hz), 12.08 (IH, s) . MS: 390 (M+H) + Step 3
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 2 of Production ° Example 10. mp. 165-167°C
XH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s), 2.79-3.09 (8H, m) , 6.75(1H, s), 7.16(4H, s) , 8.14(2H, brs), 12.13(1H, brs). MS: 290 (M+H) + free 5 Production Example 110: Synthesis of N- (4-{2- [4- (2-
{ [amino (imino) methyl] amino} ethyl) phenyl] ethyl }-1, 3-thiazol-2- yl) acetamide hydrochloride Step 1
N- (4-{2-[4-(2-Aminoethyl)phenyl]ethyl}-l,3-thiazol-2- 0 yl) acetamide hydrochloride (7 mg) , N,N' -bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (6.57 mg) , N,N- diisopropylethylamine (0.00748 ml), THF (0.5 ml) and DMF (0.1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 43 hours, and concentrated in vacuo. 5 The residue was purified by preparative silica gel chromatography with n-hexane / AcOEt (1:1) as an eluent to give di-tert-butyl ( (Z) -{ [2- (4-{2- [2- (acetylamino) -1, 3- thiazol-4-yl] ethyl }phenyl) ethyl] amino } - methylidene) biscarbamate (5.9 mg) as colorless oil. 0 XH-NMR [CD3CI/CD3OD (1:1)], δ (ppm) : 1.50 (18H, s) , 2.24 (3H, s) , 2.86(2H, t, J=7.0Hz), 2.95 (4H, s) , 3.62 (2H, t, J=7.0Hz), 4.24(2H, s), 6.50(1H, s) , 7.11 (2H, d, J=8.5Hz), 7.16(2H, d, J=8.5Hz) . MS: 532 (M+H) +
Step 2
The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production 5 Example 31.
XH-NMR [CD3CI/CD3OD (1:1)], δ (ppm): 2.41 (3H, s) , 2.87 (2H, t,
J=7.0Hz), 3.05(4H, s) , 3.44(2H, t, J=7.0Hz), 6.86(1H, s) ,
7.18(4H, s) .
MS: 332 (M+H) + free ι° Production Example 111: Synthesis of N-(4-{4-[(2-
{ [amino (imino) methyl] amino} ethyl) sulfonyl] phenyl }-l, 3-thiazol-
2-yl) acetamide hydrochloride.
Step 1
1- [4- (Methylthio) phenyl] ethanone (5.5 g) was dissolved in 15 AcOH (55 ml), and then 90 % pyridinium tribromide (11.8 g) and
30 % hydrobromic acid in AcOH (5.5 ml) were added to the solution at 0°C. The reaction mixture was stirred at r.t. for
30 minutes, and poured into water. The mixture was extracted with AcOEt . The organic layer was washed with saturated NaHC03 20 and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid (8.03 g) , thiourea (3.78 g) and EtOH
(55 ml) were combined. The reaction mixture was refluxed for
1.5 hours under N2 atmosphere. After cooled to r.t., the precipitate was filtered in vacuo. The solid was washed with 25 EtOH and water to give 4- [4- (methylthio) phenyl] -1, 3-thiazol-2- amine (7.48 g) as a pale yellow solid. mp . 245-246°C
XH-NMR (DMSO-de) , δ (PPm) : 2 .51 ( 3H, s ) , 7 . 18 ( IH, s ) , 7 . 35 (2H, d, J=8 . 5Hz ) , 7 . 67 (2H, d, J=8 .5Hz ) . 30 MS : 223 (M+H) +
Step 2
N-{4- [4- (Methylthio) phenyl ]-l, 3-thiazol-2-yl} acetamide was prepared from the compound of Step 1 in a similar manner according to Step 3 of Production Example 45. mp. 235-236°C
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.50 (3H, s) , 7.31 (2H, d, J=8.5Hz), 7.56(1H, s) , 7.83(2H, d, J=8.5Hz), 12.24(1H, brs) .
MS: 265 (M+H) + Step 3
N-{4-[4- (Methylthio)phenyl]-l,3-thiazol-2-yl}acetamide (2 g) was suspended in CH2CI2 (20 ml) , and then 3- chloroperoxybenzoic acid (1.44 g) was added portionwise to the suspension at 0°C. The reaction mixture was stirred at r.t. for 15 minutes. The precipitate was filtered in vacuo, and the solid was washed with lN-Na2C03, water and EtOH to give N-{4- [4- (methylsulfinyl) phenyl] -1, 3-thiazol-2-yl} acetamide (2.80 g) as a colorless solid, mp. 274-274.5°C
XH-NMR (DMSO-de), δ (ppm): 2.10 (3H, s) , 2.77 (3H, s) , 7.62 (IH, s), 7.71 (2H, d, J=8.5Hz), 8.07 (2H, d, J=8.5Hz). MS: 279(M-H)+ Step 4
N- { 4- [ 4- (Methylsulfinyl) phenyl] -1, 3-thiazol-2- yl} acetamide (1.5 g) , sodium acetate (1.54 g) , and acetic anhydride (30 ml) were combined under N atmosphere. The reaction mixture was refluxed for 2 hours. After cooled to r.t., the mixture was diluted in AcOEt. The organic solution was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid was washed with ethyl ether / n-hexane to give ({4- [2- (acetylamino) -1,3- thiazol-4-yl] phenyl}thio) methyl acetate (811.2 mg) as an off- white solid, mp. 144-145°C
XH-NMR (DMSO-de), δ (ppm): 2.07 (3H, s) , 2.17 (3H, s) , 5.53 (2H, s), 7.50(2H, d, J=8.5Hz), 7.63 (IH, s) , 7.88(2H, d, J=8.5Hz), 12 .27 ( IH, brs ) .
MS : 323 (M+H) + Step 5
( {4- [2- (Acetylamino) -1, 3-thiazol-4-yl] phenyl}thio) methyl acetate (40 mg) was dissolved in CH2C12 (0.6 ml) and MeOH (0.3 ml) under N2 atmosphere. Then magnesium monoperoxyphthalate (120 mg) was added to the solution at 0°C. The reaction mixture was stirred at r.t. for 2 hours. Water and CHC13 were added to the mixture, and the mixture was extracted. The organic layer was washed with saturated NaHC03 and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid was washed with ethyl ether to give ({4- [2- (acetylamino) -1, 3-thiazol-4-yl] phenyl} sulfonyl) methyl acetate (29.7 mg) as a- colorless solid. mp. 237-238°C
XH-NMR (DMSO-de), δ (ppm) : 2.07 (3H, s), 2.18 (3H, s) , 5.43 (2H, s), 7.94 (IH, s), 7.97 (2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz), 12.37 (IH, brs) . MS: 355-(M+H) + Step 6
( { 4- [2- (Acetylamino) -1, 3-thiazol-4- yl]phenyl} sulfonyl) methyl acetate (700 mg) , THF (8 ml), MeOH (4 ml) and IN-NaOH (1.98 ml) were combined. The reaction mixture was stirred at r.t. for 1.5 hours, and concentrated in vacuo. The residual solid was washed with ethyl ether to give sodium 4- [2- (acetylamino) -1, 3-thiazol-4-yl]phenylsulfinate (731 mg) as a colorless solid.
XH-NMR (DMSO-de), δ (ppm) : 2.16(3H, s), 7.52 (2H, d, J=8.0Hz), 7.54(1H, s), 7.84(2H, d, J=8.0Hz). MS: 281(M-H)+ free Step 7
Sodium 4- [2- (acetylamino) -1, 3-thiazol-4- yl] phenylsulfinate (600 mg) was dissolved in DMF (2 ml) under N2 atmosphere. Then 2-bromoethanol (0.168 ml) was added to the solution at 0°C. The reaction mixture was stirred at 100°C for 7 hours. After cooled to r.t., water and AcOEt were added to the mixture. The precipitate was filtered in vacuo to give N- 5 (4-{4-[ (2-hydroxyethyl)sulfonyl]phenyl}-l,3-thiazol-2- yl) acetamide (80.2 mg) as an off-white solid, mp. 258-260°C
XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s), 3.47 (2H, t, J=6.0Hz), 3.70(2H, q, J=6.0Hz), 4.89 (IH, t, J=6.0Hz), 7.89(1H, s) , ° 7.94(2H, d, J=8.5Hz), 8.13(2H, d, J=8.5Hz), 12.36(1H, brs). MS: 325(M-H) + Step 8
N- (4-{4- [ (2-Hydroxyethyl) sulfonyl] phenyl }-l, 3-thiazol-2- yl) acetamide (200 mg) , Et3N (0.102 ml) and CH2C12 (4 ml) were 5 combined under N2 atmosphere, and then MsCl (0.05 ml) was added to the suspension at 0°C. The reaction mixture was stirred at r.t. for 2 hours. MeOH/CHCl3 and water were added to the mixture, and the mixture was extracted. The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated 0 in vacuo. The residual solid (221.6 mg) was suspended in CH3CN (10 ml), and then 28 % ammonia solution (0.5 ml) was added to the suspension at 0°C. The reaction mixture was stirred at r.t. for 15 hours, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with 5 [MeOH/CHCl3 (1:30), then NH4OH/MeOH/CHCl3 (1:10:60)] as an eluent, and triturated with EtOH / ethyl ether to give N-(4- {4- [ (2-aminoethyl) sulfonyl] phenyl }-l, 3-thiazol-2-yl) acetamide (60.4 mg) as an off-white solid, mp. 287-288°C 0 XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.79 (2H, t, J=6.5Hz), 3.36 (2H, q, J=6.5Hz), 7.90 (IH, s) , 7.94 (2H, d, J=8.5Hz), 8.15(2H, d, J=8.5Hz) . MS: 326 (M+H) + Step 9
Di-tert-butyl ( (Z)-{ [2- ({4- [2- (acetylamino) -1, 3-thiazol- 4-yl]phenyl} sulfonyl) ethyl] amino}methylidene) biscarbamate was prepared from the compound of Step 8 in a similar manner 5 according to Step 3 of Production Example 31. mp. 280-281°C
XH-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 1.39 (9H, s) , 2.18 (3H, s), 3.65(4H, s), 7.88(1H, s) , 7.93(2H, d, J=8.5Hz), '8.13 (2H, d, J=8.5Hz), 8.32(1H, brs), 11.32(1H, brs), 12.35(1H, brs). ° MS: 568 (M+H) + Step 10
The title compound was prepared from the compound of Step 9 in a similar manner according to Step 4 of Production Example 31. 5 mp. 188-189.5°C
XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 3.51 (2H, m) , 3.59 (2H, t, J=6.0Hz), 7.28(3H, brs), 7.62(1H, t, J=5.5Hz), 7.93(1H, s) , 7.98 (2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz), 12.37 (IH, brs). MS: 368 (M+H) + free 0 Production Example 112: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- [3- (methylsulfonyl) benzyl]-l, 3-thiazol-2-yl}acetamide hydrochloride Step 1 5 N-Methoxy-N-methyl-3- (methylsulfonyl)benzamide was prepared from 3- (methylsulfonyl)benzoic acid in a' similar manner according to Step 1 of Production Example 31. XH-NMR (CDC13) , δ (ppm): 3.08 (3H, s) , 3.40 (3H, s) , 3.55 (3H, s) , 7.64 (IH, t, J=8.0Hz), 7.99 (IH, dt, J=8.0, 1.5Hz), 8.03 (IH, dt, 0 J=8.0, 1.5Hz), 8.28 (IH, t, J=1.5Hz). MS: 244 (M+H) + Step 2
To a stirred solution of N-methoxy-N-methyl-3- (methylsulfonyl)benzamide (5 g) in dry THF (100 ml) was added dropwise DIBALH (22.6 ml) at -78°C under N2 atmosphere. The reaction mixture was stirred for 4 hours at r.t. and then quenched with MeOH at 0°C . AcOEt and IN-HCl were added to the 5 mixture, and extracted. ' The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual oil (3.38 g) , methyl
(triphenylphosphoranylidene) acetate (6.87 g) and THF- (68 ml) were combined at r.t. under N2 atmosphere, and the reaction ° mixture was refluxed for 3 hours. The solvent was removed in vacuo, and the residue was suspended in AcOEt. The solid was filtered off, and the filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (2:1) as an eluent to give 5 methyl (2E) -3- [3- (methylsulfonyl)phenyl] acrylate (613.8 mg) as yellow oil.
XH-NMR (DMSO-de), δ (ppm) : 3.28 (3H, s) , 3..75(3H, s) , 6.85 (IH, d, J=16.0Hz), 7.74 (IH, s) , 7.93(1H, t, J=8.0Hz), 7.96(1H, d, J=8.0Hz), 8.09 (IH, d, J=8.0Hz), 8.32 (IH, d, J=16.0Hz). 0 Step 3
Methyl (2E) -3- [3- (methylsulfonyl) phenyl] acrylate (600 mg) , MeOH (6 ml) and then 10 % palladium carbon (99.9 mg) were combined under N atmosphere. The reaction mixture was stirred at r.t. for 7 hours under H2 atmosphere (1 atm), and filtered 5 through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (1:1 —» 1:2) as an eluent to give methyl 3- [3- (methylsulfonyl) phenyl]propanoate (283.3 mg) as colorless oil. 0 XH-NMR (DMSO-de), δ (ppm) : 2.70 (2H, t, J=7.5Hz), 2.97 (2H, t, J=7.5Hz), 3.20(3H, s) , 3.58(3H, s) , 7.52-7.63 (2H, ) , 7.73- 7.80(2H, m) . Step 4 Ethyl 4- [3- (methylsulfonyl) phenyl] -2-oxobutanoate was prepared from the compound of Step 3 in a similar manner according to Step 2 of Production Example 47.
XH-NMR (CDCI3) , δ (ppm): 1.35(3H, t, J=7.0Hz), 3.05(2H, t, 5 J=7.0Hz), 3.06(3H, s) , 3.24(2H, t, J=7.0Hz), 4.32(2H, q,
J=7.0Hz), 7.45-7.82 (4H, m) .
Step 5
Ethyl 3-bromo-4- [3- (methylsulfonyl) phenyl] -2-oxobutanoate was prepared from the compound of Step 4 in a similar manner ι° according to Step 1 of Production Example 46.
XH-NMR (CDCI3) , δ (PPm): 1.37 (3H, t, J=7.0Hz), 3.07 (3H, s) ,
3.34 (IH, dd, J=14.5, 8.0Hz), 3.60 (IH, dd, J=14.5, 6.5Hz),
4.35(2H, q, J=7.0Hz), 5.26(1H, dd, J=8.0, 6.5Hz), 7.49-
7.88 (4H, ) . 15 Step 6
Ethyl 2-amino-5- [3- (methylsulfonyl) benzyl] -1, 3-thiazole-
4-carboxyl-ate was prepared from the compound of Step 5 in a similar manner according to Step 2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm) : 1.24 (3H, t, J=7.0Hz), 3.20 (3H, s) , 20-4.20(2H, q, J=7.0Hz), 4.46(2H, s) , 7.10(2H, s) , 7.57-7.61 (2H, m) , 7.76-7.83(2H, m) .
MS: 341 (M+H) +
Step 7
Ethyl 2- (acetylamino) -5- [3- (methylsulfonyl) benzyl] -1, 3- 25 thiazole-4-carboxylate was prepared from the compound of Step
6 in a similar manner according to Step 3 of Production
Example 45.
XH-NMR (DMSO-de), δ (ppm): 1.27 (3H, t, J=7.0Hz), 2.10 (3H, s) ,
3.20(3H, s), 4.27(2H, q, J=7.0Hz), 4.61 (2H, s) , 7.56-7.66 (2H, 30 ) , 7.77-7.89(2H, m) , 12.47(1H, s) .
MS: 383 (M+H) +
Step 8
Ethyl 2- (acetylamino) -5- [3- (methylsulfonyl) benzyl] -1, 3- thiazole-4-carboxylate (54.7 mg) was suspended in THF (1 ml) under N atmosphere, and then lithium aluminium hydride (7.79 mg) was added portionwise to the suspension at 0°C. The reaction mixture was refluxed for 2.5 hours, and quenched with MeOH and IN-HCl at 0°C . Anhydrous MgS04 was added to the mixture, and stirred at r.t. for 1 hour. The suspension was filtered in vacuo. The filtrate was concentrated in vacuo. The residual oil (114.8 mg) , CHC13 (1 ml), CH3CN (1 ml) and Dess-Martin periodinane (88 mg) were combined at 0°C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour, and diluted in CHC13. The organic solution was washed with saturated NaHC03, water and brine, dried over anhydrous MgS04, and concentrated in vacuo to give N-{4-formyl-5- [3- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (61.2mg) as a yellow amorphous .
XH-NMR (DMSO-de), δ (ppm) : 2.13 (3H, s) , 3.17 (3H, s) , 4.67 (2H, s), 7.56-7.90(4H, m) , 10.04(1H, s) , 12.39(1H, s) . Step 9
N- {5- [3- (Methylsulfonyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared from the compound of Step 8 in a similar manner according to Step 5 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm) : 2.08(3Hx2/3, s) , 2.13(3Hxl/3, s) , 3.18(3H, s), 4.23(2Hχ2/3, s) , 4.50(2Hxl/3, s) , 6.69-8.31 (10H, m) .
Step 10
N-{4-[2-(4-Aminophenyl)ethyl]-5-[3- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide was prepared from the compound of Step 9 in a similar manner according to Step 6 of Production Example 45. MS: 430 (M+H) + Step 11
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [3- (methylsulfonyl)benzyi]-l,3-thiazol-4- yl }ethyl) phenyl] amino }methylidene) biscarbamate was prepared from the compound of Step 10 in a similar manner according to
Step 3 of Production Example 31. XH-NMR [CD3CI/CD3OD (1:1)], δ (ppm) : 1.29(9H, s) , 1.55 (9H, s) ,
2.23(3H, s), 2.89(4H, m) , 3.07(3H, s), 3.90(2H, s) , 7.11-
7.87 (8H, m) .
MS: 672 (M+H) +
Step 12 The title compound was prepared from the compound of Step
11 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (CD3OD) , δ (ppm): 2.08 (3H, s) , 2.98 (4H, ) , 3.10(3H, s) ,
3.98(2H, s), 7.10-7.88(8H, m) . MS: 472 (M+H) + free
Production Example 113: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- [ (1, l-dioxido-4- thiomorpholinyl) methyl] -1, 3-thiazol-2-yl} acetamide dihydrochloride Step 1
N- { 5- [ (1, 1-Dioxido-4-thiomorpholinyl) methyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl} acetamide in a similar manner according to Step 1 of Production Example 67.
MS: 437.12 (M+H) +
Step 2 .
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ (1,1- dioxido-4-thiomorpholinyl) methyl] -1, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared from the compound of Step 1 in a similar manner according to
Step 2 of Production Example 68.
XH-NMR (CDCI3), δ (PPm): 1.49 (9H, s) , 1.53 (9H, s) , 2.23 (3H, s) , 2.70-2.95(8H, m) , 2.95-3.12 (4H, s) , 3.45(2H, s) , 6.99(2H, d,
J=8.3Hz), 7.42 (2H, d, J=8.3Hz), 8.94-9.24 (IH, brs), 10.24 (IH, s), 11.63(1H, s) .
MS: 651.1 (M+H) +, 673.3 (M+Na) + 5 Step 3
The title compound was prepared from the compound of Step
2 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.15 (3H, s) , 2.97 (4H, s) , 3.77- ° 4.63(8H, s), 4.45(2H,s), 7.15(2H, d, J=8.3Hz), 7.32(2H, d,
J=8.3Hz), 7.46(4H, s) , 9.96(1H, s) , 12.29(1H, s) .
MS: 451.3 (M+H) +, 473.2 (M+Na) +
Production Example 11 : Synthesis of N-[4-[2-(4-
{ [amino (imino) methyl] amino}phenyl) ethyl] -5- (4- 5 morpholmylmethyl) -1, 3-thiazol-2-yl] acetamide dihydrochloride
Step 1
N-{5- (4-Morpholinylmethyl) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- 0 yl}acetamide in a similar manner according to Step 1 of
Production Example 67.
MS: 389.16 (M+H) +
Step 2
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- (4- 5 morpholmylmethyl) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylideneJbiscarbamate was prepared from the compound of Step 1 in a similar manner according to
Step 2 of Production Example 68.
XH-NMR (CDCI3) , δ (PPm) : 1.50 (9H, s) , 1.53 (9H, s) , 2.22 (3H, s) , 0 2.30-2.46(4H, m) , 2.85(4H, s) , 3.39(2H, s) , 3.58-3.75 (4H, m) ,
7.07 (2H, d, J=8.4Hz), 7.45 (2H, d, J=8.4Hz), 8.80-9.31 (IH, brs), 10.24(1H, s) , 11.63 (IH, s) .
MS: 603.3 (M+H) + Step 3
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de) , δ (ppm): 2.16 (3H, s) , 2.97 (4H, s) , 3.00-
3.12(2H, m) , 3.16-3.27 (2H, m) , 3.65-3.76 (2H, m) , 3.86-3.97 (2H, m) , 4.43(2H, s), 7.15(2H, d, J=8.4Hz), 7.31(2H, d, J=8.4Hz), 7.40(4H, s), 9.86(1H, s) , 10.54-10.84 (IH, brs), 12.34(1H, s) . MS: 403.1 (M+H) +, 426.1 (M+Na) + Production Example 115: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- [ (3-oxo-l- piperazinyl)methyl]-!, 3-thiazol-2-yl}acetamide dihydrochloride Step 1
N-{4-[ (Z)-2-(4-Nitrophenyl)vinyl]-5-[ (3-oxo-l- piperazinyl)methyl] -1, 3-thiazol-2-yl}acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl} acetamide in a similar manner according to Step 1 of Production Example 67. Z :■ E = 3 : 1 XH-NMR (DMSO-de), δ (ppm): 2.10(3Hx3/4, s) , 2.15(3Hxl/4, s) , 2.54-2.59(2Hx3/4, m) , 2.61-2.67 (2Hxl/4, m) , 2.93(2Hx3/4, s) , 3.02(2Hxl/4, m) , 3.08-3.19 (2H, m) , 3.64(2Hx3/4, s) , 3.95(2Hxl/4, s) , 6.72(lHx3/4, d, J=12.4Hz), 6.78(lHx3/4, d, J=12.4Hz), 7.34(lHxl/4, d, J=15.7Hz), 7.59(1x1/4, d, J=15.7Hz), 7.62(2Hx3/4, d, J=8.8Hz), 7.76(lHx3/4, s) ,
7.78(lHxl/4, s), 7.90(2Hxl/4, d, J=8.8Hz), 8.14(2Hx3/4, d, J=8.8Hz), 8.21(2Hxl/4, d, J=8.8Hz), 11.75-12.06 (1HX3/4, brs), 12.08-12.33(lHxl/4, brs). MS: 402.21 (M+H) + Step 2
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ (3-oxo-l- piperazinyl) methyl]-l, 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared . _ _ from the compound of Step 1 in a similar manner according to Step 2 of Production Example 68.
XH-NMR (CDCls), δ (ppm): 1.49(9H, s) , 1.53 (9H, s) , 2.24 (3H, s), 2.47-2.55(2H, m) , 2.80-2.93 (4H, m) , 3.13 (2H, s) , 3.24-3.32 (2H, 5 m) , 3.43(2H, s) , 6.02(1H, s), 7.04(2H, d, J=8.4Hz), 7.44(2H, d, J=8.3Hz), 9.02-9.26(lH, brs), 10.24(1H, s) , 11.62 (IH, s) . MS: 616.2 (M+H) +, 638.2 (M+Na) + Step 3
The title compound was prepared from the compound of Step ° 2 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.15 (3H, s) , 2.39-2.62 (2H, m) , 2.95(4H, s), 3.08-3.86(4H, m) , 4.20-4.77 (2H, brs), 7.15(2H, d, J=8.3Hz), 7.30(2H, d, J=8.0Hz), 7.35(4H, s) , 8.04-8.62 (IH, 5 brs), 9.70(1H, s) , 10.67-11.38 (IH, brs), 11.97-12.72 (IH, brs). MS: 416.2 (M+H) + free
Production Example 116: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N, N-dimethyl-1-piperazinecarboxamide 0 dihydrochloride Step 1
9H-Fluoren-9-ylmethyl 4- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -1- piperazinecarboxylate was prepared from N-{4- [ (Z) -2- (4- 5 nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 67. XH-NMR (CDCI3) , δ (PPm) : 2.10 (3H, s) , 2.26-2.61 (4H, ) , 3.39- 3.64(6H, m), 4.19-4.30 (IH, m) , 4.37-4.49 (2H, m) , 6.66(2H, s) , 7.07-7.67 (8H, m) , 7.76 (2H, d, J=6.9Hz), 8.05 (2H, d, J=8.9Hz), 0 10.03(1H, s) .
MS: 610.2 (M+H) +, 632.2 (M+Na) + Step 2
9H-Fluoren-9-ylmethyl 4- ( {2- (acetylamino) -4- [2- (4- aminophenyl) ethyl] -1, 3-thiazol-5-yl}methyl) -1- piperazinecarboxylate was prepared from the compound of Step 1 in a similar manner.according to Step 6 of Production Example 45. 5 XH-NMR (CDCI3) , δ (PPm): 2.16-2.33 (7H, m) , 2.80 (4H, s) ,
3.34(2H, s), 3.36-3.84 (6H, ) , 4.17- .30 (IH, m) , 4.36-4.47 (2H, m) , 6.57 (2H, d, J=8.4Hz), 6.86(2H, d, J=8.3Hz), 7.26-7.46 (4H, m) , 7.56(2H, d, J=7.0Hz), 7.76(2H, d, J=6.9Hz), 8.60-9.52 (IH, brs) . ° MS: 582.2 (M+H) +, 604.3 (M+Na) + Step 3
9H-Fluoren-9-ylmethyl 4- [ (2- (acetylamino) -4-{2- [4- ( { (Z)- [ (tert-butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl} amino) phenyl] ethyl}-l, 3-thiazol-5- 5 yl) methyl] -1-piperazinecarboxylate was prepared from the compound of Step 2 in a similar manner according to Step 3 of Production Example 31.
XH-NMR (CDCI3) , δ (PPm) : 1.50 (9H, s) , 1.52 (9H, s) , 2.23 (3H, s), 2.28-2.43(4H, m) , 2.86(4H, s) , 3.36-3.55 (6H, m) , 4.18-4.29 (IH, 0 m) , 4.35-4.48(2H, m) , 7.05(2H, d, J=8.5Hz), 7.13-7.66 (8H, ) , 7.75(2H, d, J=7.0Hz), 8.85-9.76 (IH, brs), 10.25(1H, Ss) , 11.63(1H, s) .
MS: 824.2 (M+H) +, 847.3 (M+Na) + Step 4 5 To a solution of 9H-fluoren-9-ylmethyl 4-[(2-
(acetylamino)-4-{2-[4-({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl } amino) phenyl ] ethyl }-l, 3-thiazol-5- yl) methyl] -1-piperazinecarboxylate (400 mg) in DMF (0.8 ml) 0 was added piperidine (0.16 ml), and the mixture was stirred for 2 h at 20°C. To the reaction mixture was added piperidine (0.16 ml), stirred at 20°C for 1 h and 40°C for 1 h, then cooled to 20°C, added AcOEt (50 ml), and the mixture was washed with water (10 mlx3) and brine (10 ml), dried over MgS04, filtered and concentrated in vacuo to give crude pale yellow oil (463 mg) . The crude oil was purified by flash column chromatography over NH silica gel with dichloromethane ' 5 / methanol (100:0) -» (100 : 1) as an eluent to give di-tert- butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (1-piperazinylmethyl) - 1, 3-thiazol-4-yl] ethylJphenyl) amino]methylidene}biscarbamate as a colorless amorphous. XH-NMR (CDC13) , δ (PPm): 1.50 (9H, s) , 1.53 (9H, s) , 2.21 (3H, s),
1° 2.27-2.47(4H, m) , 2.71-3.00 (8H, m) , 3.40(2H, s) , 7.07(2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 10.24(1H, s) , 11.47-11.74 (IH, brs) .
MS: 602.3 (M+H) \ 624.2 (M+Na) + Step 5
25 To a solution of di-tert-butyl { (Z) - [ (4-{2- [2-
(acetylamino) -5- (1-piperazinylmethyl) -1, 3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate (30 mg) in dichloromethane (0.3 ml) were added N,N-diisopropylethylamine (9.55 μl) and dimethylcarbamyl chloride (4.59 μl) , and the
20 mixture was stirred for 14 h at 20°C. To the reaction mixture was added saturated sodium hydrogen carbonate aqueous solution (2 ml) , then the mixture was extracted with diclhloromethane (5 mlx3) and the extract was dried over diatomaceous earth. •The organic layer was concentrated in vacuo to give crude oil.
25 The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ( {4- [ (dimethylamino) carbonyl] -1-piperazinyl}methyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylideneJbiscarbamate as colorless
30 oil.
XH-NMR (CDCI3), δ (ppm): 1.50(9H, s), 1.54 (9H, s) , 2.23 (3H, s), 2.35-2.42 (4H,- ) , 2.80(6H, s) , 2.81-2.89 (4H, m) , 3.17-3.27 (4H, m) , 3.41(2H, s), 7.07(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.73-8.90(lH, brs), 10.25(1H, s) , 11.63(1H, s) .
MS: 673.3 (M+H) +, 695.2 (M+Na) +
Step 6
The title compound was prepared from the compound of Step 5 5 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.16(3H, s) , 2.76 (6H, s) , 2.91-
3.06(6H, m) , 3.07-3.19 (2H, m) , 3.20-3.30 (2H, m) , 3.57-3.65 (2H, m) , 4.36-4.51(2H, m) , 7.15 (2H, d, J=8.4Hz), 7.31 (2H, d, ° J=8.4Hz), 7.41(4H, s) , 9.87(1H, s) , 10.51-10.69 (IH, brs),
12.33(1H, s) .
MS: 473.2 (M+H) +
Production Example 117: Synthesis of N-(4-[2-(4-
{ [amino (imino) methyl] amino }phenyl) ethyl] -5- { [4-(4- 5 morpholinylcarbonyl) -1-piperazinyl]methyl }-l, 3-thiazol-2- yl) acetamide dihydrochloride
Step 1
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [4- (4- morpholinylcarbonyl) -l-piperazinyl]methyl}-l, 3-thiazol-4- 0 yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound of Step 4 of Production Example 116 in a similar manner according to Step 5 of Production Example 116.
XH-NMR (CDCI3) , δ (PPm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s),
2.32-2.46(4H, m) , 2.78-2.91 (4H, m) , 3.20-3.30 (8H, m) , 3.42(2H, 5 s), 3.63-3.7K4H, ) , 7.07(2H, d, J=8.4Hz), 7.46(2H, d,
J=8.4Hz), 8.72-8.89(lH, brs), 10.25(1H, s) , 11.64(1H, s) .
MS: 715.3 (M+H) +, 737.2 (M+Na) +
Step 2
The title compound was prepared from the compound of Step 0 1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s), 2.90-3.07 (6H, m) , 3.11-
3.32(8H, m), 3.48-3.76 (6H, ) , 4.42(2H, s) , 7.15(2H, d, J=8 . 4Hz ) , 7 . 31 (2H, d, J=8 . 4Hz ) , 7 . 40 ( 4H, s) , 9. 85 (lH, s ) ,
10 .51-10 .72 (IH, brs) , 12 .34 (1H, s) .
MS : 515 .3 (M+H) + free
Production Example 118: Synthesis of N-(4-[2-(4- 5 { [amino (imino) methyl] amino}phenyl) ethyl] -5- { [4- (1- pyrrolidinylcarbonyl) -l-piperazinyl]methyl}-l, 3-thiazol-2-. yl) acetamide dihydrochloride
Step 1
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [4-(l- 1° pyrrolidinylcarbonyl) -l-piperazinyl]methyl}-l, 3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound of Step 4 of Production Example 116 in a similar manner according to Step 5 of Production Example 116.
XH-NMR (CDCls) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 1.72- I5 1.89(4H, m) , 2.23(3H, s) , 2.28-2.48 (4H, m) , 2.84(4H, s) , 3.19-
3.39(8H, m), 3.41(2H, s) , 7.07(2H, d, J=8.4Hz), 7.46(2H, d,
J=8.4Hz), 8.71-8.99(1H, brs), 10.24(1H, s) , 11.64(1H, s) .
MS: 699.2 (M+H) \ 721.3 (M+Na) +
Step 2 20 The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.70-1.83 (4H, m) , 2.16 (3H, s) , 2.89-
3.05(6H, m), 3.06-3.19 (2H, m) , 3.20-3.32 (6H, m) , 3.64-3.84 (2H, 25 m) , 4.36-4.50(2H, m) , 7.15(2H, d, J=8.2Hz), 7.31 (2H, d,
J=8.3Hz), 7.42(4H, s) , 9.88(1H, s) , 10.50-10.75 (IH, brs),
12.34(1H, s) .
MS: 499.3 (M+H) + free
Production Example 119: Synthesis of N-[4-[2-(4- 30 { [amino (imino) methyl] amino}phenyl) ethyl] -5- ( {4- [ (4-methyl-l- piperazinyl) carbonyl] -1-piperazinyl }methyl) -1, 3-thiazol-2- yl] acetamide trihydrochloride
Step 1 Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4- [ (4- methyl-1-piperazinyl) carbonyl] -1-piperazinyl }methyl) -1,3- thiazol-4-yl] ethyl }phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 4 of Production Example 116 5 in a similar manner according to Step 5 of Production Example 116.
XH-NMR (CDCls) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s) , 2.29(3H, s), 2.32-2.48 (8H, m) , 2.84(4H, s) , 3.16-3.35 (8H, m) , 3.42(2H, s), 7.07(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.69- ° 9.04(1H, brs), 10.24(1H, s) , 11.64(1H, s) . MS: 728.2 (M+H) +, 750.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production 5 Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.76(3H, d, J=4.6Hz), 2.89-3.09(8H, ) , 3.17-3.39 (8H, m) , 3.62-3.77 (4H, m) , 4.34- 4.51 (2H, brs), 7.15 (2H, d, J=8.3Hz), 7.31 (2H, d, J=8.2Hz), 7.41(4H, s), 9.87(1H, s) , 10.68-10.97 (IH, brs), 12.34(1H, s) . 0 MS: 528.3 (M+H)4 free
Production Example 120 : Synthesis of 3- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-5-yl}- N, N-dimethylpropanamide hydrochloride Step 1 5 Ethyl 3- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl ) amino] phenyl } ethyl) -1, 3-thiazol-5-yl] acrylate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1, 3-thiazole-5-carbaldehyde in a similar manner according to Step 7 of Production Example 0 61.
XH-NMR (CDCI3) , δ (ppm): 1.16-1.40 (3H, m) , 1.52 (9H, s), 2.23- 2.38(3H, m), 2.70-3.06 (4H, m) , 4.15-4.33 (2H, m) , 5.53-6.15 (IH, m) , 6.64-7.85 (6H, m) . MS : 482 .2 (M+Na) +
Step 2
A mixture of ethyl (2E) -3- [2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl}ethyl) -1, 3-thiazol-5- yl] acrylate and ethyl (2Z) -3- [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl ) amino] phenyl} ethyl) -1, 3-thiazol-5-yl] acrylate (200 mg) , THF (7 ml) and 10 % Pd/C (392 mg) were combined under nitrogen atmosphere. The mixture was stirred under 3 atm hydrogen atmosphere at 20°C for 3 h. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give ethyl 3- [2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl } ethyl) -1, 3-thiazol-5- yl]propanoate as a colorless amorphous. H-NMR (CDC13) , δ (ppm): 1.24 (3H, t, J=7.0Hz), 1.51 (9H, s) , 2.24(3H, s), 2.41(2H, t, J=7.5Hz), 2.73-2.93 (6H, m) , 4.12(2H, q, J=7.0Hz), 6.95(2H, d, J=7.2Hz), 7.23(2H, d, J=7.7Hz). MS: 484.1 (M+Na) + Step 3
Ethyl 3- (2- (acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-l, 3-thiazol-5- yDpropanoate was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (ppm): 1.24 (3H, t, J=7.1Hz), 1.50 (9H, s) , 1.53 (9H, s), 2.21(3H, s) , 2.41 (2H, t, J=7.6Hz), 2.70-3.00 (6H, m) , 4.12 (2H, q, J=7.2Hz), 7.07 (2H, d, J=8.4Hz), 7.46 (2H, d, J=8.4Hz), 8.80-9.20(lH, brs), 10.24(1H, s) , 11.63(1H, s) . MS: 604.3 (M+H) +, 626.2 (M+Na) + Step 4 3- (2- (Acetylamino) -4- { 2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl }-l, 3-thiazol-5- yl)propanoic acid was prepared from the compound of Step 3 in a similar manner according to Step 1 of Production Example 42.
XH-NMR (CDC13) , δ (PPm): 1.47 (9H, s) , 1.53 (9H, s) , 2.19 (3H, s) ,
2.25-2.45(2H, m) , 2.60-3.00 (6H, m) , 6.96(2H, d, J=8.3Hz),
7.34(2H, d, J=8.3Hz), 10.17(1H, s) , 11.30-11.90 (IH, brs). 5 MS: 598.2 (M+Na) +
Step 5
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [3-
(dimethylamino) -3-oxopropyl] -1 , 3-thiazol-4- yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared ° from the compound of Step 4 in a similar manner according to
Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (PPm): 1.49 (9H, s) , 1.53 (9H, s) , 2.21 (3H, s) , ■ 2.28-2.43 (2H, m) , 2.79-2.99 (12H, m) , 7.05(2H, d, J=8.5Hz),
7.44(2H, d, J=8.5Hz), 8.85-9.37 (IH, brs), 10.23(1H, s) , 5 11.62(1H, s) .
MS: 603.3 (M+H) +, 625.3 (M+Na) +
Step 6
The title compound was prepared from the compound of Step
5 in a similar manner according to Step 4 of Production 0 Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.10(3H, s), 2.40(2H, t, A=7.3Hz),
2.75(2H, t, J=7.3Hz), 2.77-2.84 (5H, m) , 2.84-2.95 (5H, m) ,
7.14 (2H, d, J=8.4Hz), 7.24 (2H, d, J=8.4Hz), 7.36(4H, s) ,
9.72(1H, s), 11.93(1H, s) . 5 MS: 403.3 (M+H) + free
Production Example 121: Synthesis of 3- {2- (acetylamino) -4- [2-
(4-{ [amino (imino) methyl] amino}phenyl ) ethyl] -1, 3-thiazol-5-yl}-
N-methylpropanamide hydrochloride
Step 1 0 Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [3-
(methylamino) -3-oxopropyl] -1, 3-thiazol-4- yl } ethyl) phenyl] amino }methylidene) biscarbamate was prepared from the compound of Step 4 of Production Example 120 in a similar manner according to Step 1 of Production Example 32. XH-NMR (CDC13), δ (ppm): 1.45(9H, s) , 1.54 (9H, s) , 1.79- 1.88(2H, s), 2.23(3H, s) , 2.65(3H, d, J=4.8Hz), 2.69-2.77 (2H, m) , 2.79-2.86(2H, m) , 2.86-2.95 (2H, m) , 6.04 (2H, d, J=4.4Hz), 5 6.93(2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 8.79-9.17 (IH, brs), 10.28(1H, s) , 11.60(1H, s) . MS: 589.3 (M+H) +, 611.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step ι° 1 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.10 (3H, s) , 2.22 (2H, t, J=7.3Hz), 2.53 (3H, d, J=4.8Hz), 2.72-2.82 (4H, m) , 2.82-2.90 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.26(2H, d, J=8.4Hz), 7.38 (4H, s) ,
15 7.79(1H, d, J=4.5Hz), 9.76(1H, s) , 11.95(1H, s) . MS: 389.2 (M+H) +, 411.2 (M+Na) + free
Production Example 122 : Synthesis of 3-{2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino }phenyl ) ethyl] -1, 3-thiazol-5- yl}propanamide hydrochloride
20 Step 1
Di-tert-butyl { (__) - [ (4- {2- [2- (acetylamino) -5- (3-amino-3- oxopropyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 4 of Production Example 120 in a
25 similar manner according to Step 1 of Production Example 32. XH-NMR (CDCI3) , δ (ppm): 1.47 (9H, s) , 1.53 (9H, s) , 1.57- 1.67 (2H, m) , 2.24(3H, s) , 2.65-2.76 (2H, m) , 2.76-2.87 (2H, m) , 2.87-2.99(2H, m) , 5.37 (IH, s) , 6.14(1H, s) , 6.90(2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 8.88-9.28 (IH, brs), 10.12(1H,
30 s) , 11.58(1H, s) .
MS: 575.0 (M+H) \ 597.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.10 (3H, s), 2.23 (2H, t, J=7.3Hz), 2.71-2.83(4H, m) , 2.83-2.91 (2H, m) , 6.81(1H, s) , 7.14 (2H, d, J=8.4Hz), 7.26(2H, d, J=8.4Hz), 7.31 (IH, s) , 7.35(4H, s) , 9.70(1H, S) , 11.94(1H, s) . MS: 375.2 (M+H) +, 397.0 (M+Na) + free
Production Example 123: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) ethyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N,N-dimethyl-4-piperidinecarboxamide dihydrochloride Step 1 l-[ (2- (Acetylamino) -4- { 2- [ 4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl }-l, 3-thiazol-5- yl) ethyl] -4-piperidinecarboxylic acid was prepared from ethyl l-[ (2- (acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl }-l, 3-thiazol-5- yl) methyl] -4-piperidinecarboxylate in a similar manner according to Step 1 of Production Example 42. XH-NMR (CDC13) , δ (ppm): 1.49(9H, s) , 1.51 (9H, s) , 1.76- 2.49(10H, m) , 2.69-3.00(6H, m) , 3.71 (2H, s) , 7.04(2H, d, J=8.5Hz), 7.42(2H, d, J=8.5Hz), 10.23(1H, s) , 11.13-12.07 (IH, brs) .
MS: 645.3 (M+H) +, 667.2 (M+Na) + Step 2
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( {4- [ (dimethylamino) carbonyl] -l-piperidinyl}methyl) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] methylidene}biscarbamate was prepared from the compound of Step 1 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 1.75- 1 . 89 (2H, m) , 1 . 92-2 . 03 (2H, m) , 2 .22 ( 3H, s) , 2 . 37-2 .49 ( IH, ) ,
2.80-2.95(9H, m) , 3.02(3H, s) , 3.43(2H, s) , 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.61-9.19 (IH, brs), 10.24(1H, s), 11.63(1H, s) . MS: 672.2 (M+H) +, 694.3 (M+Na) + Step 3
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.71-2.01 (4H, m) , 2.16 (3H, s) , 2.76- 2.87(4H, m), 2.87-3.1(9H, m) , 3.3-3. (2H, m) , 4.32-4.45 (2H, m) , 7.15(2H, d, J=4.2Hz), 7.31 (2H, d, J=4.2Hz), 7.41 (4H, s) , 9.83-9.93(lH, m) , 9.99-10.19 (IH, m) , 12.32-12.37 (IH, m) . MS: 472.3 (M+H) +, 494.0 (M+Na) + free Production Example 124 : Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino }phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N-methyl-4-piperidinecarboxamide dihydrochloride Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4- [ (methylamino) carbonyl] -l-piperidinyl}methyl) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene}biscarbamate was prepared from the compound of Step 1 of Production Example 123 in a similar manner according to Step 1 of Production Example 32. XH-NMR (CDCI3) , δ (PPm): 1.5 (9H, s) , 1.54 (9H, s) , 1.65-1.74 (2H, m), 1.75-1.84(2H, m) , 1.87-1.98 (2H, m) , 2-2.11(lH, m) ,
2.22(3H, s), 2.8(3H, d, J=4.8Hz), 2.82-2.91 (6H, m) , 3.39(2H, s), 5.5(1H, d, J=4.4Hz), 7.07 (2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 8.72-8.99(lH, brs), 10.23(1H, s) , 11.62(1H, s) . MS: 658.3 (M+H) +, 680.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.71-2.04 (4H, m) , 2.16 (3H, s) , 2.25-
2.37(1H, m), 2.54-2.61 (3H, m) , 2.82-2.94 (2H, m) , 2.96(4H, s) , 3.27-3.37(2H, m) , 4.31-4.44 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.30(2H, d, J=8.4Hz), 7.41 (4H, s) , 7.89-8.00 (IH, m) , 9.83- 5 10.16(2H, m) .
MS: 458.2 (M+H) +, 480.0 (M+Na) + free
Production Example 125: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl Jmethyl) -4-piperidinecarboxamide dihydrochloride ι° Step 1
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [4- (aminocarbonyl) -1-piperidinyl] methyl }-l, 3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound of Step 1 of Production Example 123 in a
25 similar manner according to Step 1 of Production Example 32. XH-NMR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 1.66-1.75 (2H, m), 1.78-1.87 (2H, m) , 1.88-1.99 (2H, m) , 2.07-2.17 (IH, m) , 2.23(3H, s), 2.77-2.92(6H, m) , 3..39(2H, s) , 5.5(2H, s) , 7.06(2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 8.94-9.25 (IH,
20 brs), 10.23(1H, s) , 11.61(1H, s) . MS: 644.2 (M+H) +, 666.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production
25 Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.68-2.08 (4H, m) , 2.16 (3H, s) , 2.25- 2.36(1H, m) , 2.82-3.09 (6H, ) , 3.27-3.44 (2H, m) , 4.30-4.45 (2H, m), 6.87-7.06(lH, m) , 7.15(2H, d, J=8.4Hz), 7.30(2H, d, J=8.3Hz), 7.36-7.52(5H, m) , 9.87-10.25 (2H, ) , 12.30-12.37 (IH,
30 m) .
MS: 444.2 (M+H) +, 466.2 (M+Na) + free
Production Example 126: Synthesis of (3R) -1- ( {2- (acetylamino) -
4- [2- (4-{ [amino (imino) ethyl] amino}phenyl) ethyl] -1, 3-thiazol- 5-yl }methyl) -N,N-dimethyl-3-piperidinecarboxamide dihydrochloride
Step 1
Ethyl (3R) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4- 5 nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -3- piperidinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 67. • MS: 459.20 (M+H) + ι° Step 2
Ethyl (3R)-l-[ (2- (acetylamino) -4- {2- [4- ( { (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl }-l, 3-thiazol-5- yl) methyl] -3-piperidinecarboxylate was prepared from the
15 compound of Step 1 in a similar manner according to Step 2 of Production Example 68.
XH-NMR (CDC13) , δ (ppm): 1.22 (3H, t, J=7.2Hz), 1.31-1.78 (21H, m) , 1.79-2.06(2H, m) , 2.07-2.18 (IH, m) , 2.22(3H, s) , 2.43- 2.62 (IH, m) , 2.62-2.75 (IH, m) , 2.84(4H, s) , 2.88-3.01 (IH, m) ,
20 3.42(2H, s), 4.11(2H, q, J=7.1Hz), 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.76-9.16 (IH, brs), 10.24(1H, s) , 11.64(1H, s) .
MS: 673.3 (M+H) +, 695.2 (M+Na) + Step 3
25 ' (3R)-l-[ (2- (Acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl ) imino]methyl}amino) phenyl] ethyl }-l, 3-thiazol-5- yl ) methyl] -3-piperidinecarboxylic acid was prepared from the compound of Step 2 in a similar manner according to Step 1 of
30 Production Example 42. MS: 645.37 (M+H) + Step 4
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ({ (3R)-3- [ (dimethylamino) carbonyl] -l-piperidinyl}methyl) -1, 3-thiazol-4- yl] ethyl Jphenyl) amino] methylidene Jbiscarbamate was prepared from the compound of Step 3 in a similar manner according to Step 1 of Production Example 32. 5 XH-NMR (CDC13) , δ (ppm): 1.39-1.57 (20H, m) , 1.66-1.73 (IH, m) , 1.74-1.83(1H, m), 1.87-1.98 (IH, m) , 2.08-2.19 (IH, m) , 2.22(3H, s), 2.72-2.94(10H, m) , 3.02(3H, s) , 3.41 (2H, s) , 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.70-9.02 (IH, brs), 10.24(1H, s) , 11.63(1H, s) . ι° MS: 672.41 (M+H) + Step 5
The title compound was prepared from the compound of Step 4 in a similar manner according to Step 4 of Production Example 31.
25 XH-NMR (DMSO-de), δ (ppm) : 1.29-1.94 (4H, m) , 2.16 (3H, s) , 2.77- 3.33(15H, m), 4.27-4.46 (2H, m) , 7.16(2H, d, J=8.3Hz), 7.27- 7.35(2H, m) , 7.36-7.48 (4H, m) , 9.8-9.98(lH, m) , 10.22-10.51 (IH, brs), 12.29-12.36 (IH, m) . MS: 472.3 (M+H) +, 494.2 (M+Na) + free
20 Production Example 127: Synthesis of (3R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}methyl) -N-methyl-3-piperidinecarboxamide dihydrochloride Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (3R) -3-
25 [ (methylamino) carbonyl] -l-piperidinyl}methyl) -1, 3-thiazol-4- yl] ethyl }phenyl) amino] methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 126 in a similar manner according to Step 1 of Production Example 32. XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.52-1.72 (12H, m) , 1.84-
30 1.98(1H, m) , 2.01-2.14(1H, m) , 2.14-2.23 (IH, m) , 2.24(3H, s) , 2.43-2.51(lH, m) , 2.64-2.76 (IH, m) , 2.76-2.94 (8H, m) , 3.32(1H, d, J=14Hz), 3.41 (IH, d, J=14Hz), 7.06 (2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 7.53(1H, brs), 8.84(1H, brs), 10.24(1H, s ) , 11 . 63 ( 1H, s ) .
MS : 658 . 39 (M+H) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.31-1.94 (4H, m) , 2.16 (3H, s) , 2.54- 3.36(12H, m) , 4.27-4.48 (2H, m) , 7.12-7.19 (2H, m) , 7.-25- 7.35(2H, m), 7.35(4H, brs), 8.05-8.37 (IH, m) , 9.79-9.92 (IH, m) , 10.16-10.42 (IH, brs), 12.29-12.37 (IH, ) . MS: 458.2 (M+H) +, 480.1 (M+Na) + free
Production Example 128 : Synthesis of (3S) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol- 5-yl}methyl) -N,N-dimethyl-3-piperidinecarboxamide dihydrochloride Step 1
Ethyl (3S) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -3- piperidinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 67. MS: 459.21 (M+H) + Step 2
Ethyl (3S)-l-[ (2- (acetylamino) -4-{2- [4- ( { (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-l, 3-thiazol-5- yl) methyl] -3-piperidinecarboxylate was prepared from the compound of Step 1 in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDCI3) , δ (ppm): 1.22(3H, t, J=7.2Hz), 1.3-1.79 (21H, m) , 1.8-2.06(2H, m) , 2.08-2.18 (l-H, m) , 2.22(3H, s) , 2.43- 2.62(1H, m) , 2.62-2.75 (IH, m) , 2.84(4H, s) , 2.88-3.01 (IH, m) , 3.42 (2H, s), 4.11 (2H, q, J=7.1Hz), 7.08 (2H, d, J=8.4Hz), 7 . 46 (2H, d, J=8 . 4Hz) , 8 . 71-9 .23 ( IH, brs ) , 10 .24 ( 1H, s ) ,
11 . 64 ( 1H, s) .
MS: 673.3 (M+H) +, 695.2 (M+Na) + Step 3 •5 (3S)-1- [(2- (Acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl ) imino]methyl } amino) phenyl] ethyl }-1, 3-thiazol-5- yl) methyl] -3-piperidinecarboxylic acid was prepared from the compound of Step 2 in a similar manner according to Step 1 of 0 Production Example 42. MS: 645.36 (M+H) + Step 4
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { (3S)-3- [ (dimethylamino) carbonyl] -1-piperidinyl} ethyl) -l,3-thiazol-4- 5 yl] ethyl }phenyl) amino] ethylidene }biscarbamate was prepared from the compound of Step 3 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (PPm): 1.4-1.64 (20H, m) , 1.65-1.73 (IH, m) , 1.73-1.82 (IH, m) , 1.86-1.97 (IH, m) , 2.08-2.18 (IH, ) , 2.22(3H, 0 s), 2.7-2.93(10H, m) , 3.02(3H, s) , 3.41(2H, s) , 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.3Hz), 8.61-8.99 (IH, brs), 10.24(1H, s) , 11.63(1H, s) . MS: 672.39 (M+H) + Step 5 5 The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 1.29-1.93 (4H, m) , 2.16 (3H, s) , 2.77- 3.35(15H, m) , 4.27-4.45 (2H, m) , 7.16(2H, d, J=8.4Hz), 7.28- 0 7.35(2H, m), 7.35-7.47 (4H, m) , 9.8-9.96(lH, m) , 10.21- 10.46(1H, brs), 12.29-12.36 (IH, m) . MS: 472.3 (M+H) +, 494.2 (M+Na) + free
Production Example 129: Synthesis of (3S) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-
5-yl}methyl) -N-methyl-3-piperidinecarboxamide dihydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ({ (3S)-3- [ (methylamino) carbonyl] -l-piperidinyl}methyl) -1, 3-thiazol-4- yl] ethyl Jphenyl) amino] methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 128 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDC13) , δ (PPm): 1.46-1.72 (21H, m) , 1.84-1.97 (IH, m) , 1.99-2.14(1H, m), 2.15-2.22 (IH, m) , 2.24(3H, s) , 2.43-2.51 (IH, m) , 2.65-2.76 (IH, m) , 2.76-2.91 (8H, ) , 3.32 (IH, d, J=14Hz) ,
3.41 (IH, d, J=14Hz), 7.06(2H, d, J=8.4Hz), 7.45 ("2H, d,
J=8.4Hz), 7.54 (IH, brs), 8.84-9.02 (IH, brs), 10.24(1H, s) ,
11.63(1H, s) . MS: 658.40 (M+H) +
Step 2
The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31. J-H- MR (DMSO-de), δ (ppm): 1.31-1.94 (4H, m) , 2.16 (3H, s) , 2.53-
3.36(12H, m), 4.24-4.46 (2H, m) , 7.12-7.19 (2H, m) , 7.25-
7.35(2H, m), 7.36(4H, brs), 8.06-8.37 (IH, ) , 9.83-9.99 (IH, m) , 10.28-10.54 (IH, brs), 12.33(1H, s) .
MS: 458.2 (M+H) +, 480.2 (M+Na) + free Production Example 130: Synthesis of N-{4- [2- (2-amino-lH- benzimidazol-6-yl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3- thiazol-2-yl }acetamide
Step 1
N- { 4- [2- (3, 4-Dinitrophenyl) inyl] -5- [4- (methylthio) benzyl] -1, 3-thiazol-2-yl}acetamide was prepared from 2- (acetylamino) -5- [4- (methylthio) benzyl] -1, 3-thiazole-4- carbaldehyde in a similar manner according to Step 5 of
Production Example 45. Z : E = 3 : 1
XH-NMR(CDC13), δ (PPm): 2.08(3Hx3/4, s) , 2.12(3Hxl/4, s) , 2.44(3H, s), 4.13(2Hx3/4, s) , 4.32(2Hxl/4, s) , 6.71(lHx3/4, d, J=12.5Hz), 6.97(lHx3/4, d, J=12.3Hz), 7.06-8.61 (7H + 2Hxl/4, m) , 11.85(lHx3/4, s) , 12.18 (lHxl/4, s) . MS: 471.1 (M+H) +, 493.9 (M+Na) + Step 2
N-{4- [2- (3, 4-Diaminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide was prepared from the compound of Step 1 in a similar manner according to Step 2 of Production Example 32 and Step 6 of Production Example 45.
XH-NMR (CDC13) , δ (PPm): 2.23 (3H, s) , 2.70-2.85 (4H, m) , 3.03(3H, s), 3.88(2H, s) , 6.34(1H, d, J=1.8Hz), 6.39(1H, dd, J=1.8, 7.8Hz), 6.56 (IH, d, J=7.7Hz), 7.14 (2H, d, J=8.3Hz), 7.79(2H, d, J=8.4Hz), 8.30-9.45 (IH, brs). MS: 445.0 (M+H) +, 467.0 (M+Na) + Step 3
To a suspension of N-{4- [2- (3, 4-diaminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl} acetamide (70.8 mg) in MeOH (0.7 ml) was added cyanogen bromide (25.3 mg) , then the mixture was stirred for 14 h at 20°C. To the reaction mixture was added IN-NaOH (0.239 ml) and the mixture was concentrated in vacuo. To the residue was added CHC1 : MeOH = 10 : 1 (10 ml) , and an insoluble material was removed by filtration. The filtrate was purified by flash column chromatography over NH silica gel with CHCI3 / MeOH (100:1 _> 10:1) as an eluent to give colorless oil. The oil was solidified with CH2C12 : Et20 = 2 : 1 to give N-{4- [2- (2-amino- lH-benzimidazol-6-yl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3- thiazol-2-yl}acetamide as a white solid.
XH-NMR (CDCI3) , δ (PPm): 2.09(3H, s) , 2.85(4H, s) , 3.16(3H, s) , 3.97(2H, s), 6.01(2H, s) , 6.55-6.77 (IH, m) , 6.78-6.90 (IH, m) , 6.96(1H, d, J=7.8Hz), 7.10-7.30 (2H, brs), 7.72(2H, d,
J=8.1Hz), 10.55(1H, d, J=10.5Hz), 11.50-12.20 (IH, brs).
MS: 470.2 (M+H) \ 492.1 (M+Na) +
Production Example 131: Synthesis of N-{4- [2- (2-amino-lH- benzimidazol-6-yl) ethyl] -1, 3-thiazol-2-yl}acetamide
Step 1
N-{4- [2- (3, 4-Dinitrophenyl) vinyl] -1, 3-thiazol-2- yljacetamide was prepared from 2- (acetylamino) -1, 3-thiazole-4- carbaldehyde in a similar manner according to Step 5 of Production Example 1.
Z : E = 8 : 1
XH-NMR (DMSO-d6), δ (ppm) : 2.13(3Hx8/9, s) , 2.17(3Hxl/9, s) ,
6.64(lHx8/9, d, J=12.6Hz), 6.80(lHx8/9, d, J=12.6Hz),
7.29(lHxl/9, d, J=15.7Hz), 7.33(lHx8/9, s) , 7.39(lHxl/9, s) , 7.63(lHxl/9, d, J=15.7Hz), 8.00-8.50 (3H, m) , 11.97 (1HX8/9, s),
12.30(lHxl/9, s) .
MS: 335.0 (M+H) \ 357.1 (M+Na) +
Step 2
N- { 4- [2- (3, 4-Diaminophenyl) ethyl] -1, 3-thiazol-2- yl} acetamide was prepared from the compound of Step 1 in a similar manner according to Step 6 of Production Example 1.
XH-NMR (CDC13), δ (ppm): 2.22 (3H, s) , 2.58-3.17 (8H, m) , 6.46-
6.56(3H, m), 6.62 (IH, d, J=8.3Hz), 8.84-10.42 (IH, brs).
MS: 277.1 (M+H) +, 299.2 (M+Na) + Step 3
The title compound was prepared from the compound of Step
2 in a similar manner according to Step 3 of Production
Example 130.
XH-NMR (CDCI3), δ (ppm): 2.11 (3H, s) , 2.79-2.97 (4H, m) , 6 (2H, s), 6.59-6.8(2H, m) , 6.91(1H, s) , 6.97(1H, d, J=7.9Hz), 10.34-
10.73 (IH, brs), 11.94-12.22 (IH, brs).
MS: 302.2 (M+H) +, 324.1 (M+Na) +
Production Example 132: Synthesis of N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3-thiazol-5- yl}methyl) -N-methylacetamide hydrochloride Step 1
N-{5-[ (Methylamino) methyl] -4- [ (Z)-2-(4- 5 nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide was prepared from N- {4- [ (Z) -2- (4-nitrophenyl) vinyl] -1, 3-thiazol-2- yl} acetamide in a similar manner according to Step 1 of Production Example 67. XH-NMR (CDC13) , δ (PPm): 2.05 (3H, s) , 2.46 (3H, s) , 3.75 (2H, s) , ° 6.67(2H, s), 7.4K2H, d, J=8.9Hz), 8.01 (2H, d, J=8.8Hz), 9.7- 11.69(1H, brs) . MS: 333.1 (M+H) +, 355.1 (M+Na) + ' Step 2
To a suspension of N-{5- [ (methylamino) methyl] -4- [ (Z) -2- • 5 (4-nitrophenyl) vinyl] -1, 3-thiazol-2-yl} acetamide (46.8 mg) in dichloromethane (0-.5 ml) were added N,N-diisopropylethylamine (27 μl) and acethyl chloride (10 μl) , and the mixture was stirred for 2 h at 20°C. To the reaction mixture were added dichloromethane (5 ml), N, N-diisopropylethylamine (27 μl) and 0 acethyl chloride (10 μl), and the mixture was stirred for 5 min. at 20°C, then washed with saturated sodium hydrogen carbonate aqueous solution (5 ml) and brine (5 ml), dried over MgS04, filtered and evaporated to give a yellow solid (67.8 mg) . The crude compound was purified by preparative silica gel 5 thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give N- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1, 3-thiazol-5-yl}methyl) -N-methylacetamide as a yellow solid. XH-NMR (CDCI3) , δ (PPm): 2.12(3Hx2/3, s) , 2.13(3Hxl/3, s) , 0 2.14(3Hx2/3, s) , 2.24(3Hxl/3, s) , 3.02(3Hx2/3, s) , 3.05(3Hxl/3, s), 4.62(2Hx2/3, s) > 4.79(2Hxl/3, s) , 6.61(lHxl/3, d, J=12.6Hz), 6.70(lHx2/3, d, J=12.6Hz), 6.77(lHxl/3, d, J=12.6Hz), 6.82(lHx2/3, d, J=12.6Hz), 7.43(2Hx2/3, d, J=8.8Hz), 7.65(2Hxl/3, d, J=8.8Hz),
8.06(2Hx2/3, d, J=8.8Hz), 8.22(2Hxl/3, d, J=8.8Hz), 9.09-
9.26(lHxl/3, brs), 9.26-9.51 (1HX2/3, brs) .
MS: 375.2 (M+H) +, 397.1 (M+Na) + 5 Step 3
N- ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1, 3- thiazol-5-yl}methyl) -N-methylacetamide was prepared from the compound of Step 2 in a similar manner according to Step 6 of
Production Example 45. ° MS: 347.25 (M+H) +
Step 4
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-
{ [acetyl (methyl) amino] methyl }-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared 5 from the compound of Step 3 in a similar manner according to
Step 3 of Production Example 31.
XH-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.06(3Hx3/4, s), 2.12(3Hxl/4, s), 2.23(3H, s) , 2.77(3Hxl/4, s) ,
2.81(3Hx3/4, s), 2.90(4H, s) , 4.20(2Hxl/4, s) , 4.46(2Hx3/4, 0 s), 7.01(2Hxl/4, d, J=8.6Hz), 7.07(2Hx3/4, d, J=8.5Hz),
7.43(2Hx3/4, d, J=8.5Hz), 7.46(2Hxl/4, d, J=8.0Hz), 8.81-
9.09(1H, brs), 10.22(lHx3/4, s) , 10.25 (lHxl/4, s) , 11.62(1H, s) .
MS: 589.2 (M+H) +, 611.2 (M+Na)'+ 5 Step 5
The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.98(3Hx3/4, s) , 2.02(3Hxl/4, s) , 0 2.11(3Hx3/4, s), 2.12(3Hxl/4, s) , 2.60(3Hxl/4, s) ,
2.82(3Hx3/4, s), 2.89(4H, s) , 4.39(2Hx3/4, s) , 4.45(2Hxl/4, s), 7.13(2Hxl/4, d, J=8.lHz), 7.14(2Hx3/4, d, J=8.4Hz),
7.22(2Hxl/4, d, J=8.4Hz), 7.25(2Hx3/4, d, J=8.4Hz), 7.31 (4H, s) , 9. 61 ( 1H, s ) , 12 . 03 ( lHx3/4, s ) , 12 . 13 ( lHxl/4 , s ) .
MS : 389 . 19 (M+H) + free
Production Example 133: Synthesis of N- [4- (2-{4- [ (2- a inoethyl) amino] phenyl } ethyl) -1, 3-thiazol-2-yl] acetamide 5 dihydrochloride Step 1
To a suspension of N- {4- [2- (4-aminophenyl) ethyl] -1, 3- thiazol-2-yl} acetamide (100 mg) in toluene were added tert- butyl (2-bromoethyl) carbamate (87.5 mg) and N,N- ι° diisopropylethylamine (52 μl) , and the mixture was stirred at 80°C for 24 h. The reaction mixture was allowed to cool to room temperature, water (10 ml) was added, and the organic layer was separated, washed with saturated aqueous NaCI, dried over MgS0, filtered, and concentrated in vacuo to give tert-
15 butyl {2-[ (4-{2- [2- (acetylamino) -1, 3-thiazol-4- yl] ethyl}phenyl) amino] ethyl}carbamate as a pale brown amorphous .
XH-NMR (CDCls), δ (ppm): 1.45 (9H, s) , 2.23 (3H, s) , 2.86(4H, s) , 3.15-3.28(2H, m) , 3.15-3.47 (2H, ) , 4.64-5.02 (IH, brs), 0 6.49(1H, s), 6.52(2H, d, J=8.0Hz), 6.95(2H, d, J=8.0Hz), 9.22- 10.10(1H, brs) . MS: 405.2 (M+H) +, 427.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 5 2 in a similar manner according to Step 2 of Production Example 10.
XH-NMR (DMSO-de), δ (ppm): 2.11 (3H, s) , 2.81 (4H, s) , 2.92- 3.05(2H, m), 3.29(2H, t, J=6.2Hz), 6.67(2H, d, J=7.7Hz), 7.01 (2H, d, J=8.1Hz), 7.87-8.24 (3H, brs), 12.08(1H, s) . 0 MS: 305.2 (M+H) +, 327.2 (M+Na) +
Production Example 134: Synthesis of N-{4-[3-(2-
{ [amino (imino) methyl] amino }ethyl) phenyl] -1, 3-thiazol-2- yl}acetamide hydrochloride Step 1
To a suspension of lithium aluminium hydride in dry tetrahydrofuran (50 ml) was added (3-bromophenyl) acetic acid (10 g) in tetrahydrofuran (100 ml) under ice cooling. The 5 mixture was refluxed for 2 hours. After cooling, to the reaction mixture were added water and aqueous Rochelle salt. The mixture was stirred for another 30 min. Aqueous layer was extracted with ethyl acetate. The organic layer was -dried over anhydrous magnesium sulfate, and concentrated in vacuo to give ι° 2- (3-bromophenyl) ethanol. This compound was used for the next reaction without further purification.
XH-NMR (200 MHz, CDC13) , δ (ppm): 1.66(1H, brs), 2.84(2H, dd, J=6.5, 14Hz), 3.85(2H, dt, J=6.5, 2.6Hz), 7.13-7.39 (4H, m) . Step 2
15 To a solution of 2- (3-bromophenyl) ethanol (7 g) in N,N- dimethylformamide (100 ml) were added tert-butyldimethylsilyl chloride (5.77 g) and imidazole (2.84 g) at 25°C. The mixture was stirred at 25°C for 12 h. The reaction mixture was poured into water (500 ml) and extracted with ethyl acetate (100
20 mlx2) . The combined organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography with mixed solvent of n- hexane and ethyl acetate to give [2- (3- bromophenyl) ethoxy] (tert-butyl) dimethylsilane as colorless
25 oil.
XH-NMR (200 MHz, CDCI3) , δ (ppm) : 0.01(6H, s) , 0.88(9H, s), 2.81 (2H, dt, J=6.5, 9.5Hz), 3.81(2H, dt, J=3.0, 6.5Hz), 7.14- 7.39 (5H, brs) . Step 3
30 To a solution of 1.6 g of [2- (3-bromophenyl) ethoxy] (tert- butyl) dimethylsilane in tetrahydrofuran (20 ml) was added n- BuLi in hexane (1.57M, 3.88 ml) at -70°C, then the reaction mixture was stirred at same temperature for 30 min. To the solution was added dimethylacetamide (1.42 ml) drop wise at the same temperature. The mixture was stirred for another 1 hour. To the reaction mixture were added water and 8 ml of IN HCl under ice-cooling. The mixture was stirred for 1 hour, then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by silica gel column chromatography with n-hexane and ethyl acetate (20/1- 10/1) as an eluent to give 1- [3- (2-{ [tert- butyl (dimethyl) silyl] oxy} ethyl) phenyl] ethanone (350 mg) as colorless oil.
XH-NMR (200 MHz, CDC1 ) , δ (ppm): 0.03(6H, s) , 0.85(9H, s) , 2.61(3H, s), 2.87(2H, t, J=6.7 Hz), 3.82(2H, t, J=6.7Hz), 7.20-7.24(lH, m) , 7.35-7.44 (2H, m) , 7.77-7.82 (2H, m) . MS: 279 (M+H) + Step 4
To a solution of 1- [3- (2- { [tert- butyl (dimethyl) silyl] oxy} ethyl) phenyl] ethanone (755 mg) in tetrahydrofuran (4 ml) was added bromine (168 ml) drop wise at o°C. The mixture was stirred at 25°C for 1 h. To the reaction mixture was added aq. saturated NaHC0, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure to give crude of 2-bromo-l- [3- (2- hydroxyethyl) phenyl] ethanone as colorless oil. This compound was used for the next reaction without further purification. Step 5
To a solution of 2-bromo-l- [3- (2- hydroxyethyl) phenyl] ethanone (crude, 658 mg) in tetrahydrofuran (15 ml) was added l-acetyl-2-thiourea (320 mg) at 25°C. The mixture was stirred at 60°C for 2 h. The residual colorless crystals were collected by filtration. The crystals were washed with isopropyl ether, and dried under reduced pressure to give N-{4- [3- (2-hydroxyethyl) henyl] -1, 3-thiazol- 2-yl}acetamide (514 mg) as a colorless crystal. XH-NMR (200 MHz, DMSO-de), δ (ppm): 2.16(3H, s) , 2.76(2H, t, J=6.9Hz), 3.63(2H, t, J=6.9 Hz), 4.89(1H, brs), 7.16(1H, d, J=7.7 Hz), 7.32 (IH, dd, J=7.7, 7.6Hz), 7.56 (IH, s) , 7.70 (2H, d, J=7.6 Hz), 7.76(1H, s) , 12.24(1H, s) . MS: 263 (M+H) + Step 6
To a suspension of N-{4- [3- (2-hydroxyethyl)phenyl] -1, 3- thiazol-2-yl}acetamide (300 mg) in CH2C12 (10 ml) were added methansulfonyl chloride (106 μl) and triethylamine (207 μl) at 5°C. The mixture was stirred at 25°C for 2 h. The reaction mixture was poured into water and extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. Resulting residue was purified by silica gel column chromatography with n-hexane and ethyl acetate (1:1) as an eluent to give 2- {3- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl} ethyl methanesulfonate (388 mg) as a colorless solid.
XH-NMR (200 MHz, DMSO-d6) , δ (ppm): 2.16(3H, s) , 3.04(2H, t, J=6.9 Hz), 3.12(3H, s) , 4.45(2H, t, J=6.9 Hz), 7.23-7.42 (2H, m) , 7.60(1H, s), 7.75-7.81 (2H, m) , 12.26(1H, s) . MS: 341 (M+H) + Step 7
To a solution of 2-{3- [2- (acetylamino) -1, 3-thiazol-4- yl]phenyl}ethyl methanesulfonate (388 mg) in N,N- dimethylformamide (5 ml) were added di-tert- butyliminodicarboxylate (322 mg) and K2CO3 (236 mg) at 25°C. The mixture was stirred at 80°C for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. Resulting colorless oil containing N- {4- (3- [2- {di- (tert- butoxycarbonyl) amino}ethyl] phenyl) -1, 3-thiazol-2-yl } acetamide was used for the next reaction without further purification. Step 8 N-{4- [3- (2-Aminoethyl) phenyl] -1, 3-thiazol-2-yl}acetamide was prepared from the compound of Step 7 in a similar manner according to Step 2 of Production Example 31. XH-NMR (200 MHz, DMSO-d6) , δ (ppm): 2.16(1H, s), 2.74(2H, dd, J=6.8, 6.2Hz), 2.88(2H, dd, J=7, 7.8Hz), 7.17(1H, d, J=7.7Hz), 7.35(1H, dd, J=7.7, 8Hz) , 7.58 (IH, s) , 7.73(1H, d, J=8Hz), 7.74(1H, s) . MS: 262 (M+H) + Step 9
Di-tert-butyl { (Z)-[ (2-{3- [2- (acetylamino) -1, 3-thiazol-4- yl] phenyl} ethyl) amino]methylidene }biscarbamate was prepared from the compound of Step 8 in a similar manner according to Step 5 of Production Example 18.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 1.45(9H, s) , 1.50(3H, s), 2.27(3H, s), 2.92(2H, t, J=7.5Hz), 3.71(2H, dt, J=7.5, 7.2Hz), 7.11-7.41(4H, d), 7.65-7.78 (IH, m) . MS: 504 (M+H) + Step 10
The title compound was prepared from the compound of Step 9 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 2.16(3H, s) , 2.83(2H, t, J=6.9Hz), 3.41 (2H, m) , 7.23(1H, d, J=7.7Hz), 7.38(1H, dd, J=7.7, 7.8 Hz), 7.52(1H, t, J=5.5Hz), 7.59(1H, s), 7.75(1H, d, J=8.lHz), 7.79(1H, s) , 12.23(1H, s) . MS: 304 (M+H) + free
Production Example 135: Synthesis of N-(4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5- {2- [4- (methylsulfonyl) phenyl] ethyl}-l, 3-thiazol-2-yl) acetamide hydrochloride
Step 1 tert-Butyl N- {4- [2- (2- (acetylamino) -5- { (E)-2-[4-
(methylsulfonyl) phenyl] vinyl }-l,3-thiazol-4- yl) ethyl] phenyl} carbamate was prepared from 2- (acetylamino) -4-
{2- [4- (tert-butoxycarbonylamino) phenyl] ethyl}-l, 3-thiazole-5- carbaldehyde in a similar manner according to Step 5 of
Production Example 45.
MS: 542 (M+H) + free Step 2 tert-Butyl N-{4- [2- (2- (acetylamino) -5- {2- [4-
(methylsulfonyl) phenyl] ethyl}-!, 3-thiazol-4- yl) ethyl] phenyl}carbamate was prepared from the compound of
Step 1 ' in a similar manner according to Step 6 of Production Example 45.
MS: 544 (M+H) +
Step 3
N- (4- [2- (4-Aminophenyl) ethyl] -5-{2- [4-
(methylsulfonyl) phenyl] ethyl}-l, 3-thiazol-2-yl) acetamide was prepared from the compound of Step 2 in a similar manner according to Step 2 of Production Example 31.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 2.23(3H, s) , 2.61(4H, s) ,
2.78(4H, s), 2.98(3H, s) , 3.55(2H, brs), 6.57(2H, d, J=8.5Hz),
6.81 (2H, d, J=8.5Hz), 7.25 (2H, d, J=8.5Hz), 7.82 (2H, d, J=8.5Hz) , 8.80 (IH, s) .
MS: 444 (M+H) +
Step 4
Di-tert-butyl [ (E) - ( {4- [2- (2- (acetylamino) -5-{2- [4-
(methylsulfonyl) phenyl] ethyl }-l, 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 3 in a- similar manner according to
Step 5 of Production Example 18.
XH-NMR (200 MHz, CDCI3) , δ (ppm): 1.49(9H, s) , 1.53 (9H, s), 2.22(3H, s), 2.59-2.73(4H, m) , 2.84(4H, s) , 2.98(3H, s) ,
6.99(2H, d, J=8.4Hz), 7.28 (2H, d, J=8.4Hz), 7.44 (2H, d,
J=8.4Hz), 7.83 (2H, d, J=8.4Hz), 8.99 (IH, bra), 10.23 (IH, s) ,
11.62(1H, s) . MS: 686 (M+H) +
Step 5
The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production
Example 31. XH-NMR (200 MHz, DMSO-d5) , δ (ppm) : 2.16(3H, s) , 2.67(4H, brs),
2.82-2.94(4H, m) , 3.14(3H, s) , 7.12 (2H, d, J=8.4Hz), 7.20(2H, d, J=8.4Hz), 7.43 (2H, d, J=8.4Hz), 7.82 (2H, d, J=8.4Hz),
9.87(1H, s), 11.97 (IH, s) .
MS: 486 (M+H) +
The compounds according to the present invention useful as VAP-1 inhibitors are listed in the following tables.
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Example 1
Inhibitory Effect of Compound A on VAP-1 enzyme (SSAO) activity in human and rat plasma.
VAP-1 enzyme (SSAO) activity in both human and rat plasma was determined by a radiochemical-enzyme assay using X4C- benzylamine as artificial substrate. The enzyme suspension prepared from blood plasma was pre-incubated with Compound A in 96-well microplate at room temperature for 30 min. The enzyme suspension was then incubated with XC-benzylamine (2xl0-5 mol/1 final concentration) in a final volume of 50 μl at 37°C for 1 hour. The enzyme reaction was terminated by adding 2 mol/1 (50 μl) citric acid. The oxidized products were directly extracted into a 200 μl toluene scintillator, and its radioactivity was measured by a scintillation spectrometer. Monoamine oxidase (MAO) and diamine oxidase (DAO, histaminase) activities were also determined by similar method using X4C- phenylethylamine and x4C-putrescine as substrate, respectively. Cloned DAO from cDNA libraries was used in human DAO assay.
Inhibition activity was expressed as IC50 (μmol/1) value. Compound A completely inhibited the enzyme activity of human and rat plasma SSAO, but not the enzyme activities of other amine oxidases, such as human platelet MAO and cloned DAO, shown in Table 1.
Table 1. Inhibitory effect (IC5u values, μM) of Compound A on various amine oxidase activities
Figure imgf000247_0001
Example 2 Effect of Compound A on ocular permeability in diabetic rats, Diabetes in rats was induced with an intraperitoneal (i.p.) injection of 65 mg/ml/kg of streptozotocin (STZ) in 2 mmol/1 citrate buffer (pH 4.5) after a 20-h fast. At the same time control rats were injected with an equal volume of 2 mmol/1 citrate buffer. Plasma glucose level was checked by a colqrimetric method. At day 3 of STZ treatment, the rats were diagnosed with diabetes showing a plasma glucose level of 350 mg/dl .
The treatment of Compound A was given daily from 2 weeks after STZ treatment for 2 weeks. At 24 hrs after final treatment of Compound A, the vascular permeability in oculus was investigated based on the leakage of dye into the vitreous 30 min after intravenous injection of fluorescein solution (40 mg/ml/kg) . Permeability was expressed as vitreous/plasma ratio of fluorescein concentration measured by a fluorophotometer. At the same time, the plasma SSAO activity was checked by the radiochemical-enzyme assay using X4C-benzylamine (2xl0~5 mol/1 final concentration) as substrate.
The significant increase of ocular permeability in diabetic rats was examined at 4 weeks after treatment of STZ and compared with that of normoglycemic normal rats . The treatment of Compound A (10 mg/kg, s.c. u.i.d.) given daily from 2 weeks after STZ treatment improved the ocular permeability, in comparison with the STZ control group (Table 2) . Plasma SSAO enzyme activity also increased in diabetic rats at 4 weeks after STZ treatment, but the treatment with Compound A exhibited dose-dependent inhibition of the increased plasma SSAO activity (Table 3) . Table 2. Vitreous/Plasma Ratio of Fluorescein Concentration (xlO-3)
Figure imgf000249_0001
Values are mean ± S.E.M.s for 10 rats. **p<0.01 vs corresponding value for STZ control by Dunnett's test.
Table 3. Plasma SSAO activity (pmol/min/ml)
Figure imgf000249_0002
Values are mean ± S.E.M.s for 10 rats. **p<0.01 vs corresponding value for STZ control by Dunnett's test.
Example 3 In the same manner as in Example 2, the effect of various
VAP-1 inhibitors on ocular permeability was determined in diabetic rats.
The treatment of Compund B (0.003%, ocular instillation, u.i.d. and 0.1 mg/kg, s.c, respectively) given daily from 2 weeks after STZ treatment improved the ocular permeability, in comparison with the STZ control group (Table 4) . Table 4. Vitreous/Plasma Ratio of Fluorescein Concentration (xlO-3)
Figure imgf000250_0001
Values are mean ± S.E.M.s for 10 rats. **p<0.01 vs corresponding value for STZ control by Dunnett's test.
Example 4
Effect of eye-drop instillation with Compound A on increased retinal VAP-1 activity in STZ diabetic rats.
A 0.1% solution of Compound A was instilled into the eyes of STZ diabetic rats (10 μl/eye) prepared in the same manner as in Example 2. To the normal group and STZ control group, a vehicle was instilled. At 6 hours from the instillation, the retina was removed from the animals and the retinal VAP-1 activity was determined.
Compound A completely inhibited the increased retinal VAP- 1 activity in STZ diabetic rats, shown in Table 5.
Table 5. Retinal VAP-1 activity (pmol/min/mg protein)
Figure imgf000250_0002
Values are mean ± S.E.M.s for 4 rats. Example 5
Effect of Compound A on increased retinal VEGF level in STZ diabetic rats.
STZ diabetic rats were prepared in the same manner as in Example 2. Compound A (0.1 mg/kg, sc, u.i.d.) was administered from 3 days to 8 weeks after the STZ administration. To the normal group and STZ control group, a vehicle was treated. At 8 weeks from the STZ administration, the retina was removed from the animals and the retinal VEGF level was determined using a Murine VEGF ELISA kit.
Compound A completely inhibited the increased retinal VEGF level in STZ diabetic rats, shown in Table 6.
Table 6. Retinal VEGF level (pg/mg protein)
Figure imgf000251_0001
Values are mean + S.E.M.s for 10 rats. *p<0.05, **p<0.01 vs corresponding value for STZ control by Dunnett's test.
The above result indicates that VAP-1 inhibitor is useful for treating a vascular hyperpermeable disease (except macular edema) .
This application is based on application No. 60/458,370 filed in the United States of America, the content of which is incorporated hereinto by reference.

Claims

1. A method for treating a vascular hyperpermeable disease (except macular edema) , which method comprises administering to a subject in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said subject for said disease.
2. The method of claim 1, wherein said disease is a disease in mucous membrane.
3. The method of claim 2, wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract.
4. The method of claim 1, wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
5. The method of claim 1, wherein the VAP-1 inhibitor is a compound of the formula (I) :
Rι_NH_x-Y-z (i) wherein Rx is acyl;
X is a bivalent residue derived from optionally substituted thiazole;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000253_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and E is optionally protected amino, -N=CH2,
Figure imgf000253_0002
wherein
Q is -S- or -NH-; and-
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
6. The method of claim 5, wherein, in the formula (I), Z is a group of the formula:
J A2 wherein R2 is a group of the formula:
NH
A 4 -G-NH NH-R* (wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl); -NH2; -CHNH2; -CH2ONH2;
-CH2ON=CH2;
,.
Figure imgf000254_0001
7. The method of claim 6, wherein, in the formula (I), R2 is a group of the formula:
NH
-G-NH ANH-R4
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl) ; -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000254_0002
8. The method of any of claims 5 to 7, wherein, in the formula (I) , Rx is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl.
9. The method of claim 1, wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide, N- [4- (2-{4- [ (a inooxy) methyl]phenyl}ethyl) -1, 3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino)methyl] aminojphenyl) ethyl]-5- [4- (methylsulfonyl) benzyl]-!, 3-thiazol-2-yl}acetamide, N-{4-[2- (4-{ [hydrazino (imino)methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl]-!, 3-thiazol-2-yl}acetamide, N-{4- [2- (4-{ [hydrazino (imino)methyl] amino}phenyl) ethyl] -1,3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino)methyl] amino}ethyl)phenyl] ethyl}- 1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
10. The method of claim 1, wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl }acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition for the treatment of a vascular hyperpermeable disease (except macular edema) , which comprises, as an active ingredient, a VAP-1 inhibitor.
12. The composition of claim 11, wherein said disease is a disease in mucous membrane.
13. The composition of claim 12, wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract.
14. The composition of claim 11,- wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
15. The composition of claim 11, wherein the VAP-1 inhibitor is a compound of the formula (I) :
R1—NH—X-Y—Z (I) wherein R1 is acyl;
X is a bivalent residue derived from optionally substituted thiazole;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000256_0001
wherein R is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-;
D is a bond, lower alkylene, -NH- or -CH2NH-; and
E is optionally protected amino, -N=CH2,
Figure imgf000257_0001
5 wherein
Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; ° or a derivative thereof; or a pharmaceutically acceptable salt thereof.
16. The composition of claim 15, wherein, in the formula (I), Z is a group of the formula:
Figure imgf000257_0002
wherein R2 is a group of the formula:
NH
A 4 -G-NH NH-R4
(wherein G is a bond, -NHC0CH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl); -NH2; -CH2NH2; -CH20NH2; 0 -CH2ON=CH2;
Figure imgf000257_0003
NH H ^NH or v
17. The composition of claim 16, -wherein, in the formula (I), R2 is a group of the formula: NH -G-NH NH-R*
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl) ; -CH2NH2; -CH2ONH2; -CH2ON=CH2;
Figure imgf000258_0001
18. The composition of any of claims 15 to 17, wherein, in the formula (I) , R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl.
■ 19 . The composition of claim 11 , wherein the VAP-1 inhibitor is
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -1,3- thiazol-2-yl}acetamide, N_[4_(2-{4-[ (aminooxy)methyl]phenyl}ethyl)-l,3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl }acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] amino}phenyl) ethyl] -1,3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino) methyl] amino}ethyl) phenyl] ethyl}-
1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
•20. The composition of claim 11,. wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl} acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
5 21. A use of a VAP-1 inhibitor for preparing a medicament for the treatment of a vascular hyperpermeable disease (except macular edema) .
22. The use of claim 21, wherein said disease is a disease in ° mucous membrane.
23. The use of claim 22, wherein said mucous membrane is a mucous membrane of ocular, cutis, otorhinology or respiratory tract. 5
24. The use of claim 21, wherein said disease is aged macular degeneration, aged disciform macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, chorioretinopathy, neovascular maculopathy, 0 neovascular glaucoma, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, 5 exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren' s ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a 0 physical injury to the eye, a symptom caused by an ocular ■inflammatory disease including itching, flare, edema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleredema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
25. The use of claim 21, wherein the VAP-1 inhibitor is a compound of the formula (I) :
RX-NH—X-Y-Z (I) wherein Rx is acyl;
X is a bivalent residue derived from optionally substituted thiazole;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000260_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and E is optionally protected amino, -N=CH2,
Figure imgf000260_0002
wherein
Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
26. The use of claim 25, wherein, in the formula (I), Z is a group of the formula:
Figure imgf000261_0001
wherein R2 is a group of the formula:
NH
A 4
-G-NH NH-R*
5 (wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl) ; -NH2; -CH2NH2; -CH2ONH; -CHON=CH2;
Figure imgf000261_0002
ι° 27. The use of claim 26, wherein, in the formula (I), R2 is a group of the formula: NH
A 4 -G-NH NH-R4
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH2; -CH2ONH2; -CH2ON=CH2;'
H3 or
Figure imgf000261_0003
.
Figure imgf000261_0004
28. The use of any of claims 25 to 27, wherein, in the formula (I), R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl.
20
29. The use of claim 21, wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino)methyl]-amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide,
N-[4-(2-{4-[ (aminooxy) methyl] henyl} ethyl) -l,3-thiazol-2- yl] acetamide,
N-{4- [2- (4-{ [amino (imino)methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl }acetamide, N-{4- [2- (4-{ [hydrazino (imino)methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1, 3-thiazol-2-yl}acetamide,
N-{4- [2- (4-{ [hydrazino (imino)methyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino) ethyl] amino}ethyl) phenyl] ethyl}-
1, 3-thiazol-2-yl) acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
30. The use of claim 21, wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) ethyl] amino}phenyl) ethyl] -1, 3- thiazol-2-yl}acetamide; or a derivative thereof; or a pharmaceutically acceptable salt thereof.
PCT/JP2004/004596 2003-03-31 2004-03-31 Method for treating vascular hyperpermeable disease WO2004087138A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2004800090708A CN1794988B (en) 2003-03-31 2004-03-31 Composition for treating vascular hyperpermeable disease
EP04724735.8A EP1608365B1 (en) 2003-03-31 2004-03-31 Method for treating vascular hyperpermeable disease
CA2520957A CA2520957C (en) 2003-03-31 2004-03-31 Method for treating vascular hyperpermeable disease
US10/550,414 US20060229346A1 (en) 2003-03-31 2004-03-31 Method for treating vascular hyperpermeable disease
JP2006507702A JP4758337B2 (en) 2003-03-31 2004-03-31 Methods for treating hypervascular disease
KR1020057018312A KR101267552B1 (en) 2003-03-31 2005-09-28 Method for treating vascular hyperpermeable disease
US11/930,466 US20080119462A1 (en) 2003-03-31 2007-10-31 Method for treating vascular hyperpermeable disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45837003P 2003-03-31 2003-03-31
US60/458,370 2003-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/930,466 Division US20080119462A1 (en) 2003-03-31 2007-10-31 Method for treating vascular hyperpermeable disease

Publications (1)

Publication Number Publication Date
WO2004087138A1 true WO2004087138A1 (en) 2004-10-14

Family

ID=33131786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004596 WO2004087138A1 (en) 2003-03-31 2004-03-31 Method for treating vascular hyperpermeable disease

Country Status (7)

Country Link
US (2) US20060229346A1 (en)
EP (1) EP1608365B1 (en)
JP (1) JP4758337B2 (en)
KR (2) KR20120045062A (en)
CN (1) CN1794988B (en)
CA (1) CA2520957C (en)
WO (1) WO2004087138A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
JP2007529413A (en) * 2004-03-18 2007-10-25 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
JP2008543886A (en) * 2005-06-24 2008-12-04 バイオトロン リミテッド Antiviral compounds and methods
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
US9598385B2 (en) 2012-02-01 2017-03-21 City Of Hope Ribonucleotide reductase inhibitors and methods of use
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
FI20050640A0 (en) * 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Compounds for treating or preventing diseases or disorders related to amine oxidases
JP2011504485A (en) * 2007-11-21 2011-02-10 ファーマクシス リミテッド SSAO / VAP-1 haloallylamine inhibitors and uses thereof
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN107271348B (en) * 2017-07-06 2019-11-15 苏州大学 A kind of medical artificial pipeline permeance property test macro and its application method

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002386A1 (en) * 1981-01-13 1982-07-22 Sakano Isao Aminothiazole derivatives,process for their preparation,and medicinal composition containing same
WO1997024343A1 (en) * 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2002002090A2 (en) * 2000-07-05 2002-01-10 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
WO2002028835A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
EP1256578A1 (en) * 2001-05-11 2002-11-13 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
WO2003006003A1 (en) * 2001-07-12 2003-01-23 Biotie Therapies Corporation Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
WO2003072557A1 (en) * 2002-02-28 2003-09-04 Novartis Ag 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699928A (en) * 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
IT1181871B (en) * 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche SELECTIVE INHIBITORS OF BENZYLAMINOXIDE COMPARED TO OTHER AMINOXIDE
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4965288A (en) * 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) * 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) * 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
DE69132293D1 (en) * 1991-03-07 2000-08-10 Hisamitsu Pharmaceutical Co DIPHENYLTHIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY
EP0639972A1 (en) * 1992-05-15 1995-03-01 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
JP2002302488A (en) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd Substituted 1,3-thiazole compound, its production method and use thereof
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002386A1 (en) * 1981-01-13 1982-07-22 Sakano Isao Aminothiazole derivatives,process for their preparation,and medicinal composition containing same
WO1997024343A1 (en) * 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2002002090A2 (en) * 2000-07-05 2002-01-10 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
WO2002002541A2 (en) * 2000-07-05 2002-01-10 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
US20020173521A1 (en) * 2000-07-05 2002-11-21 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
WO2002028835A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
EP1256578A1 (en) * 2001-05-11 2002-11-13 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
WO2003006003A1 (en) * 2001-07-12 2003-01-23 Biotie Therapies Corporation Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
WO2003072557A1 (en) * 2002-02-28 2003-09-04 Novartis Ag 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Protective Groups in Organic Synthesis", 1980, JOHN WILEY AND SONS
OHKUBO M ET AL: "STUDIES ON CEREBRAL PROTECTIVE AGENTS. VIII 1A) SYNTHESIS OF 2-AMINOTHIAZOLES AND 2-THIAZOLECARBOXAMIDES WITH ANTI-ANOXIC ACTIVITY", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 43, no. 9, 1995, pages 1497 - 1504, XP000887179, ISSN: 0009-2363 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529413A (en) * 2004-03-18 2007-10-25 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
JP4881159B2 (en) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2006011631A3 (en) * 2004-07-27 2006-04-20 Astellas Pharma Inc Thiazole derivatives having vap-1 inhibitory activity
JP2008543886A (en) * 2005-06-24 2008-12-04 バイオトロン リミテッド Antiviral compounds and methods
JP2013049676A (en) * 2005-06-24 2013-03-14 Biotron Ltd Antiviral compound and method
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
EP2599498A1 (en) 2007-06-25 2013-06-05 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
JPWO2009001857A1 (en) * 2007-06-25 2010-08-26 株式会社アールテック・ウエノ Composition for ophthalmic diseases associated with hypoxia or ischemia
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
KR101622414B1 (en) 2008-01-31 2016-05-18 가부시키가이샤 아루떼꾸 우에노 Thiazole derivative and use thereof as VAP-1 inhibitor
EP2639229A3 (en) * 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
EP2676955A1 (en) 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
RU2496776C2 (en) * 2008-01-31 2013-10-27 Р-Тек Уено, Лтд. Thiazol derivative and using it as vap-1 inhibitor
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
EP2650287A1 (en) * 2008-01-31 2013-10-16 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US8999989B2 (en) 2008-05-30 2015-04-07 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EP2886534A1 (en) 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
RU2580626C2 (en) * 2009-09-08 2016-04-10 Байотай Терапис Корп. Use of vap-1 inhibitors for fibrotic sickness treatment
US10576148B2 (en) 2009-09-08 2020-03-03 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
US9795671B2 (en) 2009-09-08 2017-10-24 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
EP3002278A1 (en) 2011-03-15 2016-04-06 Astellas Pharma Inc. Guanidine compound
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
KR20140014153A (en) 2011-03-15 2014-02-05 아스테라스 세이야쿠 가부시키가이샤 Guanidine compound
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound
US9598385B2 (en) 2012-02-01 2017-03-21 City Of Hope Ribonucleotide reductase inhibitors and methods of use
US9796692B2 (en) 2012-02-01 2017-10-24 City Of Hope Ribonucleotide reductase inhibitors and methods of use
US10155732B2 (en) 2012-02-01 2018-12-18 City Of Hope Ribonucleotide reductase inhibitors and methods of use
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain

Also Published As

Publication number Publication date
KR20060023522A (en) 2006-03-14
US20080119462A1 (en) 2008-05-22
CA2520957A1 (en) 2004-10-14
EP1608365B1 (en) 2013-10-02
JP4758337B2 (en) 2011-08-24
CN1794988A (en) 2006-06-28
JP2006522110A (en) 2006-09-28
KR101267552B1 (en) 2013-05-27
CN1794988B (en) 2010-07-28
US20060229346A1 (en) 2006-10-12
EP1608365A1 (en) 2005-12-28
KR20120045062A (en) 2012-05-08
CA2520957C (en) 2013-08-06

Similar Documents

Publication Publication Date Title
US20080119462A1 (en) Method for treating vascular hyperpermeable disease
US7442715B2 (en) Thiazole derivatives
JP4978464B2 (en) Thiazole derivatives having VAP-1 inhibitor activity
US20080015202A1 (en) Thiazole Derivatives Having Vap-1 Inhibitory Activity
US8106078B2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP2018021083A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2008508188A5 (en)
JP2008512346A5 (en)
AU2017316742A1 (en) Antibiotic compounds
CN100491361C (en) Thiazole derivatives and their use as VAP-1 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006507702

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004724735

Country of ref document: EP

Ref document number: 2006229346

Country of ref document: US

Ref document number: 10550414

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020057018312

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2520957

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048090708

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004724735

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057018312

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10550414

Country of ref document: US